https://biospectrumindia.com/rssfeed/healthcare/artificial%20intelligence artificial intelligence https://biospectrumindia.com/news/100/28648/fujifilm-india-supports-aiims-for-study-on-ai-assisted-early-detection-of-upper-gastrointestinal-cancers.html https://biospectrumindia.com/news/100/28648/fujifilm-india-supports-aiims-for-study-on-ai-assisted-early-detection-of-upper-gastrointestinal-cancers.html Wed, 14 Oct 2026 13:34:08 +0530 FUJIFILM India has announced its support through its Corporate Social Responsibility (CSR) initiative, for a landmark clinical research study led by the All India Institute of Medical Sciences (AIIMS), New Delhi. The study aims to evaluate the effectiveness of artificial intelligence (AI)-assisted endoscopy in improving the early detection of upper gastrointestinal (UGI) malignancies, an area where timely diagnosis remains critical to improving patient outcomes. Upper gastrointestinal cancers continue to contribute significantly to cancer-related morbidity and mortality in India. While early detection can substantially improve survival outcomes, many early-stage lesions remain difficult to identify during routine examinations owing to their subtle appearance and variability in detection. Emerging evidence indicates that AI-assisted endoscopy has the potential to enhance real-time lesion detection by supporting clinicians in identifying abnormalities that may otherwise be overlooked. This collaborative research seeks to generate robust clinical evidence in the Indian healthcare setting and contribute to the advancement of evidence-based endoscopic practices.  The collaboration also reflects FUJIFILM India's broader vision of advancing the endoscopy ecosystem in India through technology, clinical research and long-term healthcare partnerships. By supporting evidence generation alongside innovation, the company continues to contribute towards strengthening diagnostic capabilities and enabling more informed clinical decision-making across the healthcare ecosystem. ]]> https://biospectrumindia.com/news/100/28591/aignosis-raises-rs-4-cr-in-seed-round-to-scale-ai-assisted-autism-and-developmental-screening-across-india.html https://biospectrumindia.com/news/100/28591/aignosis-raises-rs-4-cr-in-seed-round-to-scale-ai-assisted-autism-and-developmental-screening-across-india.html Sat, 03 Oct 2026 17:35:12 +0530 Jaipur-based health-tech startup Aignosis has raised Rs 4 crore in a seed round led by Antler, Nikhil Kamath and angel investors including Varun Dua, IIMA Ventures and others, as the company moves from developing and validating its AI-assisted autism screening technology to expanding its presence across India's healthcare ecosystem. The company raised their first round in 2024 with notable angels including Rajneesh Bhandari and Amit Jain. The round lands at a credible moment. Aignosis has completed its CDSCO regulatory process, was incubated at IIM Ahmedabad Ventures, and was selected for Google's 2025 “Google for Startups Accelerator: AI First” cohort, one of just 20 startups picked nationally from over 1,600 applicants. It was also chosen among the top 5 healthcare startups for a three-week immersion programme in Europe run by BFI. Commercially, Aignosis runs primarily as a Clinic-in-Clinic model, equipping paediatricians to become holistic partners in early identification rather than selling them a standalone device. The startup is currently deployed across 20+ government Primary Health Centres in Rajasthan and has partnered with Mankind Pharma, whose nearly 1,300 medical representatives are supporting Aignosis screening camps with paediatricians across India. The company is also beginning operations with Apollo Shines, the Apollo Group's school infirmary division, across approximately 125 schools. The company now aims to conduct at least 100,000 total screenings by the end of FY26-27, compared with 8,000+ completed so far and preparing to expand into Punjab, NCR, Haryana, Tamil Nadu, Jharkhand, Karnataka and Maharashtra, using its Rajasthan experience as an operating reference for wider government adoption.   ]]> https://biospectrumindia.com/news/100/28575/prodoc-ai-secures-seed-funding-to-develop-intelligence-layer-for-indian-hospitals.html https://biospectrumindia.com/news/100/28575/prodoc-ai-secures-seed-funding-to-develop-intelligence-layer-for-indian-hospitals.html Wed, 30 Sep 2026 15:27:52 +0530 Prodoc AI, a Bengaluru-based healthcare AI startup, has raised an undisclosed amount in a seed funding round led by Dr A. Velumani Family Office. The round also saw participation from Dr. Kunal Shet, and Parth D. Bhasin. Both Dr Shet and Bhasin participated in the investment round as existing users of the platform. Hospitals currently utilise multiple independent systems across departments, including HIS, EMR, CRM, billing, telephony, and diagnostics. Prodoc AI addresses this fragmentation by building a Patient Journey OS that connects these isolated communication channels. The software creates an intelligence layer across existing technology to manage patient context and coordinate actions without requiring hospitals to replace their current infrastructure. The platform handles workflows related to patient acquisition, appointment conversion, OPD intelligence, care coordination, follow-ups, partner and referral management, Voice AI, and general hospital operations. Prodoc AI currently operates in over 100 hospitals, processes more than one million patient engagements monthly, and supports over 50 software integrations.   The company plans to use the newly raised capital to advance its Agentic AI capabilities, increase the number of available system integrations, and build AI agents designed to support complex hospital workflows across care coordination, patient engagement, operations, and revenue processes. Looking ahead, the long-term objective of the company is to function as the definitive intelligence layer across the entire patient journey. By expanding its technological footprint, Prodoc AI aims to help hospitals move toward a more connected, responsive, and highly patient-centric healthcare delivery model. ]]> https://biospectrumindia.com/news/100/28576/india-hosts-world-congress-of-gastroenterology-2026-with-focus-on-emerging-role-of-ai-in-diagnosis.html https://biospectrumindia.com/news/100/28576/india-hosts-world-congress-of-gastroenterology-2026-with-focus-on-emerging-role-of-ai-in-diagnosis.html Wed, 30 Sep 2026 16:15:49 +0530 The World Congress of Gastroenterology (WCOG) 2026 opened in New Delhi, on 30th Sept, with global and Indian gastroenterology experts examining the changing burden of gastrointestinal and liver diseases, the need for earlier diagnosis and evolving approaches to prevention and treatment. Being held in India for the first time, the four-day Congress has brought together around 3,000 delegates from 61 countries, including leading clinicians and researchers from across the world. The opening day covered the growing range of infectious, metabolic, inflammatory and malignant gastrointestinal conditions. H. pylori and intestinal worm disease continue to affect large populations. At the same time, metabolic dysfunction-associated steatotic liver disease (MASLD), inflammatory bowel disease (IBD), gastrointestinal cancers and chronic digestive disorders are placing new demands on healthcare systems. Artificial intelligence (AI) and advanced diagnostics are also emerging as important areas of discussion. Research spans deep learning for Irritable Bowel Syndrome (IBS) detection and quantitative interpretation of celiac biopsies. It also includes AI-assisted evaluation of pancreatic cysts and applications in Irritable Bowel Disease (IBD) and pancreatic cancer. Over the next three days, WCOG 2026 will span gastroenterology, hepatology, endoscopy, pancreatic diseases, GI cancers, nutrition, microbiome science and emerging technologies. Key areas include acute and chronic pancreatitis, pancreatic cancer surveillance and early detection, advanced endoscopy, liver transplantation, gut microbiota, precision medicine and the clinical application of AI. Jointly organised by the Indian Society of Gastroenterology and the World Gastroenterology Organisation, with support from leading Indian gastroenterology and hepatology associations, WCOG 2026 is being held under the theme “Transforming Gastrointestinal Health, Preserving Nature.” ]]> https://biospectrumindia.com/news/100/28558/doctorsai-summit-places-verification-at-the-centre-of-clinical-ai.html https://biospectrumindia.com/news/100/28558/doctorsai-summit-places-verification-at-the-centre-of-clinical-ai.html Mon, 28 Sep 2026 13:45:57 +0530 DoctorsAI Global Summit 2026 brought clinicians, researchers, industry experts and policy participants together around a shared challenge: making artificial intelligence useful in everyday healthcare while preserving clinical judgement and patient trust. Pre-conference workshops on 18 September preceded the main meeting on 19–20 September at Radisson Blu Plaza, New Delhi. Organising Chair Dr Amit Kumar Dey, Scientific Chair Prof. Dr. S. V. Kulkarni and the full DoctorsAI and ICAIM team deserve credit for the platform. Organising Secretary Dr Ashlesha Tawde Kelkar and Scientific Secretary Dr Shelly Sharma formed part of its leadership. Dr Dey's post-summit message thanked faculty, delegates, partners and session leaders, and encouraged continued collaboration on responsible adoption led by clinicians. Dr Anthony Chang's ABAIM–DoctorsAI workshop provided a foundation in medical AI and responsible use. A continuous glucose monitoring workshop connected interpretation of data with clinical decisions and patient experience. Further masterclasses covered prompting, healthcare data, research and AI agents. Together, they reinforced a central message: AI literacy should strengthen clinical judgement, which must include verification before technology earns patient trust. Dr Kelkar emphasised human oversight and preservation of professional skills. Documentation tools illustrated the balance: voice-based systems may reduce typing, but doctors must check the resulting record. Earlier summit accounts described MedScribe, MedStudio and Health Bridge in relation to clinician approval, structured information and continuity between visits. Demonstrated capabilities require evaluation in actual care settings. Dr Shiv Kumar Sarin's closing presentation highlighted metabolic liver disease as a population-health concern. According to summit media coordinator Dr. Paras Gangwal, he stressed fibrosis assessment, including among people without obvious obesity, and the need to connect screening with referral. His discussion of AI-assisted imaging and combined clinical information underscored the importance of reliable measurements and validation. Screening scores and liver stiffness measurements must be reported distinctly. According to summit media coordinator Dr Paras Gangwal, Sridhar Vembu encouraged doctors to explore AI and extend its benefits to people in villages, remote areas and cities. Drawing on personal experiences, he emphasised taking technology to the grassroots for wider public benefit. Industry sessions included TatvaCare and Zoho, while the catalyst platform featured InBody, Abbo Ring, MapMyGenome, DeepTek and Cyborg. Projects discussed applications and their fit within everyday workflows. Oral research presentations and e-posters covered subjects ranging from maternal health and tuberculosis to imaging, wound assessment and clinical documentation. These exchanges gave research and emerging products a forum for scrutiny alongside established clinical disciplines. The NHA and ABDM sessions connected the discussion with digital-health infrastructure. Other programme strands addressed critical care, emergency medicine, diabetes, telemedicine, public health, medical education, ethics and algorithmic bias. Participation across these areas kept the focus on how tools can serve patients throughout their care. Darpan also soft-launched under Dr Paras Gangwal's TOHFA initiative, encouraging positive, gradual health goals. It is freely available to everyone. The scientific programme also addressed diagnostic imaging, pathology, preventive paediatrics, outpatient triage and dialysis safety. These sessions placed AI within specific clinical tasks. For patients, the connection between those tasks matters: information collected at one encounter should support the next decision, while the doctor remains responsible for interpretation. Workshops, presentations and exchanges between clinicians and developers brought education and implementation into the same conversation. The summit's outcome was a platform for learning and collaboration, with the next edition announced for Mumbai on 18–19 September 2027. Its practical message for readers is that faster information becomes valuable when clinicians check it, explain it and connect it with appropriate action. Patient trust depends on that process. That requires clear communication, reliable records and a continuing relationship between the patient and the professionals providing care. ]]> https://biospectrumindia.com/news/100/28535/5c-network-launches-ai-integrated-centre-of-excellence-for-nuclear-medicine-in-bengaluru.html https://biospectrumindia.com/news/100/28535/5c-network-launches-ai-integrated-centre-of-excellence-for-nuclear-medicine-in-bengaluru.html Wed, 23 Sep 2026 21:43:02 +0530 5C Network, one of India’s largest AI-native radiology platforms, has announced the launch of its remote Centre of Excellence (CoE) for Nuclear Medicine. Headquartered in Bengaluru, the distributed, remote-delivery network is engineered to solve India’s acute shortage of nuclear medicine physicians by providing high-precision, sub-specialty remote reading capabilities directly to hospital scanners across the country. This launch directly addresses a critical bottleneck in Indian healthcare. Over 500 PET-CT installations and 350 SPECT/gamma cameras rely on just ~800 nuclear medicine physicians nationwide. With PET-CT reporting restricted strictly to licensed specialists, a pool growing by only ~40 physicians annually while scan volumes surge 13% scanners outside major metros operate far below capacity. 5C’s Centre of Excellence bridges this gap, unlocking an estimated national market potential of nearly 7,500 daily PET-CT studies.  By utilising a distributed remote-reading framework, the CoE connects local scanners to a national panel of credentialed specialists, embedding standardised reporting criteria - such as PERCIST, Lugano, PSMA-RADS, and SSTR-RADS and integrating AI decision-support tools for lesion tracking, SUV quantification, and response assessment to assist physicians with speed and precision. To lead the CoE, 5C Network has appointed Dr Ajit Shinto, a veteran with 20+ years of expertise who commissioned India's first digital PET-CT scanner and has reported over 30,000 studies. Having established nuclear medicine departments across Kovai Medical Center, Amala Institute, Apollo Proton Cancer Centre, and Bharath Hospital, Dr Shinto chairs WARMTH’s Rhenium Task Force, serves as Co-Editor-in-Chief of the International Journal of Nuclear Medicine and Research, and is Principal Investigator on the NOBLE and 68Ga Basket trials.  ]]> https://biospectrumindia.com/news/100/28513/deeptek-unveils-global-access-pricing-for-ai-powered-tb-screening.html https://biospectrumindia.com/news/100/28513/deeptek-unveils-global-access-pricing-for-ai-powered-tb-screening.html Mon, 21 Sep 2026 13:27:04 +0530 Pune-based DeepTek, a global leader in AI-powered radiology, has launched Global Access Pricing, a new pricing model enabled through its access agreement with Unitaid and the Clinton Health Access Initiative (CHAI). The initiative makes DeepTek’s WHO-recommended Chest X-ray AI solution significantly more affordable for eligible public-sector and not-for-profit healthcare providers across 138 low- and middle-income countries (LMICs), helping TB programmes expand screening within existing budgets. Tuberculosis (TB) remains one of the world’s deadliest infectious diseases, claiming an estimated 1.23 million lives in 2024. While chest X-rays are critical for TB screening, shortages of radiologists continue to limit timely diagnosis in many high-burden countries. Under Global Access Pricing, eligible programmes can access DeepTek’s AI solution at approximately one-third of its previous pricing, potentially enabling health systems to screen up to three times more people within the same budget. The annual subscription includes unlimited AI analyses per connected X-ray unit, installation, training, product updates, maintenance and technical support, with no hidden add-on costs. The solution supports online, offline and hybrid deployment, including mobile and remote healthcare settings. Beyond TB, DeepTek’s AI detects 20+ clinically relevant chest abnormalities, with transparent pricing also available for additional indications such as cardiomegaly, silicosis and lung cancer.   ]]> https://biospectrumindia.com/news/100/28487/wadhwani-school-of-data-science-and-ai-at-iit-madras-unveils-ai-studio.html https://biospectrumindia.com/news/100/28487/wadhwani-school-of-data-science-and-ai-at-iit-madras-unveils-ai-studio.html Tue, 15 Sep 2026 17:07:10 +0530 The Wadhwani School of Data Science and AI (WSAI) at the Indian Institute of Technology (IIT) Madras will launch ‘AI Studio’, a venture studio designed to build artificial intelligence (AI), machine learning and data science companies from the Institute’s research. The AI Studio is designed to help researchers and founders take research concepts from the idea stage to a viable and scalable business. Each cohort venture will be supported with seed funding, cloud and compute credits, lab access, mentoring, an Entrepreneur-in-Residence, and product-market-fit support, taking them from idea to a formal spin-out into the IIT-M Incubation Cell ecosystem. The Studio will be open to IIT Madras and WSAI researchers, academic founders from other institutions, and external entrepreneurs with an AI, ML or data science venture or idea. Applicants will go through two stages. The first will be an initial training and bootcamp open to a larger applicant pool, followed by a full studio programme for a smaller set of selected ventures. Call for applications for the inaugural cohort will be launched on October 3rd 2026. Ventures admitted to the Studio will undergo a six-month venture development and evaluation programme, which can be extended by up to three months for ventures progressing towards an institutional funding round. The Studio will run two cohorts a year, with applications opening in the winter and spring cycles. The launch builds on IIT Madras' broader deep-tech incubation ecosystem, which has supported the incubation of hundreds of deep-tech startups collectively valued at $8 billion and has resulted in the creation of over 11,000 direct jobs. ]]> https://biospectrumindia.com/news/100/28481/karnataka-government-builds-news-partnerships-to-strengthen-digital-healthcare.html https://biospectrumindia.com/news/100/28481/karnataka-government-builds-news-partnerships-to-strengthen-digital-healthcare.html Mon, 14 Sep 2026 21:54:26 +0530 Bharat1.ai has formally entered into a Memorandum of Understanding (MoU) with the Centre of Excellence for HealthTech, MedTech, and Assistive Technologies (CHARAKA CoE), an initiative by the IT BT Department, Government of Karnataka, to establish the Swasthya AI Lab. This state-of-the-art facility is dedicated to accelerating holistic health outcomes through secure, high-integrity data infrastructure for innovative discoveries in the age of AI and Beyond. A Memorandum of Understanding (MoU) has also been announced between the Jalappa Foundation for Innovation and Incubation (JFII), Sri Devaraj Urs Academy of Higher Education and Research, Karnataka (SDUAHER) and CHARAKA CoE.This collaboration marks an important step towards creating a stronger ecosystem for HealthTech, MedTech and AssistiveTech innovation, bringing together academia, healthcare, technology, entrepreneurship and incubation. CHARAKA CoE has also signed an MoU with the Telemedicine Society of India, reflecting another step towards building a stronger health innovation ecosystem, bringing innovation closer to the medical community and creating more opportunities for people to learn, experiment and build. ]]> https://biospectrumindia.com/news/100/28439/sanofi-signs-loi-with-tricog-health-to-support-ai-enabled-cardiac-diagnostics-solutions.html https://biospectrumindia.com/news/100/28439/sanofi-signs-loi-with-tricog-health-to-support-ai-enabled-cardiac-diagnostics-solutions.html Mon, 07 Sep 2026 18:36:07 +0530 Sanofi Healthcare India has signed a Letter of Intent (LoI) with Bengaluru-based Tricog Health, a Bharat Innovates startup, taking a concrete step towards enabling India's startup and entrepreneurship ecosystem.   Sanofi came in touch with Tricog Health at the Bharat Innovates 2026 summit where the Ministry of Education, Government of India showcased 120 of India’s best deep tech startups at a global stage in France.   Under this partnership, Sanofi will provide mentorship, market access support, and potential financial investment to Tricog, a health-tech startup that supplies virtual cardiac diagnostic tools and services that are built by combining artificial intelligence and medical expertise.   The three-year collaboration reflects a shared commitment to nurturing homegrown innovation and building a robust entrepreneurial ecosystem that can drive meaningful impact in healthcare and beyond. This partnership comes against the backdrop of the India-France Year of Innovation 2026 — a landmark bilateral initiative placing innovation at the core of the India-France relationship.   Sanofi also plans to engage with other healthcare innovators among the deep-tech ventures identified under the Bharat Innovates initiative, including those emerging from IITs and other higher education institutions, incubators, and innovation hubs across the country. Sanofi will be extending its support to more startups such as Ahammune Biosciences and the Translational Health Science and Technology Institute, which are addressing some of healthcare's most pressing challenges through cutting-edge research and technology.      Image caption- Prateek Golecha, Chief Growth Officer, Tricog Health (L) with Deepak Arora, Managing Director, Sanofi India (R) ]]> https://biospectrumindia.com/news/100/28421/iit-kanpur-partners-with-nobel-laureate-david-bakers-lab-for-ai-guided-drug-discovery.html https://biospectrumindia.com/news/100/28421/iit-kanpur-partners-with-nobel-laureate-david-bakers-lab-for-ai-guided-drug-discovery.html Thu, 03 Sep 2026 19:12:39 +0530 Researchers at the Indian Institute of Technology (IIT) Kanpur worked with the laboratory of Nobel Prize winner Prof. David Baker at the University of Washington to help design a new kind of small protein. These proteins can block a group of receptors called GPCRs (G protein-coupled receptors), which are present on the surface of our cells and play a part in how many modern medicines act.  The study titled “De novo design of miniproteins targeting GPCRs” has been published in the journal Nature. It shows how artificial intelligence (AI) can be used to efficiently design and find the miniproteins that attach to specific GPCRs and change how they behave.  The team designed miniproteins for several GPCRs, including two called CXCR4 and CCR5. Both are being studied as possible drug targets for cancer and for viral infections such as HIV.  IIT Kanpur also contributed to visualising how one of these designed miniproteins attaches to the CXCR4 receptor. Using a powerful imaging technique called cryo-electron microscopy at its cryo-EM facility, researchers could see exactly how the two molecules fit together and how the miniprotein affects the receptor.   The findings of the study reveal that AI-based protein design is a practical tool for drug discovery. While these specific proteins are not medicines yet, and years of further testing lie ahead before it reaches the clinic, the study offers a workable method for designing targeted, protein-based treatments for receptors that have been difficult to target with drugs.  ]]> https://biospectrumindia.com/news/100/28428/iit-m-and-cmc-vellore-build-ai-tools-for-early-kidney-disease-detection.html https://biospectrumindia.com/news/100/28428/iit-m-and-cmc-vellore-build-ai-tools-for-early-kidney-disease-detection.html Thu, 03 Sep 2026 23:09:24 +0530 Researchers from Indian Institute of Technology Madras (IIT-M) and Christian Medical College (CMC), Vellore, have developed a set of Artificial Intelligence (AI)-based tools designed to assist in the early detection and assessment of kidney diseases, which affect millions of people worldwide. The team has developed three technologies that complement each other- A machine learning model that uses clinical and laboratory information to predict the risk of chronic kidney disease (CKD). A deep learning system that automatically analyzes CT scans and classifies them into four categories: normal kidney, kidney cyst, kidney stone, and kidney tumour. A 3D imaging platformthat recreates kidneys from CT scans to precisely assess tumour volume and the percentage of kidney involvement. These tools can enable earlier diagnosis, which could help slow the disease process and reduce the need for expensive interventions like dialysis. The CT image classifier has been trained with over 12,000 images and can distinguish healthy kidneys from cysts, stones and tumors. The 3D imaging framework developed using open-source software provides an inexpensive and repeatable method for measuring tumor burden, which can provide valuable information to help guide treatment decisions. The CKD prediction model was implemented in a user-friendly prototype interface to facilitate future clinical translation. The team also worked on making it more accurate and more easily understood by the doctors who are using it to make their predictions. The team intends to test the models with more patient information sets to validate them and establish stronger partnerships with health care institutions for deployment in the real world. The researchers are also exploring the long-term integration of these AI technologies with minimally invasive wearable sensing systems and Digital Twin platforms to enable personalised kidney health monitoring ]]> https://biospectrumindia.com/news/100/28349/orange-health-labs-launches-ai-powered-personalised-diagnostic-insights.html https://biospectrumindia.com/news/100/28349/orange-health-labs-launches-ai-powered-personalised-diagnostic-insights.html Thu, 20 Aug 2026 17:00:52 +0530 Orange Health Labs, India’s on-demand diagnostics platform, has announced a new AI-powered initiative aimed at making diagnostic reports more personalised and easier for consumers to understand, as part of its new brand positioning, ‘Speed Meets Science’. The company is developing an AI-led layer that combines current test results with historical reports and relevant clinical context to provide consumers with a more comprehensive view of their health. Instead of simply highlighting individual parameters as normal or abnormal, the system is designed to identify trends and correlations across multiple biomarkers and body systems. “We are working towards a world where every report is going to feel like a personalised letter to you, from our doctor to you, saying what is going on with you and whether your current condition is worsening or getting better,” said Dhruv Gupta, Co-founder, Orange Health Labs. The initiative will also allow consumers to upload reports generated by other diagnostic providers. These reports can be incorporated into their health history on the Orange Health platform, enabling users to build a longitudinal view of their health rather than relying on individual test reports. Orange Health Labs is expected to roll out the enhanced AI-powered report experience by the end of August or early September 2026. The company currently uses AI to flag reports requiring additional attention, while doctors retain responsibility for final clinical decisions. Around 70 per cent of its reports are auto-approved through automated workflows, while the remaining reports are flagged for further review. The company said the AI system is designed to assist doctors rather than independently diagnose patients. Positive flags generated by the system are reviewed by doctors before results are released, while clinician feedback is used to improve the models. The initiative forms part of Orange Health Labs’ broader strategy to combine diagnostics, technology and longitudinal health data to give consumers a more accessible understanding of their health.   Narayan Kulkarni narayan.kulkarni@mmactiv.com ]]> https://biospectrumindia.com/news/100/28330/tata-consultancy-services-launches-agentic-ai-platform-to-transform-drug-development.html https://biospectrumindia.com/news/100/28330/tata-consultancy-services-launches-agentic-ai-platform-to-transform-drug-development.html Mon, 17 Aug 2026 21:11:40 +0530 Tata Consultancy Services (TCS), a global leader in IT services, consulting, and business solutions, has launched TCS ADD™ AgentHub, a role-based, enterprise-ready, and trusted AI platform that enables the use of agentic AI in drug development at scale. This new agentic AI workforce transforms clinical trials and pharmacovigilance services while maintaining regulatory and audit requirements. Pharmaceutical companies function in highly regulated environments, where they face challenges with trust, governance and scalability when applying AI across functions. Growing data volumes, fragmented systems, and increasing regulatory expectations across clinical development and pharmacovigilance are adding complexities to the entire R&D value chain. TCS ADD™ AgentHub provides a structured framework to mitigate these challenges. Within the framework AI agents can operate with clear roles, defined oversight, and built‑in auditability. Pharma companies can custom build their AI agent hub and deploy them across clinical workflows. The platform allows rapid and streamlined integration with minimal effort, accelerating adoption while maintaining regulatory compliance. Built on the TCS ADD™ framework, TCS ADD™ AgentHub delivers measurable operational benefits across drug development and drug safety functions. Solutions powered by the platform have demonstrated up to 40% efficiency gains in clinical data management activities, up to 30% reduction in clinical study build effort through metadata-driven automation, and up to 30% cost savings in end-to-end safety case processing. AI-powered safety agents can also reduce quality control effort by as much as 50%, helping organizations improve productivity across critical R&D processes. ]]> https://biospectrumindia.com/news/100/28312/axtria-to-build-industrys-largest-pharma-specific-ai-engineering-team-scaling-to-1000-by-dec-2026.html https://biospectrumindia.com/news/100/28312/axtria-to-build-industrys-largest-pharma-specific-ai-engineering-team-scaling-to-1000-by-dec-2026.html Fri, 14 Aug 2026 18:53:20 +0530 US-based Axtria Inc., a global leader in AI-first data analytics solutions for the life sciences industry, has announced plans to expand its Forward Deployed Engineering (FDE) organisation to 1,000 engineers by December 2026, creating the industry's largest pharma-specific AI engineering team. The expansion represents one of Axtria's largest investments in AI talent development to date and reflects growing customer demand for engineers who can deploy, scale, and operationalise enterprise AI across commercial, medical, and market access functions. Launched approximately 12 months ago, Axtria's Forward Deployed Engineering model was built on a simple premise: the future of AI in life sciences will be determined not by who has access to the best models, but by who can successfully deploy AI into complex enterprise environments and deliver measurable business outcomes. Today, Axtria's FDEs are embedded within leading life sciences organizations, deploying production-grade AI solutions across commercial and medical operations. Building on this momentum, Axtria is expanding the organisation to 1,000 engineers by December 2026 through a combination of internal talent development and strategic hiring. Through the Axtria Institute, the company is developing life sciences domain experts into certified AI engineers who deploy solutions across Industry leading platforms and Axtria's proprietary platforms—including SalesIQ™, MarketingIQ™ and DataMAx™, helping clients modernise data foundations, improve decision-making, and scale enterprise AI with strong governance and cost efficiency. ]]> https://biospectrumindia.com/news/100/28289/80-of-healthcare-professionals-believe-ai-to-improve-access-to-quality-healthcare-in-rural-areas-philips-report.html https://biospectrumindia.com/news/100/28289/80-of-healthcare-professionals-believe-ai-to-improve-access-to-quality-healthcare-in-rural-areas-philips-report.html Tue, 11 Aug 2026 15:02:38 +0530 Philips, a global leader in health technology, has announced the India findings of its Future Health Index 2026 report. The global research surveyed over 2,000 healthcare professionals and over 20,000 patients across 10 countries, including 200 healthcare professionals and 2,004 patients in India. Artificial intelligence (AI) is delivering measurable benefits across the Indian healthcare ecosystem. More than 8 in 10 (85%) healthcare professionals in India are optimistic that AI can improve patient outcomes, up from 76% in the 2025 report. AI is also expanding clinical capacity: among those who reported an increase (71%), clinicians are seeing a median of 10 additional patients per week. This underlines the growing role of AI in supporting care delivery at a time when healthcare systems are working to serve more people with existing resources. AI is also helping healthcare professionals use their time differently. 58% of healthcare professionals in India report average annual time savings of at least 132 hours, equivalent to more than three full working weeks. These efficiencies are beginning to support more meaningful care conversations, with 75% saying AI is leading to more thorough interactions with patients. As AI becomes more deeply integrated into healthcare, healthcare professionals highlighted the need for stronger AI training, technical support and governance to enable confident and responsible adoption. ]]> https://biospectrumindia.com/news/100/28290/ayati-devices-raises-rs-15-cr-to-scale-ai-driven-diabetic-foot-diagnostics-platform.html https://biospectrumindia.com/news/100/28290/ayati-devices-raises-rs-15-cr-to-scale-ai-driven-diabetic-foot-diagnostics-platform.html Tue, 11 Aug 2026 15:17:14 +0530 Ayati Devices, a Bengaluru-based medical technology and device manufacturing startup developing precision diagnostic solutions for diabetic foot complications and peripheral vascular disease, has raised Rs 15 Crore in a Pre-Series A funding round led by Inflexor Ventures.  This marks the company's first institutional investment and will accelerate the commercialisation of its next-generation diagnostic technologies, expand its domestic and international presence, strengthen manufacturing capabilities, and deepen investments in research, regulatory approvals, artificial intelligence, and global talent. Ayati Devices has been incubated at IITB-SINE as part of the institute’s translational research programme. Ayati's technologies already hold regulatory clearances across major global markets, including CDSCO (India), the US FDA, CE Mark (Europe), and approvals in Sri Lanka, Malaysia, and the UAE.  The company has deployed over 10,000 devices across 30+ countries, backed by a growing international distributor network and clinical deployments at leading institutions such as Medicover Hospital and Aster Hospital.  The capital will fund Angiocam's commercialisation, expand go-to-market operations at home and abroad, strengthen manufacturing and supply chain capacity, accelerate R&D in AI-enabled diagnostics, secure further regulatory approvals, grow the IP portfolio, and build out engineering, clinical, regulatory, and global business development teams.  Looking ahead, Ayati will deepen its presence across Europe, the US, the Middle East, Southeast Asia, Australia, and Latin America through its distribution network, while evaluating direct commercial operations in key markets as demand scales. It will also expand its pay-per-test screening model across hospitals, primary care clinics, and community programmes, making preventive diagnostics far more accessible. ]]> https://biospectrumindia.com/news/100/28285/govt-supports-commercialisation-of-indigenous-ai-powered-cervical-cancer-screening-technology.html https://biospectrumindia.com/news/100/28285/govt-supports-commercialisation-of-indigenous-ai-powered-cervical-cancer-screening-technology.html Mon, 10 Aug 2026 19:32:24 +0530 The Technology Development Board (TDB) of the Department of Science and Technology (DST), Government of India, has entered into an agreement with Griva Healthcare in Visakhapatnam. The agreement will support the manufacture and commercialisation of an indigenously developed, Artificial Intelligence (AI)-enabled portable digital colposcope 'GrivaVision'. 'Cervivision' helps in early detection of lesions before they become cancerous in the cervix. In collaboration with TDB, the company will set up manufacturing capacity in Kollam, Kerala, enabling extensive production and use of the technology on a commercial scale. This initiative aims to make cervical cancer screening more accessible and affordable, especially in primary and community healthcare centers. Simultaneously, it will help strengthen domestic capabilities in advanced medical devices and reduce dependence on imported diagnostic equipment. GrivaVision is a portable diagnostic platform that integrates a high-definition camera, in-built display, user-friendly interface, advanced optics, and indigenous AI-enabled software. Designed for visualization of the vaginal passage and the examination of cervical lesions, the system assists gynecologists in identifying pre-cancerous abnormalities during routine diagnostic check-ups. The technology is designed according to the Automated Visual Assessment (AVE) standards approved by the World Health Organization (WHO) and its software is ABDM compliant, enabling its integration with India's evolving digital health ecosystem. The product is a category B non-invasive medical device and is licensed to manufacture CDSCO category B. It is being developed to ISO 13485 quality standards. The hardware architecture is the company's own specialty and is patented by Griva Healthcare in India. The company is currently engaged in R&D work at AIC-AMTZ Medivalley, Visakhapatnam, and will help it move towards commercial production at the upcoming facility to be set up in Kerala under the TDB supported project. The technology has been developed and manufactured in India, and more than 50% of its product components are currently indigenously sourced. Large-scale commercialisation is expected to further strengthen the home medical device value chain and create a cost-effective Indian option in cervical cancer diagnosis.   ]]> https://biospectrumindia.com/news/100/28270/health-minister-releases-knowledge-paper-on-ai-in-medtech.html https://biospectrumindia.com/news/100/28270/health-minister-releases-knowledge-paper-on-ai-in-medtech.html Sat, 08 Aug 2026 19:27:24 +0530 Union Minister of Chemicals & Fertilizers and Health & Family Welfare J. P. Nadda released a knowledge paper on "AI in MedTech: Revolutionising Healthcare Through Artificial Intelligence" at the 9th Edition of India Medical Device 2026, organised by the Department of Pharmaceuticals in association with FICCI, at Vigyan Bhawan, New Delhi, on 8 August. The report highlights the growing role of Artificial Intelligence (AI) in the healthcare sector, from creating new opportunities to addressing emerging challenges. Jointly developed by Praxis Global Alliance, in association with FICCI, the knowledge paper examines India's evolving AI-enabled MedTech landscape and outlines the strategic actions needed to accelerate responsible AI adoption across healthcare. It explores AI's role in diagnostics, clinical decision support, operational efficiency and medical device innovation, while identifying the regulatory, policy and ecosystem interventions required to enable large scale adoption. The report while noting that India has already built important foundations through the Ayushman Bharat Digital Mission (ABDM), the IndiaAI Mission, SAHI, BODH and the National Medical Devices Policy, 2023, observes that moving AI solutions from successful pilots to large-scale clinical adoption is a major challenge. The report notes that this transition requires addressing fragmented health data and limited evidence, developing predictable lifecycle-based regulation for adaptive AI, and creating supportive reimbursement and procurement mechanisms. The report highlights five priorities for accelerating AI-enabled MedTech adoption in India: •MedTech represents India's most immediate and scalable AI opportunity, •India has the foundations for AI leadership, but not yet the ecosystem for scale, •India must move beyond successful pilots to routine clinical adoption by addressing three ecosystem gaps: AI-ready data and evidence, lifecycle-based regulation, and procurement and reimbursement mechanisms that recognise AI-enabled value' •AI-enabled diagnostics are expected to be the first large-scale application, •Coordinated action across government, regulators, healthcare providers, payers, industry and academia will be essential to position India as a global leader in responsible AI-enabled MedTech. ]]> https://biospectrumindia.com/news/100/28265/nanotechnology-sensors-redefine-early-disease-detection-with-ai-powered-diagnostics.html https://biospectrumindia.com/news/100/28265/nanotechnology-sensors-redefine-early-disease-detection-with-ai-powered-diagnostics.html Fri, 07 Aug 2026 23:46:46 +0530 Nanotechnology is rapidly transforming healthcare diagnostics, enabling diseases to be detected earlier, faster and more accurately than ever before. From analysing a patient's breath for metabolic disorders to identifying life-threatening infections within minutes, nanoscale sensors are emerging as one of the most promising frontiers in precision medicine. Speaking at the 14th Bengaluru INDIA NANO Conference 2026, Dr Paramita Kar Choudhury, Senior Scientist in the Embedded Devices and Intelligent Systems (EDIS) group at Tata Consultancy Services Research, highlighted how nanotechnology-enabled sensors are moving beyond laboratories to develop practical, point-of-care diagnostic solutions capable of reshaping healthcare delivery. "Nanotechnology allows us to interact with biological systems at the molecular level, providing unprecedented sensitivity and specificity for disease detection," she said, adding that the convergence of nanomaterials, microelectronics, artificial intelligence (AI), and data analytics is opening a new era of personalised healthcare. Breath Analysis for Prediabetes Among the projects presented was a non-invasive diagnostic platform that employs Chemi resistive nanosensors to detect volatile organic compounds (VOCs) in human breath for prediabetes monitoring. Unlike conventional blood-based glucose testing, breath diagnostics could offer a painless, rapid and repeatable method for identifying metabolic changes before the onset of overt diabetes. The sensor arrays identify disease-associated VOC signatures with high sensitivity, making continuous health monitoring more practical for both clinics and home-based settings. The work aligns with a growing global trend toward wearable and non-invasive diagnostics, where breath, sweat and saliva are increasingly viewed as valuable sources of health biomarkers. SERS Nanosensors Target Early Sepsis Detection Another major focus of the presentation was the application of Surface Enhanced Raman Spectroscopy (SERS)-based nanosensors for early prediction of sepsis. Sepsis remains one of the leading causes of mortality in intensive care units because diagnosis often occurs after the infection has already progressed. By amplifying molecular signals thousands to millions of times, SERS-based nanostructures enable clinicians to detect subtle biochemical changes associated with sepsis at much earlier stages. Earlier identification could significantly improve treatment decisions, reduce mortality and lower healthcare costs by enabling timely interventions. Lab-on-Chip Technology for Rapid UTI Diagnosis Dr Paramita also showcased microfluidic lab-on-chip nano biosensors designed for rapid diagnosis of urinary tract infections (UTIs). Traditional microbiological culture methods can take 24–72 hours to confirm infections. The miniaturised nanobiosensor platform integrates microfluidics with nanotechnology to rapidly analyse patient samples at the point of care, potentially reducing diagnosis times from days to minutes. Such portable diagnostic devices are expected to play an important role in primary healthcare, emergency medicine and rural health systems where laboratory infrastructure is limited. Dr Paramita emphasised that translating scientific innovation into deployable healthcare products remains a key objective. “These cutting-edge technologies are not just futuristic concepts, they are tangible innovations that promise to revolutionise disease detection, bringing us closer to a world where early, accurate, and personalised healthcare is accessible to everyone”, she concluded.   Narayan Kulkarni (narayan.kulkarni@mmactiv.com) ]]> https://biospectrumindia.com/news/100/28267/karnataka-has-consistently-invested-in-creating-an-ecosystem-to-turn-innovation-into-economic-opportunity-dr-n-manjula.html https://biospectrumindia.com/news/100/28267/karnataka-has-consistently-invested-in-creating-an-ecosystem-to-turn-innovation-into-economic-opportunity-dr-n-manjula.html Fri, 07 Aug 2026 23:57:53 +0530 “Deep-tech leadership is not built by isolated breakthroughs; it is built by ecosystems that enable science to scale into solutions. Karnataka has consistently invested in creating that ecosystem—where researchers, startups, industry and government work in partnership to turn innovation into economic opportunity. Bengaluru INDIA NANO embodies that approach” said Dr N. Manjula, Secretary, Department of Electronics, IT, BT and Science & Technology, Government of Karnataka. Speaking at the concluding ceremony of Bengaluru INDIA NANO 2026, India's flagship international conference and exhibition on nanotechnology, she said “As nanotechnology converges with AI and other frontier technologies, we are committed to ensuring that Karnataka remains the place where the world’s next generation of deep-tech solutions is conceived, commercialised and scaled.” Organised by the Department of Science & Technology, Government of Karnataka, Karnataka Science & Technology Promotion Society (KSTePS) and Jawaharlal Nehru Centre for Advanced Scientific Research (JNCASR), the 14th Edition of Bengaluru INDIA NANO concluded on August 5  after three days of scientific exchange, technology showcases and international collaboration. Centred around the theme "Nanotech's Next Frontier: AI & Beyond – Conceive, Converge, Commercialize," Bengaluru INDIA NANO 2026 explored the convergence of nanotechnology with artificial intelligence and other frontier technologies, while highlighting their transformative applications across semiconductors, healthcare, agriculture, energy and environmental sustainability.  The successful conclusion of the 14th edition reinforces Bengaluru INDIA NANO's role as India's premier platform for nanoscience and nanotechnology, fostering interdisciplinary research, promoting technology commercialisation, encouraging international collaboration and strengthening Karnataka's position as a global hub for advanced science, deep technology and innovation.   Narayan Kulkarni (narayan.kulkarni@mmactiv.com) ]]> https://biospectrumindia.com/news/100/28249/time-medical-international-ventures-announces-partnership-for-installation-of-inter-op-mri-suite.html https://biospectrumindia.com/news/100/28249/time-medical-international-ventures-announces-partnership-for-installation-of-inter-op-mri-suite.html Mon, 03 Aug 2026 17:14:05 +0530 Time Medical International Ventures (India), a wholly owned subsidiary of Fischer Medical Ventures and a global leader in advanced medical imaging solutions, has entered into a partnership with Parul Sevashram Hospital, Vadodara, to install its revolutionary DRIS–iMRI Medharanya Suite, an AI-enabled next-generation portable intraoperative MRI system. Time Medical has developed a revolutionary new variant of MRI imaging technology — DRIS–iMRI Medharanya, an AI-enabled, next-generation, portable and specialised MRI system integrating Augmented Reality (AR), Artificial Intelligence (AI), Machine Learning (ML), and Exoscope technologies. The intraoperative MRI platform is designed to transform intraoperative imaging by providing surgeons with real-time visualisation during complex neurosurgical procedures, enabling unprecedented precision, safety, and surgical control in procedures that traditionally rely on limited visual feedback. Time Medical International Ventures has entered into a partnership to install its first Modern Brain Suite: the DRIS–iMRI Medharanya system at Parul Sevashram Hospital, Vadodara. Through this upcoming partnership, the DRIS–iMRI Medharanya Suite is expected to strengthen the university's academic and clinical ecosystem, giving medical students, residents, and faculty at Parul University hands-on exposure to next-generation neurosurgical imaging technology. ]]> https://biospectrumindia.com/news/100/28244/ministry-of-ayush-and-indiaai-sign-mou-on-harnessing-artificial-intelligence-for-future-of-traditional-medicine.html https://biospectrumindia.com/news/100/28244/ministry-of-ayush-and-indiaai-sign-mou-on-harnessing-artificial-intelligence-for-future-of-traditional-medicine.html Sat, 01 Aug 2026 22:13:11 +0530 The Ministry of Ayush and IndiaAI of the Ministry of Electronics and Information Technology have signed a Memorandum of Understanding (MoU) towards promoting Artificial Intelligence (AI) driven innovation in the Ayush sector as a significant step towards leveraging emerging technologies to strengthen the Ayush systems ecosystem. The MoU was signed by Dr Kavita Jain, Joint Secretary and Chief Vigilance Officer, Ministry of Ayush and Sudeep Srivastava, Chief Operating Officer, IndiaAI Mission and Joint Secretary, MeitY in the presence of senior officials from the Ministry of Ayush and IndiaAI.   This collaboration is a significant step towards building a technology-based Ayush systems ecosystem by bringing together traditional knowledge and modern AI capabilities. The partnership will focus on accelerating the adoption and application of AI in key Ayush sectors, including research, capacity building, medicinal plants, and drug administration. Under this collaboration, the Ministry of Ayush will be connected to the AI Kosh platform that will enable sharing of relevant health research content, including datasets, metadata, AI models, toolkits, and relevant use cases. This integration is expected to foster better collaboration, innovation, and responsible development of AI solutions for the Ayush sector. The MoU will be instrumental in providing access to GPU-based and high-performance computing infrastructure at discounted rates through the IndiaAI initiative, subject to defined service-level agreements. Access to advanced computing infrastructure is expected to address critical infrastructure needs and support the expansion of sophisticated AI research and applications in healthcare and traditional medicine. ]]> https://biospectrumindia.com/news/100/28242/cdsco-is-piloting-ai-across-regulatory-processes-to-create-data-driven-regulatory-system-dcgi.html https://biospectrumindia.com/news/100/28242/cdsco-is-piloting-ai-across-regulatory-processes-to-create-data-driven-regulatory-system-dcgi.html Fri, 31 Jul 2026 12:16:17 +0530 The Global Drug Regulatory Conclave (GDRC) 2026, organised by Pharmexcil, focused on strengthening India's pharmaceutical regulatory ecosystem. India is building a future-ready drug regulatory framework to accelerate healthcare innovation while maintaining the highest standards of patient safety, quality, and efficacy, Union Minister for Health and Family Welfare J.P. Nadda said in his virtual address at the inaugural Global Drug Regulatory Conclave (GDRC) 2026, on 30 July in Delhi. Reinforcing this vision, Drugs Controller General of India (DCGI) Dr Rajeev Singh Raghuvanshi announced at the event that the Central Drugs Standard Control Organisation (CDSCO) will roll out the first phase of an end-to-end digital drug regulatory platform within the next 18 months, marking a significant step in modernising India's pharmaceutical regulatory ecosystem. Highlighting the Government's ongoing regulatory reforms, Nadda said CDSCO is undergoing a comprehensive transformation driven by transparency, scientific rigour, efficiency, accountability, and digital governance. He added that digital regulatory platforms, risk-based oversight, strengthened inspection systems, and enhanced surveillance are creating a modern regulatory ecosystem that inspires greater global confidence. Calling for deeper international collaboration, he urged regulators to strengthen information sharing, regulatory science partnerships, collaborative inspections, and the convergence of scientific standards to improve global access to safe, effective, and affordable medicines. In his opening remarks at the event, Dr Rajeev Singh Raghuvanshi outlined CDSCO's roadmap for regulatory transformation centered on digitalisation, innovation, quality assurance, and global regulatory convergence.  Dr Raghuvanshi said more than 99 percent of CDSCO's regulatory processes have already been digitised, significantly improving transparency and approval timelines. Building on this, CDSCO is piloting Artificial Intelligence (AI) across regulatory processes to create a faster, more agile, and data-driven regulatory system. He also announced that GMP and Certificate of Pharmaceutical Product (COPP) certificates will soon carry QR-code-based digital authentication, enabling overseas regulators to instantly verify their authenticity while reducing verification timelines. Highlighting initiatives to strengthen quality and innovation, Dr Raghuvanshi said CDSCO has streamlined its export regulatory framework through a fully digitised export No Objection Certificate (NOC) system, introduced globally aligned regulatory reliance mechanisms, and accelerated approval pathways to enable faster patient access to innovative therapies. Around 25–30 percent of clinical trials are currently being considered for waiver for eligible innovative products. He further highlighted MedTech Mitra, which has already supported more than 800 startups in navigating regulatory pathways, and noted that similar facilitation mechanisms are planned for biologics and other emerging technologies. Namit Joshi, Chairman, Pharmexcil, said, “India has earned its position as the pharmacy of the world, and the next step is to become a stronger regulatory partner. As global expectations on quality and compliance continue to evolve, GDRC will bring regulators and industry together to promote harmonised standards, clearer regulatory pathways, and faster access to quality, affordable medicines. It will also help translate policy into consistent compliance across the industry, strengthening confidence in Indian pharmaceuticals across global markets.” The Global Drug Regulatory Conclave 2026, organised by the CDSCO in association with Pharmexcil, brought together global drug regulatory authorities, policymakers, researchers, industry leaders, and international organisations to deliberate on the future of pharmaceutical regulation. ]]> https://biospectrumindia.com/news/100/28218/prorithm-accelerates-expansion-across-southern-india-eyes-nationwide-presence-by-early-2027.html https://biospectrumindia.com/news/100/28218/prorithm-accelerates-expansion-across-southern-india-eyes-nationwide-presence-by-early-2027.html Mon, 27 Jul 2026 17:28:18 +0530 DeepFacts, a HealthTech startup behind proRITHM (an AI- and IoT-enabled Smart Remote Patient Monitoring platform), has announced its expansion roadmap, with plans to strengthen its presence across Andhra Pradesh, Karnataka, Tamil Nadu, and Odisha before expanding across India by early 2027. It already holds a strong ground in Telangana. The company is also preparing for its entry into the US market by late 2027 or early 2028 as it continues to scale its AI-enabled healthcare solutions. As part of its innovation journey, DeepFacts has secured three granted patents, reinforcing the company's focus on building proprietary healthcare technologies. With a growing portfolio of intellectual property, expanding healthcare collaborations, and a clear roadmap for domestic and international growth, DeepFacts aims to accelerate the adoption of proRITHM, its AI-powered remote patient monitoring platform, while contributing to improved healthcare accessibility and outcomes. Vamsi Karatam, Founder & CEO of DeepFacts said "The future of healthcare lies in continuous, intelligent monitoring that enables timely interventions rather than reactive treatment. Our focus is to make clinically reliable remote monitoring accessible to healthcare providers across India while building globally relevant technology. The next phase of our expansion is centred on strengthening our presence in key Indian markets, deepening collaborations with healthcare partners, and preparing for international expansion." ]]> https://biospectrumindia.com/news/100/28197/carpl-ai-raises-10-m-led-by-ifc-to-accelerate-healthcare-ai-adoption-globally.html https://biospectrumindia.com/news/100/28197/carpl-ai-raises-10-m-led-by-ifc-to-accelerate-healthcare-ai-adoption-globally.html Fri, 24 Jul 2026 23:48:31 +0530 CARPL.ai, US and India-based radiology AI marketplace and enterprise platform, has announced a Series A round of $10 million led by International Finance Corporation (IFC), the private sector arm of the World Bank Group, with participation from Stellaris Venture Partners and other investors. The funding will accelerate CARPL’s mission to help healthcare providers adopt AI in a meaningful and safe manner. CARPL is being used by many governments, including Brazil, India, Singapore, Spain and the UAE.  Through a single integration with CARPL, healthcare providers gain access to the world's largest radiology AI marketplace with more than 300 AI applications from over 100 partners. In addition to this, the CARPL platform also enables its customers to build, test, deploy, and monitor AI across clinical workflows while remaining vendor-neutral and infrastructure-agnostic.  The investment will support continued product innovation, expansion of CARPL's global partner ecosystem, and commercial growth across North America, LATAM, Europe, Asia-Pacific, and emerging markets. The partnership also reflects a shared focus on advancing digital health innovation through CARPL’s model of building high-skill engineering, product development, and AI capabilities in India for deployment to healthcare providers around the world.  While CARPL has started in the domain of radiology, which has 1000s of AI applications waiting to be deployed, the goal is to become the integration, utilisation and procurement layer for all clinical AI that goes into healthcare organisations. “We will soon move beyond medical imaging into the domains of pathology, genomics and general medicine, and one day, if there is a robotic surgeon somewhere using AI to perform surgery, we hope that it will be running through CARPL,” said Dr Vidur Mahajan, Chief Executive Officer of CARPL.ai.    ]]> https://biospectrumindia.com/news/100/28179/researchers-in-gujarat-develop-ai-powered-device-to-identify-disease-carrying-mosquito-species-.html https://biospectrumindia.com/news/100/28179/researchers-in-gujarat-develop-ai-powered-device-to-identify-disease-carrying-mosquito-species-.html Wed, 22 Jul 2026 19:33:00 +0530 With mosquito-borne diseases such as dengue and malaria continuing to pose a significant public health challenge in India, Associate Professor Kiran Trivedi from the University of Wollongong in Gujarat has developed a low-cost artificial intelligence (AI)-powered device that can identify disease-carrying mosquito species within seconds by analysing the sound of their wingbeats. The portable AI device uses Tiny Machine Learning (TinyML) to accurately identify three of the world's most significant disease-carrying mosquito species—Aedes, Anopheles and Culex—without requiring internet connectivity or cloud-based computing. By enabling rapid, on-site identification of mosquito species, the innovation has the potential to support faster and more efficient mosquito surveillance, particularly in regions where access to laboratory infrastructure may be limited. Unlike conventional surveillance methods, which require mosquito larvae to be collected and analysed in laboratories to determine species, the AI-powered device identifies mosquitoes by their distinct acoustic signatures from wingbeats. Developed in collaboration with Professor Trivedi’s former student Harsh Shroff, the embedded AI model processes sound locally on the device, enabling real-time species identification while operating on minimal power. The model was trained using publicly available mosquito sound recordings and achieved an accuracy of 88.3 per cent. Built on a compact Arduino-based platform with an integrated microphone and display, the device provides a portable and affordable alternative for mosquito monitoring in the field. The device also has the potential to be deployed as part of wider surveillance networks, enabling continuous monitoring of mosquito populations and generating real-time data to support public health planning and outbreak preparedness. ]]> https://biospectrumindia.com/news/100/28163/india-launches-first-computational-lab-for-quantitative-sciences-to-advance-ai-in-drug-development.html https://biospectrumindia.com/news/100/28163/india-launches-first-computational-lab-for-quantitative-sciences-to-advance-ai-in-drug-development.html Mon, 20 Jul 2026 19:19:12 +0530 Dr. Ramalingam Sankaran Computational Lab for Quantitative Sciences was recently inaugurated at PSG Institute of Medical Sciences and Research (PSGIMSR) in Coimbatore. Developed through a collaboration between US-based PumasAI, the Society of Pharmacometrics and Health Analytics Sciences (SOPHAS), and PSGIMSR, the new state-of-the-art facility represents a significant investment in India's growing scientific ecosystem and is expected to become a leading center for artificial intelligence (AI), healthcare data analytics, pharmacometrics, and model-informed drug development (MIDD). Powered by a high-performance computing cluster, the laboratory gives students, researchers, and healthcare professionals access to advanced computational resources that support AI-driven drug discovery, predictive health modeling, real-world evidence generation, and quantitative sciences. The facility will support research across clinical pharmacology, pharmacometrics, machine learning, and healthcare analytics. Students and researchers will participate in live research projects, industry collaborations, and translational research initiatives. Participants will gain hands-on experience applying AI to drug development, clinical data modeling, pharmacometric simulations, and population health analytics alongside experts from academia and industry. The initiative also strengthens the educational foundation of SOPHAS' AI in Drug Development programme by providing students with dedicated computational infrastructure designed to support advanced scientific research. ]]> https://biospectrumindia.com/news/100/28156/telangana-to-establish-indias-first-green-pharma-focused-applied-ai-centre-of-excellence.html https://biospectrumindia.com/news/100/28156/telangana-to-establish-indias-first-green-pharma-focused-applied-ai-centre-of-excellence.html Sun, 19 Jul 2026 15:41:37 +0530 The Government of Telangana, in collaboration with Microsoft India 1M1B (1 Million for 1 Billion) and MeitY Startup Hub, has announced the establishment of India's first Green Skills & Applied AI Centre of Excellence (CoE) dedicated to Green Pharma. The initiative marks a significant step towards strengthening Telangana's position as a global hub for sustainable life sciences manufacturing while building a future-ready talent ecosystem.Expected to become operational by August 2026, the Centre will focus on equipping youth with industry-relevant skills in Applied Artificial Intelligence (AI), sustainable manufacturing and emerging technologies. The initiative aligns with the Telangana Next-Generation Life Sciences Policy 2026–30, which places strong emphasis on sustainability, advanced technologies and workforce development to drive the next phase of growth in the state's life sciences sector.The roadmap for the Centre was presented to ITEC and Industries Minister Sridhar Babu Duddilla at Telangana State Secretariat. The meeting was attended by Microsoft India Development Centre President and Managing Director Rajiv Kumar, Microsoft Senior Director (Elevate-CSR) Manju D., 1M1B (1 Million for 1 Billion) Founder and CEO Manav Subodh, Director - Sustainability & Government Advocacy Deepika Venkatesh, IT Advisor Sai Krishna, Telangana Life Sciences CEO Sarvesh Singh, and other senior government officials.The Centre is expected to play a key role in supporting Telangana's goal of creating over five lakh jobs across the life sciences ecosystem by developing an AI-enabled workforce equipped to meet the evolving needs of the pharmaceutical and advanced manufacturing industries. ]]> https://biospectrumindia.com/news/100/28141/gaudium-ivf-unveils-ai-powered-signature-labs.html https://biospectrumindia.com/news/100/28141/gaudium-ivf-unveils-ai-powered-signature-labs.html Thu, 16 Jul 2026 21:36:36 +0530 Gaudium IVF and Women Health, India's first publicly listed IVF chain, has kicked off its first milestone in the company's planned 19-centre expansion, as outlined in the growth roadmap shared with investors during its IPO. The launch reinforces the company's commitment to making high quality, technology driven fertility care more accessible to aspiring parents through a standardised clinical and laboratory model that combines artificial intelligence (AI) powered innovation with the highest standards of clinical excellence, patient safety and ethical care. Strategically located in South Delhi, the new centre offers comprehensive fertility care under one roof, combining experienced fertility specialists, advanced reproductive medicine and Gaudium IVF's standardised clinical protocols. At the heart of the new centre is the Gaudium Signature Lab, the company's proprietary laboratory framework that integrates advanced embryology, AI-powered technologies and internationally benchmarked quality standards to create an optimal environment for embryo development. As Gaudium IVF expands its network, the Signature Lab model will be replicated across every new centre, ensuring patients experience the same high standards of precision, safety and clinical excellence, irrespective of location. The centre also brings together Gaudium IVF's AI-powered embryology ecosystem, including SiD (Sperm Identification Device) for advanced sperm assessment and ERICA (Embryo Ranking Intelligent Classification Assistant) for embryo evaluation. By complementing the expertise of embryologists with data-driven insights, these technologies enhance precision, consistency and confidence throughout the IVF journey.   ]]> https://biospectrumindia.com/news/100/28121/cmc-vellore-iiit-h-develop-multilingual-ai-companion-for-cancer-patients.html https://biospectrumindia.com/news/100/28121/cmc-vellore-iiit-h-develop-multilingual-ai-companion-for-cancer-patients.html Tue, 14 Jul 2026 19:18:23 +0530 A multi-partner consortium led by Christian Medical College (CMC) Vellore, in collaboration with IIIT Hyderabad’s Language Technologies Research Centre (LTRC), is developing BandhuCare – a multilingual AI companion that answers patients’ queries in their own language, captures their symptoms through natural conversations, and helps clinicians understand what happens between hospital visits.  Unlike consumer AI assistants that answer virtually anything, BandhuCare emerged after years of working closely with oncology patients and understanding where healthcare delivery quietly breaks down, not during diagnosis or treatment, but between hospital visits. The consortium brings together clinical expertise from CMC Vellore, AI and language technologies from IIIT-H’s Language Technologies Research Centre, startup partner Revan AI, AIIMS Guwahati as an external clinical collaborator, and patient advocacy organisation, PatientsEngage that ensures patient voices remain central to development. The next phase, which is the pilot study on real cancer patients and specifically head and neck cancer patients, is perhaps the most important. At CMC Vellore, head and neck cancers constitute one of the largest cancer burdens, giving clinicians deep expertise and years of experience in understanding not just the disease, but the long-term challenges patients face after treatment. Supported by the National Cancer Grid and MeitY’s India AI initiative, BandhuCare has reached Technology Readiness Level 5, with ethics approvals in place for clinical pilot studies involving patients. ]]> https://biospectrumindia.com/news/100/28114/hai-conclave-2026-calls-for-responsible-adoption-of-ai-across-indias-healthcare-ecosystem.html https://biospectrumindia.com/news/100/28114/hai-conclave-2026-calls-for-responsible-adoption-of-ai-across-indias-healthcare-ecosystem.html Mon, 13 Jul 2026 17:59:11 +0530 HAI Conclave 2026, held on 10 and 11 July 2026 in Bengaluru, concluded with more than 800 participants, new collaborations between healthcare providers, AI innovators and startups, and a shared call for responsible adoption of Artificial Intelligence across India's healthcare ecosystem. Hosted by Global Healthcare Academy (GHA), the two-day conclave brought together clinicians, researchers, healthcare leaders, policymakers, technology companies, startups and investors to explore how Artificial Intelligence is moving from innovation to real-world healthcare applications while keeping patient outcomes and clinical expertise at the centre. Held under the theme "Building Future-Ready Health Ecosystems," the conclave featured five scientific tracks covering AI in Drug Discovery, AI in Preventive Medicine, AI in Treatment, AI in Health Informatics and AI in Diagnostics. Across more than 40 keynote sessions, panel discussions and case-based presentations, experts showcased how AI is already transforming healthcare through faster drug discovery, earlier diagnosis, clinical decision support, precision medicine, improved workflows and expanded access to quality care. The conclave featured participation from 100+ speakers across healthcare, technology, academia and industry, highlighting practical applications of AI and reinforcing the importance of ethical implementation, clinical relevance and collaboration between healthcare professionals and technology innovators. A major highlight was The Pitch Dock, the dedicated Health AI startup pavilion that enabled startups to connect directly with hospital leaders, investors, technology partners and decision-makers. The platform accelerated conversations around adoption, partnerships and future investment while creating opportunities for real-world implementation of emerging healthcare solutions. Adding to the conclave's key milestones, the Global Surgical Institute (GSI), part of the Global Healthcare Academy ecosystem, unveiled ALEX, an AI-powered Patient Communication Simulator. Designed to strengthen clinical reasoning, communication and decision-making through immersive simulation, the launch reflects GHA's continued commitment to advancing AI-enabled healthcare education and preparing future-ready healthcare professionals. The conclave also featured a dedicated roundtable with Vice Chancellors from across different states, focusing on the role of Artificial Intelligence in strengthening India's education ecosystem. The discussion explored opportunities to integrate AI into healthcare education, build future-ready professionals and create responsible frameworks to prepare the next generation of healthcare leaders. Dr B. S. Ajaikumar, Executive Chairman, Global Healthcare Academy, said, "What we witnessed over the past two days was not simply interest in Artificial Intelligence, but genuine collaboration between healthcare and technology. The coming together of clinicians, researchers, innovators and policymakers reflects a shared commitment to ensuring that AI is developed and adopted responsibly to create meaningful impact for patients." Anitha Niranjan, Managing Director, Global Healthcare Academy, said, "HAI Conclave was envisioned as a platform where healthcare, technology and policy could come together to shape the future of health. The conversations started here should continue through partnerships, research, education and implementation, creating a connected Health AI ecosystem that drives meaningful change beyond the conclave." As conversations concluded, one message resonated across HAI Conclave 2026: The future of healthcare will not be shaped by technology alone, but by meaningful collaboration between clinicians, researchers, innovators, startups, investors and policymakers working together to improve patient care. By bringing together diverse stakeholders from across the healthcare and technology ecosystem, HAI Conclave 2026 has strengthened the foundation for a more connected, responsible and future-ready Health AI landscape. ]]> https://biospectrumindia.com/news/100/28061/mankind-pharma-partners-with-denovo-sciences-to-drive-ai-led-innovation-in-drug-discovery.html https://biospectrumindia.com/news/100/28061/mankind-pharma-partners-with-denovo-sciences-to-drive-ai-led-innovation-in-drug-discovery.html Wed, 01 Jul 2026 22:55:35 +0530 Mankind Pharma has announced a strategic collaboration with Armenia-based Denovo Sciences to launch an AI-led drug discovery programme, marking an important step in the company’s focus on innovation-driven and technology-enabled research and development. The partnership will bring together Mankind Pharma’s strong R&D capabilities, experimental validation infrastructure, and clinical development expertise with Denovo Sciences’ proprietary platform for AI-driven molecular generation and prioritisation. Together, both organisations will work under a human-in-the-loop model, where AI generates and evaluates molecular candidates while scientific experts guide, validate, and refine the results at every stage. The collaboration is focused on three key goals: reducing early drug discovery timelines, improving the quality of lead candidates, and ensuring that only candidates with the strongest development potential move ahead. By using computational precision in the early stages of discovery, both partners aim to reduce the time and resources spent on candidates that may not succeed later. The long-term goal, as highlighted by both organisations, is to benefit patients. Faster discovery cycles and better candidate selection can help bring differentiated, effective, and accessible therapies to patients sooner. For Mankind Pharma, this collaboration reflects a clear move beyond traditional drug discovery methods. The company has been expanding its R&D ambitions in recent years, and the partnership with Denovo Sciences represents its strongest step yet towards using AI as a core tool in the drug development process. ]]> https://biospectrumindia.com/news/100/28051/mykare-ai-raises-3-2-m-to-address-healthcare-accessibility-and-gaps.html https://biospectrumindia.com/news/100/28051/mykare-ai-raises-3-2-m-to-address-healthcare-accessibility-and-gaps.html Tue, 30 Jun 2026 18:52:51 +0530 Bengaluru-based startup Mykare.ai has raised a total of $3.2 million, including an additional $1 million in its latest funding round. The round included participation from Andrew and Alfredo, founders of Papa.com, and a leading family office from the Middle East. At a time when investors are pouring billions into AI startups promising to revolutionise healthcare with futuristic technologies, Mykare.ai is focused on a far more fundamental problem: helping clinics and hospitals improve patient access, engagement and overall experience through better operational efficiency.     The startup is building an AI-native healthcare operating system that helps clinics and hospitals grow by automating the entire patient journey, from patient acquisition and appointment booking to follow-ups, feedback, and retention. Founded by Senu Sam, Mykare.ai aims to help healthcare providers scale with a single intelligent AI layer that works across fragmented systems. Its AI agents can acquire new patients, identify patient intent, answer calls through voice agents, book appointments, manage follow-ups, collect feedback, and automatically update CRM records, creating a unified patient journey. Mykare has expanded across the United States, United Kingdom, Middle East, and India, and currently has a waiting list of more than 20 hospitals and healthcare providers. The new funding will be used to enhance Mykare’s AI capabilities, accelerate product development, and support global expansion. ]]> https://biospectrumindia.com/news/100/28041/jupiter-hospital-deploys-indias-first-ai-driven-chiller-optimisation-system.html https://biospectrumindia.com/news/100/28041/jupiter-hospital-deploys-indias-first-ai-driven-chiller-optimisation-system.html Mon, 29 Jun 2026 18:48:27 +0530 Jupiter Hospital, Dombivli, Thane, has implemented India’s first healthcare deployment of Johnson Controls India’s Chiller Plant Optimiser (CPO), bringing artificial intelligence (AI) into one of the most critical yet often overlooked areas of hospital infrastructure—cooling systems. Designed as a fully on-premises solution, the CPO processes and stores all operational data within the hospital premises, without relying on the cloud. This ensures high levels of cybersecurity and data privacy, a key requirement for healthcare environments. Cooling infrastructure in hospitals extends far beyond comfort. Critical spaces such as operation theatres, ICUs, blood banks, pharmacies and imaging suites depend on tightly controlled temperature, humidity and air quality. Stable cooling is also essential for the reliable operation of high-value diagnostic equipment such as MRI and CT systems. Any disruption can affect clinical workflows, equipment uptime, medication storage and infection-control environments. HVAC systems account for 40–60% of a hospital’s total energy consumption, making them one of the largest contributors to operating costs. The chiller plant alone can account for up to 35% of a hospital’s electricity consumption. The AI-driven CPO integrates and automatically controls the entire chiller ecosystem, including chillers, primary pumps, condenser pumps and cooling towers. Using real-time adaptive controls, the system continuously adjusts equipment performance based on cooling demand and ambient conditions. The platform provides real-time visibility into plant operations and power consumption. Engineering teams can remotely monitor performance, receive control updates and track operational changes instantly. Every optimisation decision taken by the AI server generates notifications and control messages, ensuring complete transparency and traceability. Compared with traditional manual systems, the Chiller Plant Optimiser is expected to deliver energy savings of 15–20% on chiller plant consumption. Based on current estimates, this translates into an annual reduction of 127,500 kg of CO₂ emissions, supporting the hospital’s sustainability and ESG goals.   ]]> https://biospectrumindia.com/news/100/28035/artelus-wins-startup-indias-drishti-healthtech-challenge.html https://biospectrumindia.com/news/100/28035/artelus-wins-startup-indias-drishti-healthtech-challenge.html Sat, 27 Jun 2026 18:13:47 +0530 Bengaluru-based healthcare startup ‘Artelus’ - an AI-based provider of healthtech solutions, aiming to enhance diagnosis and treatment for improved patient outcomes, was recognised as the winner of Startup India’s Drishti HealthTech Challenge, a joint initiative by the Department for Promotion of Industry and Internal Trade (DPIIT) and Roche Pharma India.   Aimed at identifying and supporting healthtech startups in India to develop transformative, scalable solutions for some of the country’s most important health challenges, the Drishti HealthTech Challenge received high-impact applications from 80+ startups working in the areas of digital health.   The Jury comprising of retinal health experts, startup mentors and select members of the Roche India leadership evaluated the applications through a rigorous, multi-stage evaluation criteria focused on problem relevance, impact potential, market readiness, leadership credibility, and regulatory, legal & IP moats.   Artelus emerged as the winner and will receive a financial grant of Rs 35 lakh to co-develop, enhance and pilot its pioneering solution in partnership with Roche Pharma India.   The award ceremony, hosted at the Swiss Embassy in New Delhi in the presence of Maya Tissafi, Ambassador of Switzerland to India and Bhutan, marks another milestone in Indo-Swiss collaboration, driven by Roche's partnership with Startup India and DPIIT to strengthen the healthcare ecosystem in India.     ]]> https://biospectrumindia.com/news/100/27963/autovrse-raises-2-4-m-to-transform-ai-powered-training-for-global-pharma-and-medtech-sectors.html https://biospectrumindia.com/news/100/27963/autovrse-raises-2-4-m-to-transform-ai-powered-training-for-global-pharma-and-medtech-sectors.html Mon, 15 Jun 2026 15:56:24 +0530 Bengaluru-based AutoVRse, India’s fastest-growing industrial AI transformation platform, has announced a $2.4 million funding round, co-led by Singularity AMC's Large Value Fund III and Early Opportunities Fund, and existing investor Lumikai, India's leading interactive media, digital platforms and games VC. AutoVRse deploys VR-based training and smart-glasses-enabled field guidance across pharmaceuticals, medical devices and healthcare. The company serves 500,000+ users at more than 50 enterprise customers across North America, Europe, the GCC and India, including five out of the Top-12 pharmaceutical companies globally (by market cap), one of the largest medical device manufacturers in the world, and several other major companies such as Intas, Abbott, Panasonic etc.  The company's platform, VRseBuilder, works directly with an enterprise's own domain experts — QA leads, cleanroom technicians, clinical applications specialists — to capture their procedural knowledge in a structured, machine-readable format. Every module is authored, reviewed and validated by these subject-matter experts (SME), ensuring that the AI layer is grounded in verified expert knowledge rather than generalised data. The result is an enterprise-grade "AI Brain": a continuously enriched knowledge layer that converts siloed expertise into structured operational intelligence accessible to every technician, field service engineer and researcher — exactly when they need it, in context, and on the device they are using. The new capital raised will be used to fund compliance certifications — critical in regulated healthcare environments operating under GMP, QSR and ISO frameworks — and deepen integrations with customer infrastructure including learning management (LMS) and quality management (QMS) systems. The company also intends to scale its go-to-market in North America, where it is already running deployments with several Fortune 500 companies, and further expand its presence in Europe, the GCC and India. ]]> https://biospectrumindia.com/news/100/27966/pulsus-group-targets-6000-jobs-at-ameenpur-ai-healthcare-hub.html https://biospectrumindia.com/news/100/27966/pulsus-group-targets-6000-jobs-at-ameenpur-ai-healthcare-hub.html Mon, 15 Jun 2026 16:15:10 +0530 PULSUS Group has announced plans to expand its Ameenpur AI Healthcare and Digital Innovation Hub, targeting a workforce of 6,000 direct and 30,000 indirect jobs as it scales operations at the 35-acre campus in Telangana. The move follows a Supreme Court ruling that upheld the project's IT/ITeS and SEZ status, clearing the way for accelerated development and fresh investment. PULSUS is backing its expansion plans with a proven employment record. Parliamentary records under the India BPO Promotion Scheme show that Omics International generated 2,836 direct jobs by March 2022 and is targeting around 6,000 jobs in Visakhapatnam, while supporting an estimated 30,000 indirect jobs. The records also recognise the company's Ameenpur operations, where employment has created about 1,500 of the 6,000 direct jobs. With the legal status recently received from the Supreme Court, PULSUS has fast-tracked plans to scale the Rs 500 crore Ameenpur campus into a major AI healthcare and digital services hub and increase its workforce to 6,000. For Telangana, the project represents another investment in sectors where the state has built a strong presence, particularly information technology, life sciences, healthcare innovation and Global Capability Centres (GCCs). The location near the Miyapur growth corridor is expected to strengthen the region's technology ecosystem while creating employment opportunities for graduates and skilled professionals. Beyond employment generation, PULSUS plans to collaborate with universities, research institutions, healthcare organisations, startups and technology companies to develop an ecosystem supporting innovation, research and global service delivery. The AI Healthcare hub is expected to drive demand for highly skilled professionals, including software engineers, AI specialists, healthcare data scientists, clinical research associates, bioinformatics experts and digital services professionals. ]]> https://biospectrumindia.com/news/100/27953/who-searo-and-george-institute-for-global-health-lay-focus-on-digital-health-and-ai-for-ncds.html https://biospectrumindia.com/news/100/27953/who-searo-and-george-institute-for-global-health-lay-focus-on-digital-health-and-ai-for-ncds.html Sat, 13 Jun 2026 13:26:37 +0530 Recognising the growing burden of non-communicable diseases (NCDs) across the WHO South-East Asia Region and the potential of digital health and AI to strengthen primary healthcare systems, WHO and The George Institute for Global Health, India have signed a Project Collaboration Agreement to strengthen the design, implementation, evaluation, and scale-up of evidence-based digital health and AI interventions for primary healthcare and non-communicable disease prevention and management. Non-communicable diseases account for more than half of all deaths in the Region, with nearly half of these deaths occurring before the age of 70. Yet, primary healthcare systems remain ill-equipped to respond to health workers that are concentrated in urban centres, and treatable conditions frequently go undetected or poorly managed at the community level. The objectives of the collaboration between WHO and The George Institute for Global Health, India are to: Advance implementation science for digital health interventions in primary health care, particularly for NCD prevention and management. Generate real-world evidence on the effectiveness, feasibility, scalability, cost-effectiveness and equity impact of digital health programmes integrated within health systems. Support the development of guidance, frameworks, and tools for designing and implementing AI-powered digital health programmes aligned with WHO digital health strategies. Facilitate knowledge exchange and capacity building through technical workshops, webinars, and collaborative learning platforms for policymakers, researchers, and implementers working on digital health. Strengthen collaboration with ministries of health and global partners to support the integration of digital health innovations into national programmes and health system strategies. Create and disseminate technical guidance, evaluation frameworks, and toolkits for responsible AI deployment in LMIC healthcare systems. Support WHO in convening regional dialogue on ethical AI governance, data privacy, and interoperability standards.   ]]> https://biospectrumindia.com/news/100/27942/ihh-healthcare-collaborates-with-infosys-for-ai-powered-erp-transformation.html https://biospectrumindia.com/news/100/27942/ihh-healthcare-collaborates-with-infosys-for-ai-powered-erp-transformation.html Thu, 11 Jun 2026 16:39:39 +0530 Bengaluru-based tech giant Infosys, a global leader in AI first business consulting and technology services, has announced a strategic collaboration with IHH Healthcare, one of the world’s largest private healthcare providers, to drive a multi year, enterprise wide Enterprise Resource Planning (ERP) transformation programme. This collaboration will enable IHH to standardise and harmonise business processes across all its markets starting with Hong Kong, Malaysia, and Singapore. It will help streamline operations, enhance agility and scalability, optimise costs, and strengthen regulatory compliance. The collaboration brings together Infosys’ AI first capabilities through Infosys Topaz, an AI-first offering powered by generative and agentic AI technologies, to embed intelligence into IHH’s core business workflows. This approach will help IHH unlock AI-powered business value at scale. Infosys will help consolidate IHH’s legacy, siloed ERP landscape by integrating critical functions such as finance, procurement, supply chain, human capital management, and enterprise performance management. As part of this transformation, IHH will gain enhanced real-time data visibility and decision intelligence, strengthening its ability to drive faster, and insight-led decision-making. By establishing a centralised, digital enterprise foundation, Infosys will support IHH’s journey toward a more connected, data-driven, and future-ready healthcare ecosystem. ]]> https://biospectrumindia.com/news/100/27935/remidio-receives-grant-from-gates-foundation-to-advance-maternal-healthcare.html https://biospectrumindia.com/news/100/27935/remidio-receives-grant-from-gates-foundation-to-advance-maternal-healthcare.html Wed, 10 Jun 2026 11:58:05 +0530 Bengaluru-based Remidio Innovative Solutions has received a grant from the Gates Foundation to advance its Oculomics platform, which uses retinal imaging and AI to detect signs of systemic disease, for maternal health applications in low- and middle-income countries (LMICs). The initiative will focus on improving early risk assessment for major pregnancy complications, including pre-eclampsia (PE), anemia and gestational diabetes mellitus (GDM). The program will be carried out across countries in Africa and India, regions that together bear the overwhelming share of the global maternal and perinatal disease burden. "The women most at risk from pre-eclampsia and gestational diabetes are often the least likely to reach a laboratory or a specialist in time," said Dr Anand Sivaraman, Chief Executive Officer and Founding Director, Remidio. "A retinal image takes seconds and can be captured by a frontline worker with minimal training. This grant allows us to ask a clear question with real rigour: can the platform already deployed widely for diabetic retinopathy also help identify pregnancies at risk, in the places where that information is needed most." The biological link between retinal microvascular changes and systemic vascular and metabolic disease is now well established. Yet in the primary care and community settings where maternal mortality is concentrated, the diagnostic tools that currently support early risk stratification, namely complex laboratory assays, biochemical biomarkers and Doppler-based assessments, are largely unavailable at the point of care, requiring laboratory infrastructure, trained personnel and referral pathways that simply do not exist for most pregnant women in LMICs. Non-invasive retinal imaging, by contrast, is quick, easy to perform by frontline health workers with minimal training, and inherently scalable, making it uniquely suited to bringing advanced risk assessment to the front lines of antenatal care. Remidio's portable, smartphone-based retinal imaging platform is already widely deployed across primary care and community screening programmes for diabetic retinopathy, glaucoma and AMD. The grant will extend this platform into maternal health, with implementation across partner sites in Africa and India. ]]> https://biospectrumindia.com/news/100/27937/oval-fertility-inks-mou-with-merck-to-strengthen-reproductive-care-standards-in-india.html https://biospectrumindia.com/news/100/27937/oval-fertility-inks-mou-with-merck-to-strengthen-reproductive-care-standards-in-india.html Wed, 10 Jun 2026 15:03:38 +0530 At a time when access to high-quality reproductive treatment remains limited, Oval Advanced Fertility Care and Merck Specialities, the Indian healthcare arm  of Merck KGaA, Darmstadt, Germany, and a global leader in fertility sciences with decades of scientific leadership in reproductive medicine, have signed a strategic Memorandum of Understanding (MoU).  The collaboration aims to enhance access to advanced fertility care by strengthening clinical capabilities, improving transparency and patient experience, and driving more predictable, high-quality outcomes through integrated expertise, technology, and data-led approaches. India's IVF market, valued at approximately $2.35 billion in 2024, is projected to reach $5.03 billion by 2034, growing at a compound annual growth rate of 7.9 per cent. However, market growth alone does not ensure better outcomes for patients, and the collaboration aims to address the disconnect between rapid market expansion and consistent treatment standards. This collaboration seeks to address the gap between growth and consistent standards of care by combining scientific expertise, digital innovation, patient support frameworks, and clinical capability building to improve both access and treatment outcomes. Veena Reddy, Co-Founder & Director, Oval Fertility, said, "The partnership with Merck brings together shared values around transparency, clinical excellence, and putting the patient at the centre of every decision." Pratima Reddy, Managing Director, Merck Specialities Private Limited, said, “Fertility care in India is evolving rapidly, with patients seeking greater transparency, a more seamless experience, and stronger confidence in outcomes. As a leader in IVF, Merck is well positioned to partner with progressive care providers to address these expectations through an integrated approach, combining clinical expertise, advanced technologies, and data-driven insights." With a longstanding legacy in reproductive healthcare, Merck brings deep expertise across fertility treatments, IVF technologies, and clinical education, supporting healthcare professionals in delivering evidence-based fertility care.  Oval Advanced Fertility Care is backed by GVK, one of India's most established business conglomerates, and is led by an internationally acclaimed medical team. ]]> https://biospectrumindia.com/news/100/27926/10-countries-come-together-to-draw-up-roadmap-for-global-south-on-responsible-ai.html https://biospectrumindia.com/news/100/27926/10-countries-come-together-to-draw-up-roadmap-for-global-south-on-responsible-ai.html Tue, 09 Jun 2026 19:12:28 +0530 Under India's BRICS Presidency 2026, the Indian National Science Academy (INSA) recently organised the first meeting of the BRICS Science Academy Forum 2026. The virtual forum on the theme "Using AI for Sustainable Development and Strengthening Global South Cooperation" will feature 10 countries- Brazil, China, Egypt, Ethiopia, Indonesia, Russia, South Africa, Belarus. The science academies of Nigeria and Vietnam – participated to advance a joint declaration on responsible and equitable AI development. The participating academies presented targeted recommendations to make the declaration more effective: China (Chinese Academy of Sciences) called for collaborative AI readiness criteria, scientific data-sharing frameworks, open-source infrastructure, and responsible AI evaluation mechanisms addressing bias, reliability, and local context Egypt (ASRT) emphasised the potential of AI for food security, healthcare, education, energy, and climate change, and called for greater investment in research, capacity building, and equitable AI deployment Indonesia emphasised the role of AI in disaster risk management, mitigating climate change, early warning systems, reduction of greenhouse gases, and sustainable agriculture. Ethiopia advocated higher education and research partnerships, as well as dedicated cooperation on cybersecurity, digital security and combating cross-border cybercrime Vietnam proposed the establishment of joint task forces, thematic working groups, and shared digital public infrastructure with joint training programs to address the gaps in AI skills Nigeria emphasised the importance of advancing the applications of AI for scientific innovation, governance, and national development priorities South Africa discussed the role of AI for future generations, expressed concerns about cost and social science dimensions, and supported open-source AI models Belarus emphasised the responsible use of AI, with a special emphasis on healthcare innovation, data security, and advanced cybersecurity measures in the AI era The suggestions made in the meeting will be incorporated in the revised manifesto. Dr Brajesh Pandey, Executive Director, Indian National Science Academy announced that delegations from BRICS countries and partner countries will gather in person for the second meeting on 22-23 July 2026 at IIT Hyderabad, where the declaration is expected to be finalised.   ]]> https://biospectrumindia.com/news/100/27930/fujifilm-india-announces-first-installation-of-ai-powered-digital-mammography-system-at-nm-medical.html https://biospectrumindia.com/news/100/27930/fujifilm-india-announces-first-installation-of-ai-powered-digital-mammography-system-at-nm-medical.html Tue, 09 Jun 2026 22:19:45 +0530 Fujifilm India, a leader in advanced diagnostic imaging solutions, has announced the installation of its latest AI Powered Digital Mammography System, AMULET SOPHINITY at NM Medical, Mmbai. India’s healthcare ecosystem is witnessing a growing emphasis on preventive healthcare and early disease detection, particularly in women’s health. According to estimates from the Indian Council of Medical Research, National Cancer Registry Programme, breast cancer is projected to remain the leading cancer among women in India, with over 2.32 lakh cases estimated in 2025.   As timely screening continues to play a critical role in enabling early diagnosis and improving clinical outcomes, rising awareness, expanding access to diagnostic services, and increasing adoption of advanced imaging technologies are further accelerating the need for clinically reliable, patient-friendly, and workflow-efficient mammography solutions across healthcare institutions in the country.Designed with a strong focus on patient comfort, diagnostic precision, and workflow efficiency, AMULET SOPHINITY represents Fujifilm’s next-generation mammography platform built around the philosophy of “Sophisticated Features. Human Comfort.”   The system integrates advanced AI-enabled technologies, high-definition imaging capabilities, and ergonomically designed patient-centric features to support radiologists and technologists in delivering accurate, efficient, and comfortable breast imaging experiences.Further strengthening workflow efficiency and positioning accuracy, the system integrates Fujifilm’s REiLI Medical AI technologies, including Intelligent AEC for optimised dose management based on breast composition, Positioning MAP for reproducible positioning support, and AI-driven Positioning Analysis tools that assist technologists in continuously improving imaging quality and consistency.The AMULET SOPHINITY platform also features a compact, space-saving footprint through integrated system architecture, enabling easier deployment across high-throughput hospitals, diagnostic centres, and space-constrained imaging environments. Its streamlined workflow design, user-friendly operation console, and rapid quality control tools further support operational efficiency and reliable clinical performance. ]]> https://biospectrumindia.com/news/100/27885/medielaj-raises-100k-to-bring-ai-powered-healthcare-kiosks-to-underserved-regions.html https://biospectrumindia.com/news/100/27885/medielaj-raises-100k-to-bring-ai-powered-healthcare-kiosks-to-underserved-regions.html Mon, 01 Jun 2026 16:42:34 +0530 India's healthcare technology landscape has taken a significant step forward with the official launch of MediElaj, an AI-powered healthcare app and smart diagnostic kiosk and mobile app platform developed by MedPredict. The Faridabad-based startup has raised approximately $100,000 from friends and family. In parallel, the founders have also bootstrapped and invested nearly $500,000 into building the company’s technology platform, AI healthcare ecosystem, kiosk infrastructure, and operational capabilities. The company is building a connected healthcare ecosystem that utilises smart healthcare kiosk and mobile app to deliver at-home, AI-assisted health screenings and non-invasive health measurements, provide conversational assistance for healthcare issues, and offer access to digital health records. The funds have enabled product development, kiosk prototyping, integrating healthcare devices and sensors, cloud architecture and software development, preparation for pilot deployments, and building a research and operational foundation for scalable growth. MediElaj's kiosks combine AI-assisted health screening, non-invasive diagnostics, conversational healthcare guidance, and digital health records, bringing intelligent healthcare support directly to communities in smaller towns and rural regions, without requiring patients to travel to urban centres. The company is now preparing to build its manufacturing capabilities for scalable production, establish nationwide deployment capacity, advance its AI technologies and cybersecurity infrastructure, and develop partnerships to form a healthcare ecosystem that reaches Tier 2, Tier 3, rural, and underserved markets. ]]> https://biospectrumindia.com/news/100/27887/teen-neuroscience-researcher-adya-anubhuti-turns-adhd-struggles-into-startup-innovation.html https://biospectrumindia.com/news/100/27887/teen-neuroscience-researcher-adya-anubhuti-turns-adhd-struggles-into-startup-innovation.html Mon, 01 Jun 2026 17:00:15 +0530 University of California, Davis, freshman Adya Anubhuti is balancing neuroscience research, community advocacy, and startup leadership. Her latest AI startup venture, ADHD Copilot, is an AI-powered platform designed to reduce stress and mental overload for people with Attention Deficit Hyperactivity Disorder (ADHD). Within months of launch, the free to sign-up ADHD Copilot gained strong traction with 3,500+ followers and a curated platform of 50+ top-rated AI tools for the ADHD community. The platform is designed to redefine how technology supports and interacts with non-linear minds. ADHD Copilot is a centralised hub that integrates more than 50 AI applications and productivity resources into one interface. At its center is a conversational Artificial Intelligence (AI) system that helps users categorise tools, structure workflows, and receive personalised support for executive functioning challenges such as task paralysis, overwhelm, and focus. ADHD is a neurodevelopmental condition most often diagnosed in childhood, though symptoms frequently persist into adulthood. It combines challenges with attention such as distractibility, forgetfulness, and difficulty focusing with hyperactivity and impulsivity, including restlessness, fidgeting, and acting without thinking. “What’s been most validating is the response,” Adya noted. “We have built a community of over 3,500 people who connect with our blend of humor, honesty, and actionable systems that reflect real ADHD experiences.”   ]]> https://biospectrumindia.com/news/100/27878/sanofi-launches-ai-powered-rare-disease-pre-diagnosis-tool-in-india.html https://biospectrumindia.com/news/100/27878/sanofi-launches-ai-powered-rare-disease-pre-diagnosis-tool-in-india.html Fri, 29 May 2026 13:25:24 +0530 In a country where a patient with a rare disease waits too long before receiving a correct diagnosis, Sanofi has announced the India launch of AccelRare®, an artificial intelligence (AI)-powered digital pre-diagnosis tool designed to transform the way healthcare professionals diagnose rare diseases; and dramatically reduce the time it takes for patients to access life changing treatment. The launch marks a defining moment in Sanofi's ambition to become the first pharmaceutical company powered by artificial intelligence at scale, deploying AI not just in laboratories and clinical trials, but directly at the point of care, where the distance between a patient and a diagnosis can mean years of suffering. Co-developed and validated by 67 rare disease experts across 13 rare disease networks, AccelRare® is built on MedVir™, which is certified as a Class I medical device in Europe. In India, AccelRare® is approved as a web-based pre-diagnostic tool for suspected rare diseases and classified as a Class A (non-sterile and non-measuring) medical device. It is available free of charge, requires no registration, is highly secure and collects no patient identification data, making it as accessible as it is powerful. Dr Mayur Shah, Head of Rare Diseases Business, Sanofi India said, "Behind the word 'rare' lies a staggering reality. An estimated 72-96 million people in India are living with a rare disease2, and by the time many receive an accurate diagnosis, irreversible damage may already have occurred. AccelRare® is our call to transform compassion into concrete action, democratizing rare disease expertise and putting the diagnostic intelligence of 50 world class specialists into the hands of every doctor in every corner of India." ]]> https://biospectrumindia.com/news/100/27838/zenmd-brings-ai-clinical-intelligence-to-india.html https://biospectrumindia.com/news/100/27838/zenmd-brings-ai-clinical-intelligence-to-india.html Fri, 22 May 2026 16:15:04 +0530 ZenMD, an India-focused clinical AI platform built for doctors and healthcare institutions, has announced its official launch in India, marking its entry into one of the world’s fastest-growing healthcare ecosystems. Designed specifically for the realities of Indian clinical practice, ZenMD brings a unified AI layer across documentation, diagnostics, and decision support to help doctors save time, improve accuracy, and focus more on patient care. The platform introduces four core products, ZenScribe, ZenNotes, ZenConsult, and ZenScan, each addressing critical challenges faced by clinicians in high-volume healthcare environments. From real-time voice-to-clinical documentation and automated OPD notes to evidence-based clinical decision support and AI-powered medical imaging analysis, ZenMD provides an integrated ecosystem that supports over 80 medical specialties. The platform is designed as a “clinical intelligence layer” that works seamlessly across workflows, offering real-time, validated outputs for everyday use in hospitals and clinics . “India’s healthcare system operates under immense pressure, where doctors are expected to make fast, accurate decisions while managing significant administrative workloads,” said Rithika Reddy, Founder and CEO of ZenMD. “We built ZenMD to act as a reliable clinical co-pilot—one that understands the nuances of Indian healthcare and supports doctors at the point of care. Our goal is to bring both speed and safety into every patient interaction.” ZenMD features a proprietary hallucination correction layer that verifies every AI-generated response before it reaches clinicians, strengthening trust and reliability in healthcare AI. The platform has already gained early traction across hospitals and medical institutions, recording over 60,000 users and 90,000 page views within weeks of launch. Tailored for Indian healthcare settings, the platform combines workflow integration, clinical-grade validation, multilingual support, and specialty-specific intelligence to help reduce doctors’ administrative burden.   ]]> https://biospectrumindia.com/news/100/27833/annora-pharma-expands-collaboration-with-ai-native-traceability-platform-altiushub.html https://biospectrumindia.com/news/100/27833/annora-pharma-expands-collaboration-with-ai-native-traceability-platform-altiushub.html Tue, 19 May 2026 12:17:19 +0530 Annora Pharma, the formulations subsidiary of Hetero Group and a leading Indian pharmaceutical manufacturer, has expanded its collaboration with AltiusHub. The company is deploying AltiusHub’s AI-native serialisation, track & trace, and regulatory compliance platform across its export operations. The deployment is designed to improve serialisation efficiency by up to 45%. It will also strengthen operational visibility across Annora Pharma’s global supply chain. The rollout supports compliance across key export markets, including the US, EU, GCC, LATAM, and ASEAN regions. Annora Pharma aims to achieve real-time visibility across 100% of serialized drug products within three months. This visibility will span the full journey from packaging line to export dispatch. The unified platform replaces fragmented legacy systems. It supports serialization, aggregation, and multi-market regulatory reporting. It also integrates with Annora Pharma’s Level 3 packaging infrastructure. AltiusHub’s AI-driven analytics and automated exception management help improve operational efficiency. They also accelerate issue resolution and strengthen compliance oversight across markets. The rollout reflects a broader shift in the pharmaceutical industry. Manufacturers are moving away from fragmented and vendor-dependent serialization systems. They are now adopting unified platforms that offer better control, faster implementation, and stronger supply chain visibility. The deployment has already resulted in faster serialization processing and improved packaging floor productivity. It has also enhanced real-time visibility across export supply chains. These capabilities are becoming critical as pharmaceutical manufacturers respond to evolving regulatory mandates and increasing supply chain complexity. AltiusHub has also supported pharmaceutical traceability requirements for public health supply programs serving African markets under global healthcare initiatives.   Image caption- (Left to Right) Siddharth Reddy, Managing Director of AltiusHub, and Bhaskar Reddy, Director at Hetero Group ]]> https://biospectrumindia.com/news/100/27818/archimedis-digital-strengthens-focus-on-advanced-ai-led-innovation-with-2-m-investment.html https://biospectrumindia.com/news/100/27818/archimedis-digital-strengthens-focus-on-advanced-ai-led-innovation-with-2-m-investment.html Thu, 14 May 2026 20:15:46 +0530 Chennai-based Archimedis Digital, a life sciences-focused technology company, is strengthening its focus on advanced artificial intelligence (AI)-led innovation with a committed investment of $2 million. These investments are directed at accelerating AI-first scientific solutions and products, including but not limited to histopathology and cancer diagnosis. The investment aligns with the growing demand for intelligent systems that can improve speed, accuracy, and predictability across the life sciences value chain. As part of this broader push, Archimedis Digital is deepening its engagement with industry and academic ecosystems to expand its innovation capabilities. The company’s association with NVIDIA’s startup ecosystem reflects its alignment with advanced AI infrastructure and development frameworks, enabling it to build and scale solutions more effectively for enterprise use cases. This comes at a time when Archimedis Digital is already part of the Stanford Seed Transformation Programme, a highly selective initiative designed to support high-potential startups in emerging economies, positioning the company to align its AI investments and strategic partnerships with its long-term growth roadmap. Through this engagement, the company is enabling itself to scale sustainably while accelerating innovation across its core focus areas, in line with its broader strategic growth plans. Archimedis Digital is advancing its life sciences strategy through a strong focus on AI-led cancer diagnosis and its ConnectX integration, with added momentum from its collaboration with NVIDIA. ConnectX addresses the industry’s “connectivity gap” by unifying fragmented systems such as ERP, QMS, LIMS, and legacy infrastructure into a seamless, non-disruptive digital layer using custom IoT and AI, creating a real-time data backbone for predictive insights and optimized operations. Furthermore, Archimedis Digital’s active investement into AI-led cancer diagnosis capabilities enable faster and more precise analysis of complex molecular and diagnostic data, accelerating early detection and research timelines. The integration of ConnectX with advanced AI infrastructure further strengthens scalability and performance, positioning the company to deliver high-impact, compliant innovation across diagnosis, discovery, and manufacturing.   ]]> https://biospectrumindia.com/news/100/27796/healthquad-invests-in-lifesigns-to-advance-ai-led-predictive-patient-monitoring.html https://biospectrumindia.com/news/100/27796/healthquad-invests-in-lifesigns-to-advance-ai-led-predictive-patient-monitoring.html Tue, 12 May 2026 14:27:00 +0530 HealthQuad, the growth venture arm of Quadria Group focused on backing new-age healthcare models, has announced its latest investment in LifeSigns, India’s leading artificial intelligence (AI) powered remote patient monitoring platform. Chennai-based startup LifeSigns is using AI to build a new layer of care that detects early signs of deterioration, enables timely clinical decisions, and ultimately saves lives.With deployment across tier 2 cities, an occupancy-based frugal pricing model and easy-to-scale solution, LifeSigns is driving access to high-quality healthcare where it is most needed.    For HealthQuad, this represents a high conviction investment in the next wave of healthcare innovation, where AI delivers measurable clinical impact at scale. As LifeSigns’ first institutional investor, HealthQuad brings more than just capital. Backed by Quadria’s global healthcare ecosystem, the partnership will focus on two key priorities for LifeSigns: international expansion across Southeast Asia and the GCC and strengthening its AI-led technology stack through selective integrations. The global remote patient monitoring devices market stands at $26 billion in 2025 as health systems globally are shifting from episodic care toward continuous, decentralised monitoring. LifeSigns has developed an integrated, US-FDA approved continuous monitoring platform that integrates a medical grade wearable, cloud dashboard, and predictive AI engine. It operates across the care continuum, from ambulances and emergency rooms to ICUs, wards, and home care. The platform tracks key vitals including ECG, heart rate, respiration, temperature, blood pressure, and oxygen saturation. Its AI engine can detect early signs of deterioration up to 26 hours in advance and flag critical risk within a four-hour window, enabling timely intervention. Across more than 50 leading hospitals in India, LifeSigns has delivered over 87,000 life-saving alerts, reduced code blue incidents by nearly 90 percent, and lowered ICU readmissions by close to 78 percent. Its central monitoring command center enables scalable remote surveillance and helps address structural challenges. ]]> https://biospectrumindia.com/news/100/27800/laxmi-dental-introduces-worlds-first-ai-connected-platform-for-remote-dental-monitoring.html https://biospectrumindia.com/news/100/27800/laxmi-dental-introduces-worlds-first-ai-connected-platform-for-remote-dental-monitoring.html Tue, 12 May 2026 15:03:45 +0530 Mumbai-based Laxmi Dental has announced the launch of ‘i Scope360’, a fully integrated artificial intelligence (AI)-connected remote dental monitoring ecosystem that combines aligner tracking, oral health assessment, and virtual consultations into one connected platform. The launch is aimed at solving some of the biggest operational, accessibility, and patient engagement challenges currently faced by the dental industry while making dental care more convenient, connected, and scalable for both clinics and consumers. Developed and manufactured in India using dental-grade materials, the platform is designed to support digitally connected treatment workflows for both Indian and global clinical requirements. The company estimates that i Scope360 can help reduce physical follow-up visits by up to 30–50% and improve treatment compliance by nearly 20–30% through remote monitoring, virtual supervision, and connected patient engagement. Built around three integrated modules, iTrack, iHealth, and iTrack Live, the platform enables patients to upload guided scans through their smartphones while allowing dentists to monitor treatment progress, assess oral health concerns, and conduct virtual consultations remotely. The platform is designed to improve treatment visibility, monitoring continuity, and communication between clinics and patients throughout the treatment journey. The dental industry continues to face challenges including fragmented workflows, delayed interventions, inconsistent patient compliance, dependence on physical clinic visits, and limited access to specialist-led digital dentistry across several regions. Patients also experience gaps related to appointment scheduling, travel requirements, limited visibility into treatment progress, and missed follow-ups. i Scope360 has been introduced to address these gaps through digitally connected monitoring and communication workflows. ]]> https://biospectrumindia.com/news/100/27792/american-medtech-firm-zimmer-biomet-opens-gcc-in-bengaluru.html https://biospectrumindia.com/news/100/27792/american-medtech-firm-zimmer-biomet-opens-gcc-in-bengaluru.html Mon, 11 May 2026 16:20:58 +0530 US-based Zimmer Biomet has opened its Global Capability Centre (GCC) in Bengaluru. This GCC will serve as a high-velocity hub for digital transformation, integrating the company’s nearly century-long heritage in musculoskeletal health with India’s digital engineering ecosystem.  By embedding its digital future within India’s premier talent ecosystem, the company is future-proofing its operations, ensuring it possesses the agility and technological prowess required to lead the next era of personalised, robotic-assisted healthcare. The GCC will focus on developing the next generation of patient-monitoring software; streamlining procurement and supply chain for the APAC market; and accelerating the development of AI-driven surgical platforms. The firm is aggressively pushing the boundaries of AI and robotics, highlighted by the regulatory clearance of ROSA® Knee with OptimiZe™, the most advanced upgrade to its flagship robotic system, and its comprehensive digital care platform, ZBEdge.   ]]> https://biospectrumindia.com/news/100/27778/indiaai-partners-with-icmr-to-boost-ai-adoption-in-healthcare.html https://biospectrumindia.com/news/100/27778/indiaai-partners-with-icmr-to-boost-ai-adoption-in-healthcare.html Fri, 08 May 2026 14:00:10 +0530 India AI and the Indian Council of Medical Research (ICMR) have signed a Memorandum of Understanding (MoU) to accelerate responsible AI adoption in healthcare. The Ministry of Electronics and Information Technology said that the partnership marks a significant step towards advancing healthcare outcomes through the responsible and scalable application of Artificial Intelligence. The MoU establishes a structured framework for collaboration, bringing together IndiaAI’s technology infrastructure and AI ecosystem capabilities with ICMR’s deep domain expertise in biomedical research and public health. Under this collaboration, both institutions will leverage their complementary strengths, IndiaAI’s compute infrastructure, dataset platforms, and AI skilling initiatives alongside ICMR’s biomedical research expertise and its Medical Information Data for AI Solutions (MIDAS) framework. ]]> https://biospectrumindia.com/news/100/27763/iit-guwahati-launches-one-of-its-kind-m-tech-degree-programme-in-robotics-and-ai.html https://biospectrumindia.com/news/100/27763/iit-guwahati-launches-one-of-its-kind-m-tech-degree-programme-in-robotics-and-ai.html Wed, 06 May 2026 14:01:13 +0530 Indian Institute of Technology (IIT) Guwahati has launched a unique M. Tech. degree programme in Robotics and Artificial intelligence (AI), designed for both fresh graduates and working professionals aiming to enhance their skills on AI-driven robotics systems. Offered by the School of Interdisciplinary Studies and Sustainability, this degree programme will be conducted in hybrid mode (online classes, with on-campus labs and final exams on IIT Guwahati campus). The programme is designed to bridge multiple engineering disciplines for development in sectors such as agriculture, defense, manufacturing, healthcare, transportation, and smart infrastructure, among others. The minimum duration of the programme will be 2 years, with the flexibility to extend it to a maximum of 5 years allowing the students to balance their studies and professional commitments. Throughout the programme, the students will be able to visit the IIT Guwahati campus to connect with experts, gain hands-on training in various relevant fields, and receive support from faculty members for their project work. The programme will also give students a chance to work on real-world problems with industry experts after completing the core courses. Students will be required to use their knowledge in practical situations, get hands-on experience, and build problem-solving skills relevant to actual industry challenges. ]]> https://biospectrumindia.com/views/100/27728/accelerating-ais-role-in-biopharma-innovation.html https://biospectrumindia.com/views/100/27728/accelerating-ais-role-in-biopharma-innovation.html Fri, 01 May 2026 00:00:00 +0530 AI is expected to address these structural challenges across the R&D value chain. It can reduce early-stage failures, predict biological relevance, and shorten discovery timelines, with quantifiable, industry-validated impact. The technology can cut preclinical R&D costs significantly, driven by improvements in target selection, virtual screening, and molecule property prediction. Discovery cycles are likely to become more efficient, shrinking from years to months. Across the drug lifecycle, lower costs and shorter development cycles are expected, varying by molecule complexity and degree of enterprise AI adoption. AI can also accelerate regulatory submissions by automating data compilation across internal and external sources. It can enhance quality by anticipating regulator queries and embedding responses upfront. Transforming Drug Discovery AI is shifting drug discovery from traditional trial-and-error to computation-led, in silico pipelines. Modern approaches integrate computer-aided drug design (CADD), molecular docking, physics-based simulations, and deep-learning–driven generative models to evaluate vast chemical spaces rapidly. Machine learning (ML) enables ultra-large virtual screening of millions of molecules in days, predicts drug target interactions with high precision, and optimises molecular properties. This computational acceleration has powered breakthroughs such as AI-generated Parkinson’s candidates exploring novel disease modifying pathways.  Personalising Precision Medicine AI has become the analytical backbone of precision medicine, integrating genomic sequences, clinical histories, radiology, pathology, and patient-level phenotypes into unified predictive frameworks. This multimodal fusion enables highly individualised treatment pathways. In oncology, advanced AI agents using multimodal tools are achieving pinpoint accuracy in tool usage and clinical decision-making, outperforming standard models. AI models such as DeepMind’s AlphaFold are transformative for precision medicine and oncology. It provides accurate protein structure predictions, allowing researchers to understand disease-driving mutations, design personalised therapeutics, and model protein-to-protein interactions at patient-specific mutation sites. Optimising Clinical Trials  Organisations are leveraging AI to enhance patient recruitment, improve site selection, forecast trial outcomes, design dosage schedules for patients, and predict adverse effects—transforming how clinical trials run. AI-powered monitoring makes trials faster, safer, and more efficient. The implications are important: clinical development accounts for a major portion of the total drug development costs, making it by far the most expensive stage. Gains in clinical trials will guide the economics of bringing new drugs to market. Augmenting Regulatory Workflows Regulators are increasingly accepting AI-generated evidence and advanced data-analytics outputs, marking a major shift in regulatory science. AI now automates protocol reviews, flagging inconsistencies, missing elements, eligibility misalignments, and statistical design flaws before human review. This reduces early development timelines by several weeks and prevents costly amendments. Equally significant is AI-driven document generation, where models trained on regulatory schemas can automatically compile clinical study reports and investigator brochures, enabling generation of submission-ready dossiers. Enabling Smart Manufacturing  AI ensures predictive quality control, reduces batch failures, and optimises pharmaceutical production. Smart manufacturing systems powered by AI and Internet of Things (IoT) allow continuous monitoring of critical process parameters, flagging deviations in real time before they escalate and predicting equipment failures before they occur. Digital twins help teams simulate and optimise process conditions without interrupting live production. In supply chains, AI forecasts demand, prevents stockouts, and improves medicine distribution across global networks. AI-enabled track-and-trace systems go beyond traditional serialisation, using ML to monitor end-to-end product movement across manufacturing sites, distribution hubs, cold-chain routes, and international borders. They deliver real-time visibility of product location, temperature, and chain of custody, while instantly detecting diversions, counterfeits, or cold-chain breaches. Driving Enterprise-Scale Transformation Biopharma is rapidly shifting from scattered, one-off AI pilots to integrated, enterprise-wide operating models that embed computation intelligence into every stage of the drug lifecycle. Organisations are building unified data fabrics, model hubs, and reusable AI services connecting discovery, development, manufacturing, regulatory, and commercial teams. AI is becoming the backbone of end-to-end R&D, powering in silico target discovery, generative molecule design, AI-orchestrated clinical trials, real-time manufacturing optimisation, and predictive commercial analytics. A case in point is the landmark Eli Lilly–Insilico Medicine deal. Valued around $2.7-$2.8 billion, the deal signals pharma’s growing trust in AI-generated drug candidates. Insilico’s AI platform identifies targets, designs and molecules and predicts biological behaviour, accelerating early-stage R&D. Eli Lilly’s investment validates AI as a credible enabler and engine for drug discovery. Scaling Global Biopharma Innovation: India’s Role India’s role in global biopharma innovation is being reshaped as multinational pharma companies increasingly establish Global Capability Centers (GCCs) in the country to drive AI-led drug discovery, digital clinical development, and advanced analytics. India’s life sciences & healthcare GCC sector is expected to grow significantly in the coming years, with global drug makers relying on these hubs for AI-powered discovery, clinical trial analytics, regulatory operations, and commercial insights.  This reflects a broader change: India is moving beyond its identity as a high-volume, low-cost generic manufacturer to a strategic contributor to computational R&D and biologics innovation. India’s pharma industry is now integrating GenAI, AI/ML, and large-scale data platforms to shorten drug development timelines. It is no longer the ‘pharmacy of the world’; it is strengthening its position as a co-innovation engine, shaping next-generation therapeutics, biologics, and AI-driven R&D for global markets. Building Guardrails for Meaningful Impact As AI continues to reshape biopharma innovation, its true impact will depend on technological capability as well as on the guardrails that govern its use. While operational readiness to scale AI in R&D is key, getting the organisational culture right is crucial because AI requires people to make it work properly, a point sometimes lost amid talk of technological advances. It is also imperative to build AI and data platforms to establish the R&D foundation and own the infrastructure and knowledge needed to gain long-term strategic advantage from AI. Ensuring data integrity, regulatory alignment, model transparency, and ethical deployment will be essential to realising AI’s full potential across the drug discovery and development lifecycle while maintaining trust of patients and regulators.    Atul Kurani, Vice President, Global Head for Medical Practice & IoT, Capgemini Engineering ]]> https://biospectrumindia.com/news/100/27733/cn-water-drives-key-ai-conversations-at-pharmacore-india-2026-in-mumbai.html https://biospectrumindia.com/news/100/27733/cn-water-drives-key-ai-conversations-at-pharmacore-india-2026-in-mumbai.html Mon, 27 Apr 2026 00:00:00 +0530 CN Water will be upgrading its digital lifecycle platform, CNtinel, with artificial intelligence (AI)-driven extensions, adding a strong layer of decision intelligence to pharma water system operations. The company showcased some of its key AI use cases at the recently held PharmaCore India, in Mumbai, from April 24-26. Water system operations in pharmaceutical plants are inherently complex, with high consequences of error, fragmented knowledge across manuals, SOPs, logs, and SCADA systems, and constant real-time decision pressure on engineers. CN Water is investing in proprietary AI technologies to help engineers and site teams quickly understand and respond to plant conditions in real time.  By bringing together live system data, historical trends, operating procedures, and past incidents, the extended AI capabilities will help enhance key operational processes such as: Blending operational data with domain expertise to improve water quality, uptime, and system reliability Offering well-informed guidance on key operational issues to expedite resolution, improve plant performance and minimise downtime Reducing the risk of human error arising from fragmented data, reliance on individual experience, and trial-and-error in plant-specific contexts CNtinel is a purpose-built digital platform for water system lifecycle management, combining remote monitoring, paperless maintenance, cost optimisation and workforce efficiency into a unified system. With the strengthening of its AI layer, CNtinel is evolving into a foundational layer for intelligent, connected, and performance-driven water system operations. ]]> https://biospectrumindia.com/news/100/27737/archimedis-digital-expands-ai-centre-of-excellence-in-tiruchirappalli-.html https://biospectrumindia.com/news/100/27737/archimedis-digital-expands-ai-centre-of-excellence-in-tiruchirappalli-.html Mon, 27 Apr 2026 00:00:00 +0530 Archimedis Digital, a life sciences-focused IT services company, has announced a significant expansion of its AI-led capabilities with the scaling of its AI Centre of Excellence (CoE) in Tiruchirappalli, Tamil Nadu, alongside an ambitious plan to double its workforce over the next 12 months. This strategic move underscores the company’s focus on building deep AI expertise tailored to the life sciences sector, even as global demand shifts toward intelligent, data-driven systems across pharma, biotech, and medical devices. The Tiruchirappalli-based AI CoE has been established as a dedicated hub for artificial intelligence, machine learning, and data science innovation, supporting the development of next-generation digital platforms and AI-led solutions for global clients. The centre is already witnessing rapid scale-up, with a strong pipeline of AI-driven projects across pharmacovigilance, regulatory compliance, and digital transformation initiatives in life sciences. Archimedis Digital currently operates with a workforce of approximately 250–300 employees, with a majority based in Chennai and a fast-growing team in Tiruchirappalli. The company plans to double its headcount within the next year, with hiring heavily skewed toward AI and data-centric roles. Notably, around 50% of new hires will bring expertise in AI, machine learning, and data science, while the remaining workforce will strengthen domain capabilities across life sciences and core engineering. The company is actively tapping into high-potential talent pools beyond traditional metros, focusing on candidates from diverse socio-economic backgrounds and investing in structured training to build specialised capabilities. ]]> https://biospectrumindia.com/news/100/27716/karnataka-govt-approves-rs-20-cr-coe-for-ai-in-biotechnology-at-electronics-city-bengaluru.html https://biospectrumindia.com/news/100/27716/karnataka-govt-approves-rs-20-cr-coe-for-ai-in-biotechnology-at-electronics-city-bengaluru.html Fri, 24 Apr 2026 00:00:00 +0530 The IT BT Department, Karnataka Government, continues to strengthen the state’s deep-tech ecosystem with the approval of a Rs 20 crore Centre of Excellence (CoE) for artificial intelligence (AI) in Biotechnology at Electronics City, Bengaluru.Implemented over 4 years in collaboration with Institute of Bioinformatics and Applied Biotechnology (IBAB) and Centre for Cellular and Molecular Platforms (C-CAMP), the initiative will accelerate innovation at the intersection of AI and life sciences. The AI Centre will offer labs, tools and expertise to help startups and researchers grow faster and build better products. This initative will strengthen the state's research ecosystem, accelerate innovation, and enable Karnataka to lead in high-impact, next-generation technologies.   ]]> https://biospectrumindia.com/news/100/27714/page-and-8chili-partner-to-launch-indias-first-ai-and-vr-powered-pharma-training-platform.html https://biospectrumindia.com/news/100/27714/page-and-8chili-partner-to-launch-indias-first-ai-and-vr-powered-pharma-training-platform.html Thu, 23 Apr 2026 00:00:00 +0530 The Pharmaceutical Academy for Global Excellence (PAGE), an initiative of the Indian Pharmaceutical Alliance (IPA), has announced a strategic partnership with 8chili Inc. to launch India’s first artificial intelligence (AI) and virtual reality (VR) powered training platform for pharmaceutical manufacturing. The collaboration aims to address the industry’s shortage of job-ready talent in quality, production, and regulatory roles as India targets $130 billion in pharmaceutical growth by 2030. The initiative also reflects a broader shift in the industry toward technology-enabled workforce development, as global regulators place increasing emphasis on demonstrable shop-floor competence, training rigor, and data integrity. By introducing immersive and AI-driven training at scale, PAGE and 8chili aim to establish a new benchmark for industry-led pharma education in India. By integrating 8chili’s HintVR immersive learning library with the SkillsForge AI platform, PAGE will move from classroom-based instruction to a continuous, industry-grade capability model. Learners will be able to interact with intelligent digital twins of real machines, SOPs, and manufacturing processes, enabling hands-on experience before entering a live plant. The platform will support PAGE’s flagship programmes for both fresh graduates and practising professionals. Deployment begins immediately, and the technologies will form a core component of PAGE’s upcoming state-of-the-art training facility in Ahmedabad, scheduled to open in 2027. ]]> https://biospectrumindia.com/news/100/27706/omron-healthcare-and-tricog-health-strengthen-collaboration-in-india-with-tricog-cardiocheck.html https://biospectrumindia.com/news/100/27706/omron-healthcare-and-tricog-health-strengthen-collaboration-in-india-with-tricog-cardiocheck.html Wed, 22 Apr 2026 00:00:00 +0530 OMRON Healthcare Co., a global leader in clinically proven medical devices for home health monitoring and treatment, has announced the integration of its ECG-enabled upper arm blood pressure monitors with Tricog Health’s clinically validated AI-powered cardiac triage service, Tricog CardioCheck (TCC). The service is scheduled for rollout at health centers across India from April 2026. Tricog CardioCheck (TCC) enables ECG data recorded using OMRON Healthcare’s Complete™ blood pressure monitors with integrated ECG monitoring to be transmitted to the cloud and analyzed by Tricog’s AI algorithms. Within approximately 10 seconds, the system provides a three-level risk assessment, supporting patient triage and timely clinical evaluation. Results are displayed via a dedicated smartphone application designed for healthcare professionals, allowing front-line care providers to review patient risk levels in real time and quickly determine the need for further examination, even where a cardiology specialist is not immediately available. Since its initial investment in Tricog in fiscal year 2023, OMRON Healthcare has continued to strengthen its partnership with the company in order to address key healthcare challenges in India. Through ongoing collaboration, both companies aim to expand access to innovative diagnostic solutions and contribute to improving cardiovascular health outcomes across the country. ]]> https://biospectrumindia.com/news/100/27696/ils-hospitals-partners-with-medlern-to-transform-healthcare-workforce-learning.html https://biospectrumindia.com/news/100/27696/ils-hospitals-partners-with-medlern-to-transform-healthcare-workforce-learning.html Tue, 21 Apr 2026 00:00:00 +0530 GPT Healthcare, operator of ILS Hospitals, has announced a strategic partnership with MedLern, an AI-enabled digital learning platform for healthcare. The collaboration marks a significant step in ILS Hospitals’ digital transformation journey, reinforcing its commitment to clinical quality, operational excellence, and patient outcomes. As healthcare delivery in India grows more complex, the need for continuous upskilling has become critical. Through this partnership, ILS Hospitals will embed structured, role-specific, and measurable learning into daily operations across clinical and non-clinical teams. MedLern’s platform will enable deployment of curated clinical content, real-time competency tracking, and continuous learning across nurses, clinicians, and administrative staff. Its phygital training modules combining physical and digital simulation are designed to support excellence in fast-paced healthcare environments. The platform will be implemented across ILS Hospitals’ facilities in Kolkata (Dumdum, Howrah, and Salt Lake), as well as Agartala and Raipur. In the first phase, it will cover thousands of clinical and non-clinical employees, with plans for network-wide expansion in subsequent phases as part of GPT Healthcare’s broader digital transformation roadmap.   ]]> https://biospectrumindia.com/news/100/27697/medprime-solves-manual-pathology-bottlenecks-with-launch-of-cilika-ai.html https://biospectrumindia.com/news/100/27697/medprime-solves-manual-pathology-bottlenecks-with-launch-of-cilika-ai.html Tue, 21 Apr 2026 00:00:00 +0530 Incubated at Society for Innovation and Entrepreneurship (SINE), Indian Institute of Technology (IIT) Bombay, Medprime Technologies has announced the launch of CILIKA AI, a modular software ecosystem designed to enhance diagnostic precision through assistive intelligence. The platform debuts with its first specialised module, CILIKA AI Retic, which automates the traditionally labor-intensive process of reticulocyte counting. Developed as an intelligent assistant, CILIKA AI is engineered to support the pathologist's expertise. The software highlights and displays the count of candidate cells on digital images of blood samples, allowing laboratory professionals to maintain final diagnostic authority while significantly reducing manual fatigue. Reticulocyte counts are used by clinicians as vital indicators of bone marrow activity, essential for monitoring anemia, oncology recovery, and treatment responses. However, manual counting remains a slow, subjective, and labor-intensive bottleneck for many labs. In traditional manual microscopy, pathologists must identify and count immature red blood cells across multiple fields of view. This process is inherently subjective, leading to high inter-observer variability where different experts may produce different results for the same sample. Furthermore, the repetitive nature of manual counting causes significant visual and mental fatigue, which increases the risk of human error and overlooked cells, potentially impacting clinical decisions. CILIKA AI Retic addresses these clinical pain points by moving from subjective manual counting to AI-assisted detection of immature red blood cells via supravital staining; processing multiple fields of view (FOVs) and generating comprehensive reports in minutes; and enabling small to mid-sized labs to perform advanced hematological analysis without the need for expensive, dedicated automated analysers.   ]]> https://biospectrumindia.com/news/100/27688/deeptek-deepc-announce-integrated-radiology-ai-partnership.html https://biospectrumindia.com/news/100/27688/deeptek-deepc-announce-integrated-radiology-ai-partnership.html Mon, 20 Apr 2026 00:00:00 +0530 Pune-based startup DeepTek, provider of the Augmento platform and deepc, a German company behind deepcOS®, have introduced a fully integrated artificial intelligence (AI) operating environment designed to enable healthcare providers to deploy, manage, and scale clinical AI as a unified system. As healthcare systems move beyond isolated AI pilots, the core challenge is no longer access to algorithms, but the ability to operationalise multiple solutions within a governed, scalable clinical framework. This requires infrastructure, orchestration, and AI solutions to function as a single, coherent system rather than a patchwork of disconnected tools, and governance blind spots. The combined deepc–DeepTek environment addresses this directly. By tightly integrating deepcOS® and Augmento, the solution provides a single operational layer for deployment, orchestration, and governance of multi-vendor AI, enabling healthcare providers to scale AI across workflows without fragmentation or duplication of infrastructure. This integrated approach is particularly relevant for advanced healthcare systems, where providers are actively transitioning from pilot use cases to enterprise-wide AI deployment across clinical workflows, and where the need for consistent governance and scalable infrastructure is most pronounced. Rather than introducing additional layers or standalone tools, the integrated system allows healthcare providers to: ● Deploy and manage multiple AI solutions through a single environment ● Maintain centralised governance, monitoring, and control of AI performance ● Scale AI across clinical workflows without rebuilding infrastructure ]]> https://biospectrumindia.com/news/100/27675/indiaai-startups-global-acceleration-programme-selects-10-startups-for-second-batch.html https://biospectrumindia.com/news/100/27675/indiaai-startups-global-acceleration-programme-selects-10-startups-for-second-batch.html Fri, 17 Apr 2026 00:00:00 +0530 As part of its continued commitment to advancing India's AI capabilities across the globe, IndiaAI Mission under the Ministry of Electronics and Information Technology, has announced the selection of 10 cutting-edge Indian AI startups for the second batch of the IndiaAI Startups Global Acceleration Programme, an international initiative developed in partnership with Station F, Paris, and HEC Paris. The programme aligns with India's National AI Strategy, which emphasises cross-border knowledge exchange, engagement with advanced entrepreneurial ecosystems, and global market integration. By facilitating access to international markets, fostering innovation, and attracting global investment, this initiative supports India's vision of becoming a leader in AI-based solutions. Selected Startups for ISG Batch II AI Health Highway India: AI-enabled smart stethoscope to screen, identify and predict cardiovascular and respiratory disorders Aviros: A Vision AI platform that enables genital, context-aware intelligence and automation in large-scale physical environments. Cognecto: An AI Infrastructure Intelligence Platform Flaunt: Multimodal AI Agent for Beauty/Fashion Trends and Short-Form Video Marketing GreenFI.ai (ClimateForce Technologies): AI-enabled risk management software for environmental, social, and governance compliance Infiheal HealthTech : Hilo, is a multilingual AI mental health companion that features human intervention. Inlastro Learning : An AI-powered job simulation platform that verifies the execution readiness of humans and AI agents before deployment in the real world. Predco: AI-powered compliance for modern manufacturing in the field of human resources, process and product SkyServe (HiSpace Technologies): AI infrastructure for Earth and space surveillance TestAING Solutions: A comprehensive QA and compliance suite for AI solutions, ensuring reliable and responsible AI. These 10 startups have been selected through a rigorous multi-stage selection process and will represent India's dynamic AI innovation ecosystem at Station F, where they have been empanelled in an intensive program to help them expand globally. The programme consists of a 3-week online preparation module followed by a three-month intensive residential programme in Paris, France. ]]> https://biospectrumindia.com/news/100/27645/jaslok-hospital-launches-clinical-study-to-enable-ai-based-prediction-of-parkinsons-freezing-episodes.html https://biospectrumindia.com/news/100/27645/jaslok-hospital-launches-clinical-study-to-enable-ai-based-prediction-of-parkinsons-freezing-episodes.html Sun, 12 Apr 2026 00:00:00 +0530 Jaslok Hospital & Research Centre, Mumbai, has launched a pioneering artificial intelligence (AI) project aimed at predicting Freezing of Gait (FOG) in Parkinson’s disease. Patients often experience a sudden inability to initiate or continue walking, describing the sensation as if their feet are “glued to the floor.” This leads to frequent falls, injuries, progressive loss of independence and a significant caregiver burden, affecting up to 80% of patients with advanced Parkinson’s disease. Despite this high prevalence and impact, no definitive treatment is currently available. Although emerging research suggests that structured motor and cognitive training may delay onset, clinical practice still lacks reliable tools to identify individuals at risk or to determine when the condition may emerge. Most existing predictive approaches rely on clinical scoring systems, imaging biomarkers or biochemical tests, which are often expensive, resource-intensive and largely confined to specialised research settings. Besides none of the tool can definitely predict at individual level if one would develop freezing of gait in the course of disease. The proposed AI-based system under this collaboration addresses this gap by introducing a dual approach that estimates both the likelihood of FOG and its probable time to FOG, enabling earlier clinical intervention and more targeted preventive planning.  The unique aspect of time to FOG is being explored for the first time. This has been possible due availability of longitudinal clinical and video data over 25 years of more than 750 patients who have undergone DBS surgery at Jaslok Hospital and Research Centre. The system is designed around a simple yet highly scalable framework that analyses routine video recordings of a patient’s walking pattern. It will use computer vision and machine learning techniques to identify subtle changes in gait and body coordination that may signal early vulnerability to freezing episodes. Since the approach does not rely on specialised wearable devices or high-cost diagnostic infrastructure, it is intended for deployment across hospitals, outpatient clinics and telemedicine platforms, including resource-limited settings. To ensure clinical robustness, the research has been structured in two distinct phases. The first phase focuses on model development using retrospective clinical data and video recordings from more than 150 Parkinson’s patients who developed Freezing of Gait during long-term follow-up. The second phase will validate the model prospectively in a cohort of 337 patients followed over a period of up to three years. The long-term objective of this initiative is to develop an open-access and user-friendly AI application that enables clinicians to identify at-risk patients early, estimate likely onset timelines, introduce preventive interventions at the right stage, and ultimately reduce falls, disability and overall disease burden while improving quality of life for patients and caregivers. ]]> https://biospectrumindia.com/news/100/27636/mlhealth360-partners-with-madhya-pradesh-govt-to-pilot-ai-driven-radiology-solutions-.html https://biospectrumindia.com/news/100/27636/mlhealth360-partners-with-madhya-pradesh-govt-to-pilot-ai-driven-radiology-solutions-.html Thu, 09 Apr 2026 00:00:00 +0530 Bengaluru-based startup mlHealth360 has signed a Memorandum of Understanding (MoU) with the Government of Madhya Pradesh to introduce artificial intelligence (AI)-enabled radiology solutions across public healthcare facilities in the state. This strategic collaboration aims to strengthen diagnostic capabilities by improving accuracy, reducing reporting delays, and enabling faster, more informed clinical decision-making in real-world healthcare settings. As part of the initial phase, the solution will be deployed across ten district hospitals, serving as a pilot for potential statewide expansion based on performance and learnings. The initiative brings together advanced AI-led diagnostics with existing hospital infrastructure, ensuring seamless integration with systems such as PACS and RIS while maintaining continuity in clinical workflows. It also enables the use of data-driven insights to support more informed public health planning and resource allocation. At the core of the deployment is mlHealth360 proprietary Scaida AI platform, which is designed to detect and triage abnormalities in CT scans, provide real-time decision support to clinicians, and assist in generating standardized, consistent reports. The platform is built for scalability, with cloud-based deployment, remote expert connectivity, and data residency within India, making it well-suited for high-volume, resource-constrained environments. The initiative is expected to significantly improve patient outcomes by enabling early and accurate diagnosis of critical conditions such as stroke, hemorrhage, trauma, and tumors. AI-driven prioritisation of cases will help clinicians focus on urgent cases more effectively, while access to specialist-level insights within district hospitals will reduce dependency on referrals to tertiary care centres. The rollout will take place in a phased manner over the coming months, beginning with site readiness, followed by system integration and clinician training, and culminating in full operational deployment and evaluation.    ]]> https://biospectrumindia.com/news/100/27620/astrazeneca-india-signs-mou-with-telangana-govt-to-bring-ai-powered-lung-cancer-screening-to-public-hospitals.html https://biospectrumindia.com/news/100/27620/astrazeneca-india-signs-mou-with-telangana-govt-to-bring-ai-powered-lung-cancer-screening-to-public-hospitals.html Tue, 07 Apr 2026 00:00:00 +0530 AstraZeneca Pharma India has signed a Memorandum of Understanding (MoU) with the Government of Telangana to introduce artificial intelligence (AI)-enabled lung cancer screening across public healthcare facilities in the state. The collaboration aims to strengthen early detection and improve outcomes for patients in both urban and rural areas. Lung cancer is among the most pressing public health challenges in India today. National incidence is projected to rise from approximately 63,700 cases in 2015 to over 81,200 by 2025, a 27% increase over the decade, driven by tobacco use, environmental pollution, and critically, the near absence of routine screening.  Telangana reflects these national pressures acutely. The state is projected to record 46,762 new cancer cases among adults in 2026, rising to 47,314 by 2030, an estimated 13% increase by 2027. Women bear a disproportionate share, with 25,510 new cases expected this year against 21,252 in men.  Under the MoU, AstraZeneca will facilitate the deployment of Qure.ai's AI-powered chest X-ray solution to be integrated into routine workflows at public health facilities across Telangana. The technology helps clinicians flag the high-risk pulmonary nodules, a predominant precursor of lung cancer along with 29 other lung conditions. The high-risk patients will be triaged for lung cancer confirmation or future follow up to ensure stage-shift of lung cancer at diagnosis. A similar model has already been adopted in Goa, Tamil Nadu, and Karnataka.  The initiative is expected to roll out across 20 public health facilities, covering urban and rural health systems. It includes training and upskilling of healthcare professionals to support effective and sustainable adoption, as well as infrastructure enhancements where needed to ensure seamless integration into the public health system. ]]> https://biospectrumindia.com/news/100/27616/aiims-partners-with-medisim-vr-to-drive-adoption-of-vr-skill-training-in-medical-education.html https://biospectrumindia.com/news/100/27616/aiims-partners-with-medisim-vr-to-drive-adoption-of-vr-skill-training-in-medical-education.html Mon, 06 Apr 2026 00:00:00 +0530 Chennai-based MediSim VR has announced its partnership with the All India Institute of Medical Sciences (AIIMS), New Delhi, to integrate its AI-enabled Virtual Reality (VR) solutions into medical and nursing education.  This collaboration represents a strategic milestone in advancing research on the integration of VR-based skill training within India’s medical education curriculum. As India’s leading academic and research home for medicine, AIIMS has consistently set the standards for excellence in healthcare education and training. Through this partnership, AIIMS and MediSim VR will jointly research and evaluate how VR can be embedded into the medical and nursing curriculum, studying its impact on skill development, standardisation, and long-term adoption. This collaborative effort reinforces AIIMS’ role as the benchmark institution for advancing new methods of medical learning in India. Dr M Srinivas, Director, AIIMS, New Delhi, said, speaking at the launch event stated, “If the country as a whole is to be in the best league, that has to extend to all spheres, including medical innovations, medical teaching, training and learning as well. VR-based simulation training allows for a learning environment where you are immersed and exposed to all things you will experience in a clinical setting. This collaboration enables us to further study how immersive technologies can contribute to skill development, assessment and training standardisation.” Dr Adith Chinnaswami, COO and co-founder of MediSim VR, added, “When AIIMS adopts a teaching tool, it sends a strong signal across the medical education ecosystem. This collaboration is centred around creating a framework where VR becomes part of standard training, and eventually, part of regulations." ]]> https://biospectrumindia.com/news/100/27605/gabify-raises-175000-in-pre-seed-funding-round-to-advance-ai-driven-neurodevelopmental-care.html https://biospectrumindia.com/news/100/27605/gabify-raises-175000-in-pre-seed-funding-round-to-advance-ai-driven-neurodevelopmental-care.html Thu, 02 Apr 2026 00:00:00 +0530 Delhi-based health-tech startup Gabify, a platform dedicated to solving neurodevelopmental challenges in children, has raised $175,000 in a pre-seed funding round led by Inflection Point Ventures.  The startup has also been awarded Rs 25 lakh under the Nidhi Seed Support Scheme by GHRTBI (G H Raisoni Technology Business Incubator Foundation), a government-backed initiative that supports early-stage startups with high innovation potential. The capital raised will be strategically deployed towards clinical validation, technology enhancement, and team expansion, key priorities aimed at accelerating growth and building a sustainable revenue model. Gabify is part of the 4th cohort of IPV IdeaSchool, an exclusive cohort-based incubator programme designed for Pre-Seed to Seed-stage startups. Having successfully conducted 5 cohorts so far, the programme has supported a strong pipeline of emerging startups. The startup is India's first fully hosted speech and neurodevelopmental condition SaaS ecosystem. Gabify has an end-to-end AI screening and therapy platform specifically designed for speech and neurological disorders such as Autism and ADHD.  Gabify's use of dual-AI (voice + vision) provides a comprehensive view of the child's speech patterns as well as facial expressions, eye gaze, and behaviours based on 189+ clinically validated criteria that are aligned with DSM-5 and CARS. The system employs a human-in-loop (HITL) approach for clinical validation to review all AI-based clinical outputs to ensure they are accurate and reflect expert professional input. Although the model has been designed for Bharat but has the potential to be scaled globally considering that it is multilingual, low bandwidth, and suited to rural communities.     ]]> https://biospectrumindia.com/news/100/27606/gaudium-ivf-introduces-ai-led-infertility-treatment.html https://biospectrumindia.com/news/100/27606/gaudium-ivf-introduces-ai-led-infertility-treatment.html Thu, 02 Apr 2026 00:00:00 +0530 Gaudium IVF, an innovation leader and a pioneering force in India’s fertility healthcare sector, has introduced artificial intelligence (AI)-led infertility treatment, marking yet another industry first—just one month after becoming India’s first publicly listed IVF chain.   The development involves the integration of advanced AI-driven embryology systems, including SiD (Sperm Identification Device) and ERICA (Embryo Ranking Intelligent Classification Assistant), into routine clinical practice.    This integration has been undertaken in collaboration with IVF 2.0, a UK-headquartered embryology innovation organisation founded by renowned embryologists Dr Jacques Cohen and Dr Alejandro Chave. This partnership brings globally advanced embryology intelligence into the Indian clinical ecosystem.   Commenting on the development, Dr Manika Khanna, Chairperson and Managing Director, Gaudium IVF, said, “Fertility care is entering a new era where precision and intelligence will define outcomes. By integrating AI into infertility treatment, Gaudium IVF is not only improving success rates but also bringing greater predictability, transparency, and trust to the patient journey. Our collaboration with IVF 2.0 ensures that global innovations are now accessible to patients within India.”     Early clinical observations suggest that the integration of these AI systems can significantly improve fertilisation and blastocyst development rates. By improving precision and consistency, the adoption of AI has the potential to reduce the need for repeat cycles, thereby lowering the emotional, physical, and financial burden on patients while inspiring confidence among clinicians and stakeholders.    ]]> https://biospectrumindia.com/features/100/27567/ai-takes-india-pharma-reins.html https://biospectrumindia.com/features/100/27567/ai-takes-india-pharma-reins.html Wed, 01 Apr 2026 00:00:00 +0530 AI may be the buzzword of the moment, but in reality it represents a structural shift rather than a standalone technology. It is emerging as an enabling layer across the pharmaceutical value chain — from drug discovery and clinical development to manufacturing and patient engagement. While AI is widely touted as transformative for the pharma industry, its adoption is not without caveats. There are several ifs and buts around data quality, regulatory expectations, integration with legacy systems, talent readiness, validation standards, and cultural acceptance. The promise is significant, but real impact will depend on how thoughtfully and responsibly the technology is implemented. On the sidelines of three big events related to the pharma sector recently viz, AI India Impact Summit in New Delhi, BioAsia 2026 in Hyderabad and IPA Summit in Mumbai, pharma stalwarts all agreed to one fact that embracing AI is the only option as it will not only help the sector rise to newer heights but also make people gain more knowledge and work faster. However, a few experts gave a worrying outlook where questions on the job at stake lingered. While concerns around employment continue to surface in industry discussions, the broader consensus among experts is that AI adoption is no longer optional. Beyond the headlines and speculation, the real driver for adoption lies in the tangible advantages AI offers across research, development, regulatory processes, and manufacturing operations. Understanding why companies are investing heavily in AI provides greater clarity on the sector’s long-term strategic direction.   Why leverage AI? AI has a huge role to play in the pharma industry. Ranging from drug discovery, a formulation scientist's assistant, a manufacturing optimiser, a clinical trial accelerator, a regulatory tool, a safety surveillance system etc, AI is being touted as a game changer for the pharma sector. Generative AI and molecular simulation tools can explore chemical space orders of magnitude faster than bench chemistry allows, and the first AI-designed drug candidates have already entered human clinical trials.  On one hand where the industry loses enormous value to late-stage trial failures that could potentially have been predicted earlier, AI has a much larger role to play. Even the FDA published draft guidance in 2025 on using AI to support regulatory decision-making for drug and biological products. AI-assisted literature review, benefit-risk modelling, and labelling are becoming part of the submission workflow.  As the potential of AI becomes clearer, leaders across India’s pharmaceutical ecosystem are increasingly outlining how these technologies could reshape the way companies operate. Several senior executives emphasise that while the opportunity is enormous, successful adoption will depend on organisational readiness, workforce transformation, and a willingness to rethink traditional ways of working.    What the pharma stalwarts are saying? Pharma stalwarts while being optimistic about the role of AI that needs to be embraced also urged the need to upskill the workforce. According to Dilip Shanghvi, Executive Chairman, Sun Pharmaceutical Industries, there is an enormous opportunity to look at AI. He mentioned using AI to identify the root causes, for identifying the right CAPA (Corrective and Preventive Action). “We can immediately embrace it and it will help us make our product more consistently and also possibly at much better cost. All of this level requires a change in culture,” says Shanghvi. Adding to it, Sharvil Patel, Managing Director, Zydus Lifesciences & President, Indian Pharmaceutical Alliance (IPA), says “Everyone will have to find new skill sets, new skilling capabilities, new ways of doing things, new ways of using knowledge rather than brute force and repetitiveness. You have to go AI tech with the enterprise mindset. AI will completely revolutionise ERP systems. So, AI will truly transform the manufacturing sector and other sectors all around. We all have to get re-skilled, including at the very top. These will lead to significantly better efficiencies in terms of speed and time to do a manufacturing process including technology.” Lilly has made significant investments in this space and recently opened a new centre in Hyderabad dedicated to technology and AI. According to Winselow Tucker, Senior Vice President and Chief Commercial Officer, Loxo Oncology, Lilly, AI is accelerating innovation across the pharmaceutical value chain. The real question is not just how quickly we can innovate, but how we can bring that innovation to market in a way that delivers a more personalised experience for patients. Sudarshan Jain, Secretary General, Indian Pharmaceutical Alliance (IPA) emphasises that AI represents affordable innovation at scale, and embarking on that journey could be a transformative starting point for India’s pharmaceutical sector. While the industry continues to strengthen quality standards and manufacturing capabilities—areas where quick wins are possible—he stressed that the larger priority must be advancing affordable innovation. Nilesh Gupta, Managing Director, Lupin mentions, “To unlock India’s healthcare potential, we must innovate relentlessly. By placing AI at the forefront of transformation, India can redefine global manufacturing standards and emerge as a healthcare leader by 2047.”While providing his outlook on AI, Madan Mohan Reddy, Whole-Time Director at Aurobindo Pharma, shares that global credibility—particularly with regulators—must be continuously reinforced rather than taken for granted. The adoption of AI is set to become inevitable. Sustaining operational continuity without AI will be difficult highlighting that regulators increasingly demand greater data transparency and tighter oversight.” He argued that manufacturing must transition to fully digital systems, where real-time analytics replace manual, retrospective reviews. While industry leaders highlight the importance of adopting AI, the responsibility of preparing the next generation of professionals also falls on academic institutions and specialised training bodies. Universities and skill-development platforms are increasingly integrating AI into their curricula to ensure that future pharmacists and researchers are equipped to work in an AI-enabled healthcare ecosystem.   Role of institutions For India, which supplies roughly 20 per cent of the world's generic medicines, getting AI-enabled Quality by Design right is not just an academic interest; it is a supply chain imperative.  JSSAHER JSS College of Pharmacy, Mysuru is engaging students with AI as a support tool for future pharmaceutical research. The institute has established a dedicated AI Unit within JSS College of Pharmacy. A white paper was also released covering responsible AI in pharmacovigilance, Software as a Medical Device, biomarkers, and data governance. That is not the output of an institution that is tentatively exploring AI. The institute has revised the pharmacy curriculum to include AI, ensuring that the graduates are equipped for the evolving landscape of medicine.  Says, Dr TM Pramod Kumar, Dean, Faculty of Pharmacy & Principal, JSS College of Pharmacy, JSS Academy of Higher Education & Research (JSSAHER), “Our curriculum reforms, industry partnerships, AI Unit, and research collaborations are all oriented toward producing graduates who will not merely survive the AI transition but will drive it. We believe the pharmacy profession, with its unique combination of clinical knowledge, drug expertise, and patient-centered care, is exceptionally well positioned to assume leadership roles in the AI-enabled healthcare ecosystem of tomorrow.” Similarly Pharmaceutical Academy for Global Excellence (PAGE), an initiative of the Indian Pharmaceutical Alliance, being promoted by 13 top pharma companies, has been formed with the objective of setting up a worldclass, cutting edge institute to provide state-of-the-art training to fresh pharmacy graduates and existing employees of leading pharma companies, thereby promoting a culture of manufacturing and quality excellence. At present, PAGE is developing various courses based on virtual reality (VR), where participants will have the chance to: Explore equipment and processes in immersive environments, undergo SOP training with gamification elements, experience post training assessments enhanced by AI. Dr Pranav Jogani, Professor Consultant, Pharmaceutical Academy for Global Excellence (PAGE) mentions, "We are seeing great potential of AI in the area of post training assessment. With the help of AI, we will generate dynamic scenarios to test participants in real time. I see great potential for AI in addressing concerns in critical areas such as data integrity, compliance, and patient safety. I would like to see AI applied more and more in preventing errors, ensuring real-time quality assurance, and supporting workforce training and knowledge." Beyond workforce training, industry analysts are also observing a deeper structural shift taking place across the pharmaceutical ecosystem. Strategic reports and research studies suggest that AI is not only improving individual processes but is fundamentally reshaping how innovation, manufacturing, and supply chains interact within the industry.   Reshaping speed and decision-making EY-Parthenon India launched its latest report “Pharma’s New Architecture: Where Novel Science Meets AI and Manufacturing Power” at Bio Asia 2026. The report highlighted that the industry is moving beyond incremental product development toward platform-led innovation models that integrate discovery science, AI-native R&D, advanced manufacturing and resilient supply chains into unified systems. Elaborating more on the report, Suresh Subramanian, National Lifesciences Leader, EY Parthenon India said, “Indian biopharma is undergoing a structural reset. Scientific breakthroughs alone are no longer enough. The winners will be those who integrate discovery, AI-native intelligence and manufacturing into disciplined, repeatable platforms. The shift from one-off products to reusable engines – from mRNA and CRISPR to AI-driven design stacks – is redefining speed, reliability and scale. It is about building systems that compound learning and consistently deliver therapies to patients. This will help India pivot to large molecules and new modalities where the larger opportunities moving forward will emerge.” During Bio Asia 2026, Shakthi Nagappan, CEO, Telangana Lifesciences said that the life sciences sector is being reshaped by a deeper integration of biology and digital technologies. He mentions, “As research becomes more data-intensive, AI and advanced analytics are helping bridge the gap between discovery and real-world application — accelerating insight while maintaining scientific rigour. This shift extends beyond R&D into clinical development and manufacturing, creating more coordinated and resilient systems.”  At the same time, technology providers are developing practical AI-driven platforms designed to address everyday operational challenges in pharmaceutical manufacturing and compliance. These solutions aim to simplify workflows, reduce human errors, and improve regulatory readiness.   Simplifying pharma manufacturing AI powered platform Leucine simplifies pharmaceutical manufacturing, making it faster, fully compliant, and always audit-ready. The company helps to streamline workflows, reduce errors, and achieve lasting excellence in pharma production. LeucineOS connects 16 applications across the manufacturing compliance workflow - from batch execution through cleaning validation, training, environmental monitoring, deviation management, change control, and quality release - on a single data platform with purpose-built AI agents that operate inside the compliance context. Vivek Gera, CEO, Leucine mentions, “The pharmaceutical industry is right to be excited about AI. The technology is genuinely transformative. AI that generates a report which a human must then act on adds a step. Most pharmaceutical manufacturers are trying to layer AI on top of fundamentally disconnected systems. The result is a copilot that accelerates paperwork - not an agent that prevents compliance failures.” CitiusTech brings healthcare ready AI to pharma and health organisations by combining deep clinical and operational expertise with advanced data, cloud, and engineering capabilities. The AI platform CitiusTech Knewron helps teams work faster and smarter with copilots, taskspecific agents, clinical information extraction, automated testing, and more than 100 healthcare accelerators. Says Srinath Rao, EVP, CitiusTech, "We expect to see deeper use of agent‑driven automation, domain‑specific models, and policy‑aware AI systems that work reliably in real clinical and operational settings. Healthcare and pharma will increasingly rely on AI systems that can interpret multimodal data, encode clinical and regulatory knowledge, and work safely within high‑stake environments. The shift will come from understanding entire value chains rather than building disconnected use cases."  Despite these technological advancements, the rapid adoption of AI has also sparked anxiety among sections of the pharmaceutical workforce. Concerns around automation and potential job losses continue to surface in industry discussions and conferences.   Will AI reduce employment opportunities Panic has set in among the major work force in the pharma sector. With random Chinese whispers and a few sections of the industry openly announcing that AI will gobble up jobs has raised eyebrows among many. At one of the pharma conferences held in Mumbai, one expert was critical about jobs being taken away by AI.  That AI will transform and not eliminate pharmaceutical employment is what should ponder over.  Routine, high-volume, and repetitive tasks such as manual data entry in pharmacovigilance case processing, literature screening, MedDRA coding, and basic quality checks will increasingly be automated.  Pharmacists and scientists can focus their expertise toward complex clinical decision-making, safety signal interpretation, regulatory strategy, and patient engagement—activities where human judgment, ethical reasoning, and contextual knowledge remain irreplaceable. And all these can be achieved when an employee can embrace AI, get more educated on recent AI tools and keep a positive outlook. According to Amit Sheth, Founding Director, India AI Research Organisation (IAIRO) & Professor, University of South Carolina, the pharma sector is one of the highest R&D-investing industries globally. The value creation potential is enormous, and AI can have an immediate and measurable impact.” Sheth outlined three priorities:  First, to create world-class AI talent in India. Second, to generate original intellectual property and move rapidly from research to products. Third, to work with startups and corporations to create near-term economic impact. Historically, technological shifts in pharma — from automation in manufacturing to digital clinical trials — have led to role evolution rather than large-scale displacement. This according to Joydeep Ghosh, Life Sciences & Healthcare Industry Leader, Deloitte India will increasingly move toward higher-value analytical roles, cross-functional digital capabilities and human-AI collaboration models over the next 10–20 years. The key will be reskilling and upskilling to ensure talent evolves alongside technology.   Ghosh adds, “The principal challenge is availability of data on several fronts, in the right quality, quantity, granularity and timeliness. One example is fragmented healthcare data, which is scattered across different healthcare providers, laboratories, insurance companies, and pharmaceutical companies. The data is often stored in different legacy systems with limited interoperability.” Beyond workforce concerns, another major challenge for AI adoption lies in organisational readiness. Many pharmaceutical companies are experimenting with AI tools, but integrating them into existing processes, governance structures, and decision-making frameworks remains a significant hurdle.   Organisational readiness The reality is that most pharma companies are already leaning heavily into AI, but the real bottleneck is not the technology, it is organisational readiness. Legacy workflows, siloed data structures, and traditional team models were never designed for AI-native ways of working.  Says Dr Purav Gandhi, Founder and CEO, Healthark, “The challenge today is less about adopting AI tools and more about reorienting processes, governance, and talent structures to embed AI seamlessly into day-to-day decision-making. The transition will not happen overnight, but over a 10 to 20 year horizon it will become deeply integrated into how organisations operate. Importantly, history tells us that such shifts do not necessarily eliminate jobs, they reshape them. When ATMs were introduced, there was widespread fear that bank jobs would disappear. Instead, banks evolved, routine tasks were automated, and employees moved to higher value, relationship-driven and advisory roles.” Taken together, the perspectives of industry leaders, analysts, academic institutions, and technology providers point to a common conclusion: AI is not merely another digital tool but a foundational shift in how the pharmaceutical industry will operate in the future.   Embracing AI holds the key On how quickly and deliberately Indian pharma can use AI to shift from world's largest supplier by volume to its most valuable innovation hub.People will need to get reskilled. According to experts, future plants will have less human interaction and AI will have a major role to play. One has to build the capability to manage future compliance. Adopting the capability will lead India to become the most trusted manufacturing powerhouse. Sanjiv Dassanjiv.das@mmactiv.com ]]> https://biospectrumindia.com/features/100/27569/how-global-alliances-are-powering-indias-ai-healthcare-innovation.html https://biospectrumindia.com/features/100/27569/how-global-alliances-are-powering-indias-ai-healthcare-innovation.html Wed, 01 Apr 2026 00:00:00 +0530 Through collaborations with governments, multinational technology companies, global health organisations, and international research institutions, India is now leveraging artificial intelligence (AI) to build new solutions and address healthcare challenges. As AI continues to reshape healthcare worldwide, India’s collaborative approach is positioning it as a key global hub for AI healthcare innovation. Marking a significant step towards strengthening cooperation in AI-based healthcare between India and France, Union Minister for Health & Family Welfare, J P Nadda and Emmanuel Macron, President of the French Republic inaugurated the Indo French Centre for AI in Health (IF-CAIH) at the All India Institute of Medical Sciences (AIIMS), New Delhi, during Macron’s recent visit to India, along the lines of the India AI Impact Summit 2026. The IF-CAIH is a pioneering initiative aimed at advancing AI-driven research, medical education and clinical innovation to address complex healthcare challenges. It has been established pursuant to a Joint Memorandum of Understanding (MoU) signed between AIIMS New Delhi, Sorbonne University and Paris Brain Institute.  AIIMS New Delhi has also entered into a partnership with Germany’s TU Dresden to drive innovation in surgery through AI and deep-tech solutions, focusing on translational research, clinical application of digital technologies, and joint startup incubation to develop cost-effective, next-generation tools for surgical care. India and Germany are also currently collaborating for the development of AI-based diagnostic systems designed to provide faster, more precise, and highly accurate care for animal health. Likewise, India and the Netherlands have collaborated in health-tech and AI, with both countries focusing on digital health, remote monitoring, and AI-powered solutions, particularly developed by companies in Karnataka. Further, India has joined the HealthAI Global Regulatory Network (GRN), collaborating with international regulators including European partners to develop safe and responsible AI governance frameworks for healthcare. Another recent development has been made when University of Toronto’s President Melanie Woodin met with Indian officials at an innovation-focused event in Mumbai, earlier in March 2026. University of Toronto and the Indian Institute of Science (IISc), Bengaluru have agreed to develop a centre of excellence that uses AI to build predictive healthcare systems, to improve early diagnosis, enhance clinical decision-making and expand equitable access to medical services. Looking at the US, Google has announced a new round of investments and partnerships to expand its AI footprint in India, adding to its previously announced $15 billion plan to establish an AI hub in Visakhapatnam. Under the new plan, Google DeepMind is collaborating with Anusandhan National Research Foundation to provide AI-for-science models; and generative AI tools are being integrated into over 10,000 schools through Atal Tinkering Labs under NITI Aayog’s innovation mission.  On the other hand, Apollo Hospitals has partnered with Microsoft to integrate AI and digital transformation into healthcare delivery, to focus on co-innovation, research, and the development of advanced healthcare solutions. Key areas of work include disease progression, genomics, and multi-modal models. In addition, Microsoft is investing $3 billion in cloud and AI infrastructure in India over the next two years, including the establishment of new data centres. Australia is another key collaborator for India to leverage complementary strengths in AI. For instance, Andhra Pradesh government has launched the Bharat Biodesign Research and Innovation (BRAIN) programme, with the APAC Biodesign Alliance, and Stanford Biodesign (USA), along with the AIM Foundation of the University of Western Australia, to accelerate AI-powered affordable healthcare and medical technology innovation. Simultaneously, in a significant step towards strengthening Australia–India cooperation in the field of AI, Deakin University, Australia, and the Department of Information Technology, Electronics and Communications (ITE&C), Government of Telangana have collaborated in multiple areas including healthcare, among others. At the industry level, TeleMedC, an Australia-based leader in artificial intelligence (AI)-powered retinal disease diagnostics is expanding its footprint in India, through a strategic partnership with Mumbai-based startup AND Healthcare Solutions to deliver low-cost, AI driven eye screening solutions to millions. “Global partnerships will be critical to scale innovations. However, important considerations remain. Many AI models are developed and validated in high-income settings and often lack high-quality, representative data relevant to India’s diverse population and health systems. Without deliberate efforts to build inclusive datasets, AI tools risk reinforcing existing inequities rather than reducing them. At the same time, the growing involvement of large technology companies in health data ecosystems raises important questions around ownership, control, downstream use of data, and equitable distribution of benefits derived from it. Establishing transparent data governance frameworks—covering data access, privacy, and benefit sharing—will therefore be critical. In an increasingly geopolitically contested technological landscape, international partnerships must also balance collaboration with the protection of national interests”, said Lakshmy Ramakrishnan, Associate Fellow, Observer Research Foundation. Within Asia, one of the most notable collaborations has emerged through the India–Korea AI Quantum Healthcare Alliance, which focuses on developing next-generation medical technologies using AI and quantum computing. Moreover, Japanese firms are partnering with the Telangana government to build a large AI data centre cluster with an investment of about Rs 10,500 crore (around $1.25 billion). This facility is expected to become India’s largest AI computing cluster, enabling research and development across sectors including healthcare, pharmaceuticals, and medical analytics. India and Singapore are jointly supporting the creation of a Network of AI-for-Science Institutions, for connecting researchers, companies, and policymakers to accelerate scientific discovery using AI technologies. Additionally, the Indonesia–India CEOs Forum held in New Delhi in 2026 emphasised strengthening alliances in sectors such as digital technology, pharmaceuticals, and healthcare innovation, which can support AI-based healthcare development. Undoubtedly, as the global healthcare industry continues to embrace AI, cross-border partnerships will become increasingly important for translating research into real-world solutions. And with India expanding its AI capabilities and research ecosystem, its role as a key partner in global AI collaborations is likely to grow even stronger in the years ahead. According to Neeti Sharma, Chief Executive Officer, TeamLease Digital, “The opportunity for AI to transform healthcare in India is huge. Gen AI alone could improve productivity in the sector by nearly 30-32 per cent by 2030, especially in areas like diagnostics, clinical workflows, and hospital operations. But actual progress will depend on fixing some basic challenges, as health data today is fragmented, digital infrastructure is uneven across regions, and there is a shortage of specialised AI and health-tech talent. Companies and governments will need to invest in digital health skills, build strong, secure data platforms, and implement clear guardrails for responsible AI use. If these foundations are built well, India has the potential not just to scale AI in healthcare at home, but also to create global models for affordable, technology-led and inclusive care.”   Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/news/100/27586/nit-rourkela-develops-multi-sensor-ai-system-for-accurate-sleep-posture-detection.html https://biospectrumindia.com/news/100/27586/nit-rourkela-develops-multi-sensor-ai-system-for-accurate-sleep-posture-detection.html Mon, 30 Mar 2026 00:00:00 +0530 Researchers at the National Institute of Technology (NIT) Rourkela have developed an artificial intelligence (AI)-enabled system that can track human sleep postures. This is useful in healthcare settings, as it provides a non-intrusive way to monitor patients while maintaining their privacy, even when they are covered with a blanket. Studies from around the world show that poor sleeping posture can cause long-term health conditions by putting sustained, uneven pressure on the spine, joints, and nerves for hours at a time. Currently, patient posture monitoring is mostly done manually, which can be inconsistent and prone to human error. Although wearable sensors can be an option, but they are uncomfortable and costly for the end users. Additionally, some systems use cameras, however they can be limited by factors including insufficient lighting, obstructions such as bed covers, and privacy issues. To address these limitations, researchers have developed an AI-based system that uses three types of sensors: An imaging sensor in the long-wave infrared spectrum that captures and uses body heat to track sleep postures, and does so without using visual data, even if the subject is covered by a blanket; A depth sensor that captures the shape and posture of a person; A pressure sensor that assesses how the weight is distributed on the bed. To process the data from these sensors, the team developed a generative AI model to represent the human body, and a graph-based neural network to classify the various postures of body joints. By combining heat-based imaging, body shape data, and pressure information, the system can deliver accurate results. Lab experiments show that this no-contact model achieves around 98% accuracy, making it reliable for real-world use. To be used as an integrated module with multi-modal imaging systems, the approximate cost of the developed technology will be Rs 30,000, with scope for further reduction with mass-scale development. As a next step, the research team plans to extend the usage of this technology for identification of specific incorrect sleep posture-related health issues and other diseases.   ]]> https://biospectrumindia.com/news/100/27564/infosys-to-acquire-optimum-healthcare-it-to-unlock-ai-powered-digital-transformation.html https://biospectrumindia.com/news/100/27564/infosys-to-acquire-optimum-healthcare-it-to-unlock-ai-powered-digital-transformation.html Thu, 26 Mar 2026 00:00:00 +0530 Infosys has announced a definitive agreement to acquire Optimum Healthcare IT, recognised as a Best in KLAS healthcare digital transformation and consulting firm recognised for helping provider organisations drive large-scale transformation. The acquisition of Optimum Healthcare IT underscores Infosys' commitment to strengthening its healthcare capabilities, particularly in collaboration with health systems and provider organizations to deliver measurable outcomes across complex clinical and operational environments. Optimum Healthcare IT brings deep provider–domain expertise and a proven delivery model – making it a strong strategic fit for Infosys' scale and healthcare growth strategy. This investment significantly enhances Infosys' presence in the provider segment, adding new clients and relationships, expanding technology capabilities, and creating synergies across new buying centres. Healthcare providers served by Optimum Healthcare IT will now have access to Infosys' broader offerings across Infosys Topaz AI offerings, Infosys Cobalt cloud offerings, cloud engineering, infrastructure services, cybersecurity and application transformation. Salil Parekh, Chief Executive Officer, Infosys, said, "Optimum Healthcare IT has established a strong position in the healthcare sector by consistently delivering measurable outcomes through deep domain expertise and trusted client engagements. By bringing together Optimum's provider experience with Infosys Topaz and Infosys Cobalt, we are positioned to create a differentiated value proposition for healthcare providers – accelerating end–to–end cloud, data, and digital transformation at scale." ]]> https://biospectrumindia.com/news/100/27542/garbh-ini-to-strengthen-indias-fight-to-combat-premature-birth-through-ai.html https://biospectrumindia.com/news/100/27542/garbh-ini-to-strengthen-indias-fight-to-combat-premature-birth-through-ai.html Mon, 23 Mar 2026 00:00:00 +0530 Union Minister of State (Independent Charge) for Science and Technology, Dr Jitendra Singh said that India's largest pregnancy cohort study on 12,000 women under the GARBH-INi initiative is aimed at solving the problem of preterm births indigenously. The aim is to develop an artificial intelligence (AI)-based solution. Premature birth is one of the leading causes of neonatal mortality and morbidity in adulthood. Dr Jitendra Singh was addressing an event titled "Dissemination of Findings and Outcomes of GARBH-INi (Interdisciplinary Group for Advanced Research on Birth Outcomes)" at India Habitat Centre in New Delhi. The programme is an initiative of the Department of Biotechnology.  The Minister said that around 12,000 pregnant women have been successfully enrolled under this initiative, creating one of the largest pregnancy cohorts in South Asia. The programme has generated a vast repository of over 1.6 million well-classified bio-samples and more than one million ultrasound images, creating a strong foundation for advanced research. Dr Jitendra Singh said the outcomes of the programme include the development of AI-based pregnancy dating models specifically tailored for the Indian population, identification of microbiome-based indicators of preterm birth, rapid diagnostic tools, and identification of genetic markers for early risk assessment. He also said that such indigenous solutions are extremely important for improving maternal and child health outcomes in the country. The Minister released a compendium documenting the key learnings and outcomes of the GARBH-INi programme. He said that the initiative has also established the National Bio-Repository and the GARBH-INi-DRISHTI data-sharing platform, enabling wider access for the research community and contributing to global scientific publications. On the occasion, key partnerships and technology transfer programmes were formalised- The transfer of microbiome-based biotherapeutics technology to GARBH-INi-AnandiMaa initiative from DOTO Health; and signing of Letters of Intent with DOTO Health and Qure.ai Technologies for AI-enabled ultrasound reporting systems and risk stratification platforms under the GARBH-INi-AnandiMaa initiative. ]]> https://biospectrumindia.com/news/100/27494/agilisium-invests-rs-50-cr-to-transform-ai-based-life-sciences-enterprises-.html https://biospectrumindia.com/news/100/27494/agilisium-invests-rs-50-cr-to-transform-ai-based-life-sciences-enterprises-.html Tue, 17 Mar 2026 00:00:00 +0530 Agilisium, a leading life sciences domain-native AI services company, has announced a Rs 50 crore investment — close to $5.5 million — to fundamentally transform how pharmaceutical, biotech, and medtech enterprises operationalise AI. At the heart of this initiative is the development and deployment of FDX, Forward Deployment Experts, a new professional standard defined by Agilisium built across four dimensions: Domain, AI & Technology, Consultative Solutioning, and Systems & Process Thinking.  Unlike traditional AI services, FDX professionals are embedded directly inside Life Sciences organizations working alongside scientific, regulatory, and commercial teams not advising from the outside but driving transformation from within. The investment will reskill and deploy Agilisium's global workforce of more than 1,000 professionals as embedded AI transformation partners, making this the world's first forward deployment experts built exclusively for life sciences. Life sciences organisations worldwide are accelerating adoption of context-aware agentic AI across drug discovery, clinical trials, pharmacovigilance, regulatory operations, and commercial operations yet most enterprise AI initiatives stall not because the technology fails, but because the talent required to operationalise it does not exist at scale.   Unlike traditional consulting model, Agilisium’s forward-deployment model combines deep life sciences domain expertise with AI engineering and data science capability and then keeps both inside the client’s organisation for the duration of the transformation. Agilisium professionals sit beside scientists, clinical teams, regulatory leaders, and commercial stakeholders, designing, deploying, and continuously operating AI-driven capabilities rather than handing them over.   ]]> https://biospectrumindia.com/news/100/27502/beable-health-jeevaniyam-iit-h-sign-mou-to-develop-ai-based-rehab-for-children.html https://biospectrumindia.com/news/100/27502/beable-health-jeevaniyam-iit-h-sign-mou-to-develop-ai-based-rehab-for-children.html Tue, 17 Mar 2026 00:00:00 +0530 BeAble Health, a Hyderabad-based healthtech startup developing artificial intelligence (AI)-enabled, game-based rehabilitation technologies, has signed a tripartite agreement with Jeevaniyam Research Center, and Centre for Healthcare Entrepreneurship (CfHE) at the Indian Institute of Technology (IIT) Hyderabad to develop, clinically validate, and scale affordable AI-led rehabilitation for children with neuro-developmental and neuro-muscular conditions such as Cerebral Palsy (CP), Autism Spectrum Disorder (ASD), and attention deficit hyperactivity disorder (ADHD). The partnership is aimed at bridging the technology gap, the clinical evidence gap, and the skill gap that currently prevent Indian children with disabilities from accessing modern, validated rehabilitation devices. By bringing together BeAble’s engineering expertise, Jeevaniyam’s clinical experience and paediatric patient access, and IIT Hyderabad’s innovation ecosystem and academic strength, the collaboration creates a platform to advance technology-driven rehabilitation. Jeevaniyam currently operates the Jeevaniyam Ayurveda Hospital and Research Centre in Kochi and is preparing to inaugurate its new flagship facility, Jeevaniyam Medipolis. The centre is envisioned as a Centre of Excellence for Child Care, Neuro Care, Mind Care, and Family Care. It blends the Ayurveda system of medicine with modern diagnostic tools, innovative research, and synergistic therapies to create a holistic and effective rehabilitation environment.  The collaboration will focus on advancing paediatric rehabilitation through technology development, clinical research, and workforce training. On the technology front, BeAble’s flagship device ArmAble, designed for motor rehabilitation in children with cerebral palsy (CP) and neuromuscular disorders, will undergo usability testing, clinical validation, and formal clinical trials at Jeevaniyam’s Cochin facility. Product improvements will be guided by real-world feedback from paediatric patients and therapists to ensure the device is safe, age-appropriate, and effective for Indian children. On the training and skills front, structured programmes will be delivered for paediatric therapists, clinicians, and students to build confidence in using rehabilitation technology in paediatric care. Student internships and academic projects at Jeevaniyam and IIT Hyderabad will help develop a skilled workforce at the intersection of clinical rehabilitation and biomedical engineering. ]]> https://biospectrumindia.com/news/100/27506/birac-to-commence-evaluation-for-first-set-of-bio-ai-hub-proposals-from-april-2026.html https://biospectrumindia.com/news/100/27506/birac-to-commence-evaluation-for-first-set-of-bio-ai-hub-proposals-from-april-2026.html Tue, 17 Mar 2026 00:00:00 +0530 The Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) have announced a rolling call for proposals to establish Bio-Artificial Intelligence (Bio-AI) Hubs in key areas including Biomolecular Design, Synthetic Biology, Agricultural Innovations, Genome Diagnostics, and Ayurveda.   The evaluation of the first set of proposals will commence from April 2026 onwards. To be considered in the first round of evaluation, interested applicants are encouraged to submit their proposals by 31 March 2026 (05:00 PM). Proposals received after this date will be taken up in subsequent rounds of review as per the evaluation schedule. The Bio-AI Hubs will focus on interdisciplinary and interinstitutional collaborations. These Hubs will be anchored by organisations (academia/industry) with established expertise in AI/ML, supported by robust infrastructure and advanced computational methodologies. Startup/SMEs and other academic institutions can participate as spokes, contributing to the hub's research and innovation ecosystem. Bio-AI Hubs are expected to develop AI-guided closed  loop platforms, in which predictions, experiments and analyses are integrated into the system to improve performance. All of these would be connected in a positive feedback loop leading to accelerate scientific discoveries, optimise processes and decision-making. Bio-AI hubs with state-of-art facilities in PPP mode will be established as a shared DBTL facility for scaling-up of various research activities in academia/ industrial or joint industry-academia settings. ]]> https://biospectrumindia.com/news/100/27489/lt-technology-services-launches-nvidia-powered-ai-lung-digital-twin-platform.html https://biospectrumindia.com/news/100/27489/lt-technology-services-launches-nvidia-powered-ai-lung-digital-twin-platform.html Mon, 16 Mar 2026 00:00:00 +0530 L&T Technology Services (LTTS), a global leader in AI, Digital & R&D Consulting Services, has announced its next-generation, AI-powered digital twin platform for lung navigation, surgical planning and respiratory diagnostics. The platform combines LTTS’ industry-leading MedTech expertise across medical imaging, AI-driven diagnostics, and connected healthcare systems with NVIDIA AI infrastructure to enable greater precision and enhanced outcomes. LTTS’ lung digital twin solution integrates directly with CT imaging workflows and leverages deep learning models to reconstruct a comprehensive 3D digital twin of the lungs. This redefines visualization of critical anatomical structures including airways, blood vessels, lung lobes, and lesions, enabling clinicians to explore patient-specific lung anatomy in an immersive digital environment and simulate procedural pathways for bronchoscopy and biopsy planning. The platform is powered by NVIDIA Physical AI infrastructure, including: NVIDIA Omniverse and OpenUSD for interactive 3D digital twin visualization of lung anatomy and supporting immersive exploration of complex structures, NVIDIA TensorRT to drive optimized AI inference performance across high-speed clinical workflows, and NVIDIA MONAI to enable advanced medical image segmentation, enabling automated identification of airways, vessels, tumors and lung lobes. LTTS’ scalable digital twin platform transforms static CT scans into dynamic, simulation-ready lung models, allowing clinicians to analyze anatomical relationships, plan surgical pathways and navigate bronchoscopic procedures with enhanced accuracy. The framework also supports advanced visualization, automated segmentation, volumetric analysis, and navigation path planning, helping clinicians reduce pre-operative planning time and improve overall procedural safety.   ]]> https://biospectrumindia.com/news/100/27488/uttar-pradesh-government-and-wadhwani-ai-advance-public-health-partnership-.html https://biospectrumindia.com/news/100/27488/uttar-pradesh-government-and-wadhwani-ai-advance-public-health-partnership-.html Sun, 15 Mar 2026 00:00:00 +0530 Building on the partnership between the Government of Uttar Pradesh and Wadhwani AI (LEHS AI Unit), the state government is now advancing the collaboration by outlining an implementation roadmap for deploying a suite of AI-powered solutions across the state’s public health programs, with scope to expand the collaboration to additional solutions in the future. The collaboration aims to embed responsible AI solutions within Uttar Pradesh’s public health systems across priority areas such as tuberculosis care and management, telemedicine, maternal and child health, eye health screening, and frontline health worker support.  During the initial phase of implementation, a key focus will be on deploying seven AI-powered solutions across key public health programs. Wadhwani AI will serve as a technical partner to the state, supporting the deployment of AI-driven tools aligned with the government’s public health priorities.  The collaboration aligns with the UP AI Mission, a three-year initiative launched by the Government of Uttar Pradesh to build a state-led artificial intelligence ecosystem and accelerate the use of AI across sectors including governance, healthcare, and agriculture. In tuberculosis care, the Cough Against TB (CATB) mobile phone-based screening application will enable frontline healthcare workers to identify individuals with presumptive pulmonary TB by analyzing cough sounds and accompanying symptoms, enabling early detection even in community settings. Complementing this effort, Vulnerability Mapping for Tuberculosis (VMTB) will use geospatial AI analytics to identify high-risk locations by analyzing TB program data alongside multiple environmental and health indicators, helping health authorities prioritize targeted interventions and active case-finding activities. The Prediction of Adverse TB Outcomes (PATO), an AI-powered risk stratification tool, will help identify patients at higher risk of adverse outcomes at the onset of TB treatment and facilitate prompt, targeted, and effective interventions that, over time, will help lower mortality rates and prevent drug-resistant TB. In telemedicine, the Clinical Decision Support System (CDSS) will enable clinicians to access structured patient information and offer AI-assisted differential diagnosis recommendations during consultations, supporting the quality and consistency of care delivery across primary healthcare settings.  The collaboration will also include the deployment of Health Vaani, a voice- and text-based knowledge assistant which will provide frontline health workers with instant access to government-approved health guidelines, enabling quicker decision-making and more consistent service delivery at the community level. To address the growing burden of diabetes-related vision complications, the partnership will also deploy MadhuNetrAI, an AI-enabled screening solution that will analyze retinal images to detect diabetic retinopathy and support early referral for specialist care, particularly in resource-constrained settings where specialist availability may be limited.  In maternal and newborn health, Shishu Maapan, an AI-powered newborn anthropometry tool, will enable frontline health workers to capture accurate newborn measurements using a smartphone during home-based newborn care visits.   ]]> https://biospectrumindia.com/news/100/27473/zydus-expands-companion-diagnostics-portfolio-with-launch-of-ai-powered-continuous-glucose-monitor.html https://biospectrumindia.com/news/100/27473/zydus-expands-companion-diagnostics-portfolio-with-launch-of-ai-powered-continuous-glucose-monitor.html Thu, 12 Mar 2026 00:00:00 +0530 Zydus Lifesciences has announced its new offering companion diagnostics portfolio. The company will be launching DiasensTM and GlucoLiveTM, next-generation Continuous Glucose Monitoring (CGM) devices that combine artificial intelligence-powered insights, and integrated remote care capabilities. The CGM system is designed to monitor glucose with an integrated AI layer to provide analytics and enable a closed-loop care ecosystem connecting patients, caregivers, and clinicians in real time. Zydus has partnered with Digicare Health Solutions (TatvaCareTM), a healthcare technology company to help the patients gain access to its proprietary, integrated care ecosystem GoodFlipTM to provide AI-powered report analysis, personalised diet and exercise coaching, doctor consultations, diagnostic lab booking, and a comprehensive medical record vault - all in a single mobile application.  Despite this burden, most glucose monitoring in India remains episodic - limited to periodic finger-prick tests or laboratory HbA1c checks every three to six months. Existing CGM devices in the Indian market predominantly rely on NFC technology, requiring patients to manually scan the sensor to retrieve readings. This creates gaps in data continuity, delays clinical intervention, and places the burden of vigilance entirely on the patient. DiasensTM and GlucoLiveTM will enable automatic streaming of glucose readings to the patient’s smartphone every three minutes - without manual scanning - ensuring uninterrupted capture, including overnight reading and in emergencies. Through TatvaCareTM’s GoodFlipTM app, AI analytics will detect trends, flags hypo-/hyperglycaemic episodes, link fluctuations to food and activity, and generate actionable insights. A clinician dashboard will support remote monitoring, early intervention, and data-driven treatment adjustments.   ]]> https://biospectrumindia.com/news/100/27469/lumikai-leads-1-5-m-seed-round-for-nprep-to-scale-ai-based-platform-for-indias-nursing-workforce.html https://biospectrumindia.com/news/100/27469/lumikai-leads-1-5-m-seed-round-for-nprep-to-scale-ai-based-platform-for-indias-nursing-workforce.html Wed, 11 Mar 2026 00:00:00 +0530 Lumikai, India’s pioneering venture capital fund focused on interactive media, digital platforms and games, led a $1.5 million seed round in Jodhpur-based startup NPrep, an AI-powered, video-first learning platform revolutionising preparation for high-stakes nursing entrance examinations and global healthcare careers. NPrep fits squarely into Lumikai’s thesis that interactive customised mechanics, outcome-based feedback loops, and AI-led personalisation engage, retain and scale users on digital platforms.  This is Lumikai’s third investment in the interactive learning space, following Supernova, the AI tutor for spoken English, and Vobble, the interactive AI-first audio platform for kids. India is home to one of the world’s largest nursing workforces, with approximately 3.2 million registered nurses and midwives, and over 250,000 new graduates entering the market annually. An additional 800,000 candidates appear for competitive government nursing entrance exams each year. India is also a global supplier of healthcare talent, while facing a growing shortage of nurses in the country. NPrep addresses the systemic gap in nursing education by delivering over 1,400 hours of exam-aligned original video content along with personalised study plans. An AI mentor, curated questions from historical exam data, and individual performance tracking directly drive superior exam results, unlocking access to government jobs and global roles. Within 10 months, over 1,00,000 nurses in India already use NPrep, with over 6 million minutes of video content consumed and 31 million questions answered on the platform. The round also saw participation from existing investor All In Capital, along with Velo Partners, DSP Group Family Office, and angel investors including Viren Shetty, Executive Vice Chairman of Narayana Health. ]]> https://biospectrumindia.com/news/100/27461/wellness-technologies-plans-commercialisation-of-ai-powered-smart-yoga-mat.html https://biospectrumindia.com/news/100/27461/wellness-technologies-plans-commercialisation-of-ai-powered-smart-yoga-mat.html Tue, 10 Mar 2026 00:00:00 +0530 Reinforcing its commitment to nurturing India's deep-tech startup ecosystem and enabling indigenous innovations to take from the lab to the market, the Technology Development Board (TDB) of the Department of Science and Technology (DST), Government of India, has provided financial support to Bengaluru-based startup Wellness Technologies for the commercialisation of its innovative product, the YogiFi Smart Yoga Mat. The project titled "Commercialisation of YogiFi Smart Sensor Fabric Mats with Autonomous and Self-Sustaining Systems" aims to strengthen the indigenous manufacturing capabilities of AI-powered health technology developed in India and enable mass production. This initiative is in line with the Government of India's vision to promote preventive healthcare, digital health technologies and self-reliant manufacturing within the larger framework of Aatmanirbhar Bharat. The YogiFi Smart Yoga Mat combines advanced sensor technology and artificial intelligence (AI) to provide real-time posture feedback, guided yoga sessions, and detailed performance analytics through a mobile application. Combining digital technology with the ancient science of yoga, this product represents a new category of AI-enabled preventive health solutions emerging from India's startup space.   ]]> https://biospectrumindia.com/news/100/27430/biocon-academy-launches-certificate-programme-for-ai-in-life-sciences.html https://biospectrumindia.com/news/100/27430/biocon-academy-launches-certificate-programme-for-ai-in-life-sciences.html Fri, 06 Mar 2026 00:00:00 +0530 Bengaluru-based Biocon Academy, a Centre of Excellence for Advanced Learning in Applied Biosciences and a CSR initiative of Biocon Group, an innovation-led global biopharmaceuticals company, has announced the launch of its 8th programme, and the first in the area of Artificial Intelligence (AI). The Syngene IBAB Certificate Programme in Artificial Intelligence in Life Sciences (SAILS) has been developed in partnership with Syngene, a Biocon Group Company and the Institute of Bioinformatics and Applied Biotechnology (IBAB). This first-of-its-kind Certificate Programme reflects Biocon Academy’s commitment to advancing high-quality, industry-relevant education in India’s biotechnology sector. SAILS is designed as a future-oriented, industry-aligned certification that integrates core disciplines such as Artificial Intelligence (AI), Data Science, and Life Sciences, to develop talent equipped for cutting-edge research, innovation, and discovery. Admissions are open for the programme, and the first batch of classes will commence in Q1 FY2027. The 16-week Certificate Programme is designed to equip graduates and postgraduates in Computer Science, Information Technology, Pharmacy, and Life Sciences disciplines (Biotechnology, Microbiology, and Biochemistry), with cutting-edge knowledge. The programme provides a strong foundation in applying AI to solve complex problems in the Life Sciences industry, with an emphasis on real-life problem-solving skills.  The SAILS programme aims to address this industry gap by equipping learners with practical, interdisciplinary skills and hands-on exposure to emerging technologies. ]]> https://biospectrumindia.com/news/100/27416/jubilant-bhartia-foundation-mcgill-university-to-launch-coe-in-ai-education-and-research-in-india.html https://biospectrumindia.com/news/100/27416/jubilant-bhartia-foundation-mcgill-university-to-launch-coe-in-ai-education-and-research-in-india.html Sat, 28 Feb 2026 00:00:00 +0530 The Jubilant Bhartia Foundation in collaboration with McGill University (Canada), has signed a Memorandum of Understanding (MoU) to create the Centre of Excellence (CoE) in artificial intelligence (AI) Education and Research. The MoU was signed on the margins of an event with Canada’s Minister of Foreign Affairs, Anita Anand, and Jayant Chaudhary, the Union Minister of State (Independent Charge) for Skill Development and Entrepreneurship and also Minister of State for Education, Government of India. The MoU was signed by Shyam S Bhartia, Founder & Chairman, Jubilant Bhartia Group and Hari S Bhartia, Founder & Co-Chairman, Jubilant Bhartia Group and Professor Deep Saini, President and Vice-Chancellor, McGill University. This Centre of Excellence in AI Education and Research is designed to bridge the gap between academic learning and industry-relevant applications, with the goal of producing job-ready Al engineers and future research leaders.  It will first offer a Master’s programme that combines strong academic foundations with applied learning and industry engagement. Students will work on projects connected to real technological challenges and emerging needs in the AI sector in India.   This partnership will leverage McGill University’s research led AI ecosystem to create an innovative program that integrates strong theoretical foundations with practical implementation. The Centre will also serve as a research hub to foster AI solutions tailored to India’s digital transformation journey. The Centre will offer a Master’s programme for India's graduates each year. The programme will emphasise rigorous academic quality, curriculum agility that adapts to evolving needs to remain relevant; applied learning through live projects and industry case studies; global best practices in AI research and innovation; and continuous assessment and mentorship from international faculty and leading industry experts.   ]]> https://biospectrumindia.com/news/100/27399/cohere-health-announces-launch-of-global-capability-centre-in-hyderabad-.html https://biospectrumindia.com/news/100/27399/cohere-health-announces-launch-of-global-capability-centre-in-hyderabad-.html Thu, 26 Feb 2026 00:00:00 +0530 US-based startup Cohere Health®, a leader in clinical intelligence solutions for health plans, has announced the launch of its Global Capability Centre (GCC) in Hyderabad, India. As the company continues to expand its operational capabilities globally, this milestone reinforces its commitment to scaling innovation, technological excellence, and advancing its clinically trained AI platform.   As part of its long-term vision and investment in globally distributed teams, Cohere Health is scaling the GCC into a centre of excellence that fosters a culture of innovation and collaboration, deepens clinical intelligence, and improves outcomes for health plans, clinicians, and patients worldwide. India is a cornerstone of the company’s global operating model and a key driver of its mission to ensure patients everywhere receive the right care as quickly and safely as possible.   Tapping into India’s deep talent pool, the Hyderabad GCC brings together expert engineering, analytics, and clinical operations teams to strengthen Cohere Health’s global capabilities and accelerate product advancements. Working closely with US-based colleagues, the centre expands the company’s capacity to scale clinically trained AI and deliver more connected solutions that improve payer-provider collaboration.     Looking ahead, Cohere Health plans to continue expanding the Hyderabad GCC with strategic hiring across engineering, product, data science, and compliance, strengthening its global teams and capacity. This expansion positions Cohere Health to meet the increased demand for clinically trained AI solutions that streamline complex processes, improve health outcomes, and enhance payer-provider collaboration across the healthcare continuum–reinforcing its role as the leader in enterprise clinical intelligence for health plans.   ]]> https://biospectrumindia.com/news/100/27402/ayucryam-innovations-develops-ai-powered-hole-slide-imaging-diagnostic-system.html https://biospectrumindia.com/news/100/27402/ayucryam-innovations-develops-ai-powered-hole-slide-imaging-diagnostic-system.html Thu, 26 Feb 2026 00:00:00 +0530 The Technology Development Board (TDB), Department of Science and Technology (DST), Government of India, has announced support for "Otoscope: A Fully Automated Hole Slide Imaging Diagnostic System" by Delhi-based Ayukriyam Innovations. The Otoscope platform is fully automated combined with AI-powered diagnostic capabilities. The system aims to offer high-throughput, standardised, and scalable diagnostic workflows. By leveraging indigenous research and development and AI-enabled image analysis, this technology enhances diagnostic accuracy while reducing dependence on imported high-end imaging systems. The project is indigenously developed through in-house R&D and institutional linkages. It strengthens TDB's mandate to provide financial support for commercialisation of technologies and innovation-based in critical sectors such as healthcare and medical devices.  ]]> https://biospectrumindia.com/news/100/27387/health-minister-inaugurates-ai-based-e-icu-command-centre-at-yashoda-medicity.html https://biospectrumindia.com/news/100/27387/health-minister-inaugurates-ai-based-e-icu-command-centre-at-yashoda-medicity.html Wed, 25 Feb 2026 00:00:00 +0530 J P Nadda, Union Minister of Health and Family Welfare, Government of India, inaugurated the Artificial Intelligence (AI) based e-ICU Command Centre at Yashoda Medicity, Ghaziabad. The Command Centre has been developed with the objective of integrating Artificial Intelligence with centralized surveillance systems to improve clinical outcomes and make the management of Intensive Care Units more effective, streamlined and coordinated. Union Health Minister stated that AI-enabled healthcare services integrate timely medical interventions, accuracy in disease detection, and real-time monitoring, which are of utmost importance in emergency and intensive care situations, where immediate decisions can significantly impact the patient's treatment outcomes. He mentioned that AI-assisted ICUs provide early warning in adverse clinical situations, ensure better identification of high-risk cases and help physicians make more effective decisions through data-based analytical information. He said that the inauguration of the AI-based e-ICU Command Centre will further strengthen critical care services and play a crucial role in strengthening patient safety. The AI-enabled e-ICU installed at Yashoda Medicity connects the Base Command Centre of the Command Centre with the ICU facility of MMG District Hospital, enabling Artificial Intelligence-enabled real-time monitoring of critically ill patients. The system integrates hospital information systems and bedside devices with a centralised dashboard where AI-based analytics support risk classification, issue early warnings in case of deterioration in clinical status, and ensure timely and evidence-based therapeutic intervention through round-the-clock expert monitoring. ]]> https://biospectrumindia.com/news/100/27380/sigtuple-announces-launch-of-ai-enabled-digital-morphology-analyser.html https://biospectrumindia.com/news/100/27380/sigtuple-announces-launch-of-ai-enabled-digital-morphology-analyser.html Tue, 24 Feb 2026 00:00:00 +0530 Bengaluru-based SigTuple has announced the launch of AS76, an AI-enabled digital morphology analyser designed to automate peripheral blood smear (PBS) microscopic review. AS76 combines automated digital microscopy with on-device, edge-AI computing to deliver faster, more consistent results while preserving data privacy. Powered by NVIDIA RTX, the AS76 analyser will perform high-throughput image analysis using advanced AI models, all running locally on the device. This allows the system to deliver near-instant results even for large sample batches, without dependence on internet connectivity. An AI-powered automated digital microscope with built-in computing, AS76 system can load up to six PBS slides simultaneously, scan them in full diagnostic detail, and generate an AI-assisted report for expert review — with all processing performed entirely on the device. The system automates key elements of manual PBS review, including generation of a 200-cell leukocyte differential, highlighting red blood cell morphology, and flagging platelet morphology, including detection of platelet aggregates. Equipped with 20×, 40×, and 100× objectives on an automated turret, AS76 launches with peripheral blood smear capabilities and is designed for future software upgrades to support tissues, fluids, bone marrow, and microbiology slides. This multi-application readiness positions AS76 as a digital replacement for the analog microscope in the laboratory. By applying AI-driven cell pre-classification, AS76 standardises smear review at scale and surfaces atypical findings quickly for expert confirmation. The system reduces manual effort and turnaround time. ]]> https://biospectrumindia.com/news/100/27364/mahe-teams-up-with-openai-to-integrate-artificial-intelligence-to-enhance-outcomes.html https://biospectrumindia.com/news/100/27364/mahe-teams-up-with-openai-to-integrate-artificial-intelligence-to-enhance-outcomes.html Sat, 21 Feb 2026 00:00:00 +0530 Manipal Academy of Higher Education (MAHE), an Institution of Eminence Deemed to be University in Karnataka, has partnered with OpenAI to integrate advanced artificial intelligence (AI) tools across teaching, research, and academic administration.  This collaboration aims to enhance learning outcomes, accelerate research productivity, and equip students and faculty with critical AI skills for a rapidly evolving global workforce. MAHE will implement AI-powered tools and resources across its academic programs to support personalised learning, boost critical thinking, and encourage ethical AI use. Faculty will also gain access to advanced AI tools for curriculum planning, research, and innovation. The collaboration will focus on building AI literacy across disciplines, ensuring that students from Health Sciences, Technology & Science, Management, Law, Humanities & Social Sciences, and allied fields gain practical exposure to AI applications relevant to their domains. MAHE will also promote interdisciplinary research and innovation using AI to address complex real-world challenges. MAHE will also establish structured AI governance guidelines to ensure responsible, ethical, and transparent governance use of artificial intelligence across academic functions. ]]> https://biospectrumindia.com/news/100/27352/indo-french-centre-for-ai-for-health-launches-at-aiims-new-delhi.html https://biospectrumindia.com/news/100/27352/indo-french-centre-for-ai-for-health-launches-at-aiims-new-delhi.html Thu, 19 Feb 2026 00:00:00 +0530 In a historic step towards strengthening Indo-French cooperation in the field of healthcare and emerging technologies, the Union Minister of Health and Family Welfare, Government of India, J.P. Nadda inaugurated the Indo-French Centre for AI in Health (IF-CAIH) at the All India Institute of Medical Sciences (AIIMS), New Delhi. The Indo-French Centre for AI in Health (IF-CAIH) is a pioneering initiative that aims to address complex healthcare challenges by encouraging artificial intelligence (AI)-based research, medical education, and clinical innovation. This initiative marks a significant milestone in the Indo-French collaboration in the field of digital health and reinforces India's vision to provide global leadership in equitable and technology-enabled health solutions. IF-CAIH has been established under a joint Memorandum of Understanding (MoU) signed between the AIIMS, New Delhi and the Sorbonne University and the Paris Brain Institute. The initiative is also supported by academic support from premier institutions of Indian Institute of Technology (IIT) Delhi and France. This collaboration is a significant step towards promoting interdisciplinary research in the areas of Artificial Intelligence, Brain Health, and Global Health Systems. This initiative builds on the ongoing institutional cooperation between India and France in priority areas such as digital health, antimicrobial resistance (AMR), human resources in the health sector and responsible use of health data. The collaborative efforts between research institutions and digital health organisations of both countries aim to encourage scientific discovery, strengthen evidence-based policymaking, and foster capacity building and academic exchange partnerships.   ]]> https://biospectrumindia.com/news/100/27354/wadhwani-ai-and-aiims-win-recognition-for-ai-powered-diabetic-retinopathy-screening-solution-at-india-ai-impact-summit-2026.html https://biospectrumindia.com/news/100/27354/wadhwani-ai-and-aiims-win-recognition-for-ai-powered-diabetic-retinopathy-screening-solution-at-india-ai-impact-summit-2026.html Thu, 19 Feb 2026 00:00:00 +0530 Wadhwani AI, in collaboration with AIIMS New Delhi, has announced that its artificial intelligence (AI)-powered diabetic retinopathy screening solution, MadhuNetrAI, has won the “AI for ALL: Global Impact Challenge” at the prestigious India AI Impact Summit 2026. The AI for ALL Global Impact Challenge attracted over 4,600 applications from more than 60 countries, recognising scalable, high-impact artificial intelligence solutions addressing critical societal challenges. MadhuNetrAI was recognised for its demonstrated ability to strengthen early detection of diabetic retinopathy (DR) within India’s public healthcare system and for its real-world deployment in collaboration with leading public institutions. India faces one of the world’s largest diabetes burdens, with over 101 million people living with the condition. Diabetic retinopathy remains a leading cause of preventable blindness, particularly when screening is delayed or specialist access is limited. MadhuNetrAI directly addresses this gap by enabling AI-assisted analysis of retinal fundus images to classify DR severity and identify patients requiring timely referral and intervention. Developed by Wadhwani AI in collaboration with AIIMS Delhi and under the aegis of the Ministry of Health and Family Welfare, the solution has been clinically validated and designed specifically for deployment within public health settings. It supports frontline healthcare providers, including optometrists, nurses, and community health officers, by assisting with image assessment, standardising grading based on internationally recognised benchmarks, and triaging referable cases. Importantly, the solution enables community based screenings even in under resources environments where specialist ophthalmologists may not be readily available.   ]]> https://biospectrumindia.com/news/100/27357/ai-will-open-up-high-value-opportunities-leading-to-innovation-and-entrepreneurship-pm.html https://biospectrumindia.com/news/100/27357/ai-will-open-up-high-value-opportunities-leading-to-innovation-and-entrepreneurship-pm.html Thu, 19 Feb 2026 00:00:00 +0530 Prime Minister Narendra Modi inaugurated the India AI Impact Summit 2026 at Bharat Mandapam in New Delhi, on 19th February. Addressing the gathering, Modi said that the world's largest and historic AI Impact Summit is taking place in India, which represents one-sixth of humanity. He said that India has the world's largest youth population, the largest tech talent pool and a rich technology-enabled ecosystem. He said that India not only creates new technologies but also adopts them at an unprecedented pace. The Prime Minister said that 14 crore Indians are keen to adopt new technologies, and on his behalf, he extended a warm welcome to the Heads of State, leaders of the global AI ecosystem and innovators participating in the Summit.  Modi said AI will open up high value, creative and meaningful opportunities for more people, leading to innovation, entrepreneurship and new industry opportunities. He stressed on the importance of making skill development, redevelopment and lifelong learning a people's movement. The Prime Minister said that the future of work will be inclusive, trustworthy and human-centric, and if humanity moves forward together, Artificial Intelligence will take human potential to new heights. The event was attended by the President of France, Emmanuel Macron, Secretary General of the United Nations, several Heads of State, Ministers, senior representatives of multilateral institutions and other dignitaries including technology and AI giants. Artificial intelligence is also a transformative force, it disrupts if directionless, but becomes a solution when it gets the right direction. Modi said the basic objective of the Global AI Impact Summit is to deliberate on how to make Artificial Intelligence human-centric, sensitive and responsive instead of machine-centric. ]]> https://biospectrumindia.com/news/100/27348/maverick-simulation-solutions-launches-siddh-indias-advanced-high-fidelity-critical-care-adult-patient-simulator.html https://biospectrumindia.com/news/100/27348/maverick-simulation-solutions-launches-siddh-indias-advanced-high-fidelity-critical-care-adult-patient-simulator.html Wed, 18 Feb 2026 00:00:00 +0530 Maverick Simulation Solutions, a leading manufacturer of advanced medical simulators, launched SIDDH at their corporate office in Dwarka, New Delhi. Developed and manufactured in India, SIDDH is a next-generation high-fidelity critical care adult patient simulator created to transform hands-on clinical training across medical colleges, teaching hospitals, and healthcare institutions. As a life-size, 65 kg full-body adult simulator, SIDDH is engineered to replicate real-world critical care scenarios with physiological accuracy. By integrating advanced lung simulation technology, AI-powered ultrasound capabilities, and real-time physiological response systems, SIDDH delivers a safe, immersive, and clinically realistic training environment. It enables doctors, nurses, paramedics, and medical students to practise complex procedures, manage emergencies, and make critical decisions with confidence before stepping into real patient settings. Speaking on the launch, Anuj Chahal, Founder of Maverick Simulation Solutions, said, “The global medical simulation industry is witnessing rapid growth as healthcare systems increasingly recognise the importance of safe, technology-driven training. In India, this need is even more urgent as the number of medical colleges and healthcare institutions continues to expand. However, access to high-fidelity simulators has traditionally depended on expensive imports. With SIDDH, we are proud to introduce a truly Make in India solution that matches global standards while being designed specifically for Indian healthcare realities.” SIDDH enables training across a wide range of critical care scenarios, including cardiac emergencies, respiratory distress, trauma, and complex airway management. It features realistic anatomy, advanced lung simulation, and real-time arterial blood gas feedback that dynamically responds to learner interventions. The platform also integrates an AI-powered ultrasound module with over 1,000 clinical cases, precise probe tracking, intelligent scoring, and adaptive guidance. Optional modules support communication training, structured assessments, team-based simulations, and cloud-based performance analytics for institutions.   ]]> https://biospectrumindia.com/news/100/27350/bharatgen-and-amrita-institutions-unite-to-build-indias-sovereign-ai-for-healthcare.html https://biospectrumindia.com/news/100/27350/bharatgen-and-amrita-institutions-unite-to-build-indias-sovereign-ai-for-healthcare.html Wed, 18 Feb 2026 00:00:00 +0530 In a landmark move toward self-reliance in healthcare technology, BharatGen Technology Foundation and Amrita Institutions have signed a Memorandum of Understanding (MoU) to co-develop sovereign, multilingual AI solutions tailored specifically for India's diverse medical landscape. The partnership focuses on building India-centric Medical Foundation Models, domain-specific AI frameworks for Electronic Medical Records (EMR), and speech-first multimodal systems, all designed for clinical and community use with responsible AI at the core. BharatGen, a Section-8 not-for-profit based at IIT Bombay, spearheads foundational AI research and sovereign model development. Amrita Technologies contributes deep expertise in EMR systems and healthcare data engineering. The Amrita Hospitals provide a crucial real-world clinical backbone for validation and deployment, with Amrita Vishwa Vidyapeetham serving as the overarching mission leader. First Milestone: Together, the two institutions combine sovereign AI infrastructure with clinical depth and hospital-scale validation. The collaboration’s immediate priority is scaling Med-Sum: Medical Summary via AI Scribe. Med-Sum is developed by the Amrita School of AI, Delhi NCR, Faridabad Hospital campus, and powered by BharatGen’s sovereign speech and AI models. Med-Sum enables: Real-time voice-to-text clinical transcription. Automated clinical summaries. Patient-friendly explanations in multiple Indian languages. Following rigorous clinical validation at Amrita Hospitals - Faridabad and Kochi, the platform is already being used by hundreds of doctors and patients, marking a significant leap toward inclusive, tech-enabled healthcare.     ]]> https://biospectrumindia.com/news/100/27351/4basecare-partners-with-france-based-owkin-to-advance-inclusive-cancer-research.html https://biospectrumindia.com/news/100/27351/4basecare-partners-with-france-based-owkin-to-advance-inclusive-cancer-research.html Wed, 18 Feb 2026 00:00:00 +0530 Bengaluru-based startup 4baseCare, a precision oncology company building population-relevant clinico-genomic intelligence, has collaborated with France-based Owkin, an agentic AI company focused on Biological Artificial Superintelligence (BASI), to advance inclusive cancer research. Through this collaboration, the two companies will work together to convert fragmented cancer care data into AI-ready intelligence. The goal is to bridge the data gap and long-standing underrepresentation of Asian and Middle Eastern populations in cancer care and drug development. By building more representative datasets, the partnership aims to support more inclusive research and create more equitable standards of cancer care worldwide. 4baseCare is a precision oncology company that is bridging the genomics data gap in cancer care. 4baseCare’s TarGT™ Indiegene test provides deeper insight into a patient’s disease, enabling targeted treatment decisions instead of a one-size-fits-all approach. Thomas Clozel, CEO and Co-Founder, Owkin, said, “We are on a mission to build biological artificial superintelligence to cure all diseases. Global patient data is the key to unlocking this. We are excited to enhance our collaborations in India to turn fragmented datasets into meaningful discoveries for more inclusive therapeutic breakthroughs” Kshitij Rishi, COO & Co-Founder, 4baseCare, said, “Precision oncology is only as strong as the data behind it. At 4baseCare, we build inclusive genomic datasets reflecting the diversity of the global south, non Caucasian patients and combine them with advanced AI to enable more informed treatment decisions. We look forward to working with Owkin to ensure underrepresented populations are meaningfully included in global research and next-generation drug development.” ]]> https://biospectrumindia.com/news/100/27319/superhealth-unveils-worlds-first-agentic-ai-operating-system-for-healthcare.html https://biospectrumindia.com/news/100/27319/superhealth-unveils-worlds-first-agentic-ai-operating-system-for-healthcare.html Thu, 12 Feb 2026 00:00:00 +0530 Bengaluru-based Superhealth has introduced SuperOS, the world’s first agentic AI operating system for healthcare. SuperOS runs the hospital end-to-end, improving both clinical excellence and operational efficiency. SuperOS is built in-house by Superhealth and is currently deployed at its flagship hospital in Bengaluru. It runs day-to-day hospital operations, assists doctors across consultations, differential diagnoses and surgical care, improves diagnostic scan speed and accuracy, monitors admitted patients, optimises operating-room flows and inventory management, and automatically generates discharge summaries. SuperOS is also at the heart of Superhealth’s zero-wait experience. It intelligently manages appointment slots and durations to maximise face time between doctors and patients, while predicting and proactively flagging potential delays for others.   It also manages Superhealth’s inventory and coordinates medicines and phlebotomists for blood draws, assigning actions so that both reach the patient directly in the consultation room. This eliminates the need to queue at pharmacies or wait at sample-collection areas, significantly reducing patient friction while improving efficiency and utilisation for Superhealth.     ]]> https://biospectrumindia.com/news/100/27315/immuneel-therapeutics-explores-use-of-ai-driven-frameworks-for-biologics-adcs-in-vivo-gene-based-therapies.html https://biospectrumindia.com/news/100/27315/immuneel-therapeutics-explores-use-of-ai-driven-frameworks-for-biologics-adcs-in-vivo-gene-based-therapies.html Wed, 11 Feb 2026 00:00:00 +0530 In a major step towards transforming the treatment landscape for high burden diseases such as cancers and autoimmune disorders, Bengaluru-based Immuneel Therapeutics and Manas AI, Inc. (based in the US) are entering into a strategic partnership to evaluate the potential application of artificial intelligence (AI)-native tools within the landscape of biologics, antibody-drug conjugates (ADCs), novel allogeneic and in vivo gene-based therapies. This collaboration aims to assess how Immuneel may leverage Manas AI’s neuro-symbolic models to facilitate the ability to develop and deliver advanced treatments affordably and at scale rapidly. The integration of Immuneel’s research & development, translational and GMP-grade biomanufacturing capabilities with Manas AI’s AI-native discovery engine, aims to shorten development timelines and accelerate access to therapies that can change the course of disease and improve quality of life. The collaboration has the potential to span multi-specific antibody designs, AI-optimized binders, payload/linker discovery for ADCs, manufacturability screening, and next-generation allogeneic and in vivo delivery approaches. These capabilities are critical for creating medicines that are not only scientifically advanced but also safer, more scalable, and financially accessible. Together, the companies intend to determine if a feedback loop—from AI-driven in silico design to development, preclinical testing and scalable manufacturing—can be effectively established and ultimately enable faster iteration, better predictability, and more audit-ready development pathways.   ]]> https://biospectrumindia.com/news/100/27279/forus-health-secures-cdsco-approval-for-ai-led-diabetic-retinopathy-screening-tool-.html https://biospectrumindia.com/news/100/27279/forus-health-secures-cdsco-approval-for-ai-led-diabetic-retinopathy-screening-tool-.html Wed, 04 Feb 2026 00:00:00 +0530 Bengaluru-based medtech firm Forus Health has received regulatory approval from the Central Drugs Standard Control Organization (CDSCO) for its FH-POISE™ DRT (Diabetic Retinopathy Tools). FH-POISE™ (Precision Ocular Intelligence for Systemic & Eye Health) is Forus Health’s AI-powered retinal image analysis platform designed to support the detection and screening of ocular and systemic diseases using state-of-the-art algorithms. The approval enables FH-POISE™ DRT to be used as a screening tool to identify patients at risk of diabetic retinopathy, supporting earlier clinical evaluation and timely intervention to help prevent diabetes-related vision loss. The software uses deep learning models to assess retinal images and predict disease severity, allowing for more nuanced and clinically relevant screening outcomes. It has received CDSCO approval as Class C SaMD (Software as a Medical Device), one of the most stringent risk categories, with the approach validated on real-world retinal images, spanning a diverse demography, demonstrating suitability for real-world healthcare settings. India carries one of the world’s largest diabetes burdens. According to the International Diabetes Federation, approximately 89.8 million adults in India were living with diabetes in 2024, placing sustained pressure on the healthcare system.  “India’s challenge with diabetic retinopathy is not awareness alone, but scale,” said Chandrasekhar K., Founder and CEO, Forus Health, “Embedding reliable screening into routine diabetes care is essential if we are to prevent avoidable vision loss. Regulatory approval for FH-POISE™DRT enables technology-focussed screening closer to where patients already receive care, helping strengthen early detection while making better use of limited specialist capacity.” The broader economic impact of vision impairment further underscores the importance of early detection. Peer-reviewed studies estimate that vision impairment and blindness in India result in productivity losses exceeding Rs 11,000 crore annually, highlighting the societal cost of delayed diagnosis and treatment. With CDSCO approval in place, Forus Health plans to deploy FH-POISE™ DRT across hospitals, public health initiatives, and screening programs, aligned with India’s focus on preventive healthcare and digital health–enabled early diagnosis.   ]]> https://biospectrumindia.com/features/100/27238/ai-fuels-new-era-of-cancer-detection.html https://biospectrumindia.com/features/100/27238/ai-fuels-new-era-of-cancer-detection.html Sat, 31 Jan 2026 00:00:00 +0530 Cancer continues to be a significant health issue in the country, which demands the invention of new methods for early detection, precise diagnosis, and personalised treatments. And artificial intelligence (AI) is rapidly becoming a groundbreaking component in the modern era of oncology, offering sophisticated tools across the range of cancer detection and care. As World Cancer Day is marked every year on February 4, it becomes pertinent to focus on the new developments taking place within the country to address this growing healthcare burden. According to the Indian Council of Medical Research (ICMR), 15.7 lakh new cancer cases were apparently reported in India in 2025. This projection indicates a 12.8 per cent increase in cancer incidence compared to levels seen in 2020. Reports have also suggested that India's lung cancer burden is projected to rise sharply by 2030, with the North-East emerging as the worst-affected region and women recording the fastest increase in cases. Additionally, a recent study warns that breast cancer cases in India are expected to climb by 5.6 per cent every year. As a result, we are now seeing a huge increase in technology deployment, especially the use of AI, across public and private sectors for early detection of cancer, to bring down this number as much as possible. India’s first government-run artificial intelligence (AI) clinic was recently inaugurated at the Government Institute of Medical Sciences (GIMS) in Greater Noida, marking a major step in integrating cutting-edge technology into public healthcare, to enhance early disease detection of cancer and other diseases. IndiaAI Independent Business Division (IBD), in collaboration with the National Cancer Grid (NCG), has launched the Cancer AI & Technology Challenge (CATCH) Grant Programme to support the development and deployment of innovative AI solutions to strengthen cancer screening, diagnostics, treatment support, and healthcare operations across India. The CATCH Grant Programme is providing up to Rs 50 lakh per project to selected teams comprising technology innovators and clinical institutions. Successful pilot projects may also be eligible for an additional scale-up grant of up to Rs 1 crore, facilitated by IndiaAI. The Department of Biotechnology (DBT) and Biotechnology Industry Research Assistance Council (BIRAC) are supporting the establishment of Bio-AI Hubs, which focus on interdisciplinary collaborations to develop AI-guided platforms for cancer research, diagnosis and treatment. These hubs aim to improve scientific discoveries, optimise processes, and enhance decision-making in the field of cancer treatment.  Although AI shows promise for improving cancer screening and diagnosis, its adoption and understanding have often turned out to be challenging. For instance, the lack of large, representative datasets specific to India has hindered AI’s readiness for routine clinical application. Dr Jitendra Kumar, Managing Director, Biotechnology Industry Research Assistance Council (BIRAC) said, “AI must be leveraged to deepen core scientific capabilities before being widely deployed in public-facing healthcare applications. Premature use of AI in direct patient interfaces must be done cautiously, as misinterpretation, misuse and varying levels of public health literacy could undermine trust in both technology and healthcare systems. AI should act as an enabler for scientists, clinicians and manufacturers rather than a replacement, and robust validation frameworks are essential before large-scale deployment.” In order to address such challenges, the Central Drugs Standard Control Organisation (CDSCO) has now brought artificial intelligence driven cancer detection and diagnostic software under its regulatory oversight, placing it on par with medical devices. Such proactive approaches to regulation can stand to benefit both patients and developers, particularly the startups and scientists that are developing novel AI-based solutions for early cancer detection. “AI-driven startups are pivotal in addressing India’s cancer burden by democratising expertise. In a country facing a chronic specialist shortage, AI empowers clinicians in Tier-2 and Tier-3 cities with metro-level diagnostic accuracy, facilitating early-stage detection where survival rates are highest. However, the path forward involves navigating regulatory and data challenges. Classifying AI-powered diagnostic software as Class C medical devices is a critical step; it ensures clinical validity and patient safety while building the trust required for large-scale hospital adoption”, said Chirag Adatia, Partner, Health and Life Sciences and Private Capital Practices, Oliver Wyman. He further added, “By creating compounding returns across the healthcare value chain, from improved hospital utilisation to better actuarial outcomes for insurers, AI-driven diagnostics are not just improving survival rates; they are making the India healthcare system more economically resilient.”   Rise of intelligent cancer diagnosis The emergence of oncology-focused AI startups in India is marking a significant chapter in the ongoing battle against cancer. By harnessing the power of technology, these innovators are reshaping the way we used to look at the oncology landscape earlier. Experts suggest that the AI-based cancer diagnostics market in India is projected to reach $41.4 million by 2030, where startups are likely to hold a major share. Mumbai-based startup Qure.ai is currently utilising deep learning algorithms to analyse medical imaging, enabling faster and more accurate lung cancer detection. The company has recently joined hands with the global player Johnson & Johnson MedTech, to establish AI-led Incidental Pulmonary Nodule (IPN) detection clinics across leading hospitals in India. “AI helps to overcome healthcare bottlenecks, from imaging reporting backlogs and low screening uptakes. The future belongs to proactive, AI-enabled health systems that can scale care without compromising quality. AI isn’t here to replace humans, it’s here to amplify human judgment, deliver faster insights, and ultimately make healthcare more equitable”, said Prashant Warier, Founder and CEO of Qure.ai. Emerging as a game-changer in cancer diagnostics is Bengaluru-based startup SigTuple's AI100, an AI-driven smart robotic microscope. It automates the microscopic analysis of biological samples, including blood and urine, and delivers results in minutes. This technology has received US FDA approval for its blood smear application, making it the first Indian company to achieve this milestone. The company has forged crucial partnerships with diagnostic labs to secure annotated data, and with distribution partners like Horiba India, leveraging established networks for market penetration. At the other end, Punjab government has launched first-of-its-kind AI-enabled screening devices for early detection of breast cancer and cervical cancer, in partnerships with startups such as Niramai and Periwinkle. Within Punjab, RNT Health Insights is specialising in AI-assisted diagnostic solutions for the accurate detection of pathologies during endoscopic procedures. The startup has recently received US FDA Breakthrough Device Designation for its oesophageal cancer and gastric cancer detection tools. Adding to this list is Dr. Lal Path Labs that has made a significant leap in cancer diagnostics by adopting a deep learning-based AI module to detect lymph node metastasis, including micrometastasis, in cancer cases, in collaboration with Singapore-based startup Qritive. “India has the potential to become a global hub for AI-driven medical devices and diagnostics. AI is enabling earlier, more accurate, and more accessible detection of disease, reshaping preventive and precision medicine in India. AI tools can detect subtle abnormalities critical for cancer. In endoscopy, AI has significantly improved adenoma detection rates, lesion characterisation, and early cancer diagnosis”, said Koji Wada, Managing Director (Healthcare Division), Fujifilm India. Delhi-based startup Primary Healthtech has recently received support from Technology Development Board (TDB), Department of Science and Technology, Government of India, to build an AI-based point-of-care blood testing device for detecting cancer and other diseases. Around similar lines, researchers at the Indraprastha Institute of Information Technology (IIIT), Delhi, have developed cutting-edge artificial intelligence tools that can detect cancer at an early stage using a simple blood test. The test is based on Tumour Educated Platelets (TEPs), which carry molecular information altered by the presence of cancer. Using AI, the test can identify multiple cancer types from a small blood sample, offering a cost-effective alternative to invasive and expensive diagnostic procedures. “AI models have been shown to detect up to 13 different cancers with over 98 per cent accuracy in controlled studies when analysing tissue patterns that the human eye would find difficult to quantify. For India, the opportunity is particularly profound. With a large and diverse population and a limited number of specialists, AI can help bridge gaps by streamlining imaging interpretation and pathology analysis, reducing reporting times, and enabling remote diagnostics in areas with few specialists”, said Dr Mayanka Lodha Seth, Chief Pathologist, Redcliffe Labs. With these developments taking place in India, AI is no longer a secondary adjunct in oncology, it is becoming an essential, intrinsic component in advancing cancer detection. With regulatory frameworks for AI in cancer diagnostics taking shape now, there is an urgent need to unite AI researchers, oncologists and regulators to create transparent, and clinically valuable AI deployment standards, so that AI can usher in a transformative era within the oncology landscape.   Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/news/100/27258/wipro-ge-healthcare-unveils-made-in-india-ai-powered-breakthrough-in-mr-imaging.html https://biospectrumindia.com/news/100/27258/wipro-ge-healthcare-unveils-made-in-india-ai-powered-breakthrough-in-mr-imaging.html Sat, 31 Jan 2026 00:00:00 +0530 Wipro GE Healthcare, a leading global medical technology, diagnostics, and digital solutions innovator, has announced the launch of SIGNA™ Prime Elite, its latest MR imaging system, at the Indian Radiological and Imaging Association (IRIA) 2026 Annual Conference in Hyderabad.  Manufactured at Wipro GE Healthcare’s MDM facility - the company’s PLI factory, SIGNA™ Prime Elite is the latest addition to its pioneering ‘Made in India’ portfolio. The MR system combines advanced imaging intelligence with patient-centric design to deliver faster, more comfortable scans and improved diagnostic confidence. Compared to non-deep learning GE HealthCare scanners, SIGNA™ Prime Elite achieves up to 37% reduction in table time, enabling quicker throughput. AI-enabled workflow solutions further streamline MR exams, with AIR Touch™ automatically selecting optimal coil combinations, while AIR x™ applies ‘deep learning’ to detect anatomy and prescribe MRI slices — even in complex neurological and knee cases. Together, these tools eliminate sources of variation, improve reproducibility, and allow clinicians to focus on patients. Additionally, the MR system’s blanket‑like AIR™ Coils allow natural positioning and shorten preparation time, while a flared bore entrance with feet-first scanning adds clearance and headspace, easing exams for claustrophobic patients. Its compact footprint and lower 60 KVA power consumption make installation easier, enabling hospitals and diagnostic centers beyond major metros to offer advanced MR imaging and expand access to care. Additionally, with Intelligent Magnet Technology reducing helium use by up to 75%, the solution supports more sustainable operations while redefining the future of MR imaging. ]]> https://biospectrumindia.com/news/100/27230/coforge-inks-strategic-partnership-with-innovaccer-to-accelerate-ai-transformation-in-healthcare.html https://biospectrumindia.com/news/100/27230/coforge-inks-strategic-partnership-with-innovaccer-to-accelerate-ai-transformation-in-healthcare.html Tue, 27 Jan 2026 00:00:00 +0530 Noida-based Coforge Limited has announced a strategic partnership with US-based Innovaccer across the healthcare ecosystem designed to improve care delivery and patient outcomes. This partnership will combine Coforge's domain expertise in driving organisational transformation with Innovaccer’s AI infrastructure and data platform, driving measurable improvements in clinical, financial and administrative results for healthcare organisations. The two firms launched G-Forge, a joint initiative designed to help healthcare organisations scale AI, integrate siloed data, and improve enterprise decision-making. G-Forge brings together Innovaccer’s Gravity platform and Coforge’s expertise in large-scale implementation and organizational transformation to support healthcare providers, payers, life sciences organiSations, and healthcare technology companies as they modernize operations and adopt AI across the enterprise. As the preferred platinum implementation partner for Innovaccer’s Gravity AI platform, Coforge will also establish a Healthcare AI Centre of Excellence. Together, Innovaccer and Coforge will develop industry-specific accelerators and solutions in the areas of member and provider experience, care management, and revenue cycle management tailored to the needs of healthcare organisations, while offering end-to-end implementation, integration, and managed services to support Gravity deployments. ]]> https://biospectrumindia.com/news/100/27216/health-ministry-launches-online-training-programme-for-artificial-intelligence-in-medical-education.html https://biospectrumindia.com/news/100/27216/health-ministry-launches-online-training-programme-for-artificial-intelligence-in-medical-education.html Thu, 22 Jan 2026 00:00:00 +0530 Anupriya Patel, Union Minister of State for Health and Family Welfare, Government of India, recently launched the online training programme on Artificial Intelligence (AI) in Medical Education developed by National Board of Examinations in Medical Sciences (NBEMS), an autonomous body of the Ministry of Health and Family Welfare. The objective of the programme is to expose nearly 50,000 doctors to Artificial Intelligence and provide a basic understanding of its practical applications in medicine, investigation, clinical decision making, research and medical education. The initiative aims to enhance the digital competencies of physicians and enable them to make effective use of AI-based tools in healthcare delivery and academic practice. Anupriya emphasised that the use of Artificial Intelligence in the healthcare sector is not an option but a necessity. She said that the purpose of AI is not to replace doctors, but to increase the capacity of doctors, to fill the gaps caused by the shortage of medical professionals and to reduce the burden of patients. Punya Salila Srivastava, Union Health Secretary said that the launch of the online training initiative on Artificial Intelligence in healthcare is a significant step towards strengthening medical education and enhancing the competencies of doctors across the country.  ]]> https://biospectrumindia.com/news/100/27212/rajalakshmi-engineering-college-to-host-titanium-2026-positioning-chennai-as-hub-for-deep-tech-convergence.html https://biospectrumindia.com/news/100/27212/rajalakshmi-engineering-college-to-host-titanium-2026-positioning-chennai-as-hub-for-deep-tech-convergence.html Wed, 21 Jan 2026 00:00:00 +0530 Rajalakshmi Engineering College, Chennai is hosting a 3-day National Tech Fest, called TITANIUM 2026 during 12th-14th February, 2026 – billed as India’s largest Tech Fest. Rajalakshmi Engineering College is a premier autonomous institution affiliated to Anna University, accredited with the highest A++ grade by NAAC and widely recognized for its strong ecosystem in research, innovation, entrepreneurship, and industry collaboration, nurturing future leaders in engineering and technology. With 20+ international (US, UK, Germany and Malaysia) and national confirmed speakers from varied domains, 10+ plenary sessions, 75+ technical events, 35 lakh worth prizes, 50+ technology exhibits, 10+ certificate workshops and AR/VR experience zones, the fest is arguably shaping up to be India’s biggest hoping to draw 10000+ students, researchers and professionals. With Bio-Digital Convergence and Human Augmentation as one of the six plenary themes, luminaries including Prof. Bruce Gale (University of Utah), Prof Abhimanyu Veerakumarasivam (Sunway University, Malaysia), Prof. Suresh ML Raghavan (University of Iowa), Piyush Padmanabhan (Founder-CEO, Next Big Innovation Labs, Bangalore) and Dr N Murugan (Senior Scientific Officer, mfine, Chennai) will take the stage to deliberate on the intersection of biology and technology. The tech fest is also an opportunity for the participants to watch Tilly Lockey, the Bionic Woman and social media sensation from UK, speak and demonstrate the role of bionics in her daily life alongside a display of AI powered robots and Robotic rehabilitation devices by startup company Xibotix from Vellore.  The man behind this mega tech summit, Abhay Meganathan, Vice Chairman of Rajalakshmi Engineering College spoke on his vision behind TITANIUM. According to him, “TITANIUM was conceived as a platform where science, engineering, and enterprise converge with real-world relevance. India stands at a defining moment in biotechnology, from deep-tech research and translational science to scalable industry impact. Through TITANIUM, our intent is to bring academia, industry, and young innovators onto one common stage to exchange ideas, challenge assumptions, and collectively shape the next phase of India’s biotech journey. It is not just a tech summit, but a deliberate effort to nurture future-ready talent and meaningful collaborations.” The tech fest will also feature plenary sessions on defence, space technology, quantum computing, electric mobility, smart cities and circular economy. Exhibits on drone technology, autonomous vehicles, embedded systems, humanoid robots and workshops on 3D bioprinting, industry virtual twins, innovation bootcamp and microfluidics round up the dash of technology. In the iconic words of Eleanor Roosevelt, "The future belongs to those who believe in the beauty of their dreams." And, Rajalakshmi Engineering College, as a higher education institution, is no stranger to dreaming big. ]]> https://biospectrumindia.com/news/100/27202/indias-first-ai-led-digital-clinic-for-women-pinky-promise-raises-1m.html https://biospectrumindia.com/news/100/27202/indias-first-ai-led-digital-clinic-for-women-pinky-promise-raises-1m.html Tue, 20 Jan 2026 00:00:00 +0530 Pinky Promise, a first-of-its-kind artificial intelligence (AI)-led digital clinic for women, has raised $1 million in a pre-seed funding round led by the Rebalance Angel Community, India’s first accelerator and angel community focused on advancing diversity among founders and funders. The round saw participation from reputed angels such as Padma Bhushan awardee and former MD and CEO of Tata Consultancy Services, Subramanian Ramadorai, and Mala Ramadorai. Pinky Promise is designed to instantly and reliably diagnose and manage women’s health issues, addressing a critical gap in Indian healthcare for accessible, non-judgmental, and high-quality sexual and reproductive health care. The app combines advanced AI with expert gynaecologist oversight to give women confidential, instant, and affordable care, empowering them to address concerns at any stage of life or need. Through the app, women can access care 24x7, instantly chat with an experienced gynaecologist, and receive prescriptions and guidance within minutes – all at a pocket-friendly starting price of Rs 99. This model is powered by custom AI systems that work closely alongside qualified gynaecologists. This fresh capital will be used to accelerate integrated offerings, support the rollout of physical clinics, and expand a range of clinically backed nutritional supplements, enabling continuity of care at a national scale. Mumbai-based startup Pinky Promise has delivered gynaecological care to over 350,000 women on 320+ symptoms and conditions from period problems and UTIs to fertility, pregnancy, PCOS and more. They have 40,000 paying customers across every district in India.  ]]> https://biospectrumindia.com/news/100/27195/mahajan-imaging-labs-introduces-alzheimers-diagnostics-with-ai-integrated-testing.html https://biospectrumindia.com/news/100/27195/mahajan-imaging-labs-introduces-alzheimers-diagnostics-with-ai-integrated-testing.html Mon, 19 Jan 2026 00:00:00 +0530 Mahajan Imaging & Labs, a leading chain of advanced diagnostic centres in India, has expanded its Alzheimer’s diagnostic capabilities with the introduction of an artificial intelligence (AI)-integrated blood biomarker test, supported by a structured PET and MRI imaging pathway, offered under its Dementia Diagnostic Series, which includes Alzheimer’s blood biomarker testing using the pTAU217/βAmyloid1-42 ratio along with cognitive health and genetic risk panels, AI-enabled MRI brain imaging with dementia protocol, and FDG PET imaging where clinically indicated. The new pTAU/Aβ1-42 blood biomarker test, which is USFDA- and CDSCO-approved, enables the detection of Alzheimer’s-related biological changes well before severe cognitive symptoms become evident, supporting a shift from symptom-led assessment to a biology-first diagnosis in Indian clinical practice.   Recent estimates indicate that over 8.8 million Indians aged 60 and above are living with dementia, with Alzheimer’s disease accounting for the majority of cases. This number is projected to nearly double over the next decade, highlighting the growing need for early and accurate diagnostic tools that support timely intervention and care planning.    Until recently, Alzheimer’s biomarker testing relied on cerebrospinal fluid samples, which meant a more invasive procedure for patients. Today, with plasma-based testing, we can obtain the same critical information through a simple blood test. This makes diagnosis easier, safer, and far more acceptable for patients. Mahajan Imaging & Labs now performs the pTAU/Aβ1-42 blood biomarker test in its Reference Laboratory, enabling faster reporting, closer clinical integration with imaging findings, and improved affordability for both patients and clinicians.  Globally, Alzheimer’s diagnosis increasingly depends on amyloid PET imaging and cerebrospinal fluid (CSF) testing. Commenting on the Alzheimer’s diagnostics scenario in India, Dr. Harsh Mahajan, Padma Shri Awardee, Founder & Chairman of Mahajan Imaging & Labs, said, “In India, limited availability and high costs, as much as Rupees two lakhs per scan, have restricted widespread access to amyloid PET, leaving many clinicians dependent on symptom-based assessments. A key differentiator of Mahajan Imaging & Labs’ approach is the integration of laboratory diagnostics with imaging. The combination of blood biomarkers with 18F FDG can be a game-changer not only in early diagnosis of Alzheimer’s, but also in follow-up of patients on the new treatments to assess for treatment response. The conclusions of this symposium shall be sent to the Neurological Society of India to help in formulating guidelines for the diagnosis and treatment of Alzheimer’s in India. This may even have implications on the approach to early diagnosis of Alzheimer’s in other parts of the world.”   ]]> https://biospectrumindia.com/news/100/27196/google-announces-new-additions-to-gemma-open-model-family-to-advance-ai-in-healthcare-in-india.html https://biospectrumindia.com/news/100/27196/google-announces-new-additions-to-gemma-open-model-family-to-advance-ai-in-healthcare-in-india.html Mon, 19 Jan 2026 00:00:00 +0530 Highlighting the current challenge for India’s mature and fast-growing startup ecosystem, Google has announced the Google Market Access Programme, a first-of-its-kind initiative to help Indian startups strengthen their go-to-market efforts, shortening the journey from local pilots to global scale. Google has also announced new additions to its Gemma open model family, designed to help startups build population-scale and production-ready AI applications. MedGemma 1.5 addresses the growing demand for advanced healthcare AI, enabling startups to work with high-dimensional medical imaging at scale. FunctionGemma, a lightweight model optimized for function calling, supports the next generation of on-device, agent-based systems, allowing AI applications to take secure, reliable action locally. Together, these models expand the building blocks available to developers creating real-world, deployable solutions. MedGemma 1.5 represents the next generation of Google’s medical AI. Building on the success of the company’s Health AI Developer Foundations program, this new open 4-billion parameter model enables developers to build applications that support complex medical imaging workflows, including those involving 3D volumes (CT and MRI scans), whole slide histopathology, chest X-ray longitudinal analysis and anatomical localisation, and extraction of content from medical lab reports. The release of MedGemma 1.5 follows Google’s recent collaboration with India’s flagship medical institute, All India Institute of Medical Sciences (AIIMS), which is leveraging MedGemma to build India’s Health Foundation Models, contributing to India’s Digital Public Infrastructure and the outcomes being made available to the ecosystem. FunctionGemma, a specialised version of the Gemma 3 270M model, acts as a fully independent agent for private, offline tasks, or as an intelligent traffic controller for larger connected systems. It helps translate natural language commands into executable actions, allowing startups to build on-device, low-latency applications with automated workflows. FunctionGemma supports the cost-effective and lightning-fast development of mobile solutions that respect user privacy and can work seamlessly even on low-end devices without a constant internet connection. FunctionGemma supports a broad developer ecosystem and can be fine-tuned using popular tools such as Hugging Face Transformers, Unsloth, Keras, and NVIDIA NeMo, and deployed across platforms including LiteRT-LM, vLLM, Llama.cpp, Vertex AI, and other edge inference environments. These launches complement Google’s ongoing investments in India’s physical AI infrastructure, including the Global AI Hub in Visakhapatnam, which provides a 1-gigawatt foundation powered by green energy and the company’s advanced AI chips, to ensure Indian startups have access to high-performance compute.   ]]> https://biospectrumindia.com/news/100/27172/lantern-pharma-establishes-ai-centre-of-excellence-and-advanced-agentic-labs-in-bengaluru.html https://biospectrumindia.com/news/100/27172/lantern-pharma-establishes-ai-centre-of-excellence-and-advanced-agentic-labs-in-bengaluru.html Tue, 13 Jan 2026 00:00:00 +0530 US-based Lantern Pharma Inc., a pioneer in AI-driven precision oncology and computational therapeutic development, has announced the establishment of an AI Centre of Excellence and Advanced Agentic Labs in Bengaluru. This strategic initiative represents a critical inflection point in Lantern's evolution—transitioning from pioneering AI-enabled drug discovery in cancer to industrialising those capabilities at global scale for the broader drug development community. As pharmaceutical companies increasingly shift from AI experimentation to enterprise-scale deployment, Lantern's Bengaluru centre will serve as the company's global scale-up center for the AI platform, providing expanded computational capacity, specialised technical talent, and follow-the-sun development cycles that enable rapid iteration and deployment of advanced AI modules and functionality. The AI centre of excellence capabilities will support both Lantern's internal pipeline and growing roster of pharmaceutical and academic collaborators globally. The centre will expand the technical depth and throughput of Lantern's proprietary RADR® AI platform, which currently leverages hundreds of billions of oncology-focused data points and an expanding library of sophisticated machine learning algorithms and curated disease models and knowledge objects. Critically, the initiative will accelerate development of Lantern's specialised large language model (LLM) designed to assess, optimise, and generate novel molecular candidates across diverse therapeutic applications—translating complex computational insights into precision-targeted drug development strategies. Complementing this, Lantern will expand its specialised large quantitative models (LQMs) designed to aid in assessing and optimising chemical and molecular features, which will provide generative bioinformatic and medicinal chemistry reasoning and outputs. ]]> https://biospectrumindia.com/news/100/27147/bvg-india-and-senecio-robotics-to-deploy-ai-driven-sterile-mosquito-technology-in-india.html https://biospectrumindia.com/news/100/27147/bvg-india-and-senecio-robotics-to-deploy-ai-driven-sterile-mosquito-technology-in-india.html Thu, 08 Jan 2026 00:00:00 +0530 Senecio Robotics, an Israel-based deep-tech company specialising in artificial intelligence (AI) and robotics, has announced the signing of a Memorandum of Understanding (MoU) with BVG India Limited (BVG), one of India’s largest professional services providers to introduce advanced Sterile Insect Technique (SIT) mosquito control solutions in India. The MoU was signed during a formal ceremony hosted with the support of the Israeli Embassy in India and graced by the presence of Yaniv Revach, Consul General of Israel to India, underscoring the growing collaboration between India and Israel in science-driven public-health innovation. The solution is non-GMO, 100% natural, and chemical-free, involving no genetic modification, no gene editing, and no environmental spraying. It is designed to complement existing public-health measures while addressing growing concerns related to insecticide resistance, environmental impact, and long-term effectiveness. At the core of the initiative is the Sterile Insect Technique (SIT), a method recognized globally and supported within international public-health frameworks, including guidance published by the World Health Organization (WHO) for the safe planning, testing and evaluation of SIT for mosquito control. The approach involves the controlled release of locally sourced, non-biting male mosquitoes that are rendered sterile. Because female mosquitoes typically mate only once, mating with sterile males results in non-viable eggs, leading over time to a natural reduction in the local mosquito population. Senecio Robotics brings a differentiated technological capability to SIT deployment through its AI- and robotics-driven production platform, which automates mosquito rearing, sorting, and quality assurance at industrial scale. This enables production facilities to be adapted to local mosquito species, climate conditions and population density, while generating the volumes required to cover large urban and regional areas. The collaboration will focus on establishing localised production capabilities and deployment pathways in India, in coordination with relevant stakeholders and authorities. The initiative aims to support long-term mosquito population management without harming non-target species or ecosystems. ]]> https://biospectrumindia.com/news/100/27140/healthark-brings-agentic-ai-to-core-of-clinical-research-with-curie-clinical.html https://biospectrumindia.com/news/100/27140/healthark-brings-agentic-ai-to-core-of-clinical-research-with-curie-clinical.html Mon, 05 Jan 2026 00:00:00 +0530 Healthark has introduced Curie Clinical, a specialised module within its next-generation agentic AI enterprise platform, Curie. Designed to unify data, workflows, and intelligent automation across clinical research, Curie Clinical embeds agentic AI at the core of clinical operations, moving beyond task-based automation to orchestrate end-to-end study execution through goal-driven, context-aware agents, from early study design and protocol development through ongoing execution and oversight. Early implementations show that Curie Clinical can reduce documentation and review timelines by up to 70% and deliver 50% cost savings, while strengthening operational and regulatory compliance and autonomously managing a substantial share of recurring clinical tasks. These include generating monitoring visit reports, drafting narratives, tracking site deviations, supporting automated site feasibility assessments, training coordination, and site performance tracking and routine study oversight. By shifting these activities to agentic AI, clinical operations teams, clinical research associates (CRAs), medical writers, and safety specialists gain more capacity to focus on higher-value scientific and strategic work. “We are confident that with Curie Clinical, research teams can move faster, reduce operational overhead, and gain real-time control over clinical workflows. This is not incremental automation-it’s a move to agentic AI that autonomously powers insight-driven clinical operations,” said Dhaval Vasavada, Associate Director, Information, Data and Technology (IDT), Healthark.   ]]> https://biospectrumindia.com/news/100/27128/iit-d-creates-ai-agent-to-conduct-experiments-like-human-scientists.html https://biospectrumindia.com/news/100/27128/iit-d-creates-ai-agent-to-conduct-experiments-like-human-scientists.html Mon, 29 Dec 2025 00:00:00 +0530 Researchers at the Indian Institute of Technology, Delhi (IIT-D) have developed AILA (Artificially Intelligent Lab Assistant), an AI agent capable of stepping into real laboratories and carrying out scientific experiments from start to finish, much like a human scientist. The research focused on the Atomic Force Microscope (AFM), a sophisticated instrument that examines materials at incredibly tiny scales. Remarkably, AILA can now control this complex device, make real-time decisions during experiments, and analyse results independently. The research also uncovered critical safety concerns. AI agents occasionally deviated from instructions, highlighting the need for robust safeguards must be implemented to prevent accidents or equipment damage as laboratories move toward greater automation. This breakthrough aligns with India’s ambitious AI for Science initiative. The government has recently announced major funding through the Anusandhan National Research Foundation (ANRF) to accelerate AI-driven research across the country. ]]> https://biospectrumindia.com/news/100/27131/pinnacle-blooms-network-to-scale-ai-powered-child-development-operating-system-with-70-m-funding.html https://biospectrumindia.com/news/100/27131/pinnacle-blooms-network-to-scale-ai-powered-child-development-operating-system-with-70-m-funding.html Mon, 29 Dec 2025 00:00:00 +0530 A leading global healthcare investment fund has offered $70 million to Pinnacle Blooms Network, the flagship pediatric-therapy enterprise of Hyderabad-based startup Bharath Healthcare Laboratories. The proposed two-tranche Series A investment, advised by Yukon Capital, would represent one of the largest early-stage financings in child-development infrastructure anywhere in Asia. The offer comes as Pinnacle evaluates strong interest from multiple global institutional investors seeking exposure to the fast-emerging developmental health sector. Pinnacle operates more than 70 multi-disciplinary therapy centres across India - and has delivered over 20 million one-to-one therapy sessions to date. The company's proprietary Pinnacle Child Development Operating System (GPT-OS®) is a multi-patent-filed digital-therapeutic platform that measures, forecasts, and personalises every dimension of a child's developmental journey across speech, motor, cognitive, and behavioural domains. The GPT-OS® architecture integrates modules including Diagnosis, Prognosis, TherapeuticAI®, AbilityScore®, Seven Readiness Indexes®, and TherapySphere™—multi-sensory therapeutic environments designed to accelerate neurological development in children with autism, speech delays, ADHD, and related conditions. The proposed funding is structured in two phases. Phase 1 comprises $70 million for rapid domestic expansion and technology acceleration. Phase 2 envisions a follow-on tranche as Pinnacle expands into Southeast Asia and the GCC. Capital deployment would fund expansion from 70+ to 300 centres within 24 months, R&D acceleration for home-based TherapeuticAI® applications, large-scale manufacturing of TherapySphere™ sensory rooms, and regulatory submissions for international market access. Pinnacle is targeting expansion with projected annual revenue scaling from Rs 160+ crore to Rs 6,000 crore. On 23 September 2026, Pinnacle Blooms Network published a source ledger for six company measures on its Verify evidence hub. The ledger defines each measure, its 17 July 2026 cutoff, counting method and location in two accountant reports signed on 3 September 2026. Those reports have different scopes: an SRS 4400 factual-finding engagement and an SAE 3000 limited-assurance engagement. Their limits are stated beside the figures.One frequently cited figure is 31,052,382 services. In this ledger, “services” includes assessments, screenings and parent training as well as therapy-related services. It is not a count of 31 million one-to-one therapy sessions or unique children, and it does not establish clinical outcomes. The 16 patent entries are applications, not granted patents.A separate MD-5 source record identifies PinnacleAI GPT-OS version 1.0.0 as Class B, non-diagnostic developmental-support software for children aged 0–12. The record does not grant authority to diagnose autism or prove clinical effectiveness. Verify also separates research preprints, protocols and reports from any later peer-reviewed evidence, with author and version links where available.The public ledger and MD-5 record let readers inspect specific statements against dated sources. Neither registration nor company scale should be read as an endorsement or a guarantee of benefit for an individual child. Source ledger: https://www.pinnacleblooms.org/verify/evidence/claim-ledger.htmlMD-5 record: https://www.pinnacleblooms.org/verify/evidence/records/md5.html ]]> https://biospectrumindia.com/news/100/27098/iit-kharagpur-partners-with-intuitive-foundation-to-explore-use-of-ai-enabled-surgical-models.html https://biospectrumindia.com/news/100/27098/iit-kharagpur-partners-with-intuitive-foundation-to-explore-use-of-ai-enabled-surgical-models.html Sun, 21 Dec 2025 00:00:00 +0530 Indian Institute of Technology (IIT) Kharagpur has announced a new research programme in partnership with Intuitive Foundation, a non-profit organisation funded by Intuitive Surgical, a global technology leader in minimally invasive care and the pioneer of robotic-assisted surgery. The initiative aims to develop comprehensive digital models of surgical care that can underpin more reliable safety guidance, AI-enabled decision support, and responsible early-stage automation in future robotic-assisted procedures. Over time, these advancements are expected to help surgeons work with greater confidence and consistency, supporting better patient outcomes through more standardised and predictable surgical processes. To test these models, IIT Kharagpur will use the da Vinci Research Kit (dVRK), a non-clinical research platform built from retired da Vinci systems. The dVRK links digital models to physical robotic movements, enabling the development and testing of early automation modules using phantoms, synthetic tissues, and anatomical models. All testing will take place in controlled laboratory settings and will not involve human surgery. The work is guided by a multidisciplinary research team and supported by IIT Kharagpur’s long-standing collaboration with Nil Ratan Sircar Medical College and Hospital in Kolkata. By closely documenting cholecystectomy procedures (the surgical removal of the gallbladder) in real clinical settings, the researchers will gain practical insight into how surgeries unfold, helping them refine the digital models and identify where supportive tools could have the greatest impact.  The programme is expected to deliver two major outcomes. The first is a complete digital footprint of the surgical pathway, enabling AI-driven systems that combine diagnostic details, planned scenarios, intra-operative context, and recovery data to highlight safer techniques, flag deviations, and trace the sources of complications. The second is the responsible introduction of selective automation. Once the mapped workflows identify steps that are simpler, safer, and more repeatable, targeted automation modules can support surgeons during routine tasks and help them focus on higher-level decision-making. ]]> https://biospectrumindia.com/views/100/27089/creating-dependable-hardware-capable-of-accurately-capturing-ecg-signals-is-challenging.html https://biospectrumindia.com/views/100/27089/creating-dependable-hardware-capable-of-accurately-capturing-ecg-signals-is-challenging.html Thu, 18 Dec 2025 00:00:00 +0530 How do you assess the current state of India’s cardiac diagnostics and monitoring market, especially the country’s reliance on imported technologies? The Cardiac Diagnostics market is well established with ECG machines which are mostly imported, while the monitoring market is still in a nascent phase. Current players in the market either rely on imported hardware and/or use AI analytics platforms from foreign players. The very fact that Indian players are attempting these kind of solutions is very encouraging and as time progresses, dependence on imported tech will reduce further. The monitoring space itself is a massive market in India, which is largely unexplored. Therefore, vCardio can certainly play an important role in not only bridging this technological gap but also in making cardiac care more accessible and affordable.   What are the biggest challenges in building and scaling advanced cardiac monitoring devices in India? Creating dependable hardware capable of accurately capturing ECG signals was our initial challenge. After overcoming that, we implemented AI to analyse the signals, extract meaningful insights, and validated the results against conventional algorithms to improve performance and efficiency. Lastly, we scaled the solution to suit various use cases, such as cloud and mobile platforms.   Where is AI realistically adding clinical and operational value in cardiac monitoring today, and where is there still over-expectation? AI data sets for ECG signals are well established and performance is mostly above par and in few cases at par with the traditional methods. A key advantage of AI is its speed, enabling near real-time detection of cardiac events, which allows clinicians to act more quickly. Additionally, during extended monitoring periods of up to seven to ten days, AI-generated reports that provide event-specific snapshots and hourly summaries greatly reduce the time clinicians spend assessing a patient’s overall status. However, due to the nature of point-of-care use, human supervision remains essential and is always integrated into medical AI systems as part of a review and approval workflow.   What are the key barriers to adoption of advanced cardiac monitoring technologies in Tier 2 and Tier 3 cities? And how does vCardio aim to bridge these challenges? There are many factors at play here. Access and affordability are two major challenges in adoption of cardiac monitoring tech in Tier 2 and 3 cities and even more so in rural settings.  Key barriers include limited access, high costs, and a lack of awareness about available solutions. Additionally, ease of use for the final point of contact in the healthcare chain plays a significant role. vCardio offers a user-friendly wearable device with minimal learning requirements. We are entering the market with competitive pricing, targeting Tier 2 and 3 cities and building a robust dealer network to drive adoption.   What are the core differentiators that make vCardio stand out from existing cardiac monitoring devices in the domestic and international markets? Cardiac monitoring solutions involve numerous components, such as artifact-free signal capture and processing hardware, AI-driven analytics, and cloud or mobile integration. vTitan controls all three of these critical elements, offering a complete, end-to-end solution that sets it apart from competitors. This comprehensive ownership enables us to offer competitive pricing and deliver exceptional service to our customers.   How do you see India’s cardiac devices and monitoring segment evolving over the next 3–5 years? According to analyst reports, the global cardiac monitoring market is projected to grow from $669 million in 2024 to $1.71 billion by 2034, reflecting a compound annual growth rate (CAGR) of 7.8%. While specific data for India is unavailable, the rapid expansion of healthcare infrastructure in the country suggests it will capture a significant share of this growing market.   What are the major plans in store for the company in 2026? Any new launches in the pipeline? We are deepening our product portfolio in each of the categories we are currently in, that is Infusion, Radiology, Respiratory, Urology and Monitoring space. We have quite a few product launches scheduled in 2026. We are also investing in expanding our dealer networks within and outside India.   What is the revenue target for FY 25-26? Last year in 2023-2024, we registered more than 120% growth and this year also we've already crossed 100%. Given that we are comfortably growing at more than 100% growth year on year, and we expect the same trend to continue over the next 5 years.  ]]> https://biospectrumindia.com/news/100/27073/google-commits-400000-to-support-development-of-indias-health-foundation-model.html https://biospectrumindia.com/news/100/27073/google-commits-400000-to-support-development-of-indias-health-foundation-model.html Tue, 16 Dec 2025 00:00:00 +0530 Google has announced a suite of new collaborations and funding commitments to bolster India’s AI ecosystem at its “Lab to Impact” dialogue, an event supported by the India AI Impact Summit 2026. Attended by Dharmendra Pradhan, Union Minister of Education, the dialogue highlighted Google's research-driven approach to supporting Digital Public Infrastructure and empowering the research, developer, and startup ecosystem to solve national challenges and meet large-scale social needs. Google has announced funding of $400,000 to support new collaborations that will leverage MedGemma to build India’s Health Foundation Models. These models aim to improve the efficiency of healthcare providers and improve patient outcomes across India. As a first step, Ajna Lens will work with experts from the All India Institute of Medical Sciences (AIIMS) to build models that will support India-specific use cases in Dermatology and OPD Triaging. The resulting models will contribute to India’s Digital Public Infrastructure and their outcomes will be made accessible to the ecosystem. Additionally, researchers, AI experts, and clinicians from IISc will explore using AI models for broader clinical applications.  Google is also working with the National Health Authority (NHA) to deploy its advanced AI to convert millions of fragmented, unstructured medical records (such as doctor's clinical and progress notes) into the international, machine-readable FHIR standard. This shift is expected to help patients understand their medical information better, reduce documentation burden on patients and hospitals, and inform better data-driven policy decisions for India’s public healthcare strategy. Google is also working with NHA to bring over 400,000 NHA-registered health facilities, including hospitals, clinics, and diagnostic labs, on Google Maps and Search, allowing people to easily find and navigate to their nearest health centres with the most updated official information. ]]> https://biospectrumindia.com/views/100/27053/ai-powered-implantable-sleep-apnea-device-can-achieve-better-apnea-hypopnea-index-ahi-compared-to-cpap-device.html https://biospectrumindia.com/views/100/27053/ai-powered-implantable-sleep-apnea-device-can-achieve-better-apnea-hypopnea-index-ahi-compared-to-cpap-device.html Wed, 10 Dec 2025 00:00:00 +0530 What makes this AI-powered implantable device different from traditional sleep apnea treatments like CPAP, and why is it considered first-of-its-kind? Unlike CPAP devices, which require a mask connected to a machine delivering continuous positive airway pressure in hospital or home care settings, Capgemini’s partnered solution is fully implantable, eliminating discomfort, noise, and portability issues. CPAP systems provide fixed or auto-adjusting air pressure but remain reactive, adapting only to airflow changes without considering real-time physiological variations like sleep stages and body positions which tend to influence airway collapse and the severity of sleep apnea. In contrast, the AI-powered implant dynamically adjusts stimulation based on sleep stage, breathing effort, and patient-specific patterns. Thus, an AI-powered implantable sleep apnea device has the potential to achieve a better Apnea-Hypopnea Index (AHI) compared to CPAP which is key measure of sleep apnea severity. This proactive approach enables personalized therapy, by predicting and preventing airway collapse rather than responding after an event occurs. By combining adaptive algorithms with implantable neurostimulation, the device offers a discreet, intelligent alternative to CPAP, improving comfort, compliance, and overall sleep quality. How does the AI engine learn and adapt to each patient’s breathing patterns over time, and what kind of improvements have you observed? The AI engine continuously learns from each patient’s nightly breathing patterns by analyzing data from implanted sensors and stimulation feedback. Initially, it establishes a baseline of respiratory rhythm and muscle response, then applies adaptive algorithms to predict apnea risk and severity and optimize stimulation timing and intensity based on sleep stage, body position and efforts. Over time, the system personalizes therapy by recognizing variations across sleep stages and body positions, reducing unnecessary stimulation while ensuring airway stability. Observed improvements include a significant reduction in Apnea-Hypopnea Index (AHI)which is a key metric used to diagnose and assess the severity of sleep apnea along with more consistent REM cycles, fewer awakenings, and enhanced patient comfort. This adaptive approach also improves compliance compared to CPAP, as therapy becomes proactive, precise, minimally intrusive, and multi parameter based, delivering better clinical outcomes and overall sleep quality. What were the biggest engineering challenges in developing a device that can monitor, stimulate nerves, and deliver therapy in real time? Developing an implantable device that monitors, stimulates nerves, and delivers therapy in real time does pose several engineering challenges. First, miniaturization is critical element, integrating sensors, stimulation leads, and a pulse generator into a compact, biocompatible form factor without compromising performance. Second, ensuring precise timing and synchronization between breathing detection and nerve stimulation requires robust signal processing with minimum latency. Power management is equally important, as the device must operate for years on a small battery while supporting adaptive algorithms. Additionally, achieving secure wireless connectivity for data transfer to mobile and cloud platforms demands advanced encryption and low-power communication protocols. Finally, designing an AI engine that learns patient-specific patterns while running efficiently on edge hardware is complex and requires deep understanding of the clinical domain. Sensor design is typically the client’s IP and a key success factor, requiring expertise in biomedical engineering, material science, microelectronics, signal acquisition, and regulatory compliance to create sensors that accurately capture physiological signals for AI-driven therapy. How do you see implantable, AI-driven devices shaping the future of personalized healthcare beyond sleep disorders? Implantable, AI-driven devices represent a major leap toward truly personalized healthcare. Beyond sleep disorders, these systems can continuously monitor physiological signals, learn individual patterns, and deliver targeted interventions without external apparatus. For example, in cardiac care, AI-enabled implants could predict arrhythmias and adjust pacing dynamically, while in neurology, they could modulate nerve activity to manage chronic pain or epilepsy. In neurology, Deep Brain Stimulation (DBS) combined with AI can dynamically adjust stimulation for Parkinson’s disease, epilepsy, and even treatment-resistant depression, learning patient-specific neural patterns to optimize therapy. Similarly, Spinal Cord Stimulation (SCS) for chronic pain is evolving into adaptive systems that predict pain episodes and modulate signals proactively. Mental health applications are emerging, where closed loop neurostimulators monitor brain activity and deliver targeted interventions for anxiety or mood disorders. These trends reflect a shift from static implants to intelligent, connected ecosystems integrating real-time analytics, cloud-based updates, and predictive algorithms. By continuously learning from physiological and behavioral data, AI-powered implants promise proactive, personalized care, reducing hospital visits, improving compliance, and transforming chronic disease management into a seamless, personalized patient centric experience. Capgemini also works with pharma on AI for clinical trials and drug discovery—how does this sleep device fit into your larger healthcare innovation strategy? Capgemini’s Lifesciences innovation strategy spans the entire continuum—from drug discovery and clinical trials to smart connected care enabling precision medicine. Our work with pharma leverages AI tools for drug discovery, trial optimization, and predictive analytics, accelerating time-to-market of drugs. The AI-powered implantable sleep device fits into this vision by building intelligence in devices to the patient’s bedside—and even inside the body. It exemplifies closed-loop, data-driven care, where real-time physiological insights feed into adaptive algorithms for personalized treatment. Combined with mobile platforms and cloud analytics, these devices create a connected ecosystem that complements digital twins and precision medicine initiatives. By integrating IT and OT, we enable proactive interventions, reduce hospital revisits and improve outcomes. In essence, this device is not an isolated innovation, it’s a cornerstone in Capgemini’s mission to transform healthcare into a predictive, personalized, and patient-centric experience. With Capgemini’s combined IT+OT capabilities, what new healthcare problems do you believe can now be solved that weren’t previously possible? With Capgemini’s combined IT and OT capabilities, it becomes possible to integrate advanced analytics, IoT-enabled medical devices, and AI-driven automation with operational technologies, enabling real-time, closed-loop care systems. Implantable devices can stream physiological data securely through mobile platforms, which act as gateways for cloud connectivity. These mobile apps not only transfer data but also perform initial analytics, such as detecting anomalies, summarizing trends, and providing patient engagement before syncing with cloud-based predictive models. This convergence makes remote monitoring and adaptive therapy possible for chronic conditions like sleep apnea, cardiac arrhythmias, diabetes and neurodegenerative disorders. It also opens doors for digital twins of patients, enabling simulation-based treatment planning and personalized drug delivery. Our combined IT+OT capabilities don’t just transform connected care; they also enable breakthrough solutions like digital robotic surgical platforms. By integrating AI-driven analytics, IoT sensors, and automation into surgical platforms, we can deliver real-time decision support, predictive risk assessment, and precision control during complex procedures. For example, robotic-assisted knee or hip replacement systems leverage AI to analyze intraoperative imaging data, suggest the best choice of implants based on patient gait patterns and ligament tensions, enable adjustment of robotic instrument positioning dynamically, thus reducing chances of human error. Thus IT+OT synergy, with its smart connected intelligent ecosystem, will transform healthcare from reactive to proactive solutions, delivering precision medicine and improved patient outcomes.   ]]> https://biospectrumindia.com/news/100/27034/trivitron-healthcare-launches-new-venture-to-accelerate-hospital-digitisation.html https://biospectrumindia.com/news/100/27034/trivitron-healthcare-launches-new-venture-to-accelerate-hospital-digitisation.html Mon, 08 Dec 2025 00:00:00 +0530 Trivitron Healthcare, together with Dubai-based digital health innovator ResoHealth, has announced the launch of Trivitron Digital.AI, next-generation digital health venture created to accelerate the transition toward AI-enabled, interoperable, and patient-centric Smart Hospital ecosystems. Built on the combined strengths of Trivitron’s legacy in medical technology and ResoHealth’s global expertise in digital health, cloud platforms, and clinical AI, the new entity aims to bridge longstanding gaps in clinical data continuity, operational efficiency, and digital access across India and emerging global markets. The platform brings together a full set of cloud-based digital tools—such as an advanced Lab Information System (LIS), a zero-footprint Web-PACS for imaging, a mobile-first Personal Health Record (PHR), and AI-powered automation. These systems work together to connect diagnostic, clinical, and administrative workflows into one smooth, unified digital system. At its core, Trivitron Digital.AI brings together automation, AI-driven patient support, and real-time data insights to improve how hospitals function and how patients receive care. The LIS connects to any lab equipment, tracks every sample from start to finish, enables remote result approvals, and produces structured, accurate reports. The Web PACS allows clinicians to instantly view imaging studies through any browser, with options for AI-based highlights, side-by-side comparisons, and secure sharing between centres. Trivitron Digital.AI is also expanding its geographical reach, with pilot deployments planned across India’s major metros followed by phased expansion across Africa, the Middle East, and Southeast Asia—regions that face similar systemic challenges of fragmented systems, limited digital infrastructure, and rising demand for data-driven healthcare modernisation. The platform’s cloud-native model eliminates the need for heavy IT infrastructure, offering hospitals an affordable and future-ready path to digital transformation. ]]> https://biospectrumindia.com/news/100/27042/healthark-launches-next-gen-enterprise-ai-platform-curie-for-data-management.html https://biospectrumindia.com/news/100/27042/healthark-launches-next-gen-enterprise-ai-platform-curie-for-data-management.html Mon, 08 Dec 2025 00:00:00 +0530 Healthark has launched Curie, a next-generation enterprise intelligence platform built to unify systems, streamline decision-making, and automate complex workflows across global organisations. Powered by conversational GenAI, Curie integrates data, governance, and automation into one seamless AI layer. Early deployments show that Curie can reduce decision cycle time by nearly 50% while improving workforce and regulatory compliance by around 60%. With automation built into every layer of the platform, organizations are also seeing close to 90% of repetitive workflows being handled autonomously, freeing teams to focus on strategic, high-value work. At its core, Curie brings together four specialized AI-driven modules, each engineered to solve critical operational challenges while working in complete harmony with one another. Curie Clinical supports end-to-end study operations, accelerating documentation, site oversight, and compliance for life sciences teams. Curie People equips HR and workforce leaders with real-time insights, engagement analytics, and intelligent support tools to strengthen organizational performance. Curie Finance enhances financial visibility by enabling automated approvals, spend tracking, and audit-ready workflows. Finally, Curie Insights connects internal systems with live web research, helping teams uncover patterns, surface answers, and analyze information instantly to improve strategic decision-making. Speaking about the impact of Curie, Dr Purav Gandhi, Founder & CEO of Healthark, highlighted, “Curie represents a major shift in how organizations operate. Instead of working across disconnected systems, teams can now think, ask, and act through one unified AI layer. Our goal is to help organizations move from fragmented workflows to predictable, insight-driven operations.” Beyond its modular design, Curie is engineered for fast, frictionless adoption across complex environments. The platform offers API-based onboarding that allows organizations to connect existing tools, databases, and workflows without rewriting infrastructure. Its seamless integration capabilities ensure that Curie can sit on top of legacy systems as well as modern cloud platforms, creating a central intelligence hub without disrupting ongoing operations. To ensure trust and security, Curie embeds robust governance and safety features at every step. This includes automatic PHI/PII redaction, continuous audit logging, role-based access, and end-to-end compliance controls designed for regulated industries. Users can interact with their systems through natural language, asking any question and receiving clear, reliable responses within seconds. With its strong foundation of automation, intelligence, and compliance, Curie is set to redefine enterprise operations - delivering faster, clearer, and more reliable decision-making. ]]> https://biospectrumindia.com/news/100/27027/vtitan-launches-ai-powered-cardiac-monitor-vcardio.html https://biospectrumindia.com/news/100/27027/vtitan-launches-ai-powered-cardiac-monitor-vcardio.html Thu, 04 Dec 2025 00:00:00 +0530 vTitan Corporation, a MedTech company focused on innovative healthcare solutions, has announced the launch of vCardio, a single-lead, wearable point-of-care cardiac monitor. The device is entirely designed and manufactured in India, making vTitan one of the first companies in the country to deliver an end-to-end solution from hardware to cloud-based AI analytics in the health-tech space. vCardio has been engineered to provide smart, continuous monitoring for early detection of cardiac events and vigilant post-surgery care. With this launch, the company aims to make point-of-care services more accessible for patients and clinics. “The cardiac monitoring market faces a critical gap," said Prasad Maganti, CEO, vTitan. "There is an unmet need for point-of-care cardiac screening at ambulatory clinics, for continuous monitoring in pre-and-post-surgical step-down environments, and for prolonged home-based monitoring in cardiac risk patients. When we built vCardio, an edge-AI-enabled cardiac monitor, from ground up keeping clinical work flows in mind, , our aim was to meet this market need, and make cardiac care safer, smarter, and more accessible.” vCardio is a lightweight, compact point-of-care cardiac monitor designed for remote patient monitoring in homecare, geriatric care, and clinical settings. With Bluetooth connectivity, the device integrates seamlessly with the vCardio mobile app and software platform. Its lightweight construction ensures patient comfort during extended wear periods, supporting continuous monitoring throughout post-care recovery. The device employs AI-powered algorithms to detect and classify over 20 clinically significant cardiac arrhythmias in real-time as well as in the post-recording analysis of cardiac data over the course of a week. With clinically-validated accuracy, and beat-to-beat analysis, vCardio empowers healthcare professionals with faster, more precise rhythm insights, enhancing diagnostic confidence, streamlining clinical workflows, and improving patient outcomes.   ]]> https://biospectrumindia.com/features/100/26994/trends-2026-rise-of-resilient-life-sciences-innovation-.html https://biospectrumindia.com/features/100/26994/trends-2026-rise-of-resilient-life-sciences-innovation-.html Sun, 30 Nov 2025 00:00:00 +0530 A major trend in 2025 was the rise of anti-obesity drugs. Mounjaro, in particular, saw rapid uptake and became the second-highest selling weight-loss drug in India within just six months. Another  highlight was the opening of several Centres of Excellence (CoE). Notably, Miltenyi Biotec inaugurated India’s first Cell and Gene Therapy (CGT) CoE in Hyderabad, reflecting the growing focus on advanced therapies.  Much like everything in life, artificial intelligence (AI) continued to deepen its presence across healthcare, transforming diagnostics, research, and drug development. Pharma and Biotech  Policy and Innovation Driving Advanced Therapies The Government of India has launched the ‘Promotion of Research and Innovation in Pharma MedTech sector (PRIP)’ scheme to promote innovation in India. The scheme has a total financial outlay of Rs 5000 crore, which includes Rs 700 crore to establish Centers of Excellence (CoEs) at seven National Institutes of Pharmaceutical Education & Research (NIPERs), and Rs 4200 crore to accelerate investments in the R&D ecosystem within the sector. The scheme has defined three priority areas for funding: new medicines, Complex generics and biosimilars and novel medical devices. “It will be interesting to see the impact this scheme will make in 2026 and beyond. Considering the immense potential for increase in innovation within Pharma/Medtech in India, the overall ecosystem will benefit from this scheme and promote innovation at both the industry and academic level. Considering India’s large population and specific healthcare needs, we can expect good innovation momentum in these areas moving forward.  Moreover, Indian pharma needs to transform from being a generics producer to an innovation producer for long term growth,” said Prashant Khadayate, Director – Lifesciences Consulting & Research, GlobalData. This policy-driven push is expected to accelerate biology-led innovation in 2026, with advanced therapeutic modalities driving the next wave of growth. Cell therapies, autologous, allogeneic, and in vivo, are expected to shift from niche applications to scalable platforms across oncology, immunology, and regenerative medicine. While India approved its first CAR-T therapy only last year, experts anticipate a steady rise in CGT approvals in the coming years.  “Upcoming year will be defined by acceleration in high-value generics, complex formulations, and biologics. India’s role as the leading global supplier of affordable medicines will deepen, but the next phase of growth clearly lies in complex Injectables, peptides, sustained-release products, specialty therapies, and biosimilars—segments that are seeing stronger regulatory acceptance and higher demand across developed and emerging markets. With global healthcare systems seeking cost-effective alternatives, compliance strength, quality maturity, and digital transparency will become decisive factors in winning international confidence,” said Bhavin Mehta, Vice Chairman of the Pharmaceutical Exports Promotion Council of India (Pharmexcil).    Expanding to other geographies  A parallel, equally powerful trend is the broad-based diversification of export geographies. To mitigate the impact of US tariffs, pharmaceutical companies are exploring expansion into other geographies. While the US will remain a key driver, momentum is now shifting toward Africa, Latin America, Southeast Asia, the Middle East, and China, supported by rising procurement volumes and deeper commercial linkages.  “Exporters are responding by expanding Active Pharmaceutical Ingredients (APIs) capacity, Contract Development and Manufacturing Organisation (CDMO) partnerships, and resilient supply-chain models, enabling stronger participation in global tenders and reducing vulnerability to single-market fluctuations. The scale of India’s domestic market further enhances this export competitiveness, strengthening the manufacturing base and enabling a wider, more agile product portfolio. Reinforcing these sectoral tailwinds is the strong policy and trade push from the Government which is proactively shaping a future-ready export ecosystem”, said Mehta. “Production-linked incentives (PLI) for APIs and formulations, new bulk drug and medical device parks, enhanced regulatory cooperation with partner countries, trade missions, and an active FTA pipeline are collectively expanding market access for Indian manufacturers. Initiatives around digital quality systems, track-and-trace compliance, logistics modernisation, and sustainability standards are also elevating our positioning as a dependable global supplier. These measures are creating an enabling environment for exporters to scale their global footprint and transition from being primarily volume-driven suppliers to becoming high-trust, innovation-aligned partners in the global pharmaceutical value chain”, added Mehta.    AI and Gen AI in Drug Discovery & Diagnostics Artificial intelligence including generative AI is revolutionising drug discovery by accelerating candidate analysis, predicting drug-body interactions, and enabling faster, cost-effective therapy development.  “AI also advances diagnostics, facilitating early disease detection and precision treatment tailoring. For instance, Qure.ai’s AI-driven medical imaging solutions enable early diagnosis of TB, lung cancer, and stroke. Concurrently, decentralised clinical trials leveraging remote monitoring and AI analytics are increasing patient-centricity, accessibility, and efficiency, thereby accelerating therapy approval processes. The healthcare industry is projected to face continued cost pressures driven by new medical technologies, cited as the top driver by 74 per cent of insurers globally, underscoring AI’s central role in innovation and cost management,” said Ajay Mahipal - Co-Founder and General Partner, HealthKois.   Rise of Preventive Interventions  Preventive healthcare is emerging as a key growth driver, reshaping patient care globally. “We are entering a pivotal moment, where innovation and patient expectations are converging to redefine the healthcare industry. The vaccines market, valued at over $78 billion in 2023 and projected to nearly double by 2032, is a clear indicator that preventive and accessible healthcare will drive global growth in the decade ahead,” observed Sarvesh Mutha, Managing Director, IntegriMedical.  Shakul Srivastava, Vice President, Indian Immunologicals Limited, echoing similar sentiments, said, “The key trends are shifting toward preventive interventions, driven by the latest biotech innovations and enhanced through smart use of digital technologies.”    MedTech  "India’s MedTech sector is poised for remarkable growth, projected to reach $50 billion by 2026. At Medtronic, we see this momentum transforming healthcare making it more personalised, predictive, and supportive for every patient. Innovations in AI, IoMT, and personalised therapies will enable clinicians to deliver virtual care, proactive interventions, and treatments tailored to individual needs. Rising chronic diseases and an ageing population (200M+ seniors by 2030) will increase demand for remote monitoring systems bringing healthcare closer to home. By combining compassionate care with leading-edge technology, the MedTech innovations will empower patients and clinicians to achieve better health outcomes, together,” said Mandeep Singh Kumar, Managing Director and Vice President, Medtronic India.  Sharing his views Mutha said “AI-driven diagnostics and decision support systems are transforming healthcare by enabling faster, more accurate clinical decisions through predictive analytics and digital monitoring tools, ultimately improving both care quality and operational efficiency. At the same time, needle-free and innovative drug delivery technologies are rapidly gaining traction across areas such as vaccines, IVF hormones, growth hormones, and pain management, offering greater patient comfort, reducing infection risks, and improving treatment adherence. Complementing these advancements, pharmaceutical companies are increasingly forming collaborative partnerships with MedTech innovators to enhance dosing accuracy, ensure treatment consistency, and deliver more patient-centered solutions, making healthcare safer, more effective, and more accessible.”      Clinical Trials  Rise in Early-Phase Trials The regulatory reforms introduced in 2025 are expected to act as a catalyst in 2026, driving a new wave of innovation-led clinical research in India. Experts note a growing interest in early-phase studies and multi-regional clinical trials, supported by increasing expertise in complex areas such as CGT and tri-specific antibodies, which are set to become a mainstay in the coming year. Digitisation of Clinical Trials  In 2026, India's life sciences sector is expected to significantly transform, driven by the increasing integration of technologies such as AI, wearables, and data analytics. In clinical trials, this will enhance participant access and accelerate study timelines, helping to position the country as a prominent global hub for clinical research.  “Foundational to this will be to tap into the country’s rapidly growing digital ecosystem. In particular, mobile-first approaches help bridge infrastructure gaps by allowing patients to engage with trials from their own devices, wherever they are. Tools like electronic clinical outcome assessment (eCOA) and eConsent will facilitate real-time data collection and ensure patients receive comprehensive trial information from their own devices, promoting inclusive participation, including in areas such as central nervous system (CNS) and rare diseases. These tools will also ultimately improve accessibility by making trial participation less disruptive to daily life, which will in turn improve patient retention and data quality,” said Santhosh A F, Vice President, Asia Pacific South & India, Medidata.  AI will also continue to be a game changer. Morgan Stanley estimates that AI could help bring 50 new treatments to market within a decade, cutting drug discovery timelines from years to months, and reducing development costs. Beyond discovery, AI-driven study feasibility will be critical in 2026 to help sponsors and CROs identify optimal, high-performing sites across the globe. This precision in planning will significantly support study conduct and reduce overall development costs. “In India, we expect to see AI playing a pivotal role in decentralised clinical trials (DCTs), improving oversight and treatment adherence through the processing of real-time information from wearables and digital health tools, and enabling remote patient monitoring and the creation of synthetic control arms,” said Santhosh.  He added, “To capitalise on these trends, India must address some existing challenges, including skill gaps and strengthen public trust in clinical research, particularly in tier-2 and tier-3 cities. It must also navigate regulatory and ethical considerations, while providing careful oversight over patient consent and data privacy to build trust.  Looking into 2026, the future of clinical trials in India is not just about technology; it is about making trials safer, more inclusive, and more efficient for all stakeholders.”   CDMOs Digital Transformation of CDMOsAs pharmaceutical operations grow more complex, the integration of technology into quality systems is setting a new benchmark. Paperless workflows, real-time monitoring, predictive analytics, and remote oversight are embedding compliance into daily execution. For Indian CDMOs, this shift is already underway. At Syngene, for example, these efforts are visible in the use of secure remote inspection technologies such as RealWear, digitised checklists, and electronic batch records. Together, they help sustain a state of continuous audit readiness. These digital initiatives are reinforced by a broader shift toward decentralised accountability, ensuring that quality is embedded across teams and processes rather than being managed in isolation. This evolution signals both progress and opportunity for Indian CDMOs. By combining a strong quality culture with digital tools, organisations can go beyond meeting today’s compliance requirements to proactively shaping tomorrow’s standards. Those that see quality not just as a safeguard but as a strategic advantage will build stronger partnerships, operate with greater efficiency, and secure a lasting place for India in the global pharmaceutical supply chain, as highlighted by Alok Mehrotra, Chief Quality Officer, Syngene International, in an earlier op-ed with BioSpectrum India. Rise of Gene Therapy specific CDMOs Following a highly volatile period of investment peaks between 2020 and 2022, the global Cell and Gene Therapy (CGT) sector, and its associated Contract Research, Development, and Manufacturing Organisations (CRDMOs), have entered a phase of turbulence, marked by significant consolidation. Despite recent heightened regulatory scrutiny across the US and European Union (EU) and a year of leadership shifts, a robust pipeline of CGT candidates, coupled with a highly selective yet recovering venture capital (VC) landscape, still indicates substantial potential for emerging Indian CGT CRDMOs. If Indian CRDMOs can swiftly establish specialised manufacturing capacity, maintain rigorous international quality standards, and secure strategic global alliances, 2026 is poised to confirm India's trajectory towards capturing a significant, high-value portion of the worldwide CGT development and manufacturing market. “While overall biopharma VC funding remains stable, the competitive CGT space is seeing capital deployed more selectively toward companies with a clear path to commercial scalability. This targeted investment drives predictable manufacturing demand, presenting a significant opportunity for Indian CDMOs to engage early with VC-backed biotech companies and offer essential services like process development, scale-up, and GMP capacity. With US and EU CGT approvals continuing to rise and therapies expanding from rare disorders to more prevalent conditions such as cancers, autoimmune, and neurological diseases, Indian CDMOs are well-positioned to capture upstream demand and support global clinical trials and manufacturing,” said Dr Raghu Malapaka, Chief Business Officer, Nucelion Therapeutics, a wholly owned subsidiary of Bharat Biotech International Ltd.    Healthcare  Accelerated Adoption of AI in India’s Public Health System Building on significant initiatives launched in 2025, India is set to expand the use of AI across its public health system in 2026. With All India Institute Of Medical Sciences (AIIMS) Delhi, Postgraduate Institute of Medical Education and Research (PGIMER) Chandigarh, and AIIMS Rishikesh designated as Centres of Excellence for AI, and solutions like Media Disease Surveillance, Clinical Decision Support Systems in eSanjeevani, and AI tools for TB screening and outcome prediction already deployed, 2026 is expected to see broader integration of AI for disease surveillance, early diagnosis, and improved treatment outcomes.  India’s inclusion in the HealthAI Global Regulatory Network positions the country as a global leader in responsible AI deployment, enabling the sharing of best practices and fostering safer, more effective healthcare applications. The year ahead is expected to see AI increasingly driving disease surveillance, early diagnosis, and improved treatment outcomes nationwide. Digital Health, Telemedicine, and Virtual Hospitals “The evolution from telemedicine to virtual hospitals is transforming healthcare delivery. Digital platforms incorporating AI-powered chatbots, such as Wysa for mental wellbeing, and remote monitoring tools, like Beato for diabetes management in India, are improving patient access and outcomes, especially in chronic disease management. Virtual hospitals, such as Saudi Arabia’s SEHA Virtual Hospital, which serves 400,000 patients annually across 130 centres, exemplify this shift, meeting the rising demand driven by aging populations and healthcare workforce shortages,” said Mahipal.  Expanding on this, Sagar Sen, Senior Vice President – Global Life Sciences and Strategic Alliances at Qure.AI, noted that by 2026 the true impact of digital health will emerge from deeper system integration. “In 2026, digital healthcare will create a more connected ecosystem where information flows seamlessly between patients and primary health systems. It will support earlier intervention through predictive technologies that identify risks before illness becomes severe. As adoption grows, digital tools will help India build a stronger and more resilient health system capable of responding quickly to emerging challenges. The transition will simplify clinical workflows, improve data movement across EMRs and lead to a more coordinated care experience. As outcome-driven digital tools gain wider acceptance, AI will become a central part of everyday care delivery, enabling earlier diagnosis, ultimately improving health outcomes at scale.”   Ayesha Siddiqui ]]> https://biospectrumindia.com/news/100/27009/elekta-introduces-advanced-ai-enabled-ct-linac-in-india.html https://biospectrumindia.com/news/100/27009/elekta-introduces-advanced-ai-enabled-ct-linac-in-india.html Fri, 28 Nov 2025 00:00:00 +0530 In a country with over 1.4 million cases reported annually, with most being reported at later stages, adaptive radiotherapy (ART) is a major benefit to India’s ever-growing cancer burden. ART not only has the possibility to improve survival rates, but it also will enhance the overall quality of life for patients. It has become a critical tool for cancer treatment and management as it allows real-time precision therapy - making personalized treatment a reality. To further strengthen India’s fight against cancer, Elekta, a global leader in precision radiation therapy is introducing Elekta Evo, an advanced artificial intelligence (AI)-enabled CT-Linac (linear accelerator). This launch will be held during the Association of Radiation Oncologists of India conference (AROICON) at Biswa Bangla Convention Centre, Kolkata, from November 28-30, 2025. ART is a cutting-edge treatment approach that helps personalize each radiotherapy session based on real-time changes in a tumour’s characteristics and location. It ensures that the radiation dose is accurately delivered to the tumour, elevating both efficacy and safety. This in turn, offers greater control to the clinician and reduces potential side effects for the patient. ART’s potential to improve outcomes and quality of life is especially relevant in India, where head and neck cancers account for nearly 30 percent of all cases, while breast and cervical cancers remain the most common among women, and prostate cancer is the third most common among men. ]]> https://biospectrumindia.com/news/100/26985/yashoda-hospital-hitech-city-and-qure-ai-launch-ai-enabled-lung-nodule-clinic.html https://biospectrumindia.com/news/100/26985/yashoda-hospital-hitech-city-and-qure-ai-launch-ai-enabled-lung-nodule-clinic.html Wed, 26 Nov 2025 00:00:00 +0530 Yashoda Hospital, Hitech City, in collaboration with Qure.ai and AstraZeneca, has launched an artificial intelligence (AI)-enabled Lung Nodule Clinic to support earlier identification and timely management of lung cancer and other pulmonary diseases. Lung cancer is one of the leading causes of cancer-related deaths in India.  Pulmonary nodules are often subtle findings that can vary in size, density, and location, which makes them challenging to identify consistently on routine chest imaging. The new Lung Nodule Clinic at Yashoda Hospital, Hitech City, integrates Qure.ai’s AI solutions into chest X-ray workflows to flag, risk assess, and track these findings in a structured manner. Nodules can be indicators of early lung cancer or other conditions such as tuberculosis, sarcoidosis, or lymphoma. The AI-supported pathway helps clinicians prioritise higher-risk cases and ensure timely and consistent follow-up. A nurse navigator model supports the system and helps patients move from AI flagging to counselling, review, and next steps. “Standardised workflows help avoid delays and ensure consistent communication and documentation,” added Dr Vipul Garg, lead Consultant, Yashoda Hospitals Nodule Clinic. Since deployment, more than 17,000 chest X-rays have been analysed using Qure.ai’s AI. The program has identified over 960 nodules. Of these, 136 were classified as high risk and 77 patients were sent for expedited CT scans and pulmonology review. Confirmed diagnoses include lung cancers as well as other significant lung diseases, highlighting the broader value of this pathway for proactive lung health.   ]]> https://biospectrumindia.com/news/100/26970/samsung-launches-r20-ultrasound-system-in-india-by-redefining-general-imaging-with-next-gen-ai.html https://biospectrumindia.com/news/100/26970/samsung-launches-r20-ultrasound-system-in-india-by-redefining-general-imaging-with-next-gen-ai.html Mon, 24 Nov 2025 00:00:00 +0530 Samsung, India’s largest consumer electronics brand, has announced the launch of its super-premium, next-generation R20 ultrasound system for general imaging.   The R20 represents a major leap forward in general imaging, combining advanced artificial intelligence tools, superior image clarity, and an ergonomic design focused on clinician comfort and efficiency.   Built on Samsung’s state-of-the-art Crystal Architecture™, the R20 delivers exceptional image uniformity, resolution, and penetration across a wide range of general imaging applications. Its next-generation imaging engine, powerful GPU, and ultra-high-definition OLED monitor provide clinicians with remarkable visualization and diagnostic confidence in every scan.   The R20 is equipped with a comprehensive suite of AI-powered clinical and workflow enhancement tools that streamline complex procedures and automate repetitive tasks. Key technologies include:   Live LiverAssist – Detects a suspicious focal lesion during live ultrasound scan Live BreastAssist – Real-time detection of Breast lesions with BIRADS Classification and reporting. Auto measurement tools – AI-based automatic detection, measurement of internal structures with guided reporting for high consistency and maximum throughput Deep USFF – AI Based Deep Ultrasound Fat Fraction quantification with proven high correlation to the gold standard, i.e., MRI PDFF   “The R20 embodies Samsung’s commitment to advancing healthcare through intelligent innovation. With AI at its core and a focus on both image excellence and clinician comfort, the R20 is a paradigm shift in ultrasound technology helping doctors ensure detection of lesions during live scanning,” said Atantra Das Gupta, Head of HME Business, Samsung India.   ]]> https://biospectrumindia.com/news/100/26950/qure-ai-partners-with-microsoft-to-increase-access-to-lung-cancer-detection-and-management-suite-in-us.html https://biospectrumindia.com/news/100/26950/qure-ai-partners-with-microsoft-to-increase-access-to-lung-cancer-detection-and-management-suite-in-us.html Wed, 19 Nov 2025 00:00:00 +0530 Mumbai-based startup Qure.ai has announced its collaboration with Microsoft. Qure.ai will onboard its end-to-end lung cancer detection, measurement and management suite of artificial intelligence (AI)-powered solutions onto the Precision Imaging Network. This will streamline deployment of Qure.ai solutions to hospitals and health systems across the USA, driving digital healthcare transformation, improved tech integrations and ultimately enhance quality of patient care. The Qure.ai suite of lung cancer algorithms are built from Large Language Models (LLMs) and Agentic AI, the very latest forms of artificial intelligence. Qure.ai augments clinical workflows between radiologists, pulmonologists, interventionalists and thoracic surgery teams, to accelerate the patient pathway from early detection to diagnosis and treatment. It aims to answer the biggest cancer challenge in the US today, with lung cancer responsible for more deaths in the US than colon, breast and prostate cancers combined. The Qure.ai FDA-cleared lung cancer solutions can be deployed as individual products, or collectively as a suite for a unified and cohesive workflow.  ]]> https://biospectrumindia.com/news/100/26925/omron-healthcare-makes-second-investment-in-tricog-health-for-ai-based-cardiac-care.html https://biospectrumindia.com/news/100/26925/omron-healthcare-makes-second-investment-in-tricog-health-for-ai-based-cardiac-care.html Thu, 13 Nov 2025 00:00:00 +0530 Omron Healthcare Co. has announced additional investment in Bengaluru-based AI medtech startup Tricog Health. This is Omron Healthcare's second wave of investment in Tricog, following an initial investment in March 2023, further strengthening the partnership to accelerate business growth. Since 2023, Omron Healthcare and Tricog Health have been working together on the development and launch of KeeboHealth, a remote monitoring service for heart-failure patients that integrates Tricog's AI-based ECG analytics with Omron's connected electrocardiograph devices. By analysing home-recorded ECG and blood pressure data, and sharing the results with physicians, the service improves diagnostic efficiency and helps prevent post-treatment recurrence. Through this new investment, Omron Healthcare will further strengthen its strategic partnership with Tricog Health, setting ambitious joint goals to introduce solutions aligned with local clinical needs in India, while advancing the development and delivery of ever-higher-value devices and services. Dr Charit Bhograj, CEO Tricog Health said, "Together, we will accelerate a hospital-to-home rollout, pairing Omron's world-class medical devices with Keebo™ AI-powered, guideline-aware workflows, to streamline diagnosis, improve cardiovascular management, and reduce avoidable healthcare costs across Asia, Africa and other key international markets." ]]> https://biospectrumindia.com/news/100/26909/tcs-and-sintef-forge-partnership-to-deploy-artificial-intelligence-for-improving-elderly-care.html https://biospectrumindia.com/news/100/26909/tcs-and-sintef-forge-partnership-to-deploy-artificial-intelligence-for-improving-elderly-care.html Tue, 11 Nov 2025 00:00:00 +0530 Tata Consultancy Services (TCS), a global leader in IT services, consulting, and business solutions, has announced a partnership with Norwegian research and development company SINTEF—one of Europe's largest, independent research foundations. Drawing on TCS’s extensive experience in deploying Artificial Intelligence (AI) and digital solutions for clients in industries such as healthcare, energy, and smart cities, and SINTEF’s strong research capabilities, the partnership aims to create scalable, real-world innovations. Together, they will focus on using Social AI to improve elderly care, building on SINTEF’s successful eHealth initiative, SMILE (Smart Inclusive Living Environments). SMILE is a platform designed to help senior citizens live independently and safely in their own homes. It acts as both a communication tool and a support system, connecting seniors with family members, caregivers, and even peers in their community. By enabling easy communication, reminders and access to health services, SMILE fosters active living and social engagement. With multidisciplinary expertise within technology, natural sciences and social sciences, SINTEF works to create innovation through development and research assignments for business and the public sector in Norway and abroad.  Sapthagiri Chapalapalli, Head of Europe at Tata Consultancy Services, said, “The most impactful ideas are often generated in collaboration with external partners, startups, and academia. We are excited to begin our collaboration with SINTEF. Combining the academia research, TCS’ deep domain expertise and experience of implementing AI strategies will be turning ideas into action. Together with SINTEF, the identification of specific, practical AI use cases that address real business challenges focusing into usability and human-centric approach will become to full circle. Our digital technologies will add scale and speed to SINTEF’s research and innovation activities, enabling these projects to have an even greater reach and impact for society.” ]]> https://biospectrumindia.com/news/100/26891/tenthpin-expands-footprint-in-india-with-launch-of-centre-for-life-sciences-cloud-solutions-in-pune.html https://biospectrumindia.com/news/100/26891/tenthpin-expands-footprint-in-india-with-launch-of-centre-for-life-sciences-cloud-solutions-in-pune.html Thu, 06 Nov 2025 00:00:00 +0530 Switzerland-based Tenthpin Management Consultants, a global leader in management and technology consulting for Life Sciences companies, has announced the launch of Centre for Life Sciences Cloud Solutions in Pune, establishing a Global Centre of Excellence dedicated to cloud and artificial intelligence (AI)-driven solutions to help transform Life Sciences business. The mission of this centre is to develop and deploy future-ready cloud solutions for Pharmaceutical, Medtech, Biotech, Healthcare, Animal Health and CDMOs to help them address the specific compliance & life science industry related nuances, enabling regulatory compliance, real-time insights, seamless data integration and enhanced collaboration across the global value chain. This will allow Life Sciences companies to accelerate breakthroughs and improve patient outcomes. These cloud solutions are becoming specifically relevant in the new therapies, Biotech and Advanced Therapeutic Medicinal Products, the new Internet of Medical Things (IoMT) as well as in the next generation of CDMOs. The latest state-of-art facility at Baner was inaugurated by Michael Schmidt, Founder and Member of the Executive Board of Tenthpin in the presence of Stephanie Marx, Partner and Key Account Delivery lead and Sachin Bhure, Partner and Managing Director, Tenthpin India.   Tenthpin Solutions, a group company of Tenthpin is also expanding its footprint in India. The new Pune centre will serve as a global hub for innovation — further enhancing next-generation cloud-based products and accelerators that help Life Sciences companies simplify complexity, ensure regulatory compliance and scale efficiently in a rapidly evolving digital ecosystem. This centre will also collaborate with local research institutions, universities, and industry partners to drive advancements of Life Sciences in India.   ]]> https://biospectrumindia.com/news/100/26871/remidio-unveils-neubo-130-a-breakthrough-in-ai-enabled-retinal-imaging-for-newborns.html https://biospectrumindia.com/news/100/26871/remidio-unveils-neubo-130-a-breakthrough-in-ai-enabled-retinal-imaging-for-newborns.html Mon, 03 Nov 2025 00:00:00 +0530 Bengaluru-based Remidio Innovative Solutions, a leader in artificial intelligence (AI)-powered ophthalmic devices, has announced the launch of Neubo 130, a next-generation ultra-widefield neonatal retinal imaging system designed to enhance precision diagnostics for neonatal retinal conditions like Retinopathy of Prematurity (ROP). India sees over three million premature births each year, translating to nearly 15 million retinal examinations if every baby is screened as per protocol. With the limited number of ROP specialists, it’s impossible to bridge this gap without technology. Built to support clinicians working in both hospitals and neonatal intensive care units (NICUs), Neubo 130 combines innovative optical engineering with edge AI to assist in the detection of ROP in real time, even without internet connectivity. With a 130° field of view, through-the-lens illumination, and light-shaping technology, Neubo 130 ensures uniform retinal brightness and exceptional peripheral visualisation, critical for identifying subtle changes in the newborn retina that guide timely treatment decisions. Key highlights of the Neubo 130 include: Consistent peripheral detail (uniform illumination and reduced glare). Small-pupil imaging possible (high-quality imaging at pupils ≥3 mm). Bedside triage that’s instant, private, and standardised (offline AI assists ROP and plus-disease triage; standardized workflow reduces missed cases). Panoramic views with fewer retakes (auto-montage aligns multiple gazes into a single 130° composite) Built for collaborative care (telemedicine- and cloud-ready for secure review, triage, and referral) “The launch of Neubo 130 marks a major step forward in neonatal eye care,” said Dr. Anand Sivaraman, CEO of Remidio. “This platform is our bet on certainty, reframing ROP from a resource problem to an engineering solution. By enabling dependable, on-the-spot decisions at the bedside, we move from ‘screening when possible’ to ‘protecting vision as standard’. With its lightweight design (below 500g), high-resolution imaging (2.4MP), and offline AI workflow, Neubo 130 extends Remidio’s mission to make eye care accessible, affordable, and scalable across all settings , from tertiary hospitals to special newborn care units (SNCUs). ]]> https://biospectrumindia.com/features/100/26850/the-ai-job-loss-threat-conundrum-.html https://biospectrumindia.com/features/100/26850/the-ai-job-loss-threat-conundrum-.html Fri, 31 Oct 2025 00:00:00 +0530 Fear being instilled among many when it comes to AI on whether it will usurp jobs. India’s job scenario is no better, where retrenchment is common among sectors and the life sciences sector as a whole is no exception. On one hand, we have people juggling from one company to the other looking for job opportunities. On the other hand, many struggle to make an impact at their organisations. And in this scenario, the coming of AI is leading to a fear factor among many. On whether it will lead to a major reshuffling of overall jobs. It is anticipated that AI will eventually lead pharma and healthcare companies to go in for a major institutional overhaul. Role of AI in pharma/healthcare jobs Artificial Intelligence (AI) is rapidly transforming healthcare by improving accuracy, efficiency, and personalisation in patient care from diagnosing diseases through advanced image analysis to predicting treatment outcomes and streamlining hospital operations. It enables healthcare professionals to focus on clinical judgment. Even the pharma industry is looking out for AI pharma strategists, professionals who can identify AI integration opportunities across the pharma value chain. Then come clinical data scientists, followed by digital health professionals, AI Ethics & Compliance Officers who can ensure AI tools meet regulatory standards and ethical guidelines, particularly important given India’s evolving data protection landscape. In days to come, the need for pharmacovigilance AI Specialists will be in demand to manage AI systems that monitor drug safety signals, precision medicine coordinators, and AI-Human Interface Trainers. In India, the adoption of AI in the pharma and healthcare sectors is accelerating. Approximately 40 per cent of clinicians in India are now using AI technologies, reflecting a significant increase from previous years. Indian pharma companies are implementing AI solutions in drug discovery, with 50 per cent exploring Generative AI proof-of-concept initiatives and 25 per cent having implemented AI solutions in live production environments. A reduction in headcount? While AI may automate certain tasks, it also creates new roles and enhances existing ones. Globally, AI is expected to create between 20 and 50 million new jobs by 2030, particularly in healthcare and pharmaceuticals. Says Dr Rajendra Pratap Gupta, Founder - Health Parliament and former Advisor to the Union Health Minister, Government of India, “The job losses will be majorly in the traditional field force roles - medical representatives, sales teams, and certain administrative positions that rely on manual processes. The new job creation will be in AI-specialised roles, data science, bioinformatics, and digital health management positions. The Global Capability Centres (GCCs) will create jobs with the new skill sets. I see that in a five-year time horizon, there will be a new way to look at manpower. By 2030-32, the pharmaceutical industry will shed nearly half a million workforce.” Sanjiv Navangul, MD and CEO, Bharat Serums and Vaccines, while speaking at the recently held Global Digital Health Summit in Mumbai, mentioned, “Layoffs are for jobs, not for people. Just like computers didn’t eliminate people—but created better jobs—AI will elevate human potential. Those who upgrade their skills will find better and more meaningful opportunities. The question is not about AI taking away your job; it’s about whether your skills are good enough for the evolving roles and jobs in the future. The divide between ethics and AI is crucial. As AI becomes more encompassing, leaders must ensure that AI serves people and not replaces them. Remember, the future is all about democratisation of AI.” Dr Avani Oke, Principal, K J Somaiya College of Nursing, mentions, “AI will lead to a reduction in headcount in some roles which are repetitive, but it will also create an opening for roles that require design, validation, and operations. AI will cause job displacement. The job displacement is because AI reduces time and cost in report generation, triage, and screening, which are laborious. Job displacement may be seen in administrative, routine image-reading, and data-processing roles. The requirement for a role mix involving technical, clinical analytics and product roles will be the need of the hour. I think we need to understand that AI can assist, but compassion, empathy can never be replaced, and the healthcare sector will require human touch.” At Terumo India, AI tools play a crucial role in improving efficiency and quality. Tools such as AI-driven predictive analytics can help forecast equipment demand, optimize inventory, and anticipate supply chain disruptions. Terumo India is seeing strong advancements in Clinical Decision Support Systems, AI-powered product and drug discovery platforms, and patient engagement solutions that enhance the entire care journey from appointment scheduling to treatment and post-care follow-up. Virender Bansal, Vice President, Finance, Supply Chain, IT & Legal, Terumo India said, “AI is certainly transforming the MedTech sector, but I see it more as an opportunity than a threat. While some routine and repetitive tasks may get automated, this doesn’t mean entire jobs will disappear. In fact, AI allows professionals to focus on higher-value activities such as complex problem-solving, innovation, and patient-centered care. I personally see a rise in hybrid roles – meaning domain experts refining their skills with tech expertise. The key to this is proactive upskilling. Given the growing demand for healthcare services and the shortage of specialised talent, AI can bridge workforce gaps and improve operational efficiency. Over the next 5–10 years, we expect new roles to emerge in areas like AI oversight, data analytics, digital therapeutics, patient experience, clinical technology management, and cross-functional innovation teams.” Preparing existing workforce Pharma and healthcare companies need to reskill programmes. Companies need to partner with platforms to offer courses for all its employees for upskilling and cross skilling across digital health. There will be a need to create pathways for field force to transition into digital roles - patient support programmes, telemedicine coordination, data collection and digital customer success positions. Nothing will happen overnight and gradual acceptance of AI will be beneficial both for the employer and the employees. Chances of medical representatives (MRs), the traditional ones, will become obsolete. This is where AI will play a role, where MRs will be needed to undergo training in digital therapeutics.Provided AI is well accepted among the MRs, the future will be more strategic, data-driven and digitally enabled. Needed investment Large pharma companies will be able to spend a substantial amount on adopting AI. In the case of smaller pharma players, the amount of investment remains in question. Chances of smaller players falling behind is high as AI requires significant upfront investment in infrastructure, talent. Limited access to AI talent will add to the woes. Democratisation will happen provided there is an urge among pharma and healthcare companies to invest in AI.  On the other hand using AI has cyber risk challenges, where the entire data of a company can be compromised if data is not secured. Here, a substantial amount needs to be invested to take care of the data. Creating skilled jobs India’s digital health initiatives, such as Ayushman Bharat and the national AI strategy, are creating infrastructure for scalable AI adoption. Companies are encouraged to build AI products and increase demand for the integration of data. Qure.ai, Niramai and SigTuple, from India, have been able to scale and chase global markets. This is creating skilled jobs in AI engineering, clinical validation, sales, and regulatory functions. AI adoption requires rigorous validation and workflow integration, making roles in clinical validation, regulatory and product implementation in demand. OutcomeLong-term dependency on AI may lead to specialists' jobs being reduced. The right investment in deploying AI and training the needed workforce who can bring in the necessary growth to the company will lead to lesser job loss. Allaying fears, AI is already becoming a reality, and pharma and healthcare companies need to harness the potential of AI. As Dr Nipun Sharma, CEO, TeamLease Degree Apprenticeship, says, “In India, the adoption of Generative AI (GenAI) in the pharma and healthcare sectors is anticipated to unlock 30-40 per cent productivity gains. This indicates a shift towards more specialised, higher-value positions that require human oversight and expertise. However, the integration of AI also presents challenges like workforce reductions, especially in entry-level positions. This highlights the importance of reskilling and upskilling initiatives to prepare the workforce for the evolving demands of the industry.”   Sanjiv Dassanjiv.das@mmactiv.com ]]> https://biospectrumindia.com/news/100/26865/can-ai-become-indias-stethoscope.html https://biospectrumindia.com/news/100/26865/can-ai-become-indias-stethoscope.html Fri, 31 Oct 2025 00:00:00 +0530 India stands on the cusp of a healthcare transformation defined not by incremental upgrades, but by disruptive technologies engineered for access, equity, and scale. This conviction underscored the latest session of the Pune International Centre (PIC)–Wipro Lecture Series titled “Breakthroughs to Better Health: Making Disruptive Technologies Work for India”, delivered by Dr Soumya Swaminathan — Principal Advisor, National Tuberculosis Elimination Program, Union Ministry of Health and Family Welfare — and attended by healthcare, technology, and policy leaders at Pune International Centre. Speaking at the session, P.S. Narayan, Global Head – Sustainability & Social Initiatives at Wipro, emphasised that the company’s commitment to societal impact draws from the values enshrined in the Indian Constitution. He highlighted Wipro’s partnership with the Pune International Centre as a strategic collaboration centered on climate action, urban advancement, and public well-being, with technology — especially artificial intelligence — enabling scalable change. Public engagement in science, Narayan warned, is essential to ensure citizens become active shapers of technology, not passive consumers. Major General Nitin Gadkari, Director, Pune International Centre, alongside Dr R.A. Mashelkar, President, PIC and Dr Vijay Kelkar, Vice President, PIC welcomed the audience and introduced Dr. Soumya Swaminathan as a leader who has built rare bridges between frontier research and population-scale health programmes. Dr Soumya set the global context starkly: the leading cause of death in 2021 was COVID-19; by 2023, ischemic heart disease had resurged. Today, heat stress — driven by climate change — is claiming more lives worldwide, signaling how environmental disruption and health emergencies are now tightly interlocked. India faces a twin paradox — the South grappling with surging diabetes and metabolic disorders, while the North continues to battle malnutrition. Progress in maternal and child health has been hard-won, yet chronic illnesses such as cancer and diabetes are rising sharply. “Global risks are escalating and converging — economic shocks, geopolitics, and climate crises now manifest as health crises,” she cautioned, citing a world where the Amazon rainforest has become a net emitter of carbon and fossil-fuel subsidies still eclipse renewable investments. Deadly infectious threats have not receded. Emerging pathogens of concern include Betacoronaviruses, Filoviruses, and Bunyaviruses, alongside the growing challenge of antimicrobial resistance. AMR alone is linked to 4.95 million deaths globally, including 1.27 million due to resistant bacteria — a silent pandemic. Non-communicable killers are equally alarming: air pollution now extends its harm to cognitive decline, while dietary risks — processed foods high in salt, sugar, and unhealthy fats — are reshaping the disease landscape. India is already home to 11.4 per cent diabetes prevalence and 15.3 per cent pre-diabetes, disproportionately concentrated in cities and southern states. By 2050, nearly 300 million Indians will be above 65, placing immense pressure on geriatric and primary healthcare systems. Meanwhile, fragmented care and variable quality cost 2.4 million lives every year — a reminder that inequality is a public-health crisis. Dr Soumya argued that a technology is truly disruptive only if it makes healthcare more affordable, more accessible, and more efficient — not just technologically advanced. She showcased emerging breakthroughs rapidly reshaping medicine. mRNA platforms enabled the fastest vaccine response in history during COVID-19 and are now being repurposed for cancer, TB, malaria, and autoimmune diseases. Prototype-pathogen research aims to accelerate vaccine development by anticipating outbreaks rather than reacting to them. Artificial Intelligence, described as “the stethoscope of the 21st century,” is now predicting heart attacks from ECGs, detecting Alzheimer’s from retinal scans, and improving tuberculosis diagnostics with high precision. AlphaFold, the AI platform recently honored with a Nobel Prize recognition, has redrawn the boundaries of protein science. Indian innovations — including Swaasa for respiratory health and Garbhini-GA2, the country’s first indigenous AI model for pregnancy dating — represent technological sovereignty in health intelligence. Wearables and remote monitoring promise to shift care from hospitals to homes, while biome-based therapies open radical new possibilities for metabolic diseases. Breakthroughs such as neurotech-enabled communication for paralysed individuals signal the start of a bio-hybrid revolution. Simple but powerful inventions like the BEMPU Bracelet — detecting neonatal hypothermia in low-resource settings — demonstrate that innovation is as much about empathy as engineering. At the same time, frontier tools such as gene drive technologies demand rigorous ethical governance, particularly in biodiversity-rich, climate-sensitive countries like India. Digital health infrastructure has advanced rapidly with the Ayushman Bharat Digital Mission. As of August 5, 2025, over 79.91 crore Ayushman Bharat Health Accounts (ABHAs) — nearly 800 million unique digital identities — have been generated, unlocking unprecedented portability and continuity of care. It signals a turning point: a nationwide shift toward unified health records and citizen-centric services. Yet, Dr Soumya underscored critical gaps that must be filled: robust primary healthcare systems, population-level data that is reliable, a trained public health workforce, and research capacity that keeps pace with innovation. India’s frontline health workers remain burdened with fragmented reporting and silos that weaken referral systems. To unlock real gains, the system must shift from input-focused reforms to outcome-driven, team-based integrated care that ensures continuity through district-level coordination and on-the-job mentoring. Standardising and strengthening vital statistics — particularly mortality data — will be crucial. Timely, disaggregated health data, she said, is the only route to targeted planning and equitable outcomes in a country as diverse as India. With its scientific talent and digital advantage, India can set global benchmarks in ethically governed, locally relevant health technologies. Dr Soumya made a compelling case for philanthropy as the risk-taker India needs — supporting high-impact early-stage research, bridging innovation gaps, aligning capital with national health priorities, and enabling ecosystems that accelerate ideas into implementation. The urgency, she reminded the audience, could not be clearer: the world still lacks an effective vaccine for Tuberculosis, a disease that remains one of India’s most persistent killers. The PIC–Wipro Lecture Series reinforced that health innovation is no longer a matter of scientific ambition, but national resilience. A future where disruptive technologies serve every Indian — regardless of income or location — will demand strong public institutions, visionary private sector engagement, and a relentless focus on equity. As Dr Soumya Swaminathan concluded, “It is the bridge built on research, context, and ethics that converts innovation into real, impactful health outcomes.” India is now poised to build that bridge — not just for itself, but for the world.   Suchetana Choudhury (suchetana.choudhuri@agrospectrumindia.com) ]]> https://biospectrumindia.com/news/100/26858/lupin-launches-ai-powered-cardiometabolic-wellness-platform.html https://biospectrumindia.com/news/100/26858/lupin-launches-ai-powered-cardiometabolic-wellness-platform.html Thu, 30 Oct 2025 00:00:00 +0530 Lupin Digital Health has announced the launch of VITALYFE™, an artificial intelligence (AI)-powered cardiometabolic wellness platform designed to help India’s working professionals reclaim their heart health. Built on the foundation of LYFE — India’s first CDSCO-approved Class C software medical device (SaMD) for critical cardiac conditions — VITALYFE™ extends hospital-grade cardiac expertise to preventive wellness for its users. India’s corporate employees face a growing cardiometabolic crisis. Studies indicate that up to 80 percent show early signs of hypertension and dyslipidemia — silent accelerators of heart aging. Long work hours, chronic stress, sedentary routines, poor nutrition, and inadequate sleep are causing hearts to age faster than bodies. If unaddressed, this would leave millions at risk of cardiovascular disease during their most productive years. Developed with industry-leading cardiometabolic expertise, VITALYFE™ uses artificial intelligence, behavioral science, and computer-vision technology to identify early risks and provide personalised, non-medical interventions that address the root causes of heart ageing. “At Lupin Digital Health, we have seen how evidence-based digital therapeutics through LYFE have transformed cardiac recovery,” said Sidharth Srinivasan, Chief Executive Officer – Lupin Digital Health. “With VITALYFE, we are extending that scientific foundation to a much larger audience — helping professionals understand their heart age, make better lifestyle choices, and literally make their hearts younger. Our vision is to make cardiometabolic wellness both measurable and mainstream.”     ]]> https://biospectrumindia.com/news/100/26842/philips-and-nicolab-collaborate-to-advance-stroke-care-in-india.html https://biospectrumindia.com/news/100/26842/philips-and-nicolab-collaborate-to-advance-stroke-care-in-india.html Tue, 28 Oct 2025 00:00:00 +0530 Dutch firm Philips, a global leader in health technology, is expanding its collaboration with Nicolab, The Netherlands-based company pioneering in artificial intelligence (AI)-powered stroke care, to advance stroke care in India. This expansion into India represents an important milestone in addressing one of the country’s most pressing healthcare challenges by combining Philips’ world-class imaging expertise with Nicolab’s advanced platform, StrokeViewer AI. With nearly 1.8 million new cases each year, stroke has become a leading cause of disability and mortality in India, creating an urgent need for models of care that deliver speed, precision and access. Timely diagnosis and intervention are critical, yet many patients continue to face delays in accessing specialist treatment. Through this collaboration, Philips and Nicolab aim to strengthen clinical workflows, support faster decision-making and improve access to life-saving stroke treatment. StrokeViewer, the first cloud-based solution in India to receive regulatory clearance for CT Perfusion (CTP) analysis provides instant AI-generated imaging results, centralised patient information and seamless communication between specialists. Integrated with Philips’ advanced image-guide therapy platform Azurion, the combined solution is designed to help clinicians deliver more efficient and effective stroke care. Azurion brings together real-time high-resolution imaging, advanced navigation tools, and seamless integration of advanced AI solutions such as Nicolab’s StrokeViewer to empower clinicians to act faster and more precisely. For example, physicians can review all relevant DICOM scans and AI results directly on Azurion, to determine eligibility for interventional treatment. The 3D planning view enables the interventional team to determine the best access route and viewing angles before the patient enters the interventional suite.  Nicolab’s StrokeViewer applies advanced AI to analyse multiple stroke imaging biomarkers, supporting faster and more confident diagnosis. Stroke teams can then collaborate seamlessly by securely sharing images and patient details through a DICOM viewer that is certified for diagnostic use on both mobile and desktop. This diagnostic-grade capability ensures that each patient gets the best possible chance of recovery – as every second matters. Philips is working closely with a global network of hospitals, research institutions, and technology partners such as Nicolab—alongside its strategic collaboration with the World Stroke Organization (WSO)—to advance the diagnosis and treatment of stroke. ]]> https://biospectrumindia.com/news/100/26837/bayosthiti-ai-and-narayana-health-partner-to-build-indias-first-ai-powered-heart-disease-predictor.html https://biospectrumindia.com/news/100/26837/bayosthiti-ai-and-narayana-health-partner-to-build-indias-first-ai-powered-heart-disease-predictor.html Mon, 27 Oct 2025 00:00:00 +0530 Bayosthiti AI, an innovator in artificial intelligence (AI)-driven healthcare and molecular diagnostics, has announced a strategic partnership with Narayana Health, one of the world's largest cardiac care networks, to develop AI models that predict cardiovascular disease in Indian patients. The collaboration leverages RNA sequencing to read the active molecular instructions in cells, combined with gen AI to identify heart disease risk earlier and more accurately than conventional methods. The study will analyse transcriptomic data (the complete set of active cellular RNA messages) from over 12,000 participants at Narayana Institute of Cardiac Sciences in Bengaluru. Using Bayosthiti's proprietary BIRT™ technology, researchers will sequence complete RNA profiles from patient blood samples to train AI models. These models will be capable of detecting distinctive patterns of cellular activity that signal coronary artery disease (blockages in heart arteries) before traditional tests show abnormalities. Coronary artery disease affects 65 million Indians and strikes at younger ages than in Western populations. Yet, diagnostic tools remain largely calibrated to European and American patient data, creating what clinicians call the "Data Gap." Standard risk scores miss critical patterns in South Asian biology shaped by distinct genetic backgrounds and environmental factors, leading to late-stage diagnoses when intervention options narrow. Bayosthiti AI and Narayana Health are solving this through molecular innovation and clinical scale. "Just as Google Translate learned language patterns from billions of text examples, our AI learns disease patterns from millions of RNA expressions," said Dr Rishabh M. Shetty, Head of Business Development and Clinical Applications at Bayosthiti AI. "The transcriptome gives us a real-time readout of what the body is doing right now. Our models can spot the molecular conversation that precedes a heart attack, not just the aftermath, and can do so with the same level of accuracy and efficacy as invasive procedures or other current imaging gold standards."     ]]> https://biospectrumindia.com/news/100/26824/remidio-secures-ce-marking-for-dual-offline-ophthalmic-ai-devices.html https://biospectrumindia.com/news/100/26824/remidio-secures-ce-marking-for-dual-offline-ophthalmic-ai-devices.html Thu, 23 Oct 2025 00:00:00 +0530 Remidio Innovative Solutions, a Bengaluru based med-tech innovator, has announced that its Medios HI Glaucoma AI and Medios HI DR AI have received CE Marking as Class II Software as a Medical Device (SaMD) under the EU Medical Device Regulation (MDR). The CE Approval marks a major milestone for Remidio, validating its  offline AI that can simultaneously detect diabetic retinopathy and glaucoma from a single retinal image. Delivering results in under 10 seconds without internet connectivity or cloud inferencing. With this achievement, Remidio strengthens its position as India’s only CDSCO-approved ophthalmic AI company and a leader in making advanced eye screening more accessible and affordable. As the burden grows, a shortage of specialists limits timely screening. For the first time, a powerful offline AI-based tool can help bridge this gap bringing early detection to the point of care and protecting millions from avoidable vision loss.   Remidio’s Medios HI Glaucoma AI goes beyond traditional screening methods. Instead of relying solely on the cup-to-disc ratio, it analyzes structural changes in the optic nerve head and retinal nerve fiber layer, similar to assessments done by specialists using high-end imaging tools. The AI also uses Class Activation Maps (CAMs) to highlight regions of interest, helping doctors quickly identify potential signs of glaucoma. To ensure its accuracy for global use, the AI was validated on over 100,000 real-world images, including data from diverse populations across India and Europe.   ]]> https://biospectrumindia.com/news/100/26818/qure-ai-launches-worlds-first-ai-powered-paediatric-tb-screening-tool.html https://biospectrumindia.com/news/100/26818/qure-ai-launches-worlds-first-ai-powered-paediatric-tb-screening-tool.html Sat, 18 Oct 2025 00:00:00 +0530 Diagnosing tuberculosis (TB) in children has long been a challenge, but that is set to change. qXR from Mumbai-based startup Qure.ai is the first AI-enabled chest X-ray tool to receive regulatory clearance, earning CE Class IIb certification for children aged 0–3 years and complementing its existing capabilities for children up to 15 years, effectively covering the entire childhood spectrum.  Paediatric TB is a silent crisis that affects children, globally. In 2023, close to 1.3 million children under 15 fell ill with TB, representing about 12% of total cases worldwide. Children under 5 are particularly vulnerable due to underdeveloped immune systems, bearing the highest burden and accounting for more than 75% of TB-related deaths in this age group. Tragically, close to 200,000 children died of TB in 2023, most of them under five. Moreover, drug-resistant TB, including extensively drug-resistant forms, is rising among children, creating an urgent public health challenge.  Commenting on the announcement, Dr Shibu Vijayan, Chief Medical Officer, Global Health at Qure.ai, said, "Achieving CE clearance for AI-enabled Chest X-ray screening in children is a major step forward in the fight against paediatric TB. The youngest children have long been the hardest to reach and the most vulnerable. With this tool, we are proud to equip healthcare systems worldwide with a scalable, reliable way to detect TB early, prioritise care, and ultimately save lives." Additionally, Qure.ai has implemented the Treatment Decision Algorithm A (TDA), as outlined in the WHO Consolidated Guidelines on Tuberculosis: Module 5 – Management of Tuberculosis in Children and Adolescents (2022), within the care coordination platform- qTrack from Qure.ai. This functionality enables structured data entry and automated computation of algorithmic parameters to facilitate clinical diagnosis of tuberculosis in children who are bacteriologically negative or unable to undergo microbiological testing. ]]> https://biospectrumindia.com/news/100/26789/solh-wellness-launches-indias-first-ai-based-stress-monitoring-device.html https://biospectrumindia.com/news/100/26789/solh-wellness-launches-indias-first-ai-based-stress-monitoring-device.html Thu, 09 Oct 2025 00:00:00 +0530 In a landmark moment for India’s mental health and technology landscape, Delhi-based startup Solh Wellness has unveiled Streffie, India’s first artificial intelligence (AI)-based stress monitoring kiosk, at the Indian Mobile Congress (IMC) 2025, held at Yashobhoomi, Dwarka. Streffie marks a breakthrough in the way stress is detected, measured, and managed. Using AI-driven facial biomarker analysis, it captures 68 micro-expressions and facial points to assess stress levels in real time. These signals are then translated into measurable insights, allowing individuals, institutions, and organizations to proactively track and manage emotional well-being. “Streffie represents a new era where technology doesn’t just connect devices — it connects emotions, awareness, and action,” said a Solh Wellness spokesperson. “Through this innovation, we’re making stress visible, measurable, and manageable — bringing data-driven precision to emotional health.” Integrated within the Solh Wellness ecosystem — comprising the Solh App, Smart AI Dashboard, and REACH AI framework — Streffie offers preventive, personalised, and scalable stress management solutions for organisations, universities, and healthcare systems. Adding his perspective on the intersection of AI and mental health, Kapil Gupta, Co-Founder & CEO of Solh Wellness, said, “AI and mental health share a quiet but powerful intersection. AI helps us measure what was once invisible — the subtle weight of stress, the early signs of strain. But data alone can’t heal; empathy does. The real revolution begins when AI meets compassion — that’s where transformation truly happens.”  The Indian Mobile Congress 2025, inaugurated by Prime Minister Narendra Modi, celebrated India’s rapid ascent in global technology innovation. This year’s theme focused on AI, semiconductor innovation, quantum security, and 6G connectivity, highlighting the nation’s march toward digital self-reliance.   ]]> https://biospectrumindia.com/features/100/26743/navigating-cold-chain-challenges-with-ai-solutions.html https://biospectrumindia.com/features/100/26743/navigating-cold-chain-challenges-with-ai-solutions.html Wed, 01 Oct 2025 00:00:00 +0530 Pharmaceutical cold chain logistics has been instrumental in delivering life-saving drugs across the length and breadth of the world. It may be noted that temperature-sensitive pharma products need safety and efficacy at the highest standards. Artificial intelligence (AI) is aiding pharma cold chain logistics in a big way. Real-time IoT monitoring, AI-powered predictive analytics, expanded cryogenic infrastructure etc, have added more benefits to pharma companies to securely transfer products from one place to another. And pharma logistics players are innovating themselves with the help of AI to help pharma companies in a large way.   Role of AI Vaccines, biologics and cell and gene therapy drugs need constant temperature monitoring throughout production, distribution and transportation. With India’s cold chain logistics supporting a rapidly expanding pharmaceuticals sector, projected at $130 billion by 2030, it is touted as an ever-growing industry. By enabling real-time temperature monitoring, predictive maintenance, and route optimisation, AI is helping reduce spoilage, minimise delays, and build stronger compliance and trust for brands with their customers. AI is being used in very practical ways across the cold chain. There have been instances of inefficient route plans, natural calamities, power supply issues etc. that lead to damage or degradation of almost 20 per cent of temperature-sensitive pharma products. This is where AI has gained prominence. AI is helping pharma companies forecast demand better and schedule equipment maintenance before breakdowns occur, cutting down on delays and losses. IoT sensors can track temperature and humidity in real time, while blockchain is making it easier to verify authenticity and compliance. Electric vehicles (EVs) with built-in cooling, and even 5G-enabled systems for faster alerts, are gradually becoming part of operations. Moreover, AI‑driven warehouse systems employ machine learning and robotics to automate tasks like slotting, smart picking, and predictive demand forecasting, making operations faster, more accurate, and more efficient. All of this is helping the industry run smarter, more reliably, and with a lighter environmental footprint.   AI players in pharma cold chain logistics Navi Mumbai-based Celsius Logistics, recently launched Celcius+, a specialised logistics arm dedicated exclusively to the seamless management of the pharmaceutical supply chain. The company aims to invest Rs 50 crore to create a dedicated pharma fleet and support infrastructure, with a goal of achieving Rs 100 crore in Annual Recurring Revenue (ARR) from this segment within the next 18 months. Of this, Rs 35 crore will be allocated towards deploying 100 new reefer vehicles for Celcius+ along key pharmaceutical corridors across India. A further Rs 10–15 crore is being earmarked to build a robust pharma courier system tailored to serve high-demand urban and semi-urban markets. Celcius+ will deliver tech-enabled supply chain solutions tailored for pharmaceutical and healthcare clients. Says Swarup Bose, Founder and CEO, Celcius Logistics, “AI is fundamentally transforming the cold chain logistics sector. Predictive analytics, for example, are helping companies forecast demand better and schedule equipment maintenance before breakdowns occur, cutting down on delays and losses. IoT sensors now track temperature and humidity in real time, while blockchain is making it easier to verify authenticity and compliance. AI‑driven warehouse systems employ machine learning and robotics to automate tasks like slotting, smart picking, and predictive demand forecasting, making operations faster, more accurate, and more efficient.” Gurgaon-based AWL India specialises in offering high-tech and advanced cold chain logistics. The company uses tools that are designed to collect real-time information of goods received, expired, damaged and delivered in one-go with just one click. Custom fleet management software has centralised supply chain management software, GPS tracking software for shipments and tailor-made reporting and tracking tools. According to the company, the advanced software offers software solutions for supply chain management, real-time visibility into the inventory, automated and streamlined operations, improved shipment efficiency, reduced operational, maintenance and transportation costs, logistic software development etc. Another Gurgaon-based Binary Semantics’ Fleet Robo is offering a cold chain logistics solution for managing the fleet of refrigerated vehicles. The company offers real-time visibility, geo fencing, route optimisation, driver and assets delivery, analytics, detailed report and ensures on-time delivery. CloudTrack, with its offices in Mumbai and Bengaluru, offers IoT Sensors, real-time data transmission, cloud-based software, alerts, monitoring and analytics. Lytus BLOD is Lytus Health’s AI-first medical logistics platform that covers blood components, vaccines, biologics, and other temperature-sensitive medicines with different cold-chain needs. Lytus BLOD uses a mix of AI and ML techniques that are constantly being refined. It uses forecasting models to predict temperature risks and avoid false alarms, reinforcement learning to improve dispatch timings and reduce delays, route optimisation tools that balance cost, quality, and even carbon emissions, computer vision and OCR to help with compliance checks, time stamping and audit trails. Sai Guna Ranjan Puranam, COO, Lytus Healthtech, says, “AI is shifting cold chain logistics from reactive tracking to predict-and-prevent operations. In the coming decade, AI-driven medical logistics will be as vital to public health as highways and power grids were to earlier generations.” New Delhi-headquartered Snowman Logistics offers 5PL (fifth-party logistics) solutions and a suite of services including warehousing, customised supply chain management, transportation, and consultancy. The company offers SNOWPRESERVE warehousing from +25°C to -25°C, including blast freezing in key locations. The vehicles are equipped with both GPS and data logging. Talking about the benefits of AI in today’s pharma cold chain logistics sector, Jeevan Upreti, Business Development Head, North Region, Snowman Logistics, says, “AI will automate compliance record keeping and generate auditable logs automatically, allowing for transparent, tamper-proof tracking of product conditions throughout the supply chain. Regulators will likely rely more on continuous digital monitoring and data-driven inspections rather than manual record checks. The shift will reduce audit time, minimise paperwork, and provide real-time access to historical shipment data for rapid verification.” Startups like Tagbox, CloudTrack, Pickrr, Roanbee etc., offer IoT sensors combined with AI and machine learning to dynamically track pharmaceutical shipments in real time.   Challenges Challenges like AI false alerts are known to plague the pharma cold chain logistics. The likely causes can be AI algorithms being overly sensitive to data anomalies, sensor inaccuracies, or environmental noise etc. These alerts often arise from sensor calibration issues, poor network connectivity, or inconsistent data inputs. Variations in external temperature, vibration during transport, or incorrect thresholds set in the AI system can also cause unnecessary alerts. Regular system updates and validation help reduce these errors. False alerts also happen because AI learns from limited or local contexts. This can cause errors in reading, interpreting, or projecting results. Common reasons include calibration gaps, poor sampling, or misinterpretation of short-lived temperature spikes. Other challenges include sensor calibration drift or hardware malfunctions that lead to unreliable readings, as well as environmental factors—such as temperature fluctuations in delivery vehicles—that may not actually affect product stability but still trigger alerts. In addition, poor data quality and the lack of standardisation in sensor network integration can result in fragmented information and the misinterpretation of data patterns as potential threats. Finally, overly sensitive thresholds in anomaly detection algorithms often generate excessive false alarms, creating unnecessary notifications and reducing trust in the system.   Sustainability AI in cold chain logistics doesn’t just make operations smarter but it makes them greener. By helping optimise routes, cutting fuel use and reducing wastage of perishable goods, AI indirectly lowers the sector’s carbon footprint. Many platforms are now cloud-based, which means companies don’t need heavy infrastructure to get started. As the technology matures, these tools are proving to be both environmentally and financially sustainable in the long run. Many cold chain logistics players are adopting AI tools to enhance their productivity and overcome challenges. AI is also helping in adopting sustainability measures.  The focus is on using reusable materials instead of single use, planning routes that reduce emissions while ensuring safety, creating demand-surplus matching workflows etc.   Affordability and costs Pricing of AI tools depends on deployment scale, integration needs, and service models (SaaS, on-premise, hybrid). AI-driven cold chain solutions can reduce operational costs by 10–15 per cent through lower fuel consumption, reduced waste, and streamlined labour. Many AI tools are offered on a subscription (OPEX) basis, making adoption more affordable for SMEs, while larger implementations by global logistics firms require a higher initial investment but deliver significant long-term savings. The future seems optimistic for the pharma cold chain logistics sector. And AI is only going to enhance growth. Using AI tools in the right way and avoiding false alerts will be a win-win situation both for AI and logistics players.   Sanjiv Das sanjiv.das@mmactiv.com ]]> https://biospectrumindia.com/views/100/26687/we-are-working-towards-enabling-ivf-labs-in-india-to-benefit-from-ai-powered-assessment-tools.html https://biospectrumindia.com/views/100/26687/we-are-working-towards-enabling-ivf-labs-in-india-to-benefit-from-ai-powered-assessment-tools.html Tue, 16 Sep 2025 00:00:00 +0530 DSS Imagetech has recently stepped into the IVF sector. What are the major plans in this direction? How do you plan to strengthen your presence in the IVF market in the years to come? The launch of DSS Imagetech’s IVF vertical Hanahealth comes at a very crucial time in India. Fertility rates in the country are dropping; more busy couples are postponing parenthood and changes in lifestyle are leading people to know more about assisted reproduction. In such a scenario, IVF is no longer regarded as a niche service but as a vital component of fertility care, allowing couples looking to conceive, a safe and successful alternative. Hanahealth offers a combination of cutting-edge Assisted Reproductive Technology (ART) services and products, innovation, education and support that are all crucial to build and grow the IVF ecosystem in India. As we go forward, Hanahealth will continue to train and conduct workshops for embryologists and lab technicians across India ensuring they are well equipped to adopt and manage advanced technologies. We will also intensify our efforts to help IVF clinics in Tier II/III and beyond cities and towns benefit from the strong network, infrastructure and experience of our parent company, DSS Imagetech, making advanced fertility care more accessible and affordable across India.   India continues to evolve with new reforms and developments in healthcare, but there are still major gaps when it comes to diagnostics and biotechnology. How is DSS Imagetech contributing to fill these gaps and improve access to advanced molecular diagnostics and life sciences solutions to address important health and healthcare issues? Yes. The lack of an on-going medical education process among IVF doctors is a big cause of concern. The IVF is an ever evolving medical field that relies heavily on diagnostics and biotechnology and experts in the field are expected to keep up with the fast-changing developments in the area. However, many doctors are unable to regularly update their skills or be on top of their research game which can lead to slow adoption of new techniques while also affecting the quality of care. At DSS Imagetech with a legacy of over 80 years, we are closing these gaps with our advanced molecular diagnostics and life sciences solutions that help in faster and more accurate disease detection, as well as better research outcomes. We are constantly looking at effective ways to stay ahead of the curve. We partner with leading global technology players to bring the latest innovations to India, while adapting them to local needs. We are also leveraging AI-driven tools for better assessment of embryo health, supporting clinicians in making more precise implantation decisions to be able to improve outcomes for patients. Our strong network across the country, including in Tier II/III cities, allows us to deliver, implement and support these solutions more effectively. By equipping doctors, researchers, and institutions with the latest products and services as well as through our regular training workshops, we aim to make advanced healthcare more accessible for people in India.   Even today, many patients in India don’t get tests done on time because of high cost or lack of access. As a pioneer in diagnostics, how do you see companies like yours helping bridge this gap? Lack of awareness, fear, social and cultural stigmas and financial constraints are some of the key factors responsible for keeping people away from regular tests. For other patients in rural India, the bigger concern is lack of access to medical facilities and care. At DSS Imagetech, we strive to make advanced diagnostics — the first step towards treatment — more affordable and accessible across the country. We are also now working on educating people in India about the advances made in the field of diagnostics and biotechnology through our marketing initiatives. Education is a very crucial aspect of what we offer at DSS Imagetech as being aware can save a life. By working closely with doctors, hospitals, and research institutions pan India, we aim to close the gap and ensure more patients benefit from timely and accurate diagnostics, leading to better treatment outcomes.   What’s next for DSS Imagetech? Are there new domains or technologies you’re looking to explore? At DSS Imagetech, we are always looking for new ways to bring better healthcare technologies to India. Along with our strong base in diagnostics and life sciences, we are now expanding into areas like fertility care through our IVF brand Hanahealth, offering specialised IVF and Assisted Reproductive Technology (ART) services. We are also working towards enabling IVF labs in India to benefit from AI-powered assessment tools, which will support clinicians with more accuracy, consistency, and transparency in IVF. Our aim is to make these innovations available not just in big cities but also in tier-2 and tier-3 towns, so more people can benefit. Going forward, our focus will remain on bridging gaps in healthcare and giving doctors, researchers, and patients access to world-class solutions.   Dr Manbeena Chawla (manbeena.chawla@mmactiv.com) ]]> https://biospectrumindia.com/news/100/26640/reveal-healthtech-raises-7-2-m-to-power-next-wave-of-ai-driven-healthcare.html https://biospectrumindia.com/news/100/26640/reveal-healthtech-raises-7-2-m-to-power-next-wave-of-ai-driven-healthcare.html Thu, 04 Sep 2025 00:00:00 +0530 Reveal HealthTech, a startup with operations in India and the US, has announced its $7.2 million Series A round led by Leo Capital with participation from Sanos Capital. Founded in 2023 and incubated by W Health Ventures and 2070 Health, Reveal has quickly built a reputation as the “healthcare AI specialist” at the intersection of cutting-edge artificial intelligence (AI) and deep healthcare expertise. AI in healthcare is no longer an experiment at the fringes, but is redefining how patients are diagnosed, how treatments are delivered, and how healthcare companies operate. In this landscape, Reveal HealthTech is positioned as a catalyst driving AI adoption through its world-class team that brings the best of academic excellence (from MIT, Harvard Medical, UC Berkeley amongst others) and decades of technology innovation experience (from Boston Children’s, Mass Gen, SpaceX, NASA, Athena Health, Infosys and many others). Reveal’s solutions focus on driving customer value and improving profitability of healthcare operations. Its flagship offerings include BioCanvas® which enables multimodal AI use cases such as speeding up clinical trial recruitment using AI, and Prism AI® for rapid development of intelligent agents for workflow automation. In a recent deployment for a $40 billion US medical device leader, Reveal helped improve patient adherence through AI-driven data integration and creating a re-usable blueprint for other clients.   The Series A funding will help Reveal expand its capabilities and solutions, strengthen its sales network, and extend its reach to more healthcare and life sciences leaders worldwide. As part of this commitment, Reveal HealthTech has joined the Cipher Collective, an ECG-powered AI partner network, bringing together best-in-class health technology solutions to transform care delivery. ]]> https://biospectrumindia.com/news/100/26620/alivecor-launches-groundbreaking-ai-powered-kardia-12l-ecg-system-in-india.html https://biospectrumindia.com/news/100/26620/alivecor-launches-groundbreaking-ai-powered-kardia-12l-ecg-system-in-india.html Mon, 01 Sep 2025 00:00:00 +0530 AliveCor, the global leader in artificial intelligence (AI)-powered cardiology, has announced the launch of its groundbreaking Kardia 12L electrocardiogram (ECG) system in India. Exclusively designed for use by healthcare professionals, Kardia 12L is the world's first AI-powered, handheld 12-lead ECG system with a unique single-cable design that can detect life-threatening cardiac conditions, including heart attack, with a reduced leadset. Kardia 12L, which has received Central Drugs Standard Control Organisation (CDSCO) approval for use in India, detects 35 cardiac determinations (14 arrhythmias and 21 morphologies). This includes serious conditions like acute myocardial infarction (MI) and the most common types of cardiac ischemia. "Kardia 12L enables physicians to rapidly detect heart diseases across a wide range of healthcare settings, making this critical medical device more accessible than ever before," said Priya Abani, CEO of AliveCor. "More importantly, the launch of the Kardia 12L ECG system in India marks a big win for physicians and patients in the country, at a time when the healthcare system has never been more constrained, or more in need of the access and efficiency this type of solution provides." India is projected to suffer an economic loss of approximately $2.17 trillion due to cardiovascular diseases (CVD) between 2012 and 2030. While conventional 12-lead ECG machines are considered gold-standard and effective, they are limited by their size and complexity, often confining them to traditional hospital settings. Given this immense challenge, it is critically important to leverage AI-powered solutions to make life-saving cardiac diagnostics more accessible and affordable. First launched in the US, Kardia 12L has been met with widespread clinical acceptance, laying the groundwork for a successful global rollout. The pocket-sized system offers outstanding clinical efficiency and performance, assisting clinicians in rapid disease detection and enhancing patient experience.  ]]> https://biospectrumindia.com/news/100/26592/healthark-brings-back-rwesearch-health-innovation-summit-2025-september-911.html https://biospectrumindia.com/news/100/26592/healthark-brings-back-rwesearch-health-innovation-summit-2025-september-911.html Tue, 26 Aug 2025 00:00:00 +0530 Following the success of its inaugural edition in 2024, which saw 1800+ registrations, 1100+ attendees, 45+ speakers, and participation from 30+ organizations across 10+ countries, Healthark is set to host the RWEsearch & Health Innovation Summit 2025. This year, the summit will be graced by the presence of Hon’ble Minister for Information Technology, Electronics & Communications, Industries & Commerce, & Legislative Affairs, Government of Telangana, Shri D. Sridhar Babu, who will join as  the Chief Guest, bringing an important policy, growth and innovation perspective to the conversations. This three-day global summit will unite leaders from life sciences, healthcare, MedTech, and Global Capability Centers (GCCs) to address the most pressing challenges in healthcare. Speakers from leading organizations including Novo Nordisk, Bayer, AstraZeneca, BMS, and Deloitte will share insights and expertise. “The healthcare landscape is evolving faster than ever, and collaboration is key,” said Dr. Purav Gandhi, Founder & CEO, Healthark. “Through this summit, we aim to foster dialogue, challenge assumptions, and co-create solutions that can transform healthcare and evidence generation worldwide.” The 2025 edition will feature four dedicated tracks covering real-world evidence, clinical research, AI, and healthcare delivery globally, as well as region-specific focus on India, the Middle East, and African countries. Core themes include diversity in clinical trials, validating AI-driven data, harnessing automation, and navigating dynamic markets. A special track focused on Global Capability Centers will highlight how these capability centers out of India are driving transformation through innovation, AI adoption, and availability of talent at scale. With this strong foundation and exciting line up of speakers, the summit promises to be a defining platform for shaping the future of healthcare. Registrations are now open, join this global conversation shaping tomorrow’s healthcare, click here to register. For details, visit Healthark or follow updates on LinkedIn. ]]> https://biospectrumindia.com/news/100/26606/canarys-unveils-ai-powered-compliance-assessment-platform-for-pharma-and-life-sciences-sector.html https://biospectrumindia.com/news/100/26606/canarys-unveils-ai-powered-compliance-assessment-platform-for-pharma-and-life-sciences-sector.html Tue, 26 Aug 2025 00:00:00 +0530 Bengaluru-based Canarys has announced the launch of Auryis, their artificial intelligence (AI)-powered, unified compliance assessment platform purpose-built for Pharma and Life Sciences. This marks a pivotal step in Canarys' evolution—from a services-led organisation to a product-led company. In a fast-changing regulatory landscape, Auryis delivers real-time, structured, and audit-ready compliance insights across all digital content—including SOPs, clinical trial documents, training materials, and marketing assets. It intelligently maps each element to external regulations (GxP, FDA, EMA), internal standards, and custom business rules—helping organisations anticipate and mitigate non-compliance risk before it escalates. Sheshadri Srinivas, CEO, Canarys, commented, "In today's complex regulatory environment, Pharma and Life Sciences organisations face mounting pressure—manual reviews, rapidly shifting global standards, and the costly consequences of compliance gaps that can delay approvals and impact patient safety. ]]> https://biospectrumindia.com/news/100/26564/nova-ivf-fertility-brings-artificial-intelligence-into-ivf-labs-for-smarter-embryo-selection.html https://biospectrumindia.com/news/100/26564/nova-ivf-fertility-brings-artificial-intelligence-into-ivf-labs-for-smarter-embryo-selection.html Thu, 21 Aug 2025 00:00:00 +0530 Bengaluru-based Nova IVF Fertility, India’s fastest-growing fertility chain, has announced the integration of Artificial Intelligence (AI) into its in vitro fertilisation (IVF) labs to bring in greater precision and trust to embryo selection, an extremely crucial element of fertility treatment. The fertility chain will implement Vita Embryo, an AI-based embryo assessment, across its 120 clinics in 65 cities.  This is implemented through Nova IVF’s partnership with South Korea's AI technology firm Kai Health. This technology will improve pregnancy rates, reduce time of a patient’s IVF cycle, and can bring in much better transparency in the fertility treatment. Kai Health attained medical device certification for Vita Embryo in Europe, Singapore, Korea, and India. Clinical tests indicate that AI-powered Vita Embryo can double the accuracy of embryo selection compared to human evaluation, providing couples with a better chance of attaining successful outcome. Within the IVF Lab, Clinical Embryologists apply years of expertise, grading each embryo on its capacity to develop into a pregnancy. With Artificial Intelligence, now serving as an additional pair of eyes, this helps to further improve accuracy. Technology can spot tiny details about embryo health that might be too subtle for a human eye and can give couples added confidence that the best possible embryo is being selected for their journey. ]]> https://biospectrumindia.com/news/100/26567/us-based-vyome-signs-mou-with-indias-leading-medical-device-innovation-studio-embryyo.html https://biospectrumindia.com/news/100/26567/us-based-vyome-signs-mou-with-indias-leading-medical-device-innovation-studio-embryyo.html Thu, 21 Aug 2025 00:00:00 +0530 Vyome Holdings, Inc., a US-based clinical-stage healthcare holding company, and Pune-based Embryyo Technologies have announced the signing of a Memorandum of Understanding (MoU) to jointly pursue the global artificial intelligence (AI)-enabled medical device market. This partnership will combine Vyome's healthcare industry experience and resources with Embryyo's medical technology capabilities to potentially productise and commercialise smart medical devices that can transform the standard-of-care in disease management and treatment. As part of this partnership, Vyome and Embryyo will host a global AI-enabled medical device innovation forum for companies along the US-India corridor. "We are currently developing a portfolio of transformative medical devices spanning interventional oncology, surgery, wearables, and drug delivery, and Vyome’s access to global capital markets and the US healthcare ecosystem will accelerate our mission to push the frontiers of medicine and elevate standards of care in healthcare globally,” said Nishant Kumar, Co-Founder and CEO of Embryyo Technologies. ]]> https://biospectrumindia.com/news/100/26555/dr-lal-pathlabs-pioneers-ai-integration-in-cancer-diagnosis-in-india.html https://biospectrumindia.com/news/100/26555/dr-lal-pathlabs-pioneers-ai-integration-in-cancer-diagnosis-in-india.html Wed, 20 Aug 2025 00:00:00 +0530 In a pioneering move set to transform cancer diagnostics in India, Dr. Lal PathLabs (DLPL) has become the first laboratory in the country to adopt a deep learning-based artificial intelligence (AI) module to detect lymph node metastasis, including micrometastasis, in cancer cases. This cutting-edge technology, validated in collaboration with Qritive, was showcased at United States and Canadian Academy of Pathology (USCAP) 2025, one of the world’s leading pathology conferences. Detecting micrometastases—tiny clusters of cancer cells in lymph nodes—usually takes a lot of time and special tests. The AI tool QiAI Lymph Node Dx changes that by using deep learning to quickly and accurately spot cancer cells on digital slides. Adding this technology to regular medical practice makes diagnosing cancer faster and more reliable.  The AI system was tested on digital slides from breast, colon, stomach, and esophageal cancer cases. It accurately detected single-cell and micrometastases that had been missed during manual reviews. These results were later validated through immunohistochemistry (IHC), confirming the system’s reliability.   Commenting on the development, Bruno Occhipinti, CEO, Qritive Pte. Ltd. said: “We previously got the opportunity to collaborate with the team at Dr Lal PathLabs on a study, which resulted in the abstract presented at USCAP’25 in Boston. Following extensive testing and workflow validation, we are now excited to go live and enable the transformative impact of our AI-powered solution on critical diagnoses. This has the potential to unlock massive efficiency and accuracy gains in large volume settings, further enhancing Lal PathLabs’ excellence in its operations." As cancer cases continue to rise, the integration of AI-powered diagnostic tools like QiAI Lymph Node Dx is expected to play a key role in transforming the accuracy and efficiency of cancer care in India. ]]> https://biospectrumindia.com/news/100/26552/fedex-and-iit-madras-open-smart-centre-to-research-sustainable-ai-driven-logistics-solutions.html https://biospectrumindia.com/news/100/26552/fedex-and-iit-madras-open-smart-centre-to-research-sustainable-ai-driven-logistics-solutions.html Tue, 19 Aug 2025 00:00:00 +0530 Federal Express Corporation (FedEx), the world’s largest express transportation company, and Indian Institute of Technology Madras (IIT Madras) have inaugurated the FedEx SMART Centre (Supply Chain Modelling, Algorithms, Research and Technology Centre) in the campus. A first-of-its-kind innovation hub, it will be dedicated to building sustainable, technology-driven logistics solutions. Backed by a five-year $5 million grant from FedEx, the Centre will combine cutting-edge research, advanced digital tools, and industry expertise to reimagine supply chains for agility, resilience, and environmental responsibility. “This Centre is more than just a hub for research. It’s a space where technology and talent come together with a shared purpose to shape what’s next,” said Kami Viswanathan. “By combining deep academic insight and global industry expertise, we can build smarter, more sustainable supply chains that create meaningful impact far all stakeholders,” Kami Viswanathan, President, Middle East, Indian Subcontinent, and Africa (MEISA), FedEx said. The Centre will drive interdisciplinary projects spanning carbon-neutral operations, autonomous delivery systems, EV infrastructure, predictive analytics, and AI-driven worker safety, while also building platforms for capacity development and knowledge sharing. ]]> https://biospectrumindia.com/news/100/26541/govt-supports-indigenous-ai-powered-blood-testing-device-for-primary-healthcare.html https://biospectrumindia.com/news/100/26541/govt-supports-indigenous-ai-powered-blood-testing-device-for-primary-healthcare.html Mon, 18 Aug 2025 00:00:00 +0530 The Technology Development Board (TDB), Department of Science and Technology, Government of India, has signed an agreement with Primary Healthtech, New Delhi, for the project titled “IoT-enabled Point-of-care Blood Testing Device for Affordable and Accessible Healthcare powered by AI/ML algorithms.” The company's collaborative R&D, initially supported by BIRAC, led to the creation of the Mobilab device—a portable, battery-operated clinical chemistry analyzer, IoT-enabled and powered by artificial inteligence/ machine learning (AI/ML) algorithms, capable of testing over 25 parameters related to kidney, liver, heart, vitamins, and cancer. The company holds a patent for “A transmittance-based system/kit for point-of-care quantification” transferred from IIT Guwahati and has filed over six additional patent applications related to integrated mixers, assay development, centrifuges, and proprietary optical systems. The device has already undergone trials on 10,000 patients and recently received a CDSCO manufacturing license. The project will focus on enhancing the current prototype (M1) to perform five tests simultaneously, reducing patient waiting time, and setting up commercial-scale manufacturing. This next-generation Mobilab will include tests such as Hemoglobin, Creatinine, Bilirubin, Cholesterol, Triglycerides, Uric Acid, Glucose, and GGT, among others. ]]> https://biospectrumindia.com/news/100/26535/humeta-raises-2-m-in-pre-seed-funding-round-for-global-expansion.html https://biospectrumindia.com/news/100/26535/humeta-raises-2-m-in-pre-seed-funding-round-for-global-expansion.html Fri, 15 Aug 2025 00:00:00 +0530 HealthPresso TechnoMedia has announced that the services of its artificial intelligence (AI)-based healthcare content creation platform “HUMETA” goes global and will now be available in the UAE and the US. To fund the expansion, the company is raising $2 million in its pre seed funding round after successfully completing an Angel Investing round of $300k in July 2025. The platform delivers multi-format, multilingual, regulation-ready content for every medical specialty from CME modules and discharge summaries to patient explainers and scientific publications, all aligned with FDA, EMA and CDSCO guidelines. Trained on over 3.5 million verified medical datasets and built on proprietary Retrieval-Augmented Generation (RAG) architecture, HUMETA is designed for medical precision, according to HealthPresso TechnoMedia which created HUMETA. "With our expansion, we're now enabling content creation at the point of care in UAE through hospital networks, clinics and standalone specialty centres and in the USA, where we're working with medical associations and pharma brands to ensure every piece of healthcare communication is grounded in accuracy and governance." said Daleep Manhas, CEO & Co-Founder of HUMETA. According to HealthPresso TechnoMedia, only 15–20 percent of doctors actively contribute to health content management, with nearly 10 million out of 12 million physicians remaining passive. In India, fewer than 5 percent of 1.2 million registered allopathic doctors create content, despite the country producing over 50,000 new MBBS graduates each year. This participation gap restricts the impact of pharma, hospital and Med-Tech communications, adding HUMETA is purpose-built to activate this silent 80 percent.   ]]> https://biospectrumindia.com/news/100/26533/government-of-goa-to-implement-pricing-policy-for-innovative-lifesaving-therapies.html https://biospectrumindia.com/news/100/26533/government-of-goa-to-implement-pricing-policy-for-innovative-lifesaving-therapies.html Wed, 13 Aug 2025 00:00:00 +0530 In a progressive step toward making advanced, high-cost medical treatments more accessible, the Government of Goa is set to implement Pricing Policy for Innovative Lifesaving Therapies (PPILT). The policy aims to ensure fair and sustainable pricing for critical healthcare needs including medical devices, diagnostics, medicines etc, making them more affordable and within reach for all patients, especially those battling rare or complex diseases. The policy was announced at the CME event organised on the topic: AI’s use in diagnosing Lung Cancer Early in Goa. Goa will be the first state in India to adopt this policy framework, which enables confidential and outcome-linked pricing agreements between the government and pharmaceutical innovators. The rollout will begin with lung cancer treatment. This progressive approach allows the state to procure advanced therapies at significantly reduced costs, enabling many more patients to benefit from the existing public healthcare budget. “Innovative therapies for diseases like cancer, rare genetic disorders, and autoimmune conditions can cost upwards of Rs 50 lakh per year, placing them difficult for patients especially from underserved communities. Goa’s adoption of this pricing policy is vital and a timely step to advance health equity in the state.  A value-based approach to pricing will improve access for patients and marks a new era focusing on helping more and more patients”, said Vishwajit Rane, Health Minister of Goa. Since 2024, artificial intelligence (AI) has been embedded into Goa’s public healthcare system across 18 government hospitals and health centres, delivering measurable results at scale. Through Qure.ai’s qXR AI solution, more than 70,000 chest X-rays have been screened, detecting over 6,000 pulmonary nodules and flagging more than 500 individuals with high risk for lung cancer. This early detection has already led to confirmed lung cancer diagnoses and timely treatment, saving lives and reducing costs. The programme, led by the Government of Goa in partnership with Qure.ai and AstraZeneca, is a working example of how public and private sectors can combine technology and expertise to create systemic change and inform future health policy. By establishing a new age pricing framework, it encourages both global and Indian pharma organisation to introduce novel treatments in the state sustainable, backed by a predictable and collaborative procurement pathway. Proposed by Organisation of Pharmaceutical Producers of India (OPPI), an independent body representing research based global pharmaceutical companies in India, this critical policy is expected to strengthen Goa’s preparedness for future health challenges and ensure long-term resilience by integrating affordability, innovation, and public health priorities. ]]> https://biospectrumindia.com/news/100/26503/genomics-india-2025-to-hold-first-life-science-symposium-on-ai.html https://biospectrumindia.com/news/100/26503/genomics-india-2025-to-hold-first-life-science-symposium-on-ai.html Sun, 10 Aug 2025 00:00:00 +0530 The 5th Genomics India Conference (GIC) is presenting a groundbreaking Mini Symposium titled “Biology in AI Era – A Paradigm Shift”, set to redefine how India’s life sciences community engages with Artificial Intelligence (AI). Mini Symposium: Biology in AI Era – A Paradigm ShiftDate: August 12, 2025 | Time: 2:00–5:00 PMVenue: JN Tata Auditorium, IISc BengaluruSession Chairs: Dr Raja Mugasimangalam (Genotypic Technology) & Dr Debnath Pal (IISc) This first-of-its-kind session dives deep into how AI is revolutionising biology — from agentic models for data analysis to publishing workflows, ethics, and scalable infrastructure. Symposium Highlights: The AI Shift in Scientific History – by Dr Raja Mugasimangalam Agentic Models for Data Analysis – by Rahul, Genotypic Technology AI Tools in Thesis Writing & Publishing – by Dr Ashwin B R Kumar Your Personal AI Server: Democratising Access – by Dr Debnath Pal & Vicky Amar Daiya Hardware Demands for AI Integration – by Dr Debnath Pal Expert Panel Discussion on Innovation, Patents, Testing, Regulatory, and Commercialisation – featuring leading voices from academia and industry Seats are limited and interest is soaring. Don’t miss your chance to witness India’s AI-powered leap in life sciences. Register Now: https://genomicsindia.co.in/ ]]> https://biospectrumindia.com/news/100/26495/healthcare-ai-platform-nprep-raises-funding-to-address-nursing-education-crisis.html https://biospectrumindia.com/news/100/26495/healthcare-ai-platform-nprep-raises-funding-to-address-nursing-education-crisis.html Thu, 07 Aug 2025 00:00:00 +0530 NPrep, a placement-focused company which is building an artificial intelligence (AI)-powered skilling platform for nursing students and professionals, has raised an undisclosed amount in a pre-seed funding round led by All In Capital. The round also saw participation from IIMA Ventures, Chegg’s founder Aayush Phumbhra (American educational technology company) as an investor, and several family offices and angel investors. One of the most significant early-stage raises in India’s nursing and healthcare skilling industry. NPrep will use the capital to expand its course offerings, strengthen and build its AI-driven learning platform, and deepen its placement partnerships with hospitals and healthcare institutions across India. The startup also plans to invest in growing its regional language support to better serve students from Tier 2 and Tier 3 cities. The startup aims to address this by offering an AI-powered skilling and placement platform tailored to the specific needs of nursing students and professionals. The platform aims to use generative AI to personalize learning paths based on a student’s strengths and weaknesses, simulate real-world clinical scenarios for Simulate real world clinical scenarios for superior skill training, and provide instant feedback. It will also support students through mock interviews, resume building, and automated assessment tools that help improve their job readiness. By combining technology with tailored support, the startup aims to strengthen the nursing workforce and improve healthcare delivery across the country. Looking ahead, the company plans to expand its placement services domestically in FY26 and internationally by FY27, building on its foundation of medical and technological expertise.   ]]> https://biospectrumindia.com/news/100/26468/laxmi-dental-to-acquire-majority-stake-in-ai-dent-to-expand-ai-capabilities-in-digital-dentistry.html https://biospectrumindia.com/news/100/26468/laxmi-dental-to-acquire-majority-stake-in-ai-dent-to-expand-ai-capabilities-in-digital-dentistry.html Fri, 01 Aug 2025 00:00:00 +0530 Mumbai-based Laxmi Dental, a dental products company, has announced that its Board of Directors has approved an investment in IDBG AI Dent Global, a Gujarat-based healthcare technology company focused on artificial intelligence applications in dentistry. Upon completion, Laxmi Dental Limited will hold 58% of the capital in AI Dent. The objective of the acquisition is to strengthen the company’s research and development and expand its technology offerings. The move also supports India’s efforts to promote domestic manufacturing and self-reliance under the Make in India and Aatmanirbhar Bharat initiatives. AI is becoming a foundational technology in dentistry across the world. From diagnostics to treatment planning, AI tools are improving decision-making and clinical outcomes. Through this investment, Laxmi Dental aims to build local capability in AI for dental care, enabling dentists to adopt faster, data-driven processes while reducing procedural complexity for patients. The focus is on creating systems that support dentists in delivering consistent care and give patients improved access, accuracy, and clarity in diagnosis and treatment. AI Dent is developing AI-based dental imaging and diagnostic tools, including software for image analysis and X-ray interpretation. ]]> https://biospectrumindia.com/news/100/26431/flebo-in-introduces-free-ai-powered-digital-health-record-storage.html https://biospectrumindia.com/news/100/26431/flebo-in-introduces-free-ai-powered-digital-health-record-storage.html Thu, 24 Jul 2025 00:00:00 +0530 Gurugram-based startup Flebo.in, a one-stop destination that allows convenient booking of both radiology and pathology tests from any lab of the customer's choice, has launched a new free artificial intelligence (AI)-powered digital health vault, enabling users to upload, store, and analyse lab reports from any diagnostic lab. The new service allows patients to consolidate scattered medical records, track health trends over time, and receive AI-driven insights and doctor suggestions—all without any cost. Backed by Ajay Singh, Chairman and Managing Director, SpiceJet, in his personal capacity, Flebo.in now lets users upload their health reports from any lab, including third party, and secure them in an online data vault free of cost. They can access these reports anytime, anywhere on their mobile phones by simply logging into their Flebo.in account. As soon as a report is uploaded, Flebo.in uses artificial intelligence to instantly and automatically analyse the report. It shows users the parameters that are out of range, provides an AI based analysis, which includes recommendations for lifestyle and doctor recommendations. It adds all major tested parameters to the Health Trend Graphs to see all the values for that parameter across all tests, conducted at different times in one graph, without needing to look through multiple reports. Flebo.in then sends recommendations for future tests at the appropriate time, thus ensuring timely diagnosis and treatment.   ]]> https://biospectrumindia.com/news/100/26420/kims-hospitals-medulance-unveils-thanes-first-ai-integrated-5g-smart-ambulance.html https://biospectrumindia.com/news/100/26420/kims-hospitals-medulance-unveils-thanes-first-ai-integrated-5g-smart-ambulance.html Tue, 22 Jul 2025 00:00:00 +0530 KIMS Hospitals, Thane, has announced a significant breakthrough in emergency healthcare with the launch of Thane region’s first artificial intelligence (AI)-integrated 5G Smart Ambulance- a first-of-its-kind initiative in partnership with Medulance.   This cutting-edge ambulance system is set to transform pre-hospital critical care by enabling real-time, AI-based patient monitoring and seamless 5G connectivity.   The smart ambulance showcased its ability to transmit vital patient data—including ECG, blood pressure, and oxygen saturation—live to the Emergency Room while en route. Unlike standard 5G-enabled ambulances, this next-generation system integrates artificial intelligence to continuously analyse patient vitals during transit, allowing emergency doctors to initiate care protocols before the patient arrives.   During the demonstration, attendees witnessed how real-time telemetry, AI-based analytics, and HD communication tools function seamlessly over ultra-low-latency 5G networks.   The system also allows emergency teams to communicate with ambulance staff, review data live, and prepare the emergency bay accordingly, maximising the 'Golden Hour Advantage'.   With this launch, KIMS Hospitals became the first in the Thane region to roll out a fully AI-integrated 5G Smart Ambulance, positioning itself as a leader in future-ready emergency medicine. The collaboration with Medulance brings together clinical expertise and cutting-edge tech infrastructure, setting a new benchmark for hospitals across Maharashtra and India. ]]> https://biospectrumindia.com/news/100/26408/agilisium-and-sriher-to-set-up-indias-first-agentic-ai-powered-digital-health-research-centre.html https://biospectrumindia.com/news/100/26408/agilisium-and-sriher-to-set-up-indias-first-agentic-ai-powered-digital-health-research-centre.html Mon, 21 Jul 2025 00:00:00 +0530 In a landmark move that positions India at the forefront of life sciences and healthcare innovation, Agilisium, a leading autonomous Agentic AI partner to the life sciences industry, has signed a Memorandum of Understanding (MoU) with Chennai-based Sri Ramachandra Institute of Higher Education and Research (SRIHER) to set up the country’s first Agentic AI-Powered Digital Health & Research Centre.  Dedicated to advancing scientific research, healthcare delivery, and academic excellence through AI and GenAI, the Centre will serve as a collaborative hub to drive breakthroughs in precision medicine, digital diagnostics, and data-driven clinical research. By combining Agilisium’s expertise in AI-driven solutions with SRIHER’s clinical and academic leadership, the Centre aims to develop next-generation diagnostic tools, intelligent decision-support systems, and interoperable health data frameworks, positioning India as a global leader in future-ready digital healthcare. The collaboration aims to harness powerful synergies between clinical expertise and technology innovation to address some of the most critical challenges in modern healthcare. Agilisium will contribute its deep capabilities in advanced analytics, data science, biostatistics, GenAI, and autonomous Agentic AI, while SRIHER will provide access to rich clinical datasets, domain specialists, and advanced medical facilities and expertise. A major thrust of the partnership will be on co-developing and publishing high-impact scientific research that spans AI-powered clinical trials, predictive diagnostics, and personalised medicine; efforts that will significantly raise the bar for healthcare and life sciences R&D in India. This partnership will not only address technology and research but will aid in  the growing demand for intelligent, scalable patient care tools. AI-powered chatbots and GenAI-enabled virtual assistants to support clinicians, patients, and caregivers with real-time diagnostics, documentation, and remote monitoring will be the tools developed, piloted and validated at SRIHER’s hospital environment to measure clinical impact and user experience. The MoU also outlines the development of an industry-first academic certification program on Generative AI in Healthcare. Jointly designed and delivered by Agilisium and SRIHER, the course will cover applications across drug discovery, diagnostics, predictive modeling, and patient care. While Agilisium will offer real-world technology expertise, SRIHER will embed clinical relevance and academic rigor into the curriculum. Together, they aim to build a future-ready talent pool equipped to lead AI innovation in the healthcare sector. The partnership will also explore collaborations such as joint workshops, seminars, conferences and CSR-driven research funding to support socially relevant healthcare innovations.    Image caption- Left to Right -Raj Babu, Founder and CEO Agilisium and Dr Uma Sekar, Vice Chancellor, Sri Ramachandra Institute of Higher Education and Research   ]]> https://biospectrumindia.com/news/100/26413/maharashtra-gets-first-operational-ai-powered-heart-disease-prevention-model.html https://biospectrumindia.com/news/100/26413/maharashtra-gets-first-operational-ai-powered-heart-disease-prevention-model.html Mon, 21 Jul 2025 00:00:00 +0530 Jaslok Hospital & Research Centre has partnered with AnginaX AI, India’s first licensed AI Doctor Assistant in cardiology, to launch Maharashtra’s first operational AI-powered heart disease prevention model. This collaboration places Jaslok at the forefront of India’s shift from late-stage cardiac intervention to early, technology-driven prevention. The advanced AnginaX AI system, now deployed across Jaslok’s outpatient departments, enables doctors to assess cardiovascular risk in just seconds using structured, science-backed reports that identify risk even before symptoms appear and recommend personalised lifestyle and treatment plans. With heart disease affecting millions of Indians and often going undetected until it’s too late, this prevention model brings speed, clarity, and access to the very first point of contact: the OPD. The AnginaX system evaluates more than 20 critical clinical and lifestyle-based indicators, including extended lipid profiles, blood sugar, inflammatory biomarkers, metabolic complexities, family history, and lifestyle patterns. Based on validated Indian data, the system generates a structured clinical summary that includes individualized risk stratification, investigation recommendations specific to each patient, and clear, actionable treatment and follow-up guidance. Recognising that cost and fear are often barriers to early checkups, Jaslok and AnginaX have ensured the programme is fast, accessible and affordable, making prevention routine rather than rare. Jaslok has also launched AI-powered initiative “Dil Fit, Life Hit” under the leadership of Dr Ashwin B. Mehta, bringing structured cardiovascular prevention into everyday clinical care. The programme empowers doctors, transforms OPD practice, and makes prevention accessible to every patient, not just those with symptoms.   ]]> https://biospectrumindia.com/news/100/26406/mahajan-imaging-labs-dwarka-centre-installs-indias-first-ultra-fast-ai-powered-mri-scanner.html https://biospectrumindia.com/news/100/26406/mahajan-imaging-labs-dwarka-centre-installs-indias-first-ultra-fast-ai-powered-mri-scanner.html Sun, 20 Jul 2025 00:00:00 +0530 In a major step forward for diagnostic healthcare in India, Lieutenant Governor of Delhi Vinai Kumar Saxena inaugurated the new centre of Mahajan Imaging & Labs, in Dwarka. The event also marked the launch of India's first Ultra-Fast AI-powered MRI scanner, the “Excel 3T,” positioning Delhi at the forefront of medical innovation. Marking a significant expansion in Southwest Delhi, the new facility brings together multiple branches of advanced diagnostics—including imaging, laboratory medicine, and genetic testing—within easy reach for residents of Dwarka and nearby areas. Alongside this integrated approach, the centre also offers deep specialisation in key areas, especially cardiac imaging apart from neuroimaging, and musculoskeletal scans, addressing the growing demand for precision-led, organ-specific diagnostics. Thoughtfully designed with a patient-first approach, the space features locally sourced materials, ample natural light, and calming palettes that promote comfort and well-being. Its energy-efficient systems and water reuse mechanisms underscore a conscious approach to sustainable healthcare. Making its Indian debut at this facility, the Excel 3T MRI delivers up to 50% better signal-to-noise ratio, producing sharper, high-resolution images in less time. Cardiac MRI scans, for instance, have been reduced from more than an hour to just 30–40 minutes. Its advanced technologies, such as real-time motion correction, AI-driven reconstruction, and contactless respiratory tracking, help improve precision and make scans more tolerable for children, elderly patients, and those with claustrophobia. An immersive in-bore experience and smart automation further enhances comfort during procedures. The Dwarka centre, which offers advanced preventive health checks, also features a comprehensive range of advanced diagnostic technologies, including a 128-slice cardiac CT scanner, Full Field Digital mammography, 3D/4D Ultrasound with AI, Digital X-Ray, Dexa BMD, Echocardiography, Holter, and PFT systems. Many of these, such as the MRI, CT and ultrasound machines are AI-enabled—enhancing the speed, precision, and efficiency of diagnostics. ]]> https://biospectrumindia.com/news/100/26376/indegene-launches-next-medical-writing-automation-platform-with-genai.html https://biospectrumindia.com/news/100/26376/indegene-launches-next-medical-writing-automation-platform-with-genai.html Mon, 14 Jul 2025 00:00:00 +0530 Bengaluru-based Indegene, a digital-first, life sciences commercialisation company, has announced the launch of NEXT Medical Writing Automation, an advanced platform that combines deep medical writing expertise with generative AI (GenAI) to accelerate the creation of high-quality, compliant documents across clinical development, regulatory submissions, and beyond. Medical writing teams are under constant pressure to deliver precise, regulatory-ready documents within tight timelines, often while navigating fragmented data and evolving compliance needs. NEXT Medical Writing Automation addresses these challenges head-on. It combines Indegene’s decades of domain knowledge with the power of its AI engine, Cortex. As a life sciences-specialist knowledge engineering and multi-agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance. Purpose-built by experienced medical writers, NEXT Medical Writing Automation operates within familiar environments like Microsoft Word, auto-generating compliant drafts that adapt to diverse sponsor formats and workflows. It integrates seamlessly with Regulatory Information Management (RIM) systems, maintaining traceability and consistency across documents. With automated scheduling, intelligent task assignments, and robust data flow integration, NEXT Medical Writing Automation helps life sciences organizations scale operations efficiently while maintaining a strong compliance backbone. As document requirements grow and scrutiny intensifies, such solutions become essential to sustaining operational excellence. “We see this platform as more than automation - it’s about elevating the entire practice of medical writing,” said Sameer Lal, SVP, Enterprise Medical Solutions, Indegene. “Writers can now focus on strategic tasks and critical thinking, while the platform manages the heavy lift of data and formatting.” ]]> https://biospectrumindia.com/news/100/26375/who-maps-application-of-ai-in-traditional-medicine.html https://biospectrumindia.com/news/100/26375/who-maps-application-of-ai-in-traditional-medicine.html Sat, 12 Jul 2025 00:00:00 +0530 In a significant milestone for global healthcare innovation, the World Health Organization (WHO) has released a technical brief titled "Mapping the Application of Artificial Intelligence in Traditional Medicine", acknowledging India’s pioneering efforts in integrating Artificial Intelligence (AI) with traditional medicine systems, particularly Ayush systems. The release follows India’s proposal on the subject, leading to the development of WHO’s first-ever roadmap for applying AI in traditional medicine. The document showcases a range of AI-driven applications in Ayurveda, Siddha, Unani, Sowa Rigpa, and Homoeopathy, including diagnosis support systems that integrate traditional methods like pulse reading, tongue examination, and Prakriti assessment with machine learning algorithms and deep neural networks. These efforts are enhancing diagnostic accuracy and enabling personalised preventive care. One of the standout features in the WHO brief is the mention of Ayurgenomics, a scientific breakthrough that combines genomics with Ayurvedic principles. This initiative aims to identify predictive disease markers and personalise health recommendations using AI-based analysis of Ayurvedic constitution types. The document also highlights efforts to decode the genomic and molecular basis of herbal formulations for repurposing in modern disease conditions—a major leap in integrating traditional wisdom with contemporary science. India’s initiatives to digitise traditional knowledge, such as the Traditional Knowledge Digital Library (TKDL), are praised as global models for the preservation and responsible use of indigenous medical heritage. Furthermore, AI-powered tools are being used for cataloguing and semantic analysis of ancient texts, enabling easier access to time-tested therapeutic knowledge. Another critical aspect recognised by the WHO is the use of AI for drug action pathway identification, comparative studies across systems like Ayurveda, TCM, and Unani, and the development of artificial chemical sensors to assess traditional parameters such as Rasa, Guna, and Virya. These technological interventions are helping validate and modernise traditional formulations. The document also applauds India’s broader efforts in incorporating digital platforms for online consultations, promoting digital literacy among Ayush practitioners, and building interoperable systems to integrate traditional medicine with mainstream healthcare. ]]> https://biospectrumindia.com/news/100/26361/omron-and-tricog-health-launch-keebohealth-to-combat-indias-cardiac-crisis.html https://biospectrumindia.com/news/100/26361/omron-and-tricog-health-launch-keebohealth-to-combat-indias-cardiac-crisis.html Thu, 10 Jul 2025 00:00:00 +0530 Omron Healthcare, a global leader in innovative home health monitoring solutions, has expanded its collaboration with Tricog Health, an artificial intelligence (AI)-driven cardiac care company, to launch KeeboHealth- an advanced connected health platform designed to transform remote cardiac care and accelerate progress toward Omron’s ambitious ‘Going for Zero’ vision - a world with zero cardiovascular events. KeeboHealth is a ground-breaking digital health ecosystem that leverages state-of-the-art AI technology, real-time data analytics, and home-based monitoring to empower healthcare providers and patients in managing heart conditions more effectively.  The data flows in real-time to Tricog’s AI engine, which continuously monitors heart health, flags early warning signs, and instantly alert medical teams when intervention is needed. This proactive system helps detect heart issues before a patient’s condition detoriates, significantly reducing the need for hospitalizations. The platform integrates seamlessly with Omron’s range of connected devices-including home ECG monitors, blood pressure monitors, and weighing scales-enabling continuous and personalised care. A multinational study involving Duke and UT Southwestern University hospitals in the United States, as well as Manipal Hospital in India, has demonstrated KeeboHealth’s significant impact on heart failure management. Patients demonstrated measurable improvements in exercise capacity and heart health biomarkers by 45%, while adherence to Guideline-Directed Medical Therapy (GDMT) increased to 44%, resulting in a reduction in hospital readmissions.  Omron and Tricog plan to expand KeeboHealth widely across India in 2025, marking a paradigm shift in remote cardiac care. The combined expertise of both organisations promises a scalable, cost-effective solution that brings proactive, personalised heart health management to patients worldwide, propelling Omron’s mission of Going for Zero.   Image caption- Left to Right : Hokuta Haya, Deputy Consul General of Japan in Bengaluru; Ayumu Okada, Representative Director, President and CEO  - Omron Healthcare Co. and Dr Charit Bhograj, CEO & Founder Tricog Health     ]]> https://biospectrumindia.com/news/100/26365/aiims-bibinagar-and-iiit-hyderabad-host-hackathon-and-pick-five-ai-based-healthcare-innovations.html https://biospectrumindia.com/news/100/26365/aiims-bibinagar-and-iiit-hyderabad-host-hackathon-and-pick-five-ai-based-healthcare-innovations.html Thu, 10 Jul 2025 00:00:00 +0530 In a pioneering initiative to foster innovation at the intersection of medicine and technology, AIIMS Bibinagar and the Centre for Innovation and Entrepreneurship (CIE) at IIIT Hyderabad jointly conducted the MedCare AI Impact Hackathon.  The event brought together doctors, medical students, researchers, and deep-tech innovators to co-create scalable, AI-driven healthcare solutions. Over 65 ideas were submitted for the challenge, of which 17 promising teams were shortlisted for the final round. The top five teams were awarded early-stage programme funding, access to IIIT-H’s research labs, and incubation support under a joint CIE-AIIMS initiative. Winning ideas included smart dental diagnostics, ML-based defect detection post-root canal therapy, portable caries scanners, predictive analytics for surgical planning, and real-time monitoring for critical care. The hackathon featured dual tracks—one tailored for medical practitioners and the other for med-tech researchers—focusing on building AI-enabled clinical tools, diagnostics, and care delivery models. The event was designed to translate on-ground clinical challenges into viable healthtech solutions using AI/ML, computer vision, and IoT.   Top Innovations included- o   AI Dent Triage: AI-powered multimodal triage for dental diagnostics o   NeoScreen AI: Offline-compatible stool image analyser for early detection of Extrahepatic biliary atresia (EHBA) o   TMJ 3D View: Automated 3D segmentation of the temporomandibular joint (TMJ) from MRI scans o   Gluco Pulse: Smart 3D-printed mouthguard to monitor salivary glucose o   Safeped AI: Pediatric surgical safety checklist powered by AI   ]]> https://biospectrumindia.com/news/100/26358/hyderabad-based-care-hospitals-installs-strykers-advanced-ai-powered-robotic-surgery-system.html https://biospectrumindia.com/news/100/26358/hyderabad-based-care-hospitals-installs-strykers-advanced-ai-powered-robotic-surgery-system.html Wed, 09 Jul 2025 00:00:00 +0530 In a ground-breaking move towards the future of precision medicine, CARE Hospitals, Hitech City in Hyderabad, has introduced artificial intelligence (AI)-powered Stryker Mako Robotic System, marking a new era in robotic joint replacement surgeries in Telangana.   The MACO Robo brings a new level of precision and personalisation in joint replacement procedures, marking a significant advancement in surgical outcomes and faster patient recovery.    Speaking at the launch, Arekapudi Gandhi, MLA, Serilingampally said, "The integration of such advanced AI-based robotic solutions in Telangana’s healthcare ecosystem showcases our state's progress in embracing next-gen medical technology. I commend CARE Hospitals for constantly pioneering innovations that improve patient outcomes and set new benchmarks in clinical excellence."   The Stryker Mako Robotic System, integrated with Artificial Intelligence, enhances surgical accuracy by enabling real-time decision-making, personalised surgical planning, and precision execution. This advanced system is particularly effective in total knee, partial knee and hip replacement surgeries, resulting in faster recovery, minimal post-op pain, and improved long-term outcomes.   Key Features of the AI-Assisted Robotic Surgery System include- AI-driven 3D CT-based surgical planning for patient-specific procedures; Real-time intra-operative robotic guidance with haptic feedback for enhanced precision; Minimal bone removal and reduced soft tissue damage; Improved implant positioning for better long-term outcomes; Faster recovery and reduced hospital stay.     ]]> https://biospectrumindia.com/news/100/26346/veeda-lifesciences-brings-ai-innovation-to-clinical-trial-services.html https://biospectrumindia.com/news/100/26346/veeda-lifesciences-brings-ai-innovation-to-clinical-trial-services.html Tue, 08 Jul 2025 00:00:00 +0530 Ahmedabad-based contract research organization (CRO) Veeda Lifesciences has announced an investment in Mango Sciences, a Boston-based healthcare AI and data company. With this investment, Veeda intends to leverage AI capabilities to improve the speed, efficiency and quality of clinical trial services across its expanded global network, enabling more diverse and efficient recruitment as well as globally representative patient selection. Building on the Querent platform™ powered by Mango Sciences' AI, Veeda will effectively use the technology to automate accurate patient identification and expand its reach across Europe. "Our partnership will make Veeda an AI-driven oncology drug development organisation that can meet the growing demand for diversity in clinical trials, in line with the expectations of regulators and pharmaceutical companies. We will be one of the few oncology CROs with access to this proprietary technology," said Mahesh Bhalgat, Group Executive Director and Managing Director of Veeda Clinical Research Limited. By deploying the Querent platform™ powered by AI, Veeda will streamline processes, improve data management capabilities, and ensure higher quality standards through broader representation of non-Caucasian populations. This will increase the efficiency of clinical trials through advanced data analytics, benefiting patient matching, trial design and monitoring, while reducing costs and time.   ]]> https://biospectrumindia.com/news/100/26341/deeptek-ai-solution-gains-who-recommendation-in-global-fight-against-tb.html https://biospectrumindia.com/news/100/26341/deeptek-ai-solution-gains-who-recommendation-in-global-fight-against-tb.html Mon, 07 Jul 2025 00:00:00 +0530 Pune-based startup DeepTek, a leading medical imaging AI company, has received a significant recommendation from the World Health Organization (WHO) for its Chest X-ray AI solution for TB screening. In its latest policy guidance, WHO recommended the solution as meeting the performance standards for Computer-Aided Detection (CAD) softwareused in tuberculosis (TB) screening across both community and facility-based screeningsettings. This recommendation underscores the solution’s clinical reliability, global scalability, and real-world impact—making it one of the few AI tools globally validated for identifying presumptive TB cases rapidly and accurately, particularly in low-resource settings. In 2022, 10.6 million people were diagnosed with TB, with the highest burden seen in South-East Asia, Africa, and the Western Pacific. These regions often face a shortage of radiologists and fragmented screening systems, leading to delayed diagnosis and treatment. DeepTek’s Chest X-ray AI solution addresses this challenge head-on by delivering rapid analysis of chest X-rays in under a minute, even in remote areas without internet connectivity, making early intervention possible at scale. DeepTek’s Chest X-ray AI solution is certified by both the US FDA and EU CE MDR. Beyond detecting tuberculosis, it identifies over 21 other critical lung abnormalities—including nodules, masses, and pneumothorax—making it highly versatile for public health programs and routine lung screenings. A key differentiator of our solution is its ability to interpret pediatric chest X-rays for children aged four and above. DeepTek’s platform supports end-to-end patient management across the TB screening workflow. Digital X-ray machines are used to capture chest scans, which are analysed by DeepTek’s AI engine to generate TB risk predictions in under a minute. The system operates seamlessly even in offline settings, with data securely synced to the cloud once connectivity is restored.   ]]> https://biospectrumindia.com/news/100/26324/auriga-and-san-francisco-research-institute-ink-mou-to-advance-ai-driven-clinical-research.html https://biospectrumindia.com/news/100/26324/auriga-and-san-francisco-research-institute-ink-mou-to-advance-ai-driven-clinical-research.html Thu, 03 Jul 2025 00:00:00 +0530 Delhi-based Auriga Research, a leading Contract Research Organization (CRO), has entered into a strategic Memorandum of Understanding (MoU) with San Francisco Research Institute (SFRI), a US-based healthcare research and innovation organisation. This collaboration aims to strengthen global clinical research, promote AI-integrated healthcare solutions, and expand access to compliant wellness products across India, the United States, and Africa. The partnership outlines a joint framework to support clinical trials, regulatory pathways, digital health innovation, and international business development. It brings together Auriga’s strong infrastructure and expertise in India and Asia with SFRI’s global capabilities across North America, Europe, and Africa. Key outcomes of the collaboration include Joint clinical trials using AI for patient recruitment, monitoring, and analytics; Auriga to lead clinical operations, data management, and regulatory execution in India; SFRI to drive client engagement and Market expansion in the US, Japan, and Europe; Co-development of new formulations and wellness products for global markets; Joint applications for grants and funded clinical research projects; SFRI to connect Auriga with marketers and public health agencies in Africa for expansion. San Francisco Research Institute will also support regulatory strategy, public health collaboration, and commercial partnerships in markets such as Nigeria and the US. This includes enabling product registration with national health agencies, connecting Auriga to distributors and marketers, and directly supporting sales outreach and supply chain strategies. The two organisations will jointly expand their Research Training Programme through both digital platforms and in-person sessions, while also co-developing new products and AI applications for healthcare. Additionally, they will pursue government and foundation-funded projects to further their impact on global health systems. ]]> https://biospectrumindia.com/news/100/26321/gtt-data-ai-accelerator-network-to-empower-startups-in-healthcare-and-life-sciences.html https://biospectrumindia.com/news/100/26321/gtt-data-ai-accelerator-network-to-empower-startups-in-healthcare-and-life-sciences.html Wed, 02 Jul 2025 00:00:00 +0530 GTT Data Solutions, a BSE-listed technology enabler known for its Dual Intelligence framework that blends human expertise with advanced artificial intelligence (AI), has launched GAIN (GTT Data AI Accelerator Network), a platform designed to support over 100 AI startups across industries, including a sharp focus on healthcare and life sciences. GAIN aims to fast-track innovation in AI-powered medical imaging, predictive diagnostics, hospital automation, and more, by providing selected startups with mentorship, go-to-market enablement, and potential funding support from partners such as Sangli Miraj Commercial Ventures. As part of the healthcare vertical, GTT Data is keen to help startups develop and scale AI tools that improve diagnosis accuracy, enhance clinical workflows, and support value-based care models. “We have never had an AI-first approach at GTT Data; we truly believe in the collaboration between human entities and AI to create dual intelligence. With GAIN, we’re creating a launchpad for India’s AI businesses not just to survive, but to lead with purpose. We believe the future of AI must be shaped by partnerships, not silos. And its impact must be measured not just in productivity gains, but in how it uplifts human potential. GAIN is our commitment to making India a formidable, collaborative force in the global AI movement — where machines serve mankind, and not the other way around,”  said Srikumar Kumar, President, GTT Data Solutions. The initiative has already kicked off in Pune, bringing together 22 AI companies and over 40 founders, co-founders, and technologists to showcase innovations and explore collaborations. GTT DATA invites healthtech innovators, researchers, and ecosystem enablers to be part of this platform — where responsible AI meets real-world healthcare transformation.   ]]> https://biospectrumindia.com/news/100/26293/ddmm-heart-institute-becomes-first-in-western-india-to-install-real-time-cardiac-view-recognition-ultrasound-system.html https://biospectrumindia.com/news/100/26293/ddmm-heart-institute-becomes-first-in-western-india-to-install-real-time-cardiac-view-recognition-ultrasound-system.html Thu, 26 Jun 2025 00:00:00 +0530 Nadiad’s Dharmsinh Desai Memorial Methodist Institute of Cardiology and Cardiovascular Surgery has announced the installation of an advanced artificial intelligence (AI)-enabled real-time cardiac view recognition ultrasound system at its centre. With this, the hospital is now the first in western India to have the innovative AI-enabled Acuson Origin ultrasound system by Siemens Healthineers. This technology reduces reliance on traditional Electrocardiogram (ECG) during echocardiography for patients, thereby enhancing patient experience and comfort.   Known for its state-of-the-art treatment facilities for patients with cardiac and vascular ailments, the hospital aims to provide world-class technology-driven solutions to their patients in and around the city. Although cardiovascular disease (CVD) is recognised as a major public health issue in India, access to cardiovascular care remains constrained, as reflected by the low rates of detection and treatment. Talking about the development, Dr Sanjeeth Peter, Director and Chief Cardiac Surgeon, DDMM Heart Institute, said, “With this cutting-edge technology, we are further empowering our team to diagnose and treat cardiovascular conditions with unparalleled precision and speed, ensuring the highest level of care for our patients." "At Siemens Healthineers, we are focused on pioneering innovative healthcare solutions for everyone, everywhere, sustainably. With customer and patient centricity at our core, we've introduced Acuson Origin, a cutting-edge technology designed to empower patients and doctors in managing complex cardiovascular conditions. After this new addition, DDMM Heart Institute is enabling thousands of patients in and around Nadiad to access world-class cardiac care, improving their quality of life and transforming the landscape of cardiovascular treatment in Gujarat”, said Sanjay David - Head of Ultrasound - Zone ASEAN & India, Siemens Healthcare Private Limited  This industry-first technology enhances diagnostic precision and patient outcomes through advanced ultrasound features like 2D and 4D HeartAI, which enable automated contouring and quantification of all four cardiac chambers – even without an electrocardiogram (ECG). ]]> https://biospectrumindia.com/news/100/26264/s-l-raheja-hospital-unveils-ai-enabled-digital-pet-ct-3t-mri-and-advanced-nicu-picu-units.html https://biospectrumindia.com/news/100/26264/s-l-raheja-hospital-unveils-ai-enabled-digital-pet-ct-3t-mri-and-advanced-nicu-picu-units.html Thu, 19 Jun 2025 00:00:00 +0530 S.L. Raheja Hospital, a Fortis Associate, has strengthened its commitment to delivering state-of-the-art diagnostic care with the launch of artificial intelligence (AI)-enabled Digital Positron Emission Tomography – Computed Tomography (Digital PET CT) scan and 3 Tesla Magnetic Resonance Imaging (3T-MRI) services.  These additions mark a milestone in the hospital’s journey toward providing precision-driven diagnostics and critical paediatric care in Mumbai. This is the second digital PET CT scan facility of its kind in Mumbai, bringing world-class imaging capabilities closer to patients. In addition, the hospital introduced advanced Neonatal Intensive Care Unit (NICU) and Pediatric Intensive Care Unit (PICU) services to further enhance critical care for infants and children.  The AI-enabled PET CT and MRI facilities, will be headed by Dr Mary Anne Joseph, Head-Nuclear Imaging and Dr Sanjay Bhatia, Consultant-Dept. of Radiology, respectively. The new digital PET CT delivers enhanced resolution, faster imaging time, and improved patient comfort. It is equipped with AI-enabled software to provide better precision in identifying lesions. This technology is used for cancer, neurology, infection, inflammation, and cardiology—for diagnosis, staging, and assessment of treatment response. The state-of-the-art 3 Tesla MRI machine is AI-enabled and will produce sharper more detailed high-resolution images. It has a stronger magnet that allows for faster scans, which reduces patient time in the machine and improves workflow, and comes with enhanced precision which helps in early diagnosis and more accurate treatment planning. The NICU houses seven beds, and is fully equipped with high-frequency ventilators, continuous positive airway pressure (CPAP) units, LED phototherapy systems, and medical-grade sterilisers. The PICU consists of four beds, with one dedicated isolation bed for immunocompromised or infectious cases, ensuring maximum protection and personalised care.  ]]> https://biospectrumindia.com/news/100/26257/samsung-and-iit-madras-sign-mou-to-drive-ai-based-research-in-healthcare.html https://biospectrumindia.com/news/100/26257/samsung-and-iit-madras-sign-mou-to-drive-ai-based-research-in-healthcare.html Tue, 17 Jun 2025 00:00:00 +0530 Samsung R&D Institute, Noida (SRI-N) has deepened its industry-academia engagement through a Memorandum of Understanding (MoU) with the Indian Institute of Technology Madras (IIT-M) to drive collaborative research, accelerate technology development and nurture future-ready talent. The partnership will focus on pioneering advancements in AI for Indian languages, HealthTech and emerging areas such as Generative AI, reinforcing Samsung’s commitment to build a stronger innovation ecosystem aligned with the vision of ‘Make in India’ and ‘Digital India’. The five-year MoU that was signed by Kyungyun Roo, Managing Director, SRI-N and Prof. V. Kamakoti, Director, IIT Madras, aims to provide a wide range of collaborative activities, including sponsored research projects, consultancy projects, technology licensing, trainings, facility development and sponsorship of student fellowships in future. This strategic partnership between Samsung India and IIT Madras adds to SRI-Noida’s growing network of academic collaborations, having already established long-term strategic MoUs with premier institutes including IIT Delhi, IIT Kanpur, IIT Bombay and IIT Ropar. Samsung and these institutes are charting an expansive roadmap toward a smarter, more connected world. By combining industry-scale resources with academic rigor, these partnerships are cultivating a thriving ecosystem for future breakthroughs. SRI-Noida will sponsor research and development (R&D) projects, which may be conducted at IIT Madras, the company’s premises or through a collaborative arrangement at both locations. ]]> https://biospectrumindia.com/news/100/26235/concerns-about-appropriate-implementation-of-genai-in-healthcare-persist.html https://biospectrumindia.com/news/100/26235/concerns-about-appropriate-implementation-of-genai-in-healthcare-persist.html Thu, 12 Jun 2025 00:00:00 +0530 The new 2025 Future Ready Healthcare Survey Report from Wolters Kluwer Health, conducted in partnership with the independent marketing research firm Ipsos, reveals that while healthcare professionals widely recognise the transformative potential of generative AI (GenAI), most organisations are not yet ready to harness its full value. The survey identifies strong enthusiasm for using GenAI to address the current challenges of workforce shortages, burnout, high healthcare costs, and rising administrative burdens, as well as keen interest in leveraging GenAI to achieve the next level of innovation and efficiency across the enterprise. However, the data also shows a clear disconnect between what organisations say they want to achieve with GenAI and how prepared they are to deliver on that promise. For example, while 80% of respondents cited “optimising workflows” as a top organisational goal, only 63% feel prepared to use GenAI to do so. Nurse staffing and workforce concerns are at the top of the priority list for health GenAI applications. Leaders are focusing on the basics to keep the enterprise running, but clinical staff expect more from the GenAI revolution. Also, formal GenAI policies and guidance are scarce. As a result, concerns about appropriate implementation persist: More than half (57%) believe that overreliance on GenAI may erode clinical decision-making skills, while 55% are concerned that lack of transparency around GenAI’s potential role in making diagnoses could contribute to unclear reasoning behind patient-facing decisions.  ]]> https://biospectrumindia.com/news/100/26226/spovum-technologies-and-khushi-fertility-forge-strategic-alliance-to-redefine-ivf-care-in-india.html https://biospectrumindia.com/news/100/26226/spovum-technologies-and-khushi-fertility-forge-strategic-alliance-to-redefine-ivf-care-in-india.html Wed, 11 Jun 2025 00:00:00 +0530 In a significant step toward advancing fertility care in India, SpOvum Technologies, a leading IVF technology company, has announced a strategic collaboration with Khushi Fertility, one of Bengaluru’s fastest-growing chains of fertility clinics. This first-of-its-kind partnership aims to elevate assisted reproductive technology by integrating SpOvum’s advanced Lab Management System (LMS), cutting-edge software, and proprietary hardware across Khushi’s clinical ecosystem. As the official knowledge and R&D partner, SpOvum will lead the training and upskilling of embryologists at Khushi Fertility, ensuring standardised, high-quality practices across all centres. The partnership also enables real-time, in-clinic R&D to streamline clinical trials and enable product innovation tailored specifically to the Indian IVF landscape. As part of this collaboration, SpOvum will establish an in-clinic R&D hub within Khushi Fertility centres, enabling seamless testing and refinement of emerging technologies in real-world settings. Innovations in AI-powered lab automation, embryo tracking, and data-driven patient care will be accelerated through this model. This alliance is expected to catalyze transformative change across the Indian IVF sector. By embedding AI-driven protocols and automated systems, the partnership aims to boost success rates, enhance clinical decision-making, and streamline the patient journey. Continuous feedback loops enabled by the in-clinic R&D setup will also fuel ongoing innovation and sustained clinical improvement. ]]> https://biospectrumindia.com/news/100/26231/renalyx-launches-worlds-first-indigenous-ai-based-smart-hemodialysis-machine.html https://biospectrumindia.com/news/100/26231/renalyx-launches-worlds-first-indigenous-ai-based-smart-hemodialysis-machine.html Wed, 11 Jun 2025 00:00:00 +0530 Bengaluru-based Renalyx Health Systems has launched RENALYX – RxT 21, world's first fully indigenous, artificial intelligence (AI) and cloud-enabled smart hemodialysis machine with real-time remote monitoring and clinical connectivity facility.   Price starting at Rs 6.7 lakh - significantly lower than the imported machines - RENALYX – RxT 21 will make dialysis affordable and accessible to a larger population and bridge the demand-supply gap in the renal care across semi-urban and rural regions.   Completely designed and manufactured in India, RENALYX – RxT 21 leverages latest technologies including cloud-based telenephrology platforms to offer safety and quality care to kidney patients, end-stage renal disease (ESRD) patients especially those with cardiovascular, pulmonary and acute kidney injury-related issues.   RENALYX – RxT 21 makes Renalyx the sixth company globally and first in India to produce an advanced dialysis machine with EU CE certification.   Renalyx has plans to invest Rs 800 crore in the next four years to build the manufacturing capacity of 5,000 machines by FY25-26 and will develop additional capacity of 1500 machines by FY27-28. The company also have plans to manufacture consumables indigenously. The company has manufacturing facilities at Bengaluru and Mysuru in Karnataka and at Mumbai in Maharashtra to support its scale-up plans and meet the growing demand.   The company plans to raise funds through the sale of equity, backed by strong interest from prominent Indian and international investors. In addition, it will raise debt, and the promoters will also invest capital. Renalyx also has plans to go public within the next three years.   With initial deployments of the machine planned in Maharashtra and Karnataka, Renalyx will go for rapid pan-India distribution of RENALYX – RxT 21 with its partners as well as exports to other countries. The company has successfully penetrated international markets, securing orders from South Africa, the USA, and Europe.   The Indian CDSCO approval of the machine is in its final stages and is expected by July 2025, while the US FDA approval process is underway and anticipated by March 2026.   Renalyx plans to install RxT 21 at primary health centres (PHC), community health centres (CHC), private dialysis centres and hospitals to make renal care available to a large number of people.    The company, in collaboration with its partner, will set up franchise centres across India and in international markets.   In addition, Renalyx has awarded manufacturing license to Bharat Electronics Ltd. (BEL) to produce 6,000 RENALYX – RxT 17 in the next three years. RENALYX – RxT 17 is a previously launched dialysis machine by Renalyx which comes with standard features and facilities.  ]]> https://biospectrumindia.com/news/100/26205/elucidata-and-sapien-biosciences-to-transform-biobank-assets-into-high-quality-ai-products.html https://biospectrumindia.com/news/100/26205/elucidata-and-sapien-biosciences-to-transform-biobank-assets-into-high-quality-ai-products.html Thu, 05 Jun 2025 00:00:00 +0530 US-based Elucidata, a leader in data-centric AI for drug discovery and translational research, and Hyderabad-based Sapien Biosciences, India's first and largest commercial biobank with 300,000+ patient samples founded in partnership with Apollo Hospitals, have announced a strategic partnership to convert Sapien’s extensive biobank assets into artificial intelligence (AI)-ready, multimodal data products for use in drug and diagnostic development. Through this collaboration, Sapien will harness Elucidata’s platform to integrate, standardise, and enrich its vast repository of biospecimens and curated clinical data, making them accessible for predictive modeling, synthetic data generation, and advanced genomics research. The partnership reflects a shared focus on turning real-world patient data into high-value actionable insights that drive precision medicine and improve outcomes worldwide. The first phase of the collaboration will focus on building AI models that infer genomic and transcriptomic insights from digital pathology images. By using NGS-annotated slides from Sapien’s cancer biobank, the project will enable the generation of synthetic multi-modal datasets essential for next-generation diagnostic tools and tissue-sparing research strategies. This is particularly valuable for rare cancers and limited biopsy specimens. In addition to oncology, the partnership will explore multi-disease use cases across Sapien’s biobank, including cardiovascular, autoimmune, and neurological disorders, building synthetic clinicogenomic datasets that support pharma R&D and companion diagnostic development. ]]> https://biospectrumindia.com/news/100/26200/iit-delhi-and-aiims-to-establish-centre-of-excellence-for-ai-in-healthcare.html https://biospectrumindia.com/news/100/26200/iit-delhi-and-aiims-to-establish-centre-of-excellence-for-ai-in-healthcare.html Wed, 04 Jun 2025 00:00:00 +0530 The Indian Institute of Technology (IIT) Delhi and All India Institute of Medical Sciences (AIIMS) Delhi, have signed a Memorandum of Understanding (MoU) to establish a Center of Excellence for artificial intelligence (AI) in Healthcare (AI-CoE). The MoU was signed by Prof. M. Srinivas, Director, AIIMS Delhi, and Prof. Rangan Banerjee, Director, IIT Delhi. The AI-CoE will focus on developing AI-based solutions for supporting key national health programmes in the country. Last year, the two institutes were awarded a grant of Rs 330 crore by the Ministry of Education under the initiative "Make AI in India, Make AI Work for India," following a rigorous and highly competitive selection process. The proposed Centre of Excellence will be the executing vehicle for the grant. Dr Krithika Rangarajan, Chief Project Manager, who will lead the initiative from AIIMS Delhi, said, "As we venture into this exciting new space, we look forward to guiding the marriage of healthcare with technology. We remain focused on keeping patients at the center of this effort and hope to build mechanisms that would benefit every citizen of the country." Prof. Chetan Arora, Chief Project Manager, who will lead the AI-CoE from IIT Delhi, said, "The CoE will serve as a key research and resource center at the national and international level and aims to revolutionise the national public health system using indigenously developed AI systems and solutions. Our aim is to develop cutting-edge AI solutions to upscale health services, upskill our healthcare providers, and improve the accessibility of quality healthcare to remote and marginalised sections of our population.” ]]> https://biospectrumindia.com/features/100/26156/how-ai-is-enhancing-medical-diagnostics.html https://biospectrumindia.com/features/100/26156/how-ai-is-enhancing-medical-diagnostics.html Sat, 31 May 2025 00:00:00 +0530 AI is rapidly transforming healthcare, particularly in diagnostics and imaging across the globe. The industry is continuously developing solutions in the form of new apps and devices using AI to ease out the burden on the healthcare setting. As a result, these solutions are improving diagnostic accuracy and enabling faster treatment decisions for conditions such as cancer, tuberculosis, diabetes, cardiovascular diseases etc. With India witnessing a rising burden of these diseases, coupled with a shortage of skilled healthcare professionals, AI-driven diagnostic solutions are emerging as a transformative force. By reducing diagnostic turnaround times, increasing accuracy, and enabling remote healthcare access, AI is playing a pivotal role in addressing the growing healthcare demand and disease burden, particularly in urban areas where non-communicable diseases (NCDs) are more prevalent. However, challenges persist in terms of high implementation costs, the lack of standardised AI regulations, a limited skilled workforce and concerns over data privacy and patient confidentiality. Furthermore, limited adoption of AI in rural healthcare facilities remains a significant barrier to widespread deployment in India. Despite these challenges, many new areas such as ophthalmology, dermatology, trichology, in vitro fertilisation, etc. are being touched upon by the industry where the use of AI can offer timely diagnosis and effective treatment plans.  “Diagnostics is undergoing a quiet revolution, one driven by artificial intelligence (AI). What was once a system dependent on reactive responses is now evolving into a proactive model that prioritises early detection, precision, and patient clarity. In a world where diagnostic errors contribute to 10 per cent of patient deaths, the stakes couldn’t be higher. AI brings a much-needed shift, enhancing accuracy, speeding up outcomes, and making care more understandable and accessible”, said Deepak Sahni, Founder & Chief Executive Officer, Healthians.   Setting the right vision with AI The growing number of cases of eye diseases such as diabetic retinopathy, glaucoma, cataract, and age-related macular degeneration (AMD), in the country has urged technology developers to increase the use of AI for their early detection. Studies have suggested that AI systems demonstrate strong diagnostic performance in detecting eye conditions such as diabetic retinopathy, with sensitivity and specificity comparable to or exceeding traditional clinicians. One notable example is Remidio Innovative Solutions, a Bengaluru-based healthtech startup focused on preventing avoidable blindness with the use of AI. The company has recently received regulatory approval from the State FDA, Karnataka (CDSCO), for its Medios HI (Humanising Intelligence) Glaucoma AI and Medios HI AMD AI tools. Following the success of the CDSCO-approved Medios DR HI, AI for diabetic retinopathy, which has impacted nearly 2,50,000 patients in the past year, the newly approved AI solutions are focused on early detection of glaucoma and AMD in diverse healthcare settings. A recent significant initiative leveraging Remidio’s AI technology is the announcement of Nayanamritham 2.0, India’s first government-led AI-assisted eye disease screening programme, launched by the Kerala government in February 2025. “India accounts for 12 million glaucoma patients, nearly one in eight globally. Yet over 90 per cent of these cases remain undiagnosed, often leading to irreversible vision loss. Early detection using portable, AI-enabled tools can drastically change this trajectory”, said Dr Anand Sivaraman, CEO and Founding Director, Remidio. Another example of fostering cutting-edge research in eye care is Zeiss India partnering with the Indian Institute of Science (IISc), Bengaluru, to establish a state-of-the-art research facility. This facility is focused on developing high-fidelity AI solutions for eye care and upskilling students in AI-based technologies. Supported by the Spectrum Lab at IISc, the collaboration aims to harness AI's potential to improve early diagnosis and patient outcomes in ophthalmology.  Zeiss India is also sponsoring students through its 'MTech Fellowship Programme,' further strengthening the research ecosystem and promoting advancements in AI-driven eye care solutions. Mumbai-based startup AND Healthcare Solutions is another player that is focused on delivering low-cost, AI-driven eye screening solutions to millions. The startup has partnered with Australian company TeleMedC to roll out advanced eye imaging and AI-powered diagnostics across India.  Mumbai-based institute Wadhwani AI is also emerging as another key player in this space. As a key partner, Wadhwani AI is supporting the development of multiple AI solutions for the screening of diabetic retinopathy, pulmonary and skin conditions at the All India Institutes of Medical Sciences (AIIMS). These solutions will now be scaled by the AIIMS Centre of Excellence (CoE), in collaboration with the Ministry of Health and Family Welfare, across primary and secondary healthcare settings to ensure timely care for all. “Diabetic retinopathy is a leading cause of preventable blindness, especially in India, where access to specialised eye care is limited, particularly in rural regions. Many individuals are unaware of their condition until severe vision loss occurs. AI-based solutions can empower optometrists and field investigators to screen patients, enabling early diagnosis and referral to specialists. We strongly believe in India’s ability to lead in AI innovation. With the right talent, ecosystem, and data, India can be at the forefront of AI applications”, said Nakul Jain, Director of Products and Design at Wadhwani AI. Further, Bengaluru-based startup NeuraSim Health, in collaboration with QWR, has introduced BeeVee, India’s first AI-powered VR therapy for amblyopia or lazy eye. This groundbreaking solution is transforming vision care with 3X faster recovery, making treatment more effective, engaging, and now available for at-home use. The application of AI in ophthalmology encompasses a wide range of innovations, from advanced diagnostic tools that can detect conditions like diabetic retinopathy, AMD and glaucoma with remarkable precision to personalised treatment plans that optimise therapeutic outcomes and reduce costs. Additionally, AI-driven surgical tools and teleophthalmology services are making high-quality eye care more accessible, particularly in underserved and remote areas.   Exploring dermatology and trichology AI is now also being used to detect numerous skin (eczema, acne, psoriasis, vitiligo) and hair (baldness, alopecia, scalp infection) conditions to offer better health solutions to millions across India.  For instance, in a revolutionary move set to transform the Rs 25,000 crore-worth Indian skincare market, Mumbai-based health-tech platform Skin Beyond Borders (SkinBB) has launched a pioneering Skincare Metaverse platform. This innovative digital ecosystem seamlessly integrates cutting-edge AI technology with clinical knowledge, creating a unique synergy between consumers, clinicians, and industry partners. Further, Kaya Clinic has launched a revolutionary AI app that offers an in-depth understanding of skin issues tailored to individual needs, making it the first app in India to leverage AI for personalised skin diagnosis. The app focuses on analysing acne, scars, pigmentation, fine lines, and anti-ageing concerns. Kaya holds the intellectual property, for the AI app, making it as the first AI-powered dermatology service in India. Also, Bengaluru-based startup Cureskin, a leader in AI-driven dermatology solutions, has developed the world's first AI-powered hair analyser. It is designed to accurately detect male pattern baldness and assess hairline health with advanced precision. Arshan Ommid, Founder and Chief Executive Officer of Dermose, said, “AI has the unprecedented ability to analyse the complexities of hair loss, from genetic predispositions to lifestyle factors, creating a holistic diagnostic framework. This precision equips clinicians to design truly tailored treatments, giving patients confidence in both the process and the outcome. AI tools such as computer vision and big data analytics are transforming the treatment of chronic conditions by allowing physicians to automate the identification of biomarkers for hair loss and combine thorough lab results with trichoscopic data. These developments significantly shorten diagnostic times while increasing precision, enabling patients to start receiving efficient treatments earlier.”   AI in IVF and birth management Another area where a rapid surge of AI integration is taking place is in vitro fertilisation (IVF). A type of assisted reproductive technology (ART), IVF has been revolutionising the field of infertility treatment over the past few years in India. With a market size of Rs 12000 crore, the IVF procedures are now offering better treatment plans with AI integration. A most recent example of this utilisation is the world’s first infant born (to an Indian couple in the US) using a fully automated and digitally controlled intracytoplasmic sperm injection (ICSI) process. After several failed IVF attempts, the couple was referred for ICSI treatment at a fertility clinic in Mexico, where four of the five eggs treated with AI-assisted ICSI were successfully fertilised, ultimately resulting in the first live birth. According to Dr Ramnath Babu T J, Co-founder, CEO, SpOvum Technologies, “The potential that AI and automation bring to IVF is unimaginable. They hold the possibility of increased success rates, customised treatment protocols, and lower costs, making fertility treatment affordable. The intersection of AI, automation, and IVF is a revolution in reproductive medicine. These advancements are hope in a country like India, where infertility is increasing.” Additionally, labour and delivery management is now also being handled using AI, by predicting birth times with precision and optimising hospital operations in real time. This groundbreaking AI-based obstetrics platform has been developed in a collaborative effort by US-based Birth Model with Pune-based Mindbowser. “What makes AI particularly valuable is its ability to quickly process large volumes of data and identify patterns that might be missed during routine evaluations. As the technology evolves, AI is expected to become a standard part of maternal care, not just in well-equipped hospitals but also in remote and underserved areas via mobile health tools and wearable devices. With continued research and thoughtful regulation, AI has the potential to make maternal care more personalised, accessible, and timely, ultimately improving outcomes for mothers and babies and reshaping the future of prenatal health”, said Ayush Jain, CEO & Founder, Mindbowser.   Way forward  While new avenues are opening for AI-based healthcare implementation and delivery, a strong and supportive ecosystem will need to be built in the coming years. The government is already on track to strengthen the skills for AI with its ongoing IndiaAI Mission. With Stanford University ranking India among the top four countries along with the US, China, and the UK in the Global and National AI vibrancy, AI-based innovations in India will cement the landscape further.    Vrushti Kothari (vrushti.kothari@mmactiv.com) ]]> https://biospectrumindia.com/news/100/26147/qure-ai-unveils-new-ai-powered-co-pilot-tool-for-frontline-healthcare-workers-in-lmics.html https://biospectrumindia.com/news/100/26147/qure-ai-unveils-new-ai-powered-co-pilot-tool-for-frontline-healthcare-workers-in-lmics.html Thu, 22 May 2025 00:00:00 +0530 Leveraging its strength in digital health innovation, Mumbai-based startup Qure.ai has launched a new artificial intelligence (AI)-powered co-pilot tool for frontline healthcare workers in resource-constrained geographies this week during the 78th World Health Assembly in Geneva.   ‘AIRA’ is designed to optimise limited healthcare resources in Low- and Middle-Income Countries (LMICs) by supporting AI-enabled digitisation of symptoms and patient history collection; clinical protocol adherence and decision support; and aggregated population health insights.   There are 17 million preventable deaths in LMICs and an estimated shortage of 11 million health workers by 2030. At the same time, more than 40% of community health workers’ time is spent on manual data collection, and yet countries do not have population-level data to make informed decisions.   AIRA aims to solve this urgent need by freeing up precious health worker time to engage more with patients, while digitizing data automatically.   Speaking at the World Health Assembly side-event on AI, Prashant Warier, CEO and Founder of Qure.ai, said, “With AI, we can make a seismic shift towards health equity in LMICs. AIRA in the hands of every healthcare worker will free up their time for more patient interactions via automated data collection and better clinical protocol adherence. With AI, we can multiply every dollar spent and realize significantly more impact and returns in LMIC health systems. We have demonstrated this in our last 10 years in TB and are motivated to do the same now for primary healthcare.”    AIRA is an AI co-pilot for healthcare workers in LMICs. It is built on Large Language Models (LLMs) with a deep understanding of Low- and Middle-Income Country health systems and needs. It is designed to reduce administrative workload and free up time for better patient care, while enabling better protocol adherence and population insights. ]]> https://biospectrumindia.com/news/100/26138/remidio-unveils-new-device-pristine-for-innovating-ai-powered-eye-diagnostics-.html https://biospectrumindia.com/news/100/26138/remidio-unveils-new-device-pristine-for-innovating-ai-powered-eye-diagnostics-.html Wed, 21 May 2025 00:00:00 +0530 After a decade of transforming access to eye care in India and beyond, Bengaluru-based Remidio Innovative Solutions has announced a pivotal evolution in its journey, the launch of its dual brand strategy, Remidio and Pristine, to address the full spectrum of eye care needs, from last-mile screening to advanced clinical diagnostics. Over the past decade, Remidio has focused on expanding access to eye care. Through portable technology and artificial intelligence (AI), the company has facilitated over 16 million screenings across 40+ countries, addressing low awareness and limited access to early detection. Its Insta series of portable tools for frontline workers has built an ecosystem that now directs millions more patients to ophthalmology clinics annually. Pristine’s suite of in-clinic innovations is built to drive measurable efficiency. Pristine 1.5 reduces retina imaging time per patient through automated workflows. Pristine 5.0 offers true-color, wide-field imaging in seconds, maximizing throughput without compromising quality. The Pristine VX650 enables comprehensive, multimodal diagnostics in high-volume settings, streamlining the workup process across retina and refractive care. The soon to be launched Pristine OBM 12 delivers 12 essential eye measurements in just 25 seconds, empowering technicians to manage myopia and pre-operative evaluations with precision and minimal intervention.  Together, these devices enable clinics to ‘see more, do more’, boosting patient volumes, diagnostic confidence, and workflow efficiency. These platforms are redefining efficiency in clinical ophthalmology, allowing more patients to be seen per day, with better insights, and fewer delays. With validated AI for Diabetic Retinopathy, Glaucoma, and age-related macular degeneration (AMD), the company is also working on expanding screening capabilities into systemic conditions such as cardiovascular disease (CVD) and chronic kidney disease (CKD), leveraging the eye as a window into overall health. From outreach to in-clinic diagnostics, from retina to systemic health, Remidio’s dual brand strategy sets the stage for the next decade of transformation in eye care. ]]> https://biospectrumindia.com/news/100/26123/muhs-to-pioneer-emotion-ai-in-indian-healthcare-sector-with-nihilents-emoscape-platform.html https://biospectrumindia.com/news/100/26123/muhs-to-pioneer-emotion-ai-in-indian-healthcare-sector-with-nihilents-emoscape-platform.html Fri, 16 May 2025 00:00:00 +0530 In a landmark step toward advancing holistic healthcare, the academic wing of the Maharashtra University of Health Sciences (MUHS), Nashik the country's premier institution overseeing over 600 medical, dental, Ayurveda, and allied health institutions has officially partnered with Nihilent to explore clinical applications of Emoscape, the company’s innovative AI-based emotion detection platform. This collaboration marks a transformative moment in the Indian healthcare landscape, combining the ancient Indian concept of Navarasa (the nine emotions) with modern artificial intelligence to fundamentally reshape how emotional well-being is integrated into diagnosis, treatment, and patient care. Emoscape leverages cutting-edge artificial intelligence technology to detect nine core emotions love, joy, compassion, anger, courage, fear, disgust, wonder, and calmness by capturing subtle upper-body movements (shoulder and above) in 3D. This breakthrough platform draws inspiration from Navarasa, the ancient emotional theory that has played a pivotal role in Indian performing arts for centuries. The integration of this ancient wisdom with modern AI allows for real-time emotion detection, providing unprecedented insights into a patient’s emotional state and opening new avenues for personalised care and treatment. The partnership will allow MUHS to explore clinical applications of Emoscape across a range of disciplines, including non-communicable diseases, pediatric and adolescent care, maternal mental health, pre-surgical counselling, psychiatric conditions and ensuring patient privacy. Through this initiative, MUHS aims to bring emotional diagnostics into mainstream healthcare, aligning with its commitment to delivering comprehensive, patient-centred care. In addition to its clinical applications, the collaboration will facilitate hands-on student engagement through Nihilent’s Summer Internship Program, providing MUHS students with valuable exposure to the intersection of AI and healthcare. This initiative will empower the next generation of healthcare professionals with the skills and knowledge necessary to embrace technological advancements and innovate in their respective fields.  ]]> https://biospectrumindia.com/news/100/26115/maverick-simulation-solutions-plans-to-invest-rs-50-cr-in-rd-to-advance-medical-training-simulators.html https://biospectrumindia.com/news/100/26115/maverick-simulation-solutions-plans-to-invest-rs-50-cr-in-rd-to-advance-medical-training-simulators.html Thu, 15 May 2025 00:00:00 +0530 Delhi-based Maverick Simulation Solutions has announced an investment of Rs 50+ crore into its research and development division. The investment will be used to enhance product innovation in areas such as Task Trainers, High End Simulators, CPR Trainers, etc. and to integrate advanced technologies like Artificial Intelligence (AI), Augmented Reality, and Virtual Reality into its training solutions. The funds will also support the creation of new prototypes and the strengthening of in-house capabilities across engineering, clinical integration, and content development. The R&D work will be carried out in India, with testing and feedback from academic institutions. Maverick began with 3D scanning and printing services and entered into the medical simulation domain in 2019, with manufacturing of its simulators starting in 2021, with the focus on made in India products. The company develops various medical simulators and works with institutions like AIIMS, DRDO, and IITs. Its mission is to improve healthcare skills and reduce errors through practical training tools. The objective behind this R&D investment is to support better clinical education by developing practical, realistic, re-usable training tools. The company aims to expand its R&D capabilities to meet the growing demand for hands-on training in medical, nursing, and paramedical education. Maverick has crossed a revenue of Rs 100+ crore in FY 2024-25, reflecting the increasing adoption of its solutions across institutions. Anuj Chahal, Founder & CEO of Maverick Simulation Solutions, said, “The future of healthcare education depends on how well today’s students are trained for real clinical challenges. Our goal is to change how training is delivered. We are not only making tools but also making them accessible to institutions across India. With this R&D investment, we want to improve product design, introduce new technologies like AR and VR, and make training more realistic and repeatable. Our aim is to impact more than 250 institutions and reach Rs 300 crore in revenue in the coming year. This is a step toward building strong foundations in healthcare learning.” ]]> https://biospectrumindia.com/news/100/26095/bioheaven360-introduces-ai-driven-genomics-diagnostic-platform-for-early-disease-detection.html https://biospectrumindia.com/news/100/26095/bioheaven360-introduces-ai-driven-genomics-diagnostic-platform-for-early-disease-detection.html Fri, 09 May 2025 00:00:00 +0530 Bioheaven360 Genotec, a leading Delhi-based biotechnology startup, has has introduced its cutting-edge AI-powered genomics diagnostics platform in the Indian market. Designed to enable early disease detection and personalised treatment plans, the platform marks a significant shift from reactive to proactive healthcare. The platform has been developed through rigorous research and clinical trials in collaboration with the All India Institute of Medical Sciences (AIIMS), New Delhi. It integrates deep phenotyping to capture comprehensive patient data from multiple sources including genetic information, lifestyle factors, biomarkers, and environmental influences. Through this, the platform generates highly accurate cumulative risk assessments that can identify disease predispositions decades before symptoms appear. Commenting on the same, Dr Shailendra Vyas, Founder and CEO of Bioheaven360 Genotec, shared, "Our platform aims to revolutionise preventive healthcare by providing personalized recommendations to mitigate risks and improve overall health outcomes. With our cutting-edge technology, we strive to empower individuals to take proactive steps towards a healthier future. By leveraging the latest advancements in genetic testing and data analysis, our platform offers a comprehensive approach to preventive healthcare that goes beyond traditional methods. Our goal is to empower individuals with the knowledge and tools they need to make informed decisions about their health and well-being.” The platform leverages advanced machine learning algorithms that continuously refine in real-time, enhancing diagnostic precision with every new dataset.  It includes extensive phenotyping that captures patient data from various sources, cumulative risk assessments, AI-powered  diagnostic support, and self-learning capabilities. Initially designed for the early detection of osteoporosis, the platform’s applications will soon broaden to encompass a wider range of chronic and complex conditions. It is engineered to rapidly analyse intricate medical datasets including genomic sequences, imaging results, and biomarker profiles delivering insights far faster and more accurately than conventional diagnostic tools. ]]> https://biospectrumindia.com/news/100/26087/ecosep-and-tata-elxsi-announce-strategic-partnership-to-transform-sports-medicine-through-ai.html https://biospectrumindia.com/news/100/26087/ecosep-and-tata-elxsi-announce-strategic-partnership-to-transform-sports-medicine-through-ai.html Wed, 07 May 2025 00:00:00 +0530 European College of Sport and Exercise Physicians (ECOSEP) and Tata Elxsi have announced a strategic partnership that aims to revolutionise the field of sports and exercise medicine through combining the research excellence and clinical expertise of ECOSEP with Tata Elxsi’s artificial intelligence (AI)- and machine learning–driven healthcare solutions and technology capabilities. The partnership will focus on applying artificial intelligence technologies in areas such as advanced diagnostic tools, personalised treatment plans, predictive analytics for injury prevention, and real-time monitoring of athletes' physical conditions. This innovative collaboration was initiated by Dr Pakravan, Vice Chair of ECOSEP, and facilitated by Dr Malliaropoulos, General Secretary.  Speaking on behalf of ECOSEP, Prof. Nicola Maffulli, President, stated: “These are exciting times for how technology and medical science can be brought together to transform personalised care in sports. The long-term vision of Tata Elxsi marries with the aim of ECOSEP to develop and maintain 360° care for athletes and physically active individuals. With the power of Tata Elxsi, ECOSEP shall develop comprehensive packages of care which will help to optimise performance and health. This is a unique opportunity for mutual collaboration, marrying disciplines only apparently different, and allowing close interaction of professionals.” Anup SS, Practice Head – AI and Machine Learning at Tata Elxsi, added: “This collaboration with ECOSEP represents an exciting opportunity to apply AI in ways that directly impact athlete health and performance. By combining clinical insight with advanced data science, we aim to co-create intelligent tools that support early diagnosis, enable real-time decision-making, and personalise care for every athlete. Together, we’re paving the way for a new era in sports medicine—one that is smarter, faster, and more human-centric.” The collaboration serves as a stepping stone for future interdisciplinary partnerships aimed at expanding the use of AI in sports and musculoskeletal medicine, and both organisations are committed to advancing the field through research, clinical trials, and the development of AI-driven tools that offer athletes and healthcare providers ground-breaking solutions to achieve optimal outcomes. ]]> https://biospectrumindia.com/news/100/26067/remidio-receives-regulatory-approval-from-karnataka-to-deploy-ai-based-tools-for-eye-care.html https://biospectrumindia.com/news/100/26067/remidio-receives-regulatory-approval-from-karnataka-to-deploy-ai-based-tools-for-eye-care.html Fri, 02 May 2025 00:00:00 +0530 Remidio Innovative Solutions has received approval from the State FDA, Karnataka (CDSCO), the regulatory authority for medical devices, for its Medios HI (Humanising Intelligence) Glaucoma AI and Medios HI AMD AI. This approval represents an important advancement in the use of artificial intelligence (AI) for early detection of glaucoma and age-related macular degeneration (AMD) in diverse healthcare settings. Following the success of the CDSCO-approved Medios DR HI, AI for diabetic retinopathy, which has impacted nearly 2,50,000 patients in the past year, the newly approved AI solutions for glaucoma and AMD are also designed to function offline. This offline capability allows real-time analysis without relying on internet access, making it useful for providing eye care in remote and underserved areas with limited access to specialised ophthalmic diagnostics. Medios HI Glaucoma AI exceeds conventional screening methods by analysing optic nerve head and RNFL structures, generating heat map–based reports to detect early signs of referable glaucoma. This is vital in a country like India, which accounts for 12 million glaucoma patients, nearly one in eight globally. Yet over 90% of these cases remain undiagnosed, often leading to irreversible vision loss. Early detection using portable, AI-enabled tools can drastically change this trajectory. The Medios HI AMD AI, detects early-stage age-related macular degeneration (AMD), a major cause of vision impairment among the elderly. With 2.1% of Indians over age 60 affected, amounting to nearly 6.7 million people at risk, this tool plays a crucial role in enabling timely referrals and preventive care by highlighting lesions with AI generated heat maps. Medios HI Glaucoma and Medios HI AMD Al has been clinically validated across tertiary hospitals, eye institute and vision centres showcasing high level of sensitivity and specificity. With Medios HI on Remidio’s FOP NM 10, a single tap delivers results for screening AMD, Glaucoma, and DR in few seconds.  Three critical insights, one seamless experience. Dr R. Kim, Chief Medical Officer, Senior Medical Consultant, Retina & Vitreous Services Director, Aravind Eye Hospital, Madurai said “The Remidio fundus camera isn't just an imaging device; it's a portable gateway to early detection and prevention of vision-threatening conditions, bringing quality eye care closer to those who need it most”  Dr Anand Sivaraman, CEO and Founding Director, Remidio said "The CDSCO's approval of our Medios HI Glaucoma AI and Medios HI AMD AI builds upon the foundation laid by our Medios HI DR AI, which was the first ophthalmic AI software to receive such approval in India."   ]]> https://biospectrumindia.com/news/100/26058/lifesigns-and-cura-hospital-bridge-urban-rural-healthcare-gap-with-ai.html https://biospectrumindia.com/news/100/26058/lifesigns-and-cura-hospital-bridge-urban-rural-healthcare-gap-with-ai.html Wed, 30 Apr 2025 00:00:00 +0530 Cura Hospital has partnered with Lifesigns, India’s leading artificial intelligence (AI)-powered patient monitoring platform, to enable round-the-clock, real-time tracking of vital signs across hospital, home, and in-transit care. This collaboration ensures that critical health data is continuously streamed to clinicians, helping them intervene at the right time, reduce delays, and significantly improve outcomes, especially for cardiac emergencies where every minute matters. The partnership allows the hospital to monitor patients remotely using wearable IoT devices, receive intelligent alerts, and deliver targeted care from the moment symptoms start, regardless of where the patient is located. Located in South Bangalore, Cura Hospital is emerging as a regional pioneer in advanced cardiac and emergency care. With a mission to serve both urban and rural populations, the hospital is uniquely positioned to bring state-of-the-art healthcare infrastructure to underserved communities. Through this collaboration with Lifesigns, the hospital can now deliver proactive, tech-enabled care, especially during the “golden hour”—the crucial window following a cardiac event when rapid response can save lives. Cura's clinical team receives live data to prepare and guide precise treatment plans, whether the patient is in-hospital, at home, or en route via smart ambulance. The collaboration also bridges the urban-rural healthcare divide, extending advanced monitoring, early warning systems, and expert intervention to patients from both South Bangalore and neighboring semi-urban and rural areas. The partnership reflects a shared vision between Cura Hospital and Lifesigns to create a patient-centric, technology-led healthcare future—where care is not only reactive but predictive and proactive.   ]]> https://biospectrumindia.com/news/100/26059/lytus-technologies-expands-healthcare-footprint-with-acquisition-of-blod-in.html https://biospectrumindia.com/news/100/26059/lytus-technologies-expands-healthcare-footprint-with-acquisition-of-blod-in.html Wed, 30 Apr 2025 00:00:00 +0530 Mumbai-based startup Lytus Technologies has announced the completion of its acquisition of Blod.in, India’s first on-demand blood component management and logistics platform (powered by advanced artificial intelligence- AI and machine learning algorithms) - currently operational in Chennai and soon to be available nationally. The acquisition of Blod.in, through Lytus HealthTech, its fully owned HealthTech subsidiary, underscores Lytus’ commitment to working alongside and together with hospitals and blood banks (private and public) in efficiently serving critical healthcare needs, optimising logistics, and ultimately saving lives. This last-mile partnership fosters an extremely gratifying and supportive relationship, ensuring timely access to life-saving blood products and enhancing the overall efficiency of the healthcare ecosystem. Over the last twelve months, Blod.in scaled rapidly, growing from 30 to 140 hospitals with a 20% month-on-month growth trajectory. Now operating in Chennai, it plans to expand to 100 more hospitals and 15+ blood banks, with further growth in Bengaluru, Mumbai, and Hyderabad and other cities in the next phase. Blod.in's AI-driven technology will soon expand to global markets like the US and UAE, optimising inventory, minimising wastage, and ensuring timely blood availability for patients, hospitals, and blood banks. Lytus Technologies has secured and committed Rs 1000 crore as growth capital over the next three years to scale operations both organically and inorganically, expand its digital ecosystem, and advance HealthTech innovations. A significant portion of this investment is dedicated to advancing AI- and ML-powered solutions across Lytus HealthTech, including Blod.in’s AI engine, which optimises blood inventory forecasting, real-time supply-demand mapping, and last-mile routing intelligence for temperature-sensitive deliveries. Following a successful pilot phase, Blod.in is set to officially launch, transforming blood logistics through its flagship platform, Blod+. The pilot proved its ability to cut blood procurement time from hours to just 90-120 minutes, addressing India's 650,000-unit annual blood deficit, which contributes to 12,000 daily deaths. ]]> https://biospectrumindia.com/news/100/26060/hexahealth-closes-series-a-fund-raise-of-12-m-to-redefine-surgical-care-journey-across-india.html https://biospectrumindia.com/news/100/26060/hexahealth-closes-series-a-fund-raise-of-12-m-to-redefine-surgical-care-journey-across-india.html Wed, 30 Apr 2025 00:00:00 +0530 Gurugram-based startup HexaHealth, a leading tech-enabled surgery care platform, has successfully closed its $12 million Series A funding round. The round was led by Orios Venture Partners and 3one4 Capital, with participation from new investors Enzia Ventures and ITI Growth Opportunities Fund, along with existing backers Chiratae Ventures and Omidyar Network India. This milestone funding will accelerate HexaHealth’s mission to reshape how surgical care is delivered and experienced across India. The new funds will be strategically deployed to drive HexaHealth’s next phase of growth. Key initiatives include expanding into new surgical specialities, entering additional geographies across India, building an artificial intelligence (AI)-powered platform to further personalise and enhance patient care, and strengthening the senior leadership team to accelerate innovation and impact. To date, HexaHealth has facilitated over 30,000 surgeries across India’s key cities, offering patients not just procedures but peace of mind through compassionate, end-to-end care. In FY25 alone, HexaHealth facilitated nearly 15,000 surgeries, valued at approximately Rs 150 crore, and achieved positive contribution margins, signalling strong unit economics. The company is now expanding into new cities, bringing its patient-first approach to millions in need.   By seamlessly integrating advanced technology, clinical expertise, transparent pricing, hospital partnerships, financing solutions, and compassionate support, HexaHealth — founded by Ankur Gigras, Vikas Chauhan, and Dr Aman Priya Khanna — is shaping the future of surgical care in India. The platform’s holistic approach ensures that every patient’s journey is not only safe and efficient but also grounded in trust and empathy.  ]]> https://biospectrumindia.com/news/100/26041/philips-launches-new-ai-enabled-elevate-platform-upgrade-on-epiq-elite-ultrasound-imaging-platform-in-india.html https://biospectrumindia.com/news/100/26041/philips-launches-new-ai-enabled-elevate-platform-upgrade-on-epiq-elite-ultrasound-imaging-platform-in-india.html Fri, 25 Apr 2025 00:00:00 +0530 Royal Philips, a global leader in health technology, has launched its new cutting-edge Elevate Platform upgrade release on the EPIQ Elite ultrasound imaging platform, at UltraFest 2025 in India. This pioneering solution addresses the increasing demand for streamlined workflows and greater diagnostic efficiency, enabling clinicians to deliver timely, confident decisions for a wider range of patients. Elevate platform is equipped with advanced Artificial Intelligence capabilities which have proven instrumental in enhancing diagnostic accuracy and operational efficiency. The platform also incorporates proactive system monitoring, allowing care teams to consult remotely, support diagnosis from a distance, and troubleshoot systems without the need for on-site intervention. Sachin Grover, Head of Ultrasound, Philips Indian Subcontinent commented “Elevate is a powerful example of our commitment to helping healthcare providers address today’s urgent challenges—from rising patient volumes to workforce constraints. With smarter automation, faster diagnostics, and greater clinical precision, we’re enabling clinicians to deliver high-quality care more efficiently. At Philips, we firmly believe in the transformative potential of Artificial Intelligence to make healthcare more effective, accessible, and inclusive bringing us closer to a future where we provide better care for more people.” The latest suite of automation features includes Quick Launch pre-sets to streamline platform setup and routine procedures, reducing imaging optimization time. Other features include automatic adjustment of image brightness and uniformity, as well as CEUS AutoScan, which improves image quality by fine-tuning each pixel and frame. For liver elastography, the system offers Auto ElastQ, which helps measure liver stiffness more easily and quickly, providing a simple, non-invasive way to assess liver health. ]]> https://biospectrumindia.com/news/100/26029/axtria-unveils-transformational-agentic-ai-platform-for-life-sciences-companies-.html https://biospectrumindia.com/news/100/26029/axtria-unveils-transformational-agentic-ai-platform-for-life-sciences-companies-.html Thu, 24 Apr 2025 00:00:00 +0530 US-based Axtria Inc., an artificial intelligence (AI)-first data analytics innovator transforming life sciences, has announced its next generation of Axtria InsightsMAx. Powered by agentic AI, the new Axtria InsightsMAx.ai fundamentally reimagines how life sciences organisations harness artificial intelligence through a flexible enterprise-grade platform that accelerates experimentation, deployment, and ROI. Axtria InsightsMAx.ai solves the critical "last mile" problem in enterprise AI implementation by providing not just the technology, but the entire ecosystem needed for successful adoption. The platform's library of specialised life sciences agents creates an adaptable framework that breaks down silos between data analysis, business intelligence, commercial operations, and clinical development, enabling cross-functional transformation that drives tangible business outcomes. “What sets our platform apart is its ability to serve as both the experimental sandbox and the production highway for agentic AI,” said Navdeep Chadha, Chief Technology Officer at Axtria. “Life sciences companies can start small, proving value in controlled environments, then seamlessly scale successful innovations across their organization without rebuilding infrastructure. This dramatically compresses the time from concept to enterprise-wide deployment from years to months or even weeks.”  For organisations seeking to build their innovation roadmap, Axtria InsightsMAx.ai provides a comprehensive development environment that transforms how companies move from concept to enterprise deployment. Axtria InsightsMAx.ai is already revolutionising operations at six of the top ten global pharmaceutical companies, delivering measurable business outcomes that far exceed traditional AI implementations. Axtria InsightsMAx.ai leverages 14+ years of pharmaceutical-specific data science expertise and proprietary semantic models that understand the nuanced relationships in life sciences data. The platform is powered by domain-tuned large language models (LLMs) developed in partnership with Genloop, delivering superior performance with enhanced control and transparency. ]]> https://biospectrumindia.com/news/100/26024/govt-to-launch-ai-careers-for-women-by-establishing-30-coes-in-women-colleges.html https://biospectrumindia.com/news/100/26024/govt-to-launch-ai-careers-for-women-by-establishing-30-coes-in-women-colleges.html Tue, 22 Apr 2025 00:00:00 +0530 The Ministry of Skill Development and Entrepreneurship (MSDE) and Microsoft have signed a Memorandum of Understanding (MoU) to launch AI Careers for Women, a pioneering skilling initiative aimed at empowering women in higher education institutions to pursue careers in Artificial Intelligence (AI). This strategic collaboration seeks to bridge the gender gap in emerging tech by equipping women with industry-aligned AI skills, enabling them to participate meaningfully in the digital economy and become active contributors to India’s innovation-led growth. As part of this collaboration, Microsoft will provide 240-hours training curriculum under AI skilling and Innovation framework for women, aligned to the industry standards, and developed in consultation with the National Council for Vocational Education and Training (NCVET). The training will be delivered in a hub and spoke model in partnership with the state government departments for higher education, across a network of 30 Centres of Excellence (CoEs) - Hubs and 150 educational institutions – spokes in Tier-II and Tier-III towns across six states. As one of the program partners, Edunet Foundation will implement this program, working closely with the participating academic institutions, government bodies, corporate organizations and industry bodies, building an alliance to bring ecosystem change and enable industry relevant skills and economic opportunities for Women in AI, thereby enhancing their workforce participation. ]]> https://biospectrumindia.com/news/100/26002/deepteks-chest-x-ray-ai-solution-receives-ce-mdr-class-iib-certification.html https://biospectrumindia.com/news/100/26002/deepteks-chest-x-ray-ai-solution-receives-ce-mdr-class-iib-certification.html Thu, 17 Apr 2025 00:00:00 +0530 Pune-based startup DeepTek, a leading provider of artificial intelligence (AI)-powered radiology solutions, has announced that its Chest X-ray AI solution has received CE certification under the European Union Medical Device Regulation (EU MDR) as a Class IIb medical device.  The Chest X-ray AI solution is designed to assist physicians in interpreting frontal chest X-rays (chest anterior and posterior). Powered by advanced machine learning, the solution detects a host of lung conditions such as nodules, lung masses, tuberculosis, pneumothorax, and over 20 other findings, including rib and clavicular fractures. In addition, the solution identifies multiple medical devices commonly encountered in inpatient and ICU settings, such as chest leads, pacemakers, and various tubes, providing critical support in complex clinical scenarios. A unique feature of this solution is its ability to interpret pediatric chest X-rays, including the detection of pediatric tuberculosis and pneumonia, enhancing diagnostic capabilities in younger populations, a segment often underserved by conventional AI models. The certification enables DeepTek to expand the availability of its solution across Europe and other CE-mark recognised regions, offering a powerful tool to enhance productivity, reduce diagnostic delays, and support quality care delivery at scale The need for such solutions is particularly urgent in regions grappling with a high tuberculosis (TB) burden and limited access to expert radiology. With a staggering TB burden and growing radiology workload, CE certification paves the way for deployment across Europe, Asia, Africa, and other CE-mark-recognised regions where AI-driven diagnostics are not just valuable, but vital.  ]]> https://biospectrumindia.com/news/100/26001/lhif-2025-reaffirms-growing-momentum-around-indias-ai-driven-healthcare-ecosystem.html https://biospectrumindia.com/news/100/26001/lhif-2025-reaffirms-growing-momentum-around-indias-ai-driven-healthcare-ecosystem.html Wed, 16 Apr 2025 00:00:00 +0530 The 14th edition of the Lifesciences & Healthcare Innovation Forum (LHIF) commenced on 16 April at The Leela Palace, Bengaluru, bringing together thought leaders, technologists, clinicians, policymakers, and investors to explore the theme: “AI Disrupt: Transforming Diagnosis, Discovery & Delivery.” Organized by MeitY – K-tech Nasscom Centre of Excellence (CoE), LHIF comes at a pivotal time when artificial intelligence (AI) is redefining the healthcare landscape, from early diagnosis to drug discovery, medical device innovation, and digital care delivery.   A range of panel discussions covered critical topics including: AI for Access to CarePanelists explored how AI is improving healthcare delivery in underserved regions and enabling early interventions impacting the accessibility of healthcare GenAI in PharmaA deep dive into how generative AI is being applied for drug discovery, supply chain optimization, and pharmacovigilance, featuring leaders from GSK, L’Oréal Lifesciences, Sravathi AI, and GAVS. AI in Medical DevicesInsights from R&D and Engineering heads, Clinicians and AI innovators at Danaher, BPL Medical, Aravind Eye Care Systems, and Remidio on the intersection of AI and hardware innovation. Investor PerspectiveVCs and investment leaders from 314 Capital, Mavin Ventures, Ankur Capital, and Speciale Invest discussed the funding landscape, key challenges, and the promise of healthtech startups.   The forum also featured the finale of HIC#6 (Healthcare Innovation Challenge), recognising standout digital and AI adoption use cases from leading institutions such as HCG and Sankara Nethralaya and Rajiv Gandhi Cancer Institute. Disruptive innovation showcases were held throughout the day to spotlight emerging startups and their cutting-edge solutions in diagnostics, AI-powered analytics, and medtech.   ]]> https://biospectrumindia.com/news/100/25987/australias-telemedc-partners-with-indian-startup-and-healthcare-to-expand-ai-based-eye-disease-screening.html https://biospectrumindia.com/news/100/25987/australias-telemedc-partners-with-indian-startup-and-healthcare-to-expand-ai-based-eye-disease-screening.html Tue, 15 Apr 2025 00:00:00 +0530 TeleMedC, an Australia-based leader in artificial intelligence (AI)-powered retinal disease diagnostics is expanding its footprint in India, through a strategic partnership with Mumbai-based startup AND Healthcare Solutions to deliver low-cost, AI-driven eye screening solutions to millions. The move aims to tackle the growing burden of preventable eye diseases by enabling early detection and intervention. Through its AI-powered technology, the company enables early detection of conditions such as diabetic retinopathy, glaucoma, and macular diseases, helping to prevent vision impairment and blindness.  Supported by Trade and Investment Queensland (TIQ), the Queensland Government’s global business agency, TeleMedC and AND Healthcare Solutions will roll out advanced eye imaging and AI-powered diagnostics across India. This initiative is poised to strengthen India’s healthcare innovation ecosystem, making critical eye care more affordable and accessible to all.  TeleMedC aims to screen one billion eyes over the next decade, driving early detection, disease prevention, and affordable access to advanced diagnostics. The company is actively partnering with Indian healthcare institutions, research bodies, and non-profits to accelerate innovation in eye health. Recently, TeleMedC collaborated with leading Indian healthcare institutions, including Aravind Eye Hospital, through the Australia-India Strategic Research Fund. This partnership is advancing AI-driven eye health solutions, reinforcing the company’s commitment to cutting-edge diagnostics. Expanding its impact, TeleMedC is working with SMEs and large corporations to integrate AI-powered eye screening into Corporate Social Responsibility (CSR) initiatives, making preventive healthcare more inclusive in India.      ]]> https://biospectrumindia.com/news/100/25989/spark-radiology-unveils-new-platform-in-india-to-transform-radiology-reporting-with-ai.html https://biospectrumindia.com/news/100/25989/spark-radiology-unveils-new-platform-in-india-to-transform-radiology-reporting-with-ai.html Tue, 15 Apr 2025 00:00:00 +0530 Bengaluru-based SPARK Radiology, an innovator in medical imaging solutions, has announced the India launch of SPARK.ai, a powerful new technology platform built to transform how radiologists manage their daily reporting workflows. In a healthcare environment where radiologists are under increasing pressure, SPARK.ai introduces a reimagined approach to workflow design, reducing manual overhead, enabling faster report turnaround, and helping radiologists focus on what truly matters: delivering accurate and timely diagnoses. India currently has approximately 20,000 radiologists serving a population of over 1.4 billion, resulting in a significant gap between diagnostic demand and available expertise. For every 100 scans performed daily, there’s only one radiologist available to interpret them. SPARK.ai has been developed to address this gap by automating routine documentation tasks, simplifying case management, thus allowing radiologists to focus on making the diagnosis instead of the report. The platform has been thoughtfully built to integrate seamlessly into existing systems, allowing radiologists to work more fluidly. It bridges the gap between existing processes and an entirely new way of reporting that enables the radiologist to seamlessly share any key findings they observe in a study, automatically generate a final report, and enable a quick review, approval, and distribution process. This new workflow creates the conditions for more consistent, high-quality reporting, supporting improved diagnosis without burdening the practitioner. As AI-driven solutions like SPARK.ai reshape radiology, they pave the way for healthcare professionals to provide timely and precise care in a landscape where demand far outpaces supply. ]]> https://biospectrumindia.com/news/100/25990/collaborative-ai-research-labs-foundation-joins-hands-with-atal-incubation-centre-ccmb.html https://biospectrumindia.com/news/100/25990/collaborative-ai-research-labs-foundation-joins-hands-with-atal-incubation-centre-ccmb.html Tue, 15 Apr 2025 00:00:00 +0530 Collaborative AI Research Labs Foundation (CAiRL) has announced the signing of a Memorandum of Understanding (MoU) with Atal Incubation Centre - CCMB (Cellular and Molecular Biology), a Hyderabad-based incubation centre focused on deep tech and biotech innovation. The MoU was signed by Sarvesh Singh (Director General, CAiRL) and Dr N. Madhusudhan Rao (CEO, AIC-CCMB). This collaboration is a significant step toward building a thriving innovation ecosystem at the intersection of Artificial Intelligence and Life Sciences. Through this partnership, CAiRL and AIC-CCMB will co-develop programmes that enable AI-driven research, support startup incubation, and nurture cross-disciplinary innovation. The shared vision is to accelerate scientific discovery and translational research by enabling bio-entrepreneurs and researchers to access cutting-edge AI tools, mentorship, and global exposure. The key focus areas include AI for genomics, drug discovery, and diagnostics; Startup acceleration in biotech and healthtech domains; Joint workshops, fellowships, and research grants; Collaborative projects that integrate data science and molecular biology. ]]> https://biospectrumindia.com/news/100/25992/remidio-with-retinarisk-to-strengthen-ai-driven-diabetic-retinopathy-screening-in-india-and-iceland.html https://biospectrumindia.com/news/100/25992/remidio-with-retinarisk-to-strengthen-ai-driven-diabetic-retinopathy-screening-in-india-and-iceland.html Tue, 15 Apr 2025 00:00:00 +0530 Bengaluru-based Remidio Innovative Solutions, a global leader in artificial intelligence (AI)-powered ophthalmic diagnostics, has announced a strategic partnership with RetinaRisk, a leading health tech company from Iceland, to enhance risk-based diabetic retinopathy (DR) screening in India and Iceland. This partnership brings together two powerful innovations, Remidio’s Medios DR AI for automated DR detection and RetinaRisk’s personalised risk triaging algorithm for progression to sight-threatening DR. Medios DR is an edge-AI solution that runs entirely on a smartphone without the need for internet access or cloud connectivity, offering real-time DR grading at the point of care. RetinaRisk calculates a patient’s risk level and suggests a recommended screening interval using key clinical inputs such as HbA1c, blood pressure, diabetes type and duration, and DR status. From a public health perspective, this enables more cost-effective DR screening programmes by individualising screening intervals, extending the frequency for low-risk individuals while ensuring timely follow-up for high-risk cases. The urgency of this collaboration is highlighted by growing global and national public health concerns. Globally, an estimated 22.27% of people with diabetes have diabetic retinopathy, and the number of affected adults is projected to rise from 103.12 million in 2020 to 160.50 million by 2045. India alone accounts for over 9.2 million cases, highlighting the urgent need for scalable, personalized screening models. The partnership will kick off with pilot programmes targeting high-prevalence diabetic populations in India, aiming to create a scalable framework for prioritised referrals, longitudinal tracking, and reduced vision loss due to DR.   ]]> https://biospectrumindia.com/news/100/25994/dr-mohans-diabetes-specialities-centre-launches-ai-driven-diabetic-retinopathy-screening-software.html https://biospectrumindia.com/news/100/25994/dr-mohans-diabetes-specialities-centre-launches-ai-driven-diabetic-retinopathy-screening-software.html Tue, 15 Apr 2025 00:00:00 +0530 Taking yet another pioneering and life-changing step in the field of diabetic care, Dr. Mohan’s Diabetes Specialities Centre (DMDSC) has launched a first-of-its-kind artificial intelligence (AI)-driven Diabetic Retinopathy Screening Software. This initiative aims to harness the latest artificial intelligence technology to detect early-stage diabetic retinopathy and apply this technology to offer quick and precise analysis that will help doctors make informed decisions. This move further strengthens DMDSC's vision of offering holistic preventive care in the diabetic field. Set to be available across its 50 clinics nationally, the hospital has launched this initiative in its flagship Pondicherry and Thanjavur clinics in the first phase of the rollout. Diabetic retinopathy ranks among the primary causes of vision impairment in individuals with diabetes, frequently going unnoticed until substantial damage has taken place. With this AI-powered screening, DMDSC aims to bridge the gap between early detection and effective treatment by providing quick, highly accurate, and accessible diagnostic solutions. Dr R. M. Anjana, Managing Director of Dr. Mohan’s Diabetes Specialities Centre, said, “Diabetic retinopathy is a silent but severe complication that can lead to irreversible vision loss if left undetected. With diabetes cases on the rise, it is crucial to integrate preventive eye care into routine diabetes management. This AI-powered screening initiative is a game-changer, as it enables early detection and timely intervention, significantly reducing the risk of vision impairment. We have chosen Pondicherry and Thanjavur as the first locations for this rollout due to the high prevalence of diabetes in these regions and the need to strengthen accessible eye care solutions. Our goal is to ensure that patients receive proactive, high-quality care close to home.”   ]]> https://biospectrumindia.com/news/100/25978/omron-partners-with-tricog-to-launch-ai-based-cardiac-care-platform.html https://biospectrumindia.com/news/100/25978/omron-partners-with-tricog-to-launch-ai-based-cardiac-care-platform.html Fri, 11 Apr 2025 00:00:00 +0530 Omron Healthcare, the leading player in the home monitoring health solutions space, has announced its next initiative with Tricog Health, a renowned company in the medtech space addressing cardiovascular conditions. Omron and Tricog joined hands in 2023 to announce foray into remote home heart monitoring and management segment. This collaboration involves launching and deploying “KeeboHealth”, a connected and artificial intelligence (AI)-based cardiac care solution aimed at improving heart failure management through remote monitoring and personalised care solutions. Striving to empower doctors and patients, KeeboHealth is a sophisticated platform integrating state-of-the-art AI-based medical technology with data analytics, leveraging home ECG monitoring to enhance the ability of healthcare providers to manage patient care efficiently. Besides the digital ecosystem, it offers a range of Omron products- particularly home ECG monitors along with Blood Pressure Monitors and Weighing Scales - to help cardiac care patients enhance monitoring and in turn receive more effective & timely treatment strategies from their doctors. As OMRON and KeeboHealth prepare to introduce this transformative solution to the market by early April 2025, the healthcare industry can expect a paradigm shift in the way patient care is delivered and managed in the remote cardiac care segment. ]]> https://biospectrumindia.com/news/100/25963/cureskin-to-launch-worlds-first-ai-powered-hair-analyser.html https://biospectrumindia.com/news/100/25963/cureskin-to-launch-worlds-first-ai-powered-hair-analyser.html Wed, 09 Apr 2025 00:00:00 +0530 Bengaluru-based startup Cureskin, a leader in artificial intelligence (AI)-driven dermatology solutions is set to launch the world’s first AI-powered hair analyser. It is designed to accurately detect male pattern baldness and assess hairline health with advanced precision. This breakthrough feature, integrated into the Cureskin app, leverages cutting-edge artificial intelligence (AI) and machine learning (ML) to help users monitor hair thinning early, enabling timely intervention and personalised treatment recommendations. Cureskin’s AI-powered hair analyser utilises deep-learning models trained on thousands of clinical images to identify early signs of hair recession, thinning, and density reduction. With a simple selfie in the app, users receive an instant, in-depth analysis of their hairline health, along with AI-generated insights on potential hair loss patterns. In a country where dermatologists are scarce and hair-related stigma is widespread, this innovation brings equitable, tech-enabled care to millions—especially in semi-urban and rural areas where expert access is limited. “By integrating AI and machine learning into hair health diagnostics, we are transforming how users understand and address hair loss. Our deep-learning models continuously improve, ensuring high accuracy in detecting hair loss patterns. With this feature, users can access early and expert guidance, bridging the gap between technology and personalised dermatological care,” said Ramakrishna R, Chief Technology Officer at Cureskin. Male pattern baldness (androgenetic alopecia) is a growing concern in India, with studies indicating that over 50% of Indian men experience some degree of hair loss by the age of 50, with many seeing early signs as young as their 20s. Factors such as genetics, lifestyle, and environmental stressors accelerate hair thinning, making early detection crucial for effective management. With this new AI-driven hair analysis feature, Cureskin continues to redefine personalised dermatological care through the power of technology. ]]> https://biospectrumindia.com/news/100/25967/manipal-hospitals-partners-with-google-cloud-to-advance-ai-driven-digital-healthcare-across-india.html https://biospectrumindia.com/news/100/25967/manipal-hospitals-partners-with-google-cloud-to-advance-ai-driven-digital-healthcare-across-india.html Wed, 09 Apr 2025 00:00:00 +0530 Manipal Hospitals, one of India’s largest and most trusted healthcare providers, is joining forces with Google Cloud to usher in a new era of artificial intelligence (AI)-powered digital healthcare.   The partnership will involve the hospital leveraging cutting-edge artificial intelligence, advanced data analytics, and secure cloud infrastructure from Google Cloud to drive operational efficiencies across the patient care value chain.   With support from Deloitte, Manipal Hospitals is using Google Cloud’s state-of-the-art technology to power its ePharmacy platform and AI-driven nurse handoff solution. Manipal Hospitals’ results show that it has successfully reduced ePharmacy order processing time from 15 minutes to under 5 minutes and cut nurse handover durations from 90 minutes to just 20 minutes. This enabled the hospital chain to reduce nurse handoff time by a staggering 78%, unlocking millions of minutes of caregiver productivity every month.   More than 100,000 patients today rely on the ePharmacy platform for both short- and long-term medication needs. With more than 60,000 data entries processed daily, doctors can gain valuable insights into patient trends, enabling better collaboration with pharmacists.   The nurse handoff solution, powered by Google Cloud’s generative AI capabilities, is helping enhance communication, reduce errors, and ensure continuity of care.  ]]> https://biospectrumindia.com/news/100/25944/health-tech-startup-perkant-tech-raises-rs-6-6-cr-in-seed-round.html https://biospectrumindia.com/news/100/25944/health-tech-startup-perkant-tech-raises-rs-6-6-cr-in-seed-round.html Mon, 07 Apr 2025 00:00:00 +0530 Indore-based startup Perkant Tech, inventor of an artificial intelligence (AI)-enabled med-tech multi-disease prognostic health platform, has raised Rs 6.6 crore in a seed funding round led by YourNest Venture Capital. This round includes contributions of Rs 5 crore from YourNest, Rs 1 crore from the Government of India’s Atal New India Challenge (AIM, Niti Aayog), Rs 35 lakh from Villgro Foundation, and Rs 25 lakh from the accelerator Sanchi Connect who partnered with YourNest in its Velocity fast-track funding programme. Perkant Tech was founded during COVID-19 in 2020 by Lokant Jain and Saniya Jeswani, two young engineers in their final year of college. It offers a medical device with an exclusive suite of AI-augmented health solutions which empowers individuals and healthcare providers with real-time, predictive health insights, ranging from preventative screenings to comprehensive monitoring. This sustainable, upgradable platform redefines healthcare with precision, adaptability and scalability, bridging critical gaps in accessibility and supporting a future of equitable healthcare for all. This investment will enable Perkant Tech to enhance its AI-powered prognostic technology, accelerate the R&D efforts and support market expansion, customer acquisition strategies as the company gears up for its commercial launch following successful pilots with world-class partners. Additionally, the funds will also be allocated towards technology upgrades and software development to ensure seamless integration, real-time updates, and personalized health insights, preparing the company’s solutions for widespread adoption. Perkant Tech holds a granted Indian patent and a pending US patent for an advanced apparatus designed to measure and acquire distress data from the human body, encompassing both psychological and physiological indicators. ]]> https://biospectrumindia.com/news/100/25948/narayana-health-deploys-ai-based-technologies-at-preventive-health-screening-centre-aarogyam.html https://biospectrumindia.com/news/100/25948/narayana-health-deploys-ai-based-technologies-at-preventive-health-screening-centre-aarogyam.html Mon, 07 Apr 2025 00:00:00 +0530 Narayana Health has announced the formal launch of Narayana Aarogyam, a preventive screening initiative designed to empower individuals through early detection and personalised health tests. Located in Bengaluru's tech corridor at Prestige Tech Park, Kadubeesanahalli, Aarogyam targets young working professionals with streamlined 90-minute checkups, advanced diagnostic tools and four customizable wellness packages. The Aarogyam centre is equipped with the latest artificial intelligence (AI)- enabled cardiac CT Scanner, which offers ultra-low radiation AI-enhanced imaging for heart health.  DEXA Scans are available for precision bone density analysis to detect osteoporosis risks. The centre is also equipped with Advanced 3D Mammograms that offer high-resolution breast cancer screening. The key highlight of our screening is that there is No Need For Fasting for any of these tests, keeping patient convenience on top of mind. Aarogyam provides tailored health packages for different age groups: Vital Care:Comprising gut health, thyroid and baseline metrics for people below 35 years of age. Prima:Heart, liver and lung screenings for those in the 35-40 years age group. Enhanced:For cancer risk profiling to people between 35 and 40 years. Comprehensive: Our most advanced package for all under 40 years that includes whole body diagnostics along with chronic disease markers. Dr Devi Shetty, Chairman of Narayana Health, stated, “Aarogyam redefines preventive care by merging clinical excellence with accessibility. It is important for healthy individuals with fast-paced lifestyles to prioritise preventive health screenings. Our goal is to shift healthcare from reactive treatment to proactive wellness, ensuring that early intervention becomes a lifestyle norm.”   ]]> https://biospectrumindia.com/news/100/25910/entvin-ai-secures-rs-5-cr-funding-from-y-combinator.html https://biospectrumindia.com/news/100/25910/entvin-ai-secures-rs-5-cr-funding-from-y-combinator.html Tue, 01 Apr 2025 00:00:00 +0530 Entvin AI, a startup founded by three graduates from the Indian Institute of Technology (IIT) Bombay, has officially launched out of beta and announced its funding from Y Combinator.  The company provides specialised AI solutions for pharmaceutical and life sciences companies worldwide. Y Combinator is the world's most prestigious startup accelerator and Entvin AI has raised $500K in the first round of funding with a rigorous 0.1% acceptance rate. With this funding, Entvin plans to expand its AI capabilities and accelerate customer acquisition among mid-to-large pharmaceutical companies globally. The company, founded by Sanskar Jain, Hemant Phalak and Rishabh Arya, has developed an AI platform that streamlines the notoriously time-consuming, resource-intensive and complex FDA drug approval process, a market opportunity potentially worth billions as pharmaceutical companies worldwide seek to accelerate regulatory timelines and reduce compliance costs. The company reports early success with enterprise pilot customers, demonstrating that its AI solution can save hundreds of hours for regulatory and scientific teams while improving compliance accuracy, a critical factor in an industry where regulatory missteps can cost millions. With the FDA drug approval process often taking years and costing millions, any inefficiency can significantly impact a company's bottom line and delay potentially life-saving treatments from reaching patients. Entvin AI is addressing this critical challenge head-on with their specialised AI platform designed for regulatory teams. Entvin's AI platform directly targets this bottleneck by automating document drafting, compliance verification, and regulatory monitoring tasks that traditionally consume thousands of hours of highly-skilled professional time. The platform's technical architecture leverages large language models specifically fine-tuned for regulatory documentation and FDA compliance requirements. Early users report significant efficiency gains, with some teams reclaiming hundreds of hours previously spent on manual regulatory work.   ]]> https://biospectrumindia.com/news/100/25916/care-hospitals-launches-ai-powered-non-invasive-therapy-in-telangana-andhra-pradesh.html https://biospectrumindia.com/news/100/25916/care-hospitals-launches-ai-powered-non-invasive-therapy-in-telangana-andhra-pradesh.html Tue, 01 Apr 2025 00:00:00 +0530 CARE Hospitals, a renowned healthcare provider, has announced the launch of an artificial intelligence (AI)-powered, non-invasive therapy programme in collaboration with JOGO Health. This pioneering initiative in Telangana and Andhra Pradesh, offering protocol-based, non-invasive treatment pathways for patients with complex neurological, urological, and gastroenterological conditions.   Developed in the US by a Johnson & Johnson JLABS-incubated company, JOGO Health integrates patented wearable EMG sensors, artificial intelligence, and real-time biofeedback to stimulate neuroplasticity and aid patients in regaining lost muscle function. Clinically validated through research collaborations with Harvard Medical School and the Mayo Clinic, this cutting-edge technology is already in use at top medical centers across the US, Canada, and Asia.   Dr Nikhil Mathur, Group Chief of Medical Services, CARE Hospitals, emphasised the significance of this initiative, stating, “This collaboration with JOGO Health marks a significant advancement in patient care. By leveraging AI-powered therapy, we are introducing a revolutionary treatment option that is non-invasive, effective, and accessible to patients with chronic neurological, urological, and gastroenterological conditions.”   Biju Nair, Zonal COO, CARE Hospitals, added, “At CARE Hospitals, we are committed to bringing the latest medical innovations to our patients. The integration of JOGO Health’s AI-driven therapy into our treatment protocols represents a paradigm shift in rehabilitation and recovery, reducing dependency on invasive procedures and improving overall patient outcomes.”   Siva Nadarajah, Co-founder and President of JOGO Health, shared his enthusiasm for the collaboration, saying, “JOGO Health is proud to partner with CARE Hospitals to introduce this groundbreaking AI-powered therapy in India. With our clinically validated technology, we are confident that this program will significantly enhance patient recovery and quality of life.”  ]]> https://biospectrumindia.com/news/100/25887/irelands-t-pro-opens-new-india-offices-to-meet-demand-for-ai-driven-clinical-documentation.html https://biospectrumindia.com/news/100/25887/irelands-t-pro-opens-new-india-offices-to-meet-demand-for-ai-driven-clinical-documentation.html Thu, 27 Mar 2025 00:00:00 +0530 T-Pro, a global leader in artificial intelligence (AI)-powered speech recognition and clinical documentation solutions, has announced the opening of its new offices in Chennai and Bengaluru, reinforcing its commitment to leveraging India’s rich talent pool to drive healthcare innovation worldwide. The expansion was inaugurated during the visit of Ireland’s Minister for Higher Education, Research, and Innovation, James Lawless, on the occasion of Ireland’s National Day – St. Patrick’s Day. This strategic move further solidifies T-Pro’s presence in India, allowing it to better serve its growing customer base across India, Malaysia, Singapore, Australia, and New Zealand. By harnessing the power of artificial intelligence, T-Pro’s solutions streamline clinical documentation, reduce the administrative burden on healthcare professionals, and improve patient outcomes. With a workforce of over 350 employees and contractors in India, T-Pro has experienced a steady 20% year-on-year growth since 2021. The newly established offices in Chennai and Bengaluru will initially house more than 20 full-time professionals across software development, helpdesk support, and operations, with further expansion plans in the pipeline. These modern workspaces are designed to foster innovation, collaboration, and efficiency, reinforcing T-Pro’s position as a pioneer in AI-driven healthcare solutions. As part of its long-term vision, T-Pro is actively expanding its team and inviting skilled professionals to join its journey of innovation. With opportunities in software development, AI research, customer success, and operations, T-Pro is looking to attract top-tier talent passionate about transforming healthcare technology. ]]> https://biospectrumindia.com/news/100/25881/remidio-invests-in-uks-occuity-to-enhance-eye-healthcare.html https://biospectrumindia.com/news/100/25881/remidio-invests-in-uks-occuity-to-enhance-eye-healthcare.html Tue, 25 Mar 2025 00:00:00 +0530 In a move set to redefine non-invasive disease detection, Bengaluru-based Remidio, a global leader in artificial intelligence (AI)-powered ophthalmic solutions, has made a strategic investment in Occuity, a pioneering UK-based developer of handheld, optical screening and monitoring devices that are non-contact and require no consumables. Remidio and Occuity’s partnership will begin with the integration of technologies to co-develop a comprehensive myopia screening solution, addressing India’s growing myopia epidemic. By 2050, nearly 48% of urban children are expected to be affected, with 20% experiencing rapid progression and around 4% facing complications that could lead to permanent vision loss. A key part of this solution is the introduction of India’s first-of-its-kind handheld, non-invasive, and highly accurate axial length measurement device for myopia detection and monitoring. This innovation eliminates the need for complex and expensive eye exams, making early diagnosis more accessible—particularly for children. This collaboration will also introduce a novel non-contact, handheld device for accurately assessing corneal thickness—critical for managing glaucoma patients and evaluating suitability for interventions such as LASIK. This innovation will enhance Remidio’s widely used Comprehensive Eye Clinic in a Bag, further extending access to comprehensive eye disease screening. Leveraging Remidio’s expertise in AI-powered diagnostics and scalable manufacturing, this collaboration will accelerate the development and deployment of Occuity’s non-contact, handheld screening solutions globally. This includes the Occuity Indigo, an optical glucose meter designed to measure glucose levels through a simple eye scan, eliminating the need for painful finger-prick tests currently endured by over 100 million diabetes patients in India. This will further strengthen Remidio’s leadership in AI-driven detection of chronic eye diseases like Diabetic Retinopathy, Glaucoma and Macular Degeneration.   ]]> https://biospectrumindia.com/features/100/25870/discussion-with-industry-experts-on-ai-in-life-sciences.html https://biospectrumindia.com/features/100/25870/discussion-with-industry-experts-on-ai-in-life-sciences.html Sun, 23 Mar 2025 00:00:00 +0530 A group of experienced professionals from the Kellogg School of Management in the US, led by Prof. Mohanbir Sawhney, Associate Dean at Kellogg, recently visited Axtria’s office in Gurugram. The students, each with over 10 years of industry experience, brought diverse perspectives on the evolving landscape of data, digital innovation, and AI. BioSpectrum had the opportunity to interact with Prof. Mohanbir Sawhney and Manish Mittal (Head of Global Delivery at Axtria, and India Country Head, Axtria) on the topic: "AI in Pharma & Life Sciences: What's Happening Now and the Way Forward." This conversation, enriched by the global insights of these stalwarts and the on-ground perspectives of visiting Kellogg professionals, focused on the current trends and future potential of AI in the sector. We spoke about how AI is reshaping industries, particularly life sciences and healthcare; What are some real-world examples where AI has significantly improved decision-making in life sciences and healthcare; How AI is helping businesses bridge the gap between raw data and strategic decision-making; and what are the future breakthroughs in AI-driven decision-making in the next five years. Click here to listen to the interesting discussion! ]]> https://biospectrumindia.com/news/100/25858/centre-for-digital-technologies-in-healthcare-opens-in-hyderabad.html https://biospectrumindia.com/news/100/25858/centre-for-digital-technologies-in-healthcare-opens-in-hyderabad.html Thu, 20 Mar 2025 00:00:00 +0530 Kohli Centre on Intelligent Systems (KCIS) at the International Institute of Information Technology Hyderabad (IIIT-H) marked F C Kohli’s birth anniversary on 19 March, and celebrated FC Kohli, the father of Indian IT and Founder of TCS’s 101 birth anniversary and the fifth edition of FC Kohli Talks.  The Kohli Day celebration included an annual Kohli Day Lecture by Dr D. Nageshwar Reddy, Chairman AIG Hospitals, who inaugurated the Centre for Digital Technologies in Healthcare (CDiTH). Prof PJ. Narayanan, Director of IIIT Hyderabad while giving a brief on the new centre said it is a translation lab established to apply modern digital technologies to enhance the efficacy and economy of healthcare delivery for real-world impact in India and the world by effectively bridging academic research and clinical practice.  The Kohli Centre on Intelligent Systems (KCIS), named after F.C. Kohli, houses all the AI research groups in the institute with 50 faculty and 500 researchers, which constitute one of the largest research groups in the country. Ranging from language technologies, computer vision, robotics, cognitive sciences and advanced machine learning, with applications in several domains including mobility and healthcare, the centre has AIG Hospital as a principal partner. ]]> https://biospectrumindia.com/news/100/25855/indegene-expands-presence-in-europe-with-new-centre-in-london.html https://biospectrumindia.com/news/100/25855/indegene-expands-presence-in-europe-with-new-centre-in-london.html Wed, 19 Mar 2025 00:00:00 +0530 Bengaluru-based Indegene, a digital-first life sciences commercialisation company, has announced the launch of a new centre in London. This aligns with the company’s long-term growth strategy in Europe, reiterating its commitment to enable life sciences clients in the region to be future-ready. Indegene’s Europe-based clients can now benefit from this centre as a strategic hub for consulting and commercialisation solutions and modernise their operations with an artificial intelligence (AI)-first approach. The company is strengthening its existing employee base in the region, with skillsets spanning a wide range of areas - consulting, creative, data and analytics, engineering and customer experience. “London is a vital healthcare, technology and business innovation hub, with a great talent pool - making it an important market for life sciences companies in the region”, said Manish Gupta, Chairman and CEO, Indegene. “With our new centre, we are better positioned to dial up innovation and engagement with our clients here and help them holistically improve their commercialisation processes with an AI-first approach and stay ahead of the curve.” Indegene launched a new entity in Spain last month. The company already has a significant presence in Europe, with centers in Germany, Ireland, and Switzerland. Last year, Indegene acquired Trilogy Writing & Consulting GmbH (Trilogy), a global provider of specialty medical writing capabilities with teams spread across UK, Germany and US. In 2019, Indegene acquired DT Associates (now DT Consulting), a consulting services company in the UK that supports clients in the healthcare and life sciences space. The world's top 20 global biopharma companies, including many from Europe, trust Indegene for their commercialisation needs.    ]]> https://biospectrumindia.com/news/100/25856/tech-mahindra-and-nvidia-collaborate-to-advance-drug-safety-using-agentic-ai.html https://biospectrumindia.com/news/100/25856/tech-mahindra-and-nvidia-collaborate-to-advance-drug-safety-using-agentic-ai.html Wed, 19 Mar 2025 00:00:00 +0530 Tech Mahindra, a leading global provider of technology consulting and digital solutions to enterprises across industries, has announced a pharmacovigilance (PV) autonomous solution built with NVIDIA AI software to advance drug safety management. The transformative solution leverages agentic artificial intelligence (AI) and automation to enhance the accuracy, speed, and efficiency of pharmacovigilance processes, addressing critical industry challenges such as manual delays and data overload. Powered by Tech Mahindra’s TENO framework, which is built on NVIDIA’s cutting-edge AI technology, the solution is designed to automate and optimize pharmacovigilance workflows. By integrating the NVIDIA AI Enterprise software platform, including NVIDIA NeMo, NVIDIA NIM microservices, and NVIDIA AI Blueprints, the Tech Mahindra solution streamlines case intake, data transformation, quality control, and compliance management, thereby ensuring a seamless and intelligent PV workflow. Additionally, the LLM-powered AI agents within the solution autonomously handle case classification, prioritization, and verification of pharmacovigilance emails to reduce the risk of human error. Tech Mahindra and NVIDIA work together to provide better patient outcomes by bringing agentic AI-driven intelligence to pharmacovigilance. The pharmacovigilance industry manages over 1,000 daily cases of adverse drug reaction (ADR) for major drugs. For instance, in the case of an email reporting adverse drug reaction (ADR), the AI-driven PV solution instantly flags, prioritises, and processes the request by eliminating human intervention that could potentially lead to delays and errors. The solution reduces turnaround times by up to 40%, enhances data accuracy by 30%, and cuts operational costs by 25%. This ensures timely case processing, regulatory adherence, and proactive risk mitigation, thereby transforming pharmacovigilance from reactive to predictive. Tech Mahindra has also expanded its TENO framework to encompass NVIDIA AI Enterprise, enriching it with customised AI agents to address a broad spectrum of industry challenges. The framework integrates NVIDIA NeMo  to accelerate generative AI pipeline for data collection and curation, coupled with Tech Mahindra’s VerifAI solution for data validation and governance. The distributed training and model customisation capabilities embedded within the framework ensure that the AI models continuously evolve to enhance decision-making precision. ]]> https://biospectrumindia.com/news/100/25839/peptris-technologies-out-licenses-indias-first-ai-discovered-drug-candidate-to-revio-therapeutics.html https://biospectrumindia.com/news/100/25839/peptris-technologies-out-licenses-indias-first-ai-discovered-drug-candidate-to-revio-therapeutics.html Mon, 17 Mar 2025 00:00:00 +0530 Peptris Technologies, a Bengaluru-based AI-powered drug discovery startup, has entered into a licensing agreement with US-based Revio Therapeutics, a specialty pharma startup focused on repurposing and optimizing approved medicines. Under the agreement, Peptris is licensing its preclinical-stage asset, PEPR124 (RT001) for an undisclosed amount to Revio Therapeutics for further development in Duchenne Muscular Dystrophy (DMD). The agreement is expected to accelerate Peptris’ AI-powered drug discovery efforts and expand its footprint in global biotech markets. DMD is a rare genetic disorder primarily affecting boys, leading to progressive muscle degeneration, severe disability, and reduced life expectancy.With limited treatment options available, the global DMD market is valued at over $3 billion and represents a significant unmet need, driving demand for more effective and accessible therapies. PEPR124 (RT001) was discovered by Peptris Technologies using its proprietary AI-driven drug discovery platform and has demonstrated promising efficacy in preclinical studies for DMD. It is a repurposed, mutation-agnostic, and safe therapeutic that could be a significant breakthrough therapeutic for not only DMD but other muscular dystrophies as well. Under the terms of the agreement, Revio Therapeutics will hold commercialisation rights to PEPR124 (RT001) in all markets except in BRICS countries, which will be retained by Peptris.   ]]> https://biospectrumindia.com/news/100/25832/tenthpin-launches-ai-labs-tail-in-hyderabads-life-sciences-hub.html https://biospectrumindia.com/news/100/25832/tenthpin-launches-ai-labs-tail-in-hyderabads-life-sciences-hub.html Fri, 14 Mar 2025 00:00:00 +0530 Switzerland based Tenthpin Management Consultants, a global consulting leader in technology advisory for life sciences companies, has announced the launch of Tenthpin AI Labs (TAIL) in Hyderabad, establishing a Global Centre of Excellence dedicated to AI-driven transformation in Life Sciences. TAIL's mission is to help pharmaceutical, MedTech, biotech, and research organisations distinguish between AI hype and accomplishing real value. By leveraging India's tech talent and Hyderabad's position as a life sciences hub, Tenthpin aims to support companies in accelerating AI adoption across the drug life cycle, from R&D to better patient outcomes. The facility at HITEC City was inaugurated by Jayesh Ranjan, Special Chief Secretary, Information Technology, Electronics & Communications (ITE&C) and Industries & Commerce, Govt of Telangana in the presence of Bart Reijs, Director, Tenthpin; Thomas Weber, Partner & Chief Product Officer, Tenthpin and Raghuram Janapareddy Partner & Managing Director, Tenthpin India. Tenthpin Solutions, a group company of Tenthpin is also expanding its footprint in India. Speaking on this occasion, Thomas Weber, Partner & Chief Product Officer added "Tenthpin develops new solutions under co-innovation model, jointly with the industry. Adding local talent to our development teams, coupled with AI Labs, we are far more closure to the Indian Market to develop solutions tailored to local companies." TAIL will provide expertise in integrating AI with underlying ERP systems and numerous other solutions, enabling seamless data flow and enhanced insights for improved decision-making. The lab will also collaborate with local research institutions, universities, and industry partners to drive advancements in AI for Life Sciences in India. Eckhard Drager, Founder and Member of the Executive Board of Tenthpin, says “Unlike traditional software tools implementation, AI adoption throws new challenges. There will be a need for new methodologies, new data governance models, new change management approaches etc. Tenthpin already has a tailored methodology covering all these aspects.” ]]> https://biospectrumindia.com/news/100/25830/alphadroid-unveils-ai-powered-robotics-to-revolutionise-healthcare-in-india.html https://biospectrumindia.com/news/100/25830/alphadroid-unveils-ai-powered-robotics-to-revolutionise-healthcare-in-india.html Thu, 13 Mar 2025 00:00:00 +0530 Noida-based startup AlphaDroid, a pioneer in AI-driven robotics, has launched its state-of-the-art solutions to transform India’s healthcare sector. Designed to enhance patient experiences, streamline hospital operations, and support healthcare professionals, AlphaDroid’s breakthrough technology was showcased at the International Patient Safety Conference 2025 (IPSC) at Bharat Mandapam recently, receiving overwhelming interest from industry leaders and prospective customers. AlphaDroid’s robotic solutions aim to redefine patient care by boosting efficiency, safety, and overall service quality. The strong industry response highlights growing confidence in AI-powered innovations to modernize healthcare delivery.  Speaking at the launch, Sanjeev Kumar, Founder & CEO of AlphaDroid, stated: “Healthcare is about people—caregivers, patients, and doctors. Our mission is to empower medical professionals with next-generation technology, allowing them to focus on patient well-being. The enthusiasm from industry leaders confirms that the future of smart hospitals is here, and we are ready to lead this transformation across India.” As India rapidly embraces AI and automation, AlphaDroid is at the forefront of this shift, delivering intelligent and connected healthcare solutions. By integrating automation, hospitals can optimise efficiency, improve patient safety, and ease the burden on medical staff, paving the way for a more sustainable and patient-centric healthcare ecosystem. ]]> https://biospectrumindia.com/news/100/25802/sharda-group-launches-state-of-the-art-facility-with-smart-infrastructure-in-greater-noida.html https://biospectrumindia.com/news/100/25802/sharda-group-launches-state-of-the-art-facility-with-smart-infrastructure-in-greater-noida.html Sun, 09 Mar 2025 00:00:00 +0530 Building on its legacy of excellence in healthcare and education, Sharda Group has launched Sharda Care - Healthcity, a state-of-the-art, 600+ bedded super-specialty hospital in Greater Noida. The hospital was inaugurated by Chief Minister of Uttar Pradesh, Yogi Adityanath Ji, marking a significant step in advancing high-quality healthcare for patients. During the inauguration, the Chief Minister emphasised the importance of strengthening healthcare infrastructure and making world-class medical facilities accessible to people across the country. Spread across 65 acres, Sharda Care – Healthcity has a smart JCI compliant infrastructure designed to provide comprehensive, patient-centric medical care across super-specialties, including oncology, neurosciences, orthopaedics, and cardiac science. Equipped with 160+ ICU beds, 24 modular operation theatres, and largest Level 1 Emergency & Trauma Care centre (60-beds) in the country, established in collaboration with SingHealth Singapore. The hospital houses patient driven approach, advanced diagnostics, minimally invasive surgical procedures, and precision-driven treatment pathways, ensuring early detection, advanced treatment, and seamless patient management.   ]]> https://biospectrumindia.com/news/100/25781/wipro-ge-healthcare-launches-ai-enabled-made-in-india-ultrasound-system-versana-premier-r3.html https://biospectrumindia.com/news/100/25781/wipro-ge-healthcare-launches-ai-enabled-made-in-india-ultrasound-system-versana-premier-r3.html Tue, 04 Mar 2025 00:00:00 +0530 Wipro GE Healthcare has announced the launch of the Versana Premier R3, an advanced artificial intelligence (AI)-enabled ultrasound system designed to enhance clinical efficiency and accuracy, streamline workflows, and improve patient outcomes. Catapulting Government’s ‘Make in India’ vision, the state-of-the-art ultrasound system will be manufactured at Wipro GE Healthcare’s PLI factory in Bengaluru. An extension of the Versana ultrasound range, Versana Premier R3 integrates artificial intelligence and offers automation and AI-enabled productivity tools to improve workflow and clinical features designed to enhance clinical efficiency and accuracy. The advanced ultrasound system aims to help clinicians deliver more personalised, ubiquitous, and preventive care. Addressing the skill gap, the system will optimize dynamic tissue imaging, assist with volume calculations, and streamline workflows. Its self-learning onboarding tool will empower the clinicians to enhance their skills and adapt to new workflows.  A recent report by PwC indicates that 57% of healthcare providers in India are using AI, significantly higher than the adoption rates globally. As India embraces the potential of artificial intelligence in healthcare, Versana Premier R3 represents a significant leap in diagnostic capabilities. The product’s cutting-edge ‘VisionBoost architecture’ and 8-million-channel digital processing deliver exceptional image clarity. With compatibility for 23 different probes, the system offers dynamic organ scanning. Wipro GE Healthcare has been pioneering ‘Make in India – for India and the world’ for decades. Other Made in India products from the company’s PLI factory include the Revolution Aspire CT system and Optima IGS320 AI-enabled Cath Lab, among others. Earlier this year, Wipro GE Healthcare also announced an investment of over Rs 8000 crore in manufacturing output & local R&D over the next 5 years. ]]> https://biospectrumindia.com/news/100/25738/nit-rourkela-develops-ai-powered-model-to-improve-blood-sugar-predictions-for-diabetes-management.html https://biospectrumindia.com/news/100/25738/nit-rourkela-develops-ai-powered-model-to-improve-blood-sugar-predictions-for-diabetes-management.html Tue, 25 Feb 2025 00:00:00 +0530 A research team at National Institute of Technology (NIT) Rourkela has developed a new artificial intelligence (AI)-driven approach to improve blood sugar predictions for people with diabetes. The research presents a machine-learning model that enhances the accuracy of blood glucose level prediction, helping individuals and healthcare providers make better and personalised treatment decisions.  Managing diabetes can be difficult due to a lack of specialists, unequal access to healthcare, low medication adherence, and poor self-care. These challenges make it harder for patients to keep their blood sugar levels under control, increasing the risk of serious health problems. New digital health technologies, especially those that use Artificial Intelligence (AI), offer a way to improve diabetes care and reduce costs. Machine learning (ML) has been used in many areas of diabetes research, from basic studies to predictive tools that can help doctors and patients make better and timely decisions. However, AI learning models, especially predictive AI models, have a few drawbacks. Many of these models work like a “black box,” meaning their predictions are difficult to understand. This lack of transparency makes it hard for doctors and patients to fully trust them. Furthermore, traditional models, such as statistical forecasting methods or basic neural networks, often fail to recognise long-term glucose fluctuations and require complex fine-tuning. The researchers at NIT Rourkela focused on improving glucose forecasting using deep learning techniques. Their approach incorporates a specialised AI model that learns from past blood sugar trends and predicts future levels more accurately than existing methods. Unlike traditional forecasting models, which often struggle with long-term trends and require manual adjustments, this model processes glucose data automatically, identifying key patterns and making precise predictions.  In the long run, this AI-driven approach has the potential to enhance diabetes care through various applications. It could be integrated into smart insulin pumps to automate insulin delivery, incorporated into mobile health apps for real-time glucose tracking, or used in clinical settings to support doctors in making personalised treatment plans. Currently, the researchers are planning on testing the developed technology through extensive clinical trials at hospitals, in collaboration with senior diabetologists in Odisha. ]]> https://biospectrumindia.com/news/100/25722/indegene-launches-generative-ai-platform-verticalised-for-life-sciences-industry.html https://biospectrumindia.com/news/100/25722/indegene-launches-generative-ai-platform-verticalised-for-life-sciences-industry.html Mon, 24 Feb 2025 00:00:00 +0530 Bengaluru-based Indegene, a digital-first, life sciences commercialisation company, has launched Cortex, a fit-for-purpose Generative AI (GenAI) platform, verticalised for the life sciences industry. As a life sciences-specialist knowledge engineering and multi- agent orchestration platform, Cortex by Indegene enables life sciences leaders to adopt and scale this transformative technology with enterprise-grade governance. This innovative platform is strategically essential to developing and scaling high-value life sciences use cases such as streamlining the content supply chain, making medical writing more effective and efficient, and accelerating Medical-Legal-Regulatory (MLR) reviews. Its knowledge engineering interface codifies Indegene’s 25+ years of subject matter expertise into advanced knowledge graphs using a domain- friendly interface. Moreover, its fit-for-purpose agents can be configured with any preferred Large Language Model (LLM) and evolve as LLM state-of-the-art improves. Further, its multi-agent orchestration enables use case-specific applications for enterprise-wide system integration. Together, these yield more reliable, accurate and trustworthy outcomes from LLM-based agents with substantially faster turnaround times and better ROI at lower risk, relative to industry-agnostic platforms. This GenAI platform’s embedded domain knowledge graphs capture nuances and details of life sciences’ processes and tasks and benefit from continuous improvement.   ]]> https://biospectrumindia.com/news/100/25701/zeiss-india-joins-hands-with-the-indian-institute-of-science-for-ai-based-eye-research.html https://biospectrumindia.com/news/100/25701/zeiss-india-joins-hands-with-the-indian-institute-of-science-for-ai-based-eye-research.html Wed, 19 Feb 2025 00:00:00 +0530 ZEISS in India has announced its strategic collaboration with the Indian Institute of Science (IISc), Bengaluru, to foster cutting edge research. ZEISS has established a sophisticated state-of-the-art research facility dedicated for developing high fidelity Artificial Intelligence (AI) solutions for the betterment of eye-care and to upskill students in AI technologies. The initiative, supported by the Spectrum Lab in the Department of Electrical Engineering at IISc, aims to harness the transformative potential of AI to enhance eye-care practices and improve patient outcomes. This collaboration will propel improvements in eye care solutions from India for the world considering the rising prevalence of vision impairments worldwide. The facility will act as a center for cutting-edge research, allowing IISc researchers to investigate how AI could transform early diagnosis in eye care by providing innovative solutions that streamline processes, increase accuracy, and improve patient outcomes. ZEISS India and IISc have joined forces to explore and promote the use of advanced AI technologies in ophthalmology. Ashish Modi, Head of the Centre for Application Research India (CARIn), ZEISS India expressed, "Our collaboration with IISc is a step towards bridging this gap, empowering Indian researchers with advanced resources and real-world applications. By fostering a sustainable research ecosystem, we aim to drive global breakthroughs in eye-care technology while strengthening India's position as a hub for scientific excellence."  Dr Rajesh Sundaresan, Dean of Division (Electrical Electronics, and Computer Sciences Division), IISc, said, "Long-term collaborations between industry and academia are essential for fostering a sustainable research ecosystem in India. They provide young researchers with the resources and exposure needed to drive scientific advancements while addressing real-world challenges. Our country needs more such partnerships to remain at the forefront of technological progress, ensuring that innovation is developed and applied to improve lives globally." In addition to the lab set-up, ZEISS India is also sponsoring 6 MTech students for the next 3 years through its CSR-sponsored 'MTech Fellowship Program' at IISc for students pursuing master’s degree in Signal Processing, Artificial Intelligence, Computer Science & Engineering/Computational and Data Science. ]]> https://biospectrumindia.com/news/100/25682/kauvery-hospitals-launches-indias-first-ai-driven-advanced-heart-failure-centre.html https://biospectrumindia.com/news/100/25682/kauvery-hospitals-launches-indias-first-ai-driven-advanced-heart-failure-centre.html Mon, 17 Feb 2025 00:00:00 +0530 Kauvery Hospitals, a leader in cardiac care, marked Heart Failure Awareness Week (9th–15th Feb) with the 2nd Edition of the Kauvery Annual Heart Summit 2025 in Bengaluru. The two-day summit, held on 15th and 16th February, brought together 423+ attendees, including 35+ eminent cardiologists, cardiac surgeons, and international experts, to discuss groundbreaking advancements in heart failure management and transplantation. Building on the success of last year’s inaugural summit, Kauvery Hospitals unveiled its Advanced Heart Failure Centre – India’s first artificial intelligence (AI)-powered, multidisciplinary hub for heart failure care and rehabilitation. Heart failure affects over 8 million Indians annually, with limited access to advanced, holistic care. Kauvery’s Advanced Heart Failure Centre bridges this gap by offering end-to-end solutions, from early diagnosis and AI-guided interventions to heart transplantation, under one roof. Kauvery Advanced Heart Failure Centre is aimed at treating conditions such as Systolic/Diastolic Heart Failure, Congenital Defects, Valve Disease, and Cardiomyopathy, with advanced procedures like LVAD/ECMO Support, Robotic Cardiac Surgery, TAVR, and Heart Transplants. This is India’s first programme integrating AI and IoT for real-time monitoring, personalised recovery plans, and predictive risk alerts. Dr. S. Vijayabaskaran, Executive Director, Kauvery Hospitals Bengaluru said “The launch of our Advanced Heart Failure Centre is a visionary step toward addressing India’s growing cardiac burden. By combining predictive analytics, IoT-enabled real-time monitoring, and multidisciplinary expertise, we empower patients to predict, prevent, delay, and even reverse heart failure. This initiative, spearheaded by our Lifestyle Diseases Department, reflects our commitment to futuristic, patient-centric care.” ]]> https://biospectrumindia.com/news/100/25675/iit-madras-centre-for-responsible-ai-teams-up-with-roche-diagnostics-for-rd.html https://biospectrumindia.com/news/100/25675/iit-madras-centre-for-responsible-ai-teams-up-with-roche-diagnostics-for-rd.html Fri, 14 Feb 2025 00:00:00 +0530 The Indian Institute of Technology Madras (IIT Madras) Centre for Responsible AI (CeRAI) is teaming up with Roche Diagnostics International Ltd, Switzerland, for collaboration in Research and Development (R&D). Roche is joining CeRAI as a Gold Consortium Member with a Memorandum of Understanding (MoU) signed between the two organisations.  CeRAI and Roche a global leader in in-vitro diagnostics and developer of digital health solutions, will engage in collaborative research activities in Analytics/ AI solutions as well as services for IVD diagnostics. Centre for Responsible AI (CeRAI) is a virtual interdisciplinary research centre at IIT Madras. The centre aims to pursue research in the domains of Ethical and Responsible AI and become the standard body in the country to recommend guidelines and policies to make deployable AI models/ systems more accountable, explainable and responsible. Speaking on ‘Responsible AI’, Prof. B Ravindran, Head, Centre for Responsible AI (CeRAI), IIT Madras, said, “Responsible development and deployment of AI systems requires close interaction between AI scientists and domain experts. Roche recognises this and has an active research program on ethical AI and data management. We look forward to working closely with their program in building more robust and ethical systems for AI in healthcare.” Manu Dev, Chapter Lead for IVD Analytics product domain, Roche Information Solutions said, “At Roche, we believe in the power of data. It helps healthcare providers and patients make informed decisions. The framework agreement with IIT Madras will enable us to collaborate on important research activities related to Analytics and AI in digital health solutions for in-vitro diagnostics. Sharing knowledge and expertise helps us get closer to a better healthcare system for all.” ]]> https://biospectrumindia.com/news/100/25674/neurasim-qwr-revolutionise-amblyopia-with-indias-first-ai-powered-immersive-vr-therapy.html https://biospectrumindia.com/news/100/25674/neurasim-qwr-revolutionise-amblyopia-with-indias-first-ai-powered-immersive-vr-therapy.html Thu, 13 Feb 2025 00:00:00 +0530 Bengaluru-based heath-tech startup NeuraSim Health, in collaboration with QWR - Fabless OEM XR Hardware manufacturer, is transforming the future of eye care with BeeVee, India’s first artificial intelligence (AI)-powered VR wearable for amblyopia treatment. Recently featured on Shark Tank India, this revolutionary digital therapeutic is clinically proven to deliver mild to severe recovery in just 1-3 months, offering a groundbreaking, non-invasive alternative to traditional vision therapy. After extensive market testing, BeeVee is now officially launching home therapy in the Indian market to make it accessible. Amblyopia, or lazy eye, is a rare eye condition which is estimated to jump 175.2 million by 2030 worldwide, making it the most common cause of childhood vision impairment. Traditional treatments like eye patching are slow, uncomfortable, and often ineffective due to poor compliance. BeeVee transforms this approach with AI-driven VR therapy, using adaptive exercises to retrain the brain and improve vision faster, more effectively, and with greater engagement. Recognising the need for greater accessibility and comfort for patients, the brand will also offer at-home therapy sessions across India. Looking ahead, NeuraSim and QWR are pushing the boundaries of medical XR, developing breakthrough solutions that extend far beyond amblyopia treatment. Their pipeline includes Neurametry, an AI-driven eye-tracking system for early detection of glaucoma and neuro-diseases; NeuraSport XR, a cutting-edge performance-enhancing tool for elite athletes that combines eye-tracking with cognitive training; and NeuroXR, an advanced EEG and XR-based platform for neurodegenerative screening and therapy, enabling early diagnosis and better patient outcomes. ]]> https://biospectrumindia.com/news/100/25669/lifesigns-secures-strategic-investment-from-healthcare-capital-to-advance-ai-capabilities.html https://biospectrumindia.com/news/100/25669/lifesigns-secures-strategic-investment-from-healthcare-capital-to-advance-ai-capabilities.html Wed, 12 Feb 2025 00:00:00 +0530 Gurugram-based startup Lifesigns, a pioneer in intelligent patient monitoring solutions, has secured funding from Healthcare Capital, the investment arm of the Kauvery Hospital Group. The investment will primarily advance Lifesigns’ artificial intelligence (AI) and predictive algorithm capabilities, further enhancing its proprietary patient monitoring platform. Lifesigns remains the only solution offering USFDA-approved hardware, software, dashboard, and AI integration, delivering proactive alerts and predictive insights across the patient journey—from ambulances to hospitals and home care.  While Lifesigns continues to focus on AI advancements, the company is also gearing up for its next funding round in the next couple of months, where it plans to unveil new tech product and market expansion initiatives. With this strategic investment, Lifesigns is set to accelerate innovation, solidify its position as a leader in health tech, and contribute to shaping the future of patient monitoring. Healthcare Capital, backed by over 25 years of expertise in the healthcare sector, brings deep industry knowledge and a commitment to enhancing patient care through cutting-edge technology. By investing in Lifesigns, Healthcare Capital reinforces its vision of integrating best-in-class innovations to improve patient outcomes and streamline healthcare workflows. ]]> https://biospectrumindia.com/news/100/25637/life-sciences-firms-explore-ai-to-optimise-revenue-operations-in-2025.html https://biospectrumindia.com/news/100/25637/life-sciences-firms-explore-ai-to-optimise-revenue-operations-in-2025.html Wed, 05 Feb 2025 19:00:00 +0530 Model N, the leader in revenue optimisation and compliance for life sciences and high-tech companies, has published its seventh annual State of Revenue Report, highlighting how executives in these industries are transforming their revenue operations. The report reveals that while 87% of industry leaders are shifting toward automated revenue management operations, nearly 60% still rely on multiple solutions. Additionally, 62% are using or planning to implement generative artificial intelligence (GenAI) for revenue optimization activities, including deal analytics, process automation, and forecasting. This gap between automation goals and system integration presents both a challenge and an opportunity. The research found that companies with more than 10,000 employees are 51% more likely than smaller organizations to use a unified revenue management solution.  Pharmaceutical companies are modernising their revenue management approach to navigate a complex regulatory landscape. Pricing strategy is pharmaceutical leaders’ highest priority for revenue management-related strategic investment over the next two years. Eighty-seven percent of leaders report that they have already adjusted their launch plans in response to the Inflation Reduction Act (IRA). State-level regulations like price transparency mandates and affordability boards are also a significant focus, with 76% of leaders concerned about how the regulatory changes may impact revenue management. Automation and technology, including GenAI, are key enablers, with 62% of pharmaceutical companies using or planning to use GenAI to strengthen revenue operations. The medtech sector is undergoing a similar transformation. Regulatory changes like healthcare price transparency (45%) and the European Union’s implementation of the Medical Device Regulation (MDR) (40%) top the list of impacts on revenue programmes. Nearly two-thirds of medtech companies are already seeing shifts as AI and automation are integrated into healthcare operations, and leaders are beginning to incorporate these approaches into their own company’s revenue optimization and compliance processes. Looking ahead, 38% of leaders are focusing on adapting to value-based care models, expecting further impacts on revenue optimization functions.   ]]> https://biospectrumindia.com/news/100/25626/datar-cancer-genetics-launches-ai-driven-platform-providing-optimised-treatment-options-for-cancer-patients.html https://biospectrumindia.com/news/100/25626/datar-cancer-genetics-launches-ai-driven-platform-providing-optimised-treatment-options-for-cancer-patients.html Tue, 04 Feb 2025 00:00:00 +0530 Nashik-based Datar Cancer Genetics (DCG) has launched Exacta AI, a next generation multi-analyte artificial intelligence (AI)-driven platform providing optimised treatment options for cancer patients who have exhausted the standard options. It integrates a 360° tumour work-up and AI assisted data analysis to decode complex tumour interactome data-including molecular (NGS: DNA+RNA), proteomic, genomic, functional, and clinical insights—providing personalised treatment options with thorough risk-benefit analysis. Exacta AI processes real-time wet lab data and integrates it with knowledge from multiple sources to assess drug synergy, interactions, toxicity, and contraindications for Anti-body Drug Conjugates (ADC)s, Checkpoint Inhibitors (CPIs), targeted therapies, endocrine agents, chemotherapy agents and repurposed drugs. It can recommend up to 10 evidence-based multi-drug treatment combinations for evaluation by oncologists or molecular tumour boards (MTBs), offering new hope where no standard of care exists for refractory / recurrent cancer patients. "What makes Exacta AI truly unique is its ability to think like an entire team of multi-disciplinary experts, all at once," explains Dr Vineet Datta, Senior Director – Global Strategy and Business Development, DCG. "The platform processes information the way a molecular biologist, cancer cell expert, pharmacologist, and clinical oncologist would do, only in minutes instead of several days. By applying rational scoring steps to analyze vast datasets, Exacta AI delivers highly refined interpretations, offering an unprecedented level of precision in generating treatment options." ]]> https://biospectrumindia.com/news/100/25618/centre-for-advanced-genomics-precision-medicine-opens-at-aiims-jammu.html https://biospectrumindia.com/news/100/25618/centre-for-advanced-genomics-precision-medicine-opens-at-aiims-jammu.html Mon, 03 Feb 2025 00:00:00 +0530 The Centre for Advanced Genomics & Precision Medicine recently opened at AIIMS Jammu, inaugurated by Dr Jitendra Singh, Union Minister of State (Independent Charge) for Science and Technology, Government of India. Set up in collaboration with Bengaluru-based startup 4baseCare, the Centre aims to usher in a new era of personalised medicine, leveraging cutting-edge genomic research to provide targeted treatment based on individual genetic profiles. By integrating genomic data with artificial intelligence (AI)-driven diagnostics, the centre aims to enhance early disease detection, optimise treatment strategies, and reduce the trial-and-error approach in medical prescriptions. This facility is intended to play a pivotal role in advancing precision oncology, cardiovascular genomics, and genetic screening for rare disorders. While personalised treatments have traditionally been costly, AIIMS Jammu aims to leverage indigenous research and government-backed biotech initiatives to bring down costs and integrate precision medicine into public healthcare programmes. The Minister highlighted initiatives like Ayushman Bharat, which has provided health coverage to millions, and the recently launched Bio-E3 policy, which focuses on biotechnology for economic growth, environmental sustainability, and employment generation. He stated that the government’s National Research Foundation (Anusandhan) will play a crucial role in funding next-generation research in genomics and personalised medicine. ]]> https://biospectrumindia.com/views/100/25595/remote-diagnostics-greatly-influence-accessibility-and-quality-of-healthcare.html https://biospectrumindia.com/views/100/25595/remote-diagnostics-greatly-influence-accessibility-and-quality-of-healthcare.html Sat, 01 Feb 2025 00:00:00 +0530 The diagnostics industry in India is growing rapidly, driven by growing healthcare awareness, an increasing prevalence of chronic diseases and lifestyle disorders, and advancements in technology. It encompasses pathology labs, imaging centres, and specialised diagnostic services - all of which contribute significantly to the healthcare sector. Key trends in this area include the adoption of digital diagnostics, AI-powered tools, point-of-care testing, and a surge in home-based diagnostic services and telemedicine. Despite regulatory hurdles and infrastructure gaps, the Indian diagnostics market is poised for substantial growth, improving accessibility and quality of healthcare across the country. Recent technology developments, particularly in remote diagnostics, have significantly altered the healthcare landscape. These allow medical professionals to reach patients in even the most remote areas using digital tools and telecommunication technologies to deliver diagnostic services. Remote diagnostics will have a significant impact on healthcare accessibility and quality, but there are certain issues that need to be addressed to ensure widespread adoption.   Impact of Remote Diagnostics on Healthcare Accessibility One of the most significant benefits of remote diagnostics is improving accessibility of healthcare services to the underserved and vulnerable populations such as elderly people, immobile, disabled individuals, and residents of less economically developed areas. In many rural and remote regions of India, people have limited access to healthcare and specialised doctors. Distant diagnostics bridges the gap by providing patients with timely diagnostic services, eliminating the need to travel long distances in emergent situations. For instance, telemedicine platforms, driven by strong internet connectivity, can enable patients to consult healthcare professionals on video calls. Real-time transmission of medical images to a trained pathologist or radiologist, and of the test results back to the patient and the doctor is made possible through remote diagnostic tools. This accelerates the diagnostic process and reduces the burden on healthcare facilities, enabling them to allocate resources more effectively.   Enhancing Quality of Care In addition to accessibility, remote diagnostics may facilitate quality-of-care provision to patients. Through their application of AI and machine learning (ML), remote diagnostic tools become more accurate and efficient in data interpretation, leading to faster and more precise diagnoses. This proactive approach not only improves patient outcomes but also reduces the chance of complications from delayed diagnoses. Additionally, remote diagnostics facilitate real-time monitoring of chronic care patients. The continuous supervision has led to timely interventions and well-tailored plans to manage the chronic condition of the patients, ultimately providing better health outcomes. Challenges to Widespread Adoption Despite the many promising benefits of remote diagnostics, several challenges must be addressed to ensure its adoption in the healthcare system: Regulatory Framework: Currently, there is no regulatory environment governing remote diagnostics. The absence of guidelines or an enabling framework keeps the benefits of remote diagnostic technologies away from  those  who need it the most.  The  current  guidelines  necessitate clear standards to ensure  safety,  and security of data, and the quality of services rendered to patients. Policymakers must  collaborate  with healthcare providers and technology companies to devise a holistic regulatory framework that balances fast-moving  tech with patient interests. Infrastructure and Connectivity: For remote diagnostics to be truly effective, a robust, well-designed technology infrastructure along with reliable internet connectivity, is crucial. To fully leverage digital healthcare solutions, significant expansion is necessary in underserved regions. Increased investment in telecommunications is essential to ensure access for everyone, regardless of their geographic location.  Data Security and Privacy: Data security and privacy concerns are  of paramount importance, as remote diagnostics include the sharing of confidential patient  information. Healthcare  providers must ensure that strong safeguards are in place to prevent  breaches or unauthorised access to patient data. Additionally, setting up a single  governing  body that regulates data security processes in the medical field would  significantly increase the patients' confidence in their healthcare providers. Training and Education: Healthcare workers must be properly trained in the use of digital tools and technologies for remote diagnostics to be successful. Programmes for ongoing education and training are crucial for giving healthcare professionals the know-how to successfully traverse the digital landscape and provide superior remote diagnostic services. Patient Awareness and Acceptance: Although there are many advantages to remote diagnostics, its effectiveness depends on patient acceptance and awareness. Education can be used to increase adoption, alleviate worries, and educate the patient on the benefits of remote diagnostics and the utilisation of such services.   Potential Solutions Telepathology: This allows pathologists to examine and even diagnose tissue samples remotely. This can significantly accelerate diagnoses in India, especially in resource-constrained areas. Initiatives like the National Digital Health Mission will be important enablers of data sharing and interoperability between healthcare facilities and help enable seamless telepathology services. AI-powered Imaging: AI algorithms can analyse medical images (X-rays, CT scans, MRIs) faster and better than humans resulting in quick and accurate medical diagnoses. This is crucial in areas with a shortage of radiologists. Therefore, using AI-based tools for remote diagnostics for image interpretation can significantly improve its quality and speed, particularly in underserved areas. Public-Private Partnerships: There is a strong need for collaboration between the government, private sector, and tech companies, if remote diagnostics is to be successfully implemented. Such partnerships can encourage infrastructure development, technology deployment, and training programmes for healthcare professionals. Focus on Patient-centred Care: The provision of remote diagnostics service should be driven by the patient’s needs. Availability of open communication channels, comprehensive patient education programmes, and effective ways of addressing patient concerns are essential for building trust in these technologies and ensuring their widespread adoption. By addressing these considerations and leveraging the power of technology, India can harness the potential of remote diagnostics to transform its healthcare landscape, improve access to quality care, and ultimately improve the health and well-being of its citizens.   Future Potential This unlocks immense future potential to improve the accessibility and quality of healthcare in a changing world of remote diagnostics. With such technologies cutting across geographies, patients shall have timely diagnostic services, ensuring healthy outcomes. However, for this to be possible, stakeholders must tackle the challenges facing widespread adoption. A supportive regulatory framework, and investments in infrastructure, data security, training, and patient education, will enable the environment to steer the growth of remote diagnostics. As we look to the future, embracing digital transformation in healthcare is essential to realising the goal of Universal Health Coverage and to making quality healthcare universally accessible regardless of location. The journey to a more inclusive and efficient health system has begun, and remote diagnostics will undoubtedly be one of its defining features.    Dhrubaa Ghosh, Partner, Healthcare, Management Consulting, BDO India   Disclaimer - The views, thoughts and opinions expressed in the article are solely the author’s and are not representative of the author's employer/ organisation. ]]> https://biospectrumindia.com/views/100/25596/how-ai-innovations-at-gccs-solidifying-indias-position-in-global-life-sciences-industry-.html https://biospectrumindia.com/views/100/25596/how-ai-innovations-at-gccs-solidifying-indias-position-in-global-life-sciences-industry-.html Fri, 31 Jan 2025 00:00:00 +0530 The Indian government has launched several initiatives to support the expansion of GCCs in the life sciences sector. Programmes like the "Make in India" initiative encourage foreign investment in pharmaceutical manufacturing and R&D. The National Health Policy aims to boost healthcare solutions, with a focus on local innovation, driving life sciences companies to establish R&D-focused GCCs. In AI, the $1.25 billion IndiaAI Mission strengthens the country’s AI ecosystem, helping GCCs adopt AI for faster drug development and efficient clinical trials. The Ayushman Bharat Digital Mission connects 500 million people to digital healthcare services, enhancing India’s healthcare system. Additionally, Special Economic Zones (SEZs) and Biotechnology Parks provide critical infrastructure and tax incentives, facilitating the growth of life sciences GCCs aligning with India’s broader vision to lead in pharmaceutical R&D innovation. State-Level Leadership: Karnataka and Telangana Among Indian states, Karnataka and Telangana stand out as key locations for the development of life sciences GCCs. Both states have created strong ecosystems that attract global investment and skilled professionals, enhancing the growth of the sector. Karnataka, particularly the city of Bengaluru, accounts for nearly 32 per cent of all life sciences GCCs in India. Karnataka’s GCC Policy 2024-29 is a cornerstone of its strategy to attract and expand GCCs. The policy offers a variety of incentives and provisions like targeted financial incentives such as rent coverage, tax breaks and reimbursements. The state's vision is to double the number of GCC from 500 to 1000 by 2029. Bengaluru has become a favoured destination for companies setting up GCCs due to its vast talent pool in AI, data analytics, and bioinformatics. The state government has also established Centers of Excellence for research and development, offering crucial support for startups and larger firms alike. Telangana, with Hyderabad as its epicentre, has made significant strides in establishing itself as a global hub for life sciences. Genome Valley, located in Hyderabad, is India's largest biotech and pharmaceutical cluster, home to over 200 companies involved in R&D. In 2024 alone, Telangana attracted more than $850 million in investment to bolster its life sciences capabilities. A major recent development in Telangana is the creation of the Life Sciences GCC Consortium, which has been in the spotlight. This consortium brings together the Hyderabad-based life sciences GCCs. Its primary aim is to boost collaboration, share knowledge, and address challenges in drug development and digital transformation. The consortium is expected to strengthen Telangana’s reputation as a leader in life sciences by facilitating partnerships between GCCs, academic institutions, and the government. Telangana is home to leading R&D centres like Novartis Biome, Hyderabad's first innovation hub, which focuses on integrating AI into pharmaceutical research. It collaborates with startups, researchers, and academic institutions to drive advancements in drug discovery and clinical trials. Similarly, Bristol Myers Squibb has invested $100 million to establish a GCC in Hyderabad, employing 1,500 professionals and utilising AI to accelerate drug discovery. Driving AI Adoption Artificial intelligence (AI) is playing a vital role in streamlining operations in life sciences GCCs, particularly in drug discovery, clinical trials, and supply chain management. With the average cost of bringing a new drug to market exceeding $2 billion and development timelines stretching to 10-12 years, AI is addressing these challenges by reducing costs and accelerating the process. AI-driven solutions can cut drug development costs by up to 70 per cent and shorten timelines by 40 per cent, making it indispensable for the future of pharmaceutical research. For instance, AI has made a significant impact on protein modelling, where tools like AlphaFold can model proteins in hours instead of months. This allows companies like GSK and Sanofi to speed up R&D by 30-40 per cent, enabling faster identification of drug targets. Indian GCCs are increasingly adopting these AI technologies to improve early-stage drug discovery and contribute to global pharma innovation. In the realm of clinical trials, AI-powered platforms optimise trial protocols, improve patient recruitment, and predict trial outcomes with greater accuracy. Pfizer, for example, has used AI to streamline clinical trial design, reducing costs and improving timelines. Indian GCCs play a critical role in these efforts, using AI-driven platforms to manage clinical trials more efficiently. AI is also helping GCCs with regulatory compliance, where automation has reduced the time required for submissions by 30 per cent while increasing accuracy. Indian GCCs have implemented AI tools that make the regulatory process faster and more reliable, keeping up with global standards. Implementing AI at scale requires overcoming challenges like data fragmentation and aligning strategies with parent organisations. GCCs are excelling by overcoming data fragmentation through structured management frameworks, leveraging India’s AI expertise, and aligning with global compliance standards. By utilising effective data aggregation, cleansing, and integration methods, these centres enable seamless AI deployment and innovation. Future Prospects and AI Integration The future of life sciences GCCs in India looks promising, particularly with the growing integration of AI technologies. At its peak, AI is expected to save the global pharmaceutical industry around $26 billion annually, revolutionising how drugs are developed, trials are conducted, and patient care is managed. As more pharmaceutical companies recognise India’s strengths, the number of GCCs is expected to increase, with these centres becoming key players in advancing AI-driven healthcare innovation. India’s deep talent pool, including 3.3 million software engineers and 446,000 AI/ML specialists, is a major asset that positions the country as a leader in AI-driven life sciences R&D. With scalable infrastructure, lower operating costs, and strong government backing through programmes like the IndiaAI Mission, India is poised to continue its rise as a global hub for life sciences. As regulatory frameworks evolve to support AI technologies, India’s position in the global life sciences industry is expected to strengthen further. Collaboration between government initiatives and private sector innovation will be crucial to maintaining this momentum. Life sciences GCCs will continue to lead in addressing global healthcare challenges, using AI to deliver faster, more effective solutions.   Dr Purav Gandhi, CEO and Founder, Healthark Insights ]]> https://biospectrumindia.com/news/100/25604/lytus-technologies-launches-subsidiary-lytus-healthtech-with-investment-plans-of-rs-250-cr.html https://biospectrumindia.com/news/100/25604/lytus-technologies-launches-subsidiary-lytus-healthtech-with-investment-plans-of-rs-250-cr.html Tue, 28 Jan 2025 00:00:00 +0530 Lytus Technologies, a leader in platform services and next-generation technology, has officially launched its fully owned subsidiary, Lytus HealthTech, as part of its mission to help transform the healthcare landscape in India. The newly formed entity is designed to address the growing challenges in the country’s healthcare system by integrating advanced technologies with personalised patient care solutions.   India’s healthcare system, projected to grow at a 22% CAGR, faces challenges in terms of accessibility, speed, and integration across the patient care journey. Lytus' healthtech platform will bring a personalised patient experience, where care is adapted to individual needs, alongside optimised clinical workflows that empower doctors and healthcare professionals to deliver faster, more efficient care. The platform’s AI-powered analytics and real-time data insights are designed to enable healthcare providers to make informed, data-driven decisions that may lead to better patient outcomes.   Speaking about the newly unveiled plans for the platform, Mr. Dharmesh Pandya, CEO of Lytus Technologies, stated, “The need for a unified, integrated healthcare system in India is more urgent than ever. Patients often suffer from long wait times and inefficient service delivery due to outdated healthcare infrastructure. India has long needed a comprehensive healthcare solution to address inefficiencies in service delivery, particularly in rural and underserved regions. We aim to close these gaps by launching a unified healthtech platform that connects patients, doctors, and healthcare institutions. We believe this will improve access to care, streamline workflows, and reduce wait times, directly saving lives and easing pressure on the country’s healthcare system. We believe that Lytus HealthTech will ensure that both patients and doctors have the tools they need for timely, accurate, and efficient medical care. Our goal is to help elevate the standard of healthcare in India, bringing it in line with global best practices.”   By providing personalised care pathways from diagnosis to treatment and recovery, the Lytus HealthTech Ecosystem is designed to make it easier for patients to receive timely care, reduce unnecessary delays, and improve overall healthcare outcomes.   The Ecosystem’s seamless platform is designed to provide doctors and healthcare providers benefits such as enhanced decision-making, reduction in manual errors, and speeding up clinical processes, to improve both the patient experience and operational efficiency. The platform is also designed to drive economic benefits by increasing productivity and reducing operational costs for healthcare providers, enabling them to serve more patients without sacrificing care quality. Scalable and adaptable, the system is designed to grow alongside India's expanding healthcare needs. Lytus is actively recruiting talent in healthcare technology, operations, and AI to support the successful rollout of the Lytus Healthcare Ecosystem within the next two years, setting a new benchmark in HealthTech innovation for India.   Sai Guna Ranjan Puranam, COO of Lytus HealthTech, also added, "We believe our healthtech platform is a game-changer for India’s healthcare professionals and patients alike. By integrating real-time data, our platform is designed to empower doctors with the insights they need to provide more precise and timely care, ultimately benefiting the patients who need it the most. We plan to roll out the ecosystem over the next two years, and we are expanding our teams to meet the anticipated demands of this ambitious project."   ]]> https://biospectrumindia.com/news/100/25599/royal-philips-launches-ai-enabled-ct-5300-at-asian-oceanian-congress-of-radiology-in-chennai.html https://biospectrumindia.com/news/100/25599/royal-philips-launches-ai-enabled-ct-5300-at-asian-oceanian-congress-of-radiology-in-chennai.html Mon, 27 Jan 2025 00:00:00 +0530 Royal Philips, a global leader in health technology, has launched the artificial intelligence (AI) enabled CT 5300 at the 23rd Asian Oceanian Congress of Radiology (AOCR) 2025. Philips CT 5300 system, equipped with advanced AI capabilities, is designed for diagnosis, interventional procedures and screening. The flexible X-ray CT system increases diagnostic confidence, streamlines workflow efficiency, and maximises system up-time, helping to improve patient outcomes and department productivity. With cutting-edge AI features like AI reconstruction, AI cardiac motion correction & AI smart workflows, CT 5300 is designed to enhance diagnostic accuracy coupled with high speed.  Philips also celebrated the installation of 1500+ Helium Free 1.5T wide Bore (70 cm) MRI systems worldwide. The revolutionary MRI with BlueSeal magnet technology is the industry's first wide bore 1.5T fully sealed magnet, which relieves healthcare providers from helium-related complications and unpredictability. BlueSeal magnet requires only 0.5% of helium compared to a conventional MRI system. Based on a decade of innovation, Philips BlueSeal is a fully sealed magnet designed to simplify MRI installations, reduce lengthy and costly disruptions in MRI services, and help healthcare departments transition to sustainable helium-free operations. This revolutionary magnet operates with only seven liters of liquid helium and is fully sealed – freeing up the minds of healthcare providers from potential helium complications. With BlueSeal magnet, Philips aims to help MRI facilities overcome potential helium-related issues of classic magnet design and eliminate the radiology department's dependency on scarce helium supply.    ]]> https://biospectrumindia.com/news/100/25585/iit-d-to-launch-transformative-co-innovation-centres-in-deep-tech-ai-and-robotics.html https://biospectrumindia.com/news/100/25585/iit-d-to-launch-transformative-co-innovation-centres-in-deep-tech-ai-and-robotics.html Sun, 26 Jan 2025 10:35:00 +0530 I-Hub Foundation for Cobotics (IHFC), Technology Innovation Hub of the Indian Institute of Technology Delhi (IIT-D) is embarking on a transformative journey by collaborating with ten prestigious institutes in India to establish Co-Innovation Centres (CiC). This ambitious initiative aims to nurture the spirit of innovation, technology, and entrepreneurship among the youth of India. On Januray 24, 2025, in Bengaluru, IHFC’s first CiC with PES University, Bengaluru, has been inaugurated. Among the other premier institutes ready for immediate launch of their CiCs are the Indian Institute of Engineering Science and Technology (IIEST) Shibpur, Kolkata; Thapar Institute, Patiala; SRM University of Science and Technology, Chennai; Indian Institute of Technology Gandhinagar; and many others, representing a wide geographic and academic reach. In the near future, CiC will be further opened in collaboration with the following institutes: Karunya Institute of Technology and Sciences (KITS), Coimbatore; Crescent Innovation Incubation Council (CIIC), Vandalur, Tamil Nadu; Nitte Meenakshi Institute of Technology (NMIT), Bengaluru; Delhi Technological University (DTU), Delhi; and Indraprastha Institute of Information Technology, Delhi. The vision driving this initiative is to foster innovation and technological growth among India’s young minds. These centres are being set up to groom and hone the skills of aspiring entrepreneurs and innovators. This will encourage them to think outside the box and create impactful solutions that address pressing market needs. Furthermore, they aim to promote research and development of indigenous deep-tech products.  ]]> https://biospectrumindia.com/news/100/25561/resolve360-announces-indias-first-ever-ai-ar-tech-for-online-active-physiotherapy.html https://biospectrumindia.com/news/100/25561/resolve360-announces-indias-first-ever-ai-ar-tech-for-online-active-physiotherapy.html Fri, 17 Jan 2025 00:00:00 +0530   India has only 0.6 physiotherapists per 10,000 people, compared to the WHO-recommended 1 per 10,000. In what's a significant step forward towards filling this gap, India’s first-ever Artificial Intelligence (AI) and Augmented Reality (AR) application for active physiotherapy is being developed and patented by Bengaluru-based startup Resolve360. The innovation uses deep motion algorithms to create a virtual physiotherapist, guiding patients through personalised, therapeutic active exercises. This approach contrasts with traditional passive physiotherapy, addressing underlying issues rather than just symptoms. Resolve360’s AI Virtual Therapist combines cutting-edge technology with its well-established expertise in treating the root cause of neuromuscular and musculoskeletal conditions. Unlike other AI systems prevalent in healthcare that rely on devices or infrared markers, Resolve360’s platform uses standard video cameras found on everyday electronic devices. Recently patented, the platform is currently in testing and scheduled for public release by Mid-February. It aims to tackle rising lifestyle disorders, including sedentary behaviour-related issues, by making expert-level active physiotherapy widely accessible.   ]]> https://biospectrumindia.com/news/100/25519/chandigarh-university-announces-establishment-of-ai-enabled-futuristic-campus-in-lucknow-.html https://biospectrumindia.com/news/100/25519/chandigarh-university-announces-establishment-of-ai-enabled-futuristic-campus-in-lucknow-.html Wed, 08 Jan 2025 00:00:00 +0530 Chandigarh University (CU) has announced the establishment of the first-of-its-kind Artificial Intelligence (AI) enabled next-gen futuristic campus at Unnao in Lucknow State Capital Region (SCR) of Uttar Pradesh, to provide AI-augmented multidisciplinary education tailored to the evolving needs of 21st-century learners. The AI-augmented Chandigarh University Uttar Pradesh Campus at India's first AI City in Lucknow SCR will revolutionise the country's educational landscape, with 43 AI-augmented futuristic undergraduate and postgraduate programmes. By embracing a multidisciplinary education model enriched by AI integration, these programmes will be offered across six streams, including Engineering, Business Administration, Health and Life Sciences, Humanities, Liberal Arts and Legal Studies from the 2025-26 academic year. The Uttar Pradesh government had earlier issued an 'Authorisation Letter' to Chandigarh University for its AI-integrated campus at Unnao in Lucknow SCR.  Uttar Pradesh Higher Education Minister Yogendra Upadhyay said, "Uttar Pradesh is on track to become a $1 trillion economy within the next five years as the state's GDP is projected to reach Rs 32 lakh crore by March 2025, positioning it as the fastest-growing economy in India and creating employment opportunities for 1.5 crore youth. In the past seven years, the state's economy, GDP, and per capita income have more than doubled due to the double engine government." ]]> https://biospectrumindia.com/news/100/25522/brainsightai-raises-5-m-in-pre-series-a-funding-round-to-expand-presence-in-india-.html https://biospectrumindia.com/news/100/25522/brainsightai-raises-5-m-in-pre-series-a-funding-round-to-expand-presence-in-india-.html Wed, 08 Jan 2025 00:00:00 +0530 BrainSight AI, a Bengaluru-based deep-tech neuroscience startup, has raised Pre-series A funding with $5 million led by IAN Alpha Fund, with participation from IvyCap Ventures, Silver Needle, apart from existing investors. The funding is a significant milestone in BrainSightAI’s mission to revolutionise the diagnosis and treatment of complex brain disorders through its innovative neuroinformatics platform, VoxelBox. Currently, BrainSightAI collaborates with over 40 leading hospitals across India, particularly in neurosurgery and radiology departments, focusing on brain tumour cases. The company is now expanding its solutions to neurological and psychiatric disorders, paving the way for a more holistic approach to brain care. The funds from this round will be strategically utilised to expand BrainSightAI’s presence in India, increasing its reach in Tier 1 cities and extend to Tier 2 cities. The company also plans to pursue FDA certification, opening access to the US and allied markets. Additionally, the company is gearing up to explore opportunities in Africa and Southeast Asia, based on distributor interest. The funds will also support R&D for a caregiver-focused app, aimed at empowering families of patients with brain disorders. BrainSightAI is at the forefront of understanding how the physiology of the brain correlates to its functions by mapping macro-scale neural connections in the brain, to enable precise diagnosis and prognosis of neuro-oncological and neuropsychiatric disorders. Traditionally available only at leading global research institutions like Harvard and Stanford, the platform makes this cutting-edge technology accessible to hospitals and patients worldwide. ]]> https://biospectrumindia.com/news/100/25505/aiims-delhi-to-invest-over-rs-300-cr-in-digital-infrastructure.html https://biospectrumindia.com/news/100/25505/aiims-delhi-to-invest-over-rs-300-cr-in-digital-infrastructure.html Tue, 31 Dec 2024 00:00:00 +0530 Artificial Intelligence (AI) is revolutionising everything from patient care to health communication and All India Institutes of Medical Sciences (AIIMS), Delhi, is investing over Rs 300 crore in digital infrastructure to ensure that every stakeholder, patients, doctors, and researchers benefits from this innovation, the premier institute's Director Dr M Srinivas said. "By integrating AI, we can improve efficiency, reduce delays, and enable world class research" he said at a recently held event at AIIMS. Dr Srinivas also emphasised that leveraging AI to simplify and disseminate health information will empower patients and improve their engagement with healthcare systems, ultimately leading to better health outcomes. At the event, leaders in healthcare, technology, and policy shared insights into how AI is poised to bridge critical gaps in health communication, making information more accessible, reliable, and patient-centric. Dr Kavita Narayan, Senior Technical Advisor, HRH for Health Systems at the Ministry of Health & Family Welfare said "AI can play a vital role in making healthcare more accurate, compassionate, and equitable. To truly make a difference, we must integrate technology thoughtfully and ensure collaboration between policymakers, technologists, and healthcare providers."  The insights shared by experts at AIIMS underscored the emerging and pivotal role of AI in transforming health communication. By addressing long-standing challenges in accessibility and trust, AI promises to empower patients with knowledge, enabling them to make informed decisions about their health. The discussions culminated in a collective call to action for responsible and ethical integration of AI in healthcare systems, urging policymakers, technologists, and healthcare providers to collaborate in leveraging AI for the greater good. As AI continues to evolve, experts agree that its thoughtful application has the potential to create a future where healthcare communication is more inclusive, reliable, and patient-centric. By bridging gaps in health awareness and patient education, AI is shaping a more informed and healthier society. ]]> https://biospectrumindia.com/news/100/25502/nura-plans-kerala-foray-to-launch-ai-driven-health-screening-centre-in-calicut.html https://biospectrumindia.com/news/100/25502/nura-plans-kerala-foray-to-launch-ai-driven-health-screening-centre-in-calicut.html Mon, 30 Dec 2024 00:00:00 +0530 NURA, an advanced diagnostic venture between Fujifilm Healthcare and Dr Kutty’s Healthcare, is all set to foray into Kerala by opening its artificial intelligence (AI)-driven Health Screening Facility in Calicut (Kozhikode). The facility was inaugurated by Kerala CM Pinarayi Vijayan in the presence of Teiichi Goto –President Fujifilm, V Abdurahiman, Ayisha Kutti. The debut in Kerala marks a significant milestone in NURA’s endeavour to provide early detection and comprehensive health screening services to the people of India. This Calicut centre is not just a screening facility, but it is a global training centre an experiential hub where people can experience the advantages of cutting-edge healthcare technologies, which NURA will be expanding globally. With this centre NURA aims its presence across the country and to strengthen its position as a global leader in the preventive healthcare market. The Calicut centre is designed to screen up to 50 people a day, offering world-class screening test experience with advanced technology, to facilitate faster and accurate detection of diseases at very early stages.  Currently, the centre offers Cancer and Metabolic syndrome screening but Locomotive syndrome screening and treatment plan for aging society will come up soon. In addition, NURA has an ambitious expansion plan, eyeing new centres in Chennai, Pune, Ahmedabad and other major Indian cities by the next year. By 2030, NURA envisions a network of 100 centers globally, making preventive healthcare accessible worldwide About NURA’s Kerala debut, Pinarayi Vijayan – Chief Minister – Kerala said “We welcome NURA’s entry into Kerala as the state has a dearth of advanced yet affordable screening facilities. The demand for such services is increasing exponentially in the state as the state-funded health agencies are deficient in serving a large pool of patients."    NURA has been on an ambitious expansion journey, establishing centres in India, East Asia and in ASEAN countries, the Middle East, and Africa in 2024. With the recent launch of the Calicut centre, joining other facilities in Gurugram, Mumbai, Bengaluru, and Hyderabad, NURA continues to deliver health screenings in just 120 minutes, leveraging Fujifilm’s leadership in healthcare IT and advanced screening test technology to ensure accurate, efficient, and hassle-free results. ]]> https://biospectrumindia.com/news/100/25461/aiims-signs-mou-with-wipro-ge-healthcare-to-establish-ai-health-innovations-hub-.html https://biospectrumindia.com/news/100/25461/aiims-signs-mou-with-wipro-ge-healthcare-to-establish-ai-health-innovations-hub-.html Sat, 14 Dec 2024 00:00:00 +0530 All India Institute of Medical Sciences (AIIMS), New Delhi, has signed a Memorandum of Understanding (MoU) with Wipro GE Healthcare, a leading global provider of healthcare technologies, to establish an AI Health Innovations Hub.  The new hub will focus on the development of products and solutions that enhance healthcare delivery and outcomes through more precise diagnosis, innovative treatment protocols, and real-time patient data tracking. As the technology partner, Wipro GE Healthcare will invest around $1 million over the next five years to co-develop, test, & deploy intelligent systems and workflow solutions in cardiology, oncology, and neurology. As clinical partner for the hub, AIIMS will provide multi-modal clinical inputs, and function as a real-world clinical environment for evaluation, feedback, and deployment of GE HealthCare’s AI-enabled solutions. A joint working committee from both organizations will oversee the collaboration, which will include clinical research and academic engagement. According to The National AI Portal of India (INDIAai), AI technology promises a transformative leap for India's healthcare system by 2025, potentially boosting the GDP by $25-30. Connecting longitudinal data (i.e. imaging, lab results, medical records, etc.) and layering it with analytics and AI can significantly enhance diagnosis, streamline operations, and improve patient care nationwide.      ]]> https://biospectrumindia.com/news/100/25463/sahyadri-hospitals-introduces-maharashtras-first-ai-powered-command-centre-in-partnership-with-dozee.html https://biospectrumindia.com/news/100/25463/sahyadri-hospitals-introduces-maharashtras-first-ai-powered-command-centre-in-partnership-with-dozee.html Sat, 14 Dec 2024 00:00:00 +0530 Sahyadri Group of Hospitals, a leading name in delivering cutting-edge healthcare, has announced the launch of its groundbreaking ‘AI-Powered Health Command Centre’ initiative in collaboration with Dozee, Bengaluru-based remote patient monitoring company. This transformative programme redefines patient safety standards, leveraging advanced artificial intelligence (AI) technology to deliver precision care, proactive interventions, and unparalleled clinical outcomes. It features an AI-powered patient monitoring system that continuously monitors patients' conditions and detects early signs of deterioration. Additionally, it identifies critical and severely critical cases, notifying emergency teams for immediate action, ensuring timely and life-saving interventions. Currently active in Sahyadri’s Hadapsar and Deccan units, the Command Centre will be expanded across all Sahyadri hospitals in the next six months, ensuring seamless adoption of this transformative technology chain wide. The initiative equips non-ICU ward beds with Dozee’s state-of-the-art Remote Monitoring System (RMS) and Early Warning System (EWS), enabling continuous, real-time monitoring of vital parameters such as heart rate, respiration rate, blood pressure, SPO2 levels, temperature, and ECG. Dozee’s Early Warning System (EWS) tracks the trends of vital parameters and provides alerts to healthcare providers for early detection of patients' clinical deterioration, enabling timely medical intervention. Dozee uses AI-based Ballistocardiography (BCG) for contactless vitals monitoring. Dozee’s technology is patented and made in India. ]]> https://biospectrumindia.com/news/100/25440/usibc-signs-mou-with-government-of-telangana-hosts-ai-and-gcc-industry-roundtable.html https://biospectrumindia.com/news/100/25440/usibc-signs-mou-with-government-of-telangana-hosts-ai-and-gcc-industry-roundtable.html Wed, 11 Dec 2024 00:00:00 +0530 The US Chamber of Commerce’ s US India Business Council Global Private Limited (USIBC GPL) and the Department of Information Technology, Electronics & Communications (IT E&C), Government of Telangana, have signed a Memorandum of Understanding (MoU) to bolster US-India collaboration and partnership in technological innovation. The MoU was signed in the presence of Chief Guest, Minister for Information Technology (IT), Electronics & Communications (E&C), Industries & Commerce (I&C), and Legislative Affairs, D Sridhar Babu and Special Chief Secretary to the Government of Telangana for IT E&C and I&C; Jayesh Ranjan, Guest of Honour, Jennifer Larson, US Consul General Hyderabad, and USIBC Managing Director Rahul Sharma. The MoU outlines cooperation in key focus sectors including IT, Artificial Intelligence (AI), electronics and Global Capability Centers (GCCs). The signing was followed by an industry roundtable on AI and GCCs, reinforcing Hyderabad and Telangana’s role as a global technology hub. The discussion highlighted Hyderabad’s thriving ecosystem of skilled professionals and its pivotal role in US-India collaborations. The participants explored AI-driven opportunities across sectors as well as the ways to optimally harness AI technological innovation for global good while at the same time prevent misuse via regulation, governance, ethical use, in a manner that does not stifle innovation. ]]> https://biospectrumindia.com/news/100/25428/iiit-delhi-unveils-ai-platform-for-discovering-molecules-that-promote-healthy-ageing.html https://biospectrumindia.com/news/100/25428/iiit-delhi-unveils-ai-platform-for-discovering-molecules-that-promote-healthy-ageing.html Wed, 04 Dec 2024 00:00:00 +0530 A team of researchers from Indraprastha Institute of Information Technology Delhi (IIIT-Delhi) has developed AgeXtend, a groundbreaking artificial intelligence (AI)-based platform that is set to transform the search for molecules promoting healthy ageing. Published in the journal Nature Aging, this research represents a significant step forward in understanding and addressing the biological mechanisms of aging. AgeXtend is a multimodal geroprotector prediction platform that leverages bioactivity data from known geroprotectors to identify new molecules with the potential to slow aging. The platform encompasses advanced AI modules capable of predicting geroprotective potential, evaluating toxicity, and identifying target proteins and mechanisms of action. This comprehensive approach ensures both accuracy and safety in the discovery process. The research demonstrated AgeXtend's remarkable ability to identify the longevity-enhancing effects of well-known compounds such as metformin and taurine, even when these molecules were excluded from the training data. AgeXtend further screened approximately 1.1 billion compounds, uncovering numerous promising candidates that were validated through rigorous experiments on yeast, Caenorhabditis elegans, and human cell models.   The study also explored natural metabolites from the human microbiome and their role in regulating cellular senescence. This underscores AgeXtend’s versatility and potential to uncover previously unknown mechanisms driving ageing. “AgeXtend bridges the gap between artificial intelligence and biology, enabling us to not only predict potential anti-aging molecules but also understand how they work,” said Dr Gaurav Ahuja, senior researcher and co-author of the study. “This platform has immense potential to unlock new pathways for therapeutic interventions in aging and age-related diseases.” ]]> https://biospectrumindia.com/news/100/25430/hcg-and-accenture-collaborate-on-cancer-research-and-care-using-advanced-ai.html https://biospectrumindia.com/news/100/25430/hcg-and-accenture-collaborate-on-cancer-research-and-care-using-advanced-ai.html Wed, 04 Dec 2024 00:00:00 +0530 Bengaluru-based HealthCare Global Enterprises Limited (HCG), one of the largest cancer care networks in India, is collaborating with Accenture to accelerate cancer research and care through the use of advanced artificial intelligence (AI), including generative AI and deep learning on multi-dimensional and multi-omic patient data.  This strategic teaming combines Accenture’s global expertise and talent in data and AI including AI/ML, generative AI, and quantum computing with deep clinical insights from HCG in oncology to enable early detection and treatment for various types of cancer. As part of the joint effort, Accenture will use advanced technologies including image analysis software, informatics, and novel algorithms to analyse data from cancer patients and study molecular alterations that can have a broader impact on patient care. The programme, the first of its kind in South Asia, will leverage Accenture’s generative AI studios to spur innovative research for the discovery and development of new drug targets, mechanisms and pathways, and biomarkers associated with different forms of cancer. Additionally, the initiative aims to enhance the understanding of various cancers, including their development, symptoms, and origins, to enable new treatment algorithms for precision medicine and advance the quality of therapy and care. It will showcase data-driven clinical practice and enhance the overall efficiency of patient care by applying AI, generative AI, cloud, machine learning, and quantum computing, among others. The collaboration is currently focused on identifying molecular signatures for the prognosis and response to therapy for lung adenocarcinoma, and head and neck cancers, which will then be extended to other cancer types.   ]]> https://biospectrumindia.com/news/100/25416/mahajan-imaging-and-labs-launches-ai-powered-lab-in-gurugram.html https://biospectrumindia.com/news/100/25416/mahajan-imaging-and-labs-launches-ai-powered-lab-in-gurugram.html Fri, 29 Nov 2024 00:00:00 +0530 Mahajan Imaging & Labs has announced its expansion into Gurugram with a new, fully-equipped lab and Home Collection services. This facility will bring enhanced multi-testing capabilities powered by artificial intelligence (AI) to the Gurugram region and beyond, ensuring greater accessibility and faster turnaround times for patients. The new lab is capable of processing thousand tests and offers cutting-edge diagnostic services with advanced systems designed for seamless, AI-driven analysis. This expansion reaffirms Mahajan Imaging & Labs’ commitment to providing high-quality healthcare, addressing community needs, and supporting healthcare providers across the region. Mahajan Imaging & Labs' Siemens' AI-Enhanced Multi-Testing Diagnostic System delivers faster, highly accurate results from a single vial, analyzing up to 206 parameters. Ideal for low-volume samples, especially in paediatric and complex cases, it reduces wait times drastically. Capable of performing complex diagnostics like preeclampsia screening with high precision, this system sets a new benchmark for patient comfort and rapid diagnostics in urgent care. The lab located on the ground floor of the Times Sqaure Building in downtown Sushant Lok , also boasts of highly qualified and trained phlebotomists who are able to cover all areas of Gurugram. This patient-centric approach allows individuals to book sample collections from the comfort of their homes, ensuring a seamless, hassle-free experience while maintaining the highest standards of accuracy and hygiene. The lab provides all services under one roof and is also fully equipped to cater to individuals who wish to come to the lab and get tests done.   ]]> https://biospectrumindia.com/news/100/25376/samsung-rd-institute-noida-and-iit-bombay-sign-mou-to-pioneer-research-in-digital-health-ai.html https://biospectrumindia.com/news/100/25376/samsung-rd-institute-noida-and-iit-bombay-sign-mou-to-pioneer-research-in-digital-health-ai.html Thu, 21 Nov 2024 00:00:00 +0530 Samsung R&D Institute, Noida (SRI-Noida), has strengthened its commitment to industry-academia collaboration by signing a Memorandum of Understanding (MoU) with the Indian Institute of Technology Bombay (IIT Bombay). Under this MoU, SRI-Noida and IIT Bombay will explore breakthroughs in artificial intelligence (AI), digital health, and other critical areas. The five-year partnership will facilitate joint research projects, providing IIT Bombay students and faculty an opportunity to collaborate with Samsung engineers. This approach will not only open newer avenues for the students, but will enhance their industry readiness. In addition, it will equip Samsung engineers with specialized training and certification programmes from IIT Bombay in emerging technologies such as digital health and AI. The MoU was formally signed by Kyungyun Roo, Managing Director of SRI-Noida, and Prof. Upendra V. Bhandarkar, Associate Dean of Research and Development at IIT Bombay. The event, which took place at IIT Bombay, was attended by faculty members from the Koita Centre for Digital Health (KCDH), including Prof. Ranjith Padinhateeri, Head of KCDH, Prof. Nirmal Punjabi and Dr Raghavendran Lakshminarayanan.  The MoU encourages the publication of joint research papers, promoting knowledge sharing that will drive technological progress and industry-aligned innovation. Through this partnership, Samsung and IIT Bombay are setting the foundation for a sustained exchange of expertise that will push the boundaries of next-generation technologies and inspire future breakthroughs. ]]> https://biospectrumindia.com/news/100/25351/ai-based-training-and-upskilling-in-demand-for-diabetes-care-survey.html https://biospectrumindia.com/news/100/25351/ai-based-training-and-upskilling-in-demand-for-diabetes-care-survey.html Thu, 14 Nov 2024 00:00:00 +0530 Medvarsity, Asia’s largest healthcare EdTech company, has released findings from its comprehensive survey of over 3,000 diabetologists and endocrinologists across India. Released on World Diabetes Day- i.e. 14 November, the survey highlights the priorities, barriers, and future perspectives of healthcare providers committed to advancing diabetes care through continuous learning and innovative technologies like artificial intelligence (AI). The research shows healthcare professionals are deeply committed to improving their skills, with 90% saying ongoing training is vital. When it comes to learning, doctors prefer to learn from each other. Clinical case discussions and peer reviews were chosen by 75% of participants as their preferred method for professional development, highlighting the value of collaborative, real-world applications. Prevention and management of diabetes complications is the top priority for doctors looking to enhance their expertise, with 82% wanting to learn more in this area. Close behind is advanced insulin management, with 78% of doctors keen to sharpen their skills in this specialist field. The survey found that while doctors are eager to learn, they face real challenges. Time constraints emerged as the most common barrier, affecting 65% of respondents, followed by cost of programs (60%) and difficulty balancing personal and professional life (58%). Despite these hurdles, there's a strong appetite for AI training, with 78% of doctors wanting to learn how to use automated insulin dose calculators, along with high interest in continuous glucose monitoring (CGM) analysis systems and diabetic retinopathy screening tools. The survey revealed that healthcare professionals are increasingly looking to AI to enhance diabetes management. Early detection and diagnosis of diabetes complications (88%) and personalised treatment plans (85%) were the most anticipated AI applications, while 80% of doctors see automated blood sugar monitoring as key, pointing to the importance of continuous monitoring in diabetes care. ]]> https://biospectrumindia.com/news/100/25343/venture-center-hosts-workshop-to-explore-transformative-opportunities-in-ai-healthcare.html https://biospectrumindia.com/news/100/25343/venture-center-hosts-workshop-to-explore-transformative-opportunities-in-ai-healthcare.html Tue, 12 Nov 2024 00:00:00 +0530 Venture Center, Pune hosted a successful ‘AI in Healthcare’ Workshop on 11 November, bringing together industry experts, healthcare innovators, and investors to explore AI’s vast potential to revolutionise healthcare. Supported by BFI-BIOME, the event delved into the opportunities, challenges, and diverse applications of AI across drug discovery, diagnostics, patient care, and public health, providing practical insights and valuable networking for startups and innovators focused on AI-driven healthcare technology. The workshop opened with a perspective talk by Dr Anand Deshpande, Founder and Chairman of Persistent Systems, who highlighted the massive $208 billion potential AI holds in healthcare by 2030. He emphasised the need for AI-driven solutions that could shift healthcare from reactive spending to preventive care, urging careful investment in AI infrastructure, hardware, and skilled talent to unlock its full potential. Exploring AI’s Role in Healthcare – Opportunities and Challenges The panel discussion that followed examined AI’s role in improving drug discovery, refining clinical trials for better outcomes, and enhancing both patient and provider experiences. Panelists discussed the importance of integrating AI seamlessly into healthcare workflows to maximise its impact, while noting the strides already made with non-invasive diagnostics and enhanced imaging accuracy. They also addressed ethical considerations and regulatory frameworks needed to balance AI’s advancements with patient privacy and accessibility. The panel featured Santosh Dixit, Nandini Sahasrabuddhe, Gaurav Tripathi, Ashutosh Pathak, Pankaj Doshi, and Kedar Medhi. Startup Mixer Spotlights Emerging AI-Driven Solutions One of the workshop’s highlights was the Startup Mixer, where ten early-stage startups presented lightning pitches demonstrating AI’s versatility in healthcare - From public health delivery and digital health solutions to diagnostics and traditional medicine. CareNx and Adiuvo Diagnostics took top honours, with support for the awards generously provided by Indus Biotech. Investor Perspectives on AI in Healthcare In the final session, a panel of investors shared perspectives on evaluating and supporting AI-driven healthcare startups. Emphasising a cautious yet optimistic approach, investors noted the importance of identifying genuine use cases where AI can effectively address real-world problems. The discussion touched on essential criteria like data sustainability, development of evaluation frameworks for assessing AI companies., and clarity in regulations leading to bigger AI-focused investments in healthcare. Panelists include Maneesh Bhandari, Madhukar Bhatia, Kiran Deshpande, Sanjay Kanvinde, Tanvi Ghate, and Amey Mashelkar. “This is an evolving space with exciting possibilities, and we’re thrilled to have facilitated this forum for knowledge-sharing and insights,” said Dr Premnath, Director - Venture Center. ]]> https://biospectrumindia.com/news/100/25340/zeiss-india-expands-global-capability-center-in-bengaluru.html https://biospectrumindia.com/news/100/25340/zeiss-india-expands-global-capability-center-in-bengaluru.html Mon, 11 Nov 2024 00:00:00 +0530 ZEISS, a globally leading player in optics and optoelectronics, has inaugurated its Global Capability Center (GCC) in India, marking a pivotal expansion to further bolster digital transformation, research and innovation efforts in India. Located in Bengaluru, the facility was inaugurated by Priyank Kharge, Minister of Electronics, IT & BT (Information Technology and Biotechnology), Rural Development and Panchayat Raj, Karnataka. ZEISS India Global Capability Center is a strategic hub that will tap into Bengaluru’s deep IT talent pool to drive technology solutions and further expand ZEISS’s global R&D capabilities. The premise spans across 43,000 sq.ft. and will accommodates 600+ employees with deep domain expertise in the field of application research for Medical Technologies, Vision care, Cyber Security, Artificial Intelligence (AI), Cloud Excellence and Digital Transformation. The company aims to double this current workforce by 2028. Priyank Kharge said, “India now hosts over 4,000 Global Capability Centers (GCCs), with Karnataka alone accounting for 38% of these. The state has the potential to drive growth across diverse sectors, including agritech, aerospace, and technology." ZEISS India has also collaborated with the Karnataka Government to enhance the region’s Research and Development (R&D) ecosystem for emerging technologies. This joint R&D initiative will support Karnataka’s vibrant startup ecosystem by establishing a collaborative centre where ZEISS will contribute with its infrastructure and expertise while startups bring along the agility and disruptive innovation. The collaboration shall seek to accelerate the commercialisation of cutting-edge products, such as AI-driven diagnostics and smart optical devices, aiming for a significant percentage of these developments to reach the market within 3 years. In addition to the Joint Research and Development (R&D) Program, ZEISS India has also announced the collaboration with the Karnataka Government to make quality vision-care more accessible across Karnataka's rural and underserved regions. Through the Aloka Vision Program by ZEISS, this partnership will aim to provide affordable eye-care services to 100,000 individuals over the next 3 years. ]]> https://biospectrumindia.com/news/100/25330/infinx-healthcare-establishes-center-of-excellence-in-madurai-to-drive-ai-based-innovation.html https://biospectrumindia.com/news/100/25330/infinx-healthcare-establishes-center-of-excellence-in-madurai-to-drive-ai-based-innovation.html Fri, 08 Nov 2024 00:00:00 +0530 Infinx, a trusted provider of artificial intelligence (AI)-powered solutions for patient access and revenue cycle management (RCM), has announced the opening of its newest delivery centre in Madurai, Tamil Nadu. This state-of-the-art facility will support the company’s mission of optimising revenue cycle processes for US-based healthcare providers, helping them focus on patient care while ensuring financial sustainability. This strategic investment in Madurai aligns with Infinx’s global expansion goals and marks the company’s eighth centre in India, complementing existing operations in Mumbai, Bengaluru, and Hyderabad. The centre will leverage advanced AI and automation technologies to streamline revenue cycle operations for its customers, further solidifying Infinx’s position as an industry leader. Infinx is one of the first ITES organisations to setup a centre of this kind in Madurai. The new centre will create around 700 job opportunities over the next five years, providing high-quality employment in healthcare RCM to local talent. Infinx has partnered with esteemed educational institutions to recruit and train graduates. The joiners will receive role-specific training that covers technical skills, processes, and methodologies required for healthcare revenue cycle management (RCM). It has devised various competency-based learning & development programs such as the ACE (Associate Competency Excellence) initiative and GROW (Get Ready For Opportunities for Work). These have been designed and aimed at creating future leaders from within the company. In addition to classroom sessions, employees can access self-paced e-learning courses on our digital platform, covering a range of technical and soft skills. ]]> https://biospectrumindia.com/news/100/25321/healthplix-announces-integration-with-google-to-simplify-healthcare-access-.html https://biospectrumindia.com/news/100/25321/healthplix-announces-integration-with-google-to-simplify-healthcare-access-.html Wed, 06 Nov 2024 00:00:00 +0530 HealthPlix Technologies, an artificial intelligence (AI)-powered Electronic Medical Records (EMR) software provider for doctors, has launched an integration with Google to simplify healthcare access. This integration will enable patients to book appointments directly with doctors using HealthPlix’s software, affiliated with clinics with a Google business profile. The integration marks a significant step in enhancing patient convenience, streamlining clinic operations, and enabling a frictionless experience for both doctors and patients. By allowing patients to schedule their appointments directly through Google platforms, HealthPlix is transforming clinician accessibility and making access to healthcare more efficient.   With over 14,000 doctors currently using HealthPlix EMR across India, this integration ensures that all appointments booked via Google are unified into the clinic’s existing HealthPlix EMR system, simplifying appointment flow management.   With over 560 million internet users in India, the demand for digital healthcare solutions is growing rapidly. This collaboration between HealthPlix and Google aims to address that need by providing a quicker, more user-friendly way for patients to access healthcare services. It also enables clinics to focus more deeply on other critical areas of patient care.   Chaitanya Raju, Executive Director and Chief Product Officer of HealthPlix Technologies, commented on the partnership, "Our partnership with Google is a game-changer for healthcare access in India. By leveraging Google’s wide-reaching platform, we are enabling clinics to connect with their patients more efficiently. The seamless integration with our EMR system ensures that clinics experience no disruptions while improving their operational flow. This initiative further positions HealthPlix as a leader in healthcare innovation." ]]> https://biospectrumindia.com/news/100/25267/govt-to-establish-5-centres-of-excellence-in-virtual-reality-and-mixed-reality-at-national-skill-training-institutes.html https://biospectrumindia.com/news/100/25267/govt-to-establish-5-centres-of-excellence-in-virtual-reality-and-mixed-reality-at-national-skill-training-institutes.html Tue, 15 Oct 2024 00:00:00 +0530 The Ministry of Skill Development & Entrepreneurship (MSDE), government of India, has announced its partnership with Meta for the launch of two key initiatives: an artificial intelligence (AI) Assistant for the Skill India Mission and establishing 5 Centres of Excellence (CoEs) in Virtual Reality (VR) and Mixed Reality (MR) at National Skill Training Institutes (NSTIs) located at Hyderabad, Bengaluru, Jodhpur, Chennai and Kanpur. Under this partnership, an innovative AI-chatbot powered by Meta’s open-source Llama model will be developed, which will enhance the learner experience on the Skill India Digital (SID) Portal. Sarvam AI, the technical partner for the AI assistant project, will be responsible for the development and deployment of the chatbot, which will be piloted over a six-month period.   Further, the 5 CoEs at NSTIs will equip learners and instructors with the latest VR technology to learn and enhance existing skills in a safe, immersive and engaging environment. The partnership on AI assistant aims to streamline information access, improve learning outcomes and provide students with seamless support through an intuitive digital interface. The 5 CoEs will also provide realistic simulations, improve engagement and increase accessibility to skill development training. With the launch of the AI chatbot, MSDE and Meta are taking a significant step forward in revolutionizing how students interact with course content and prepare for the future. Further, Skillveri, the technical partner for establishing the CoEs, will provide cutting-edge VR and MR resources, curriculum, and trained professionals to equip learners and instructors with the latest technology, enabling immersive and interactive learning experiences. ]]> https://biospectrumindia.com/news/100/25244/dozee-unveils-ai-powered-remote-parent-health-monitoring-service.html https://biospectrumindia.com/news/100/25244/dozee-unveils-ai-powered-remote-parent-health-monitoring-service.html Wed, 09 Oct 2024 00:00:00 +0530 Bengaluru-based Dozee has unveiled Dozee Shravan, a clinical-grade artificial intelligence (AI)-powered Remote Parent Monitoring (RPM) service. Monitoring a parent’s health while living overseas is a significant concern for the Indian diaspora. Dozee Shravan now enables families abroad to regularly track their parents' health in India. Dozee’s AI-powered, contactless remote health monitoring technology is designed for seamless use by the elderly. The health data is securely shared with both families and healthcare providers. Dozee’s continuous health monitoring and real-time alerts help detect subtle deviations in vital parameters, ensuring timely medical intervention.  Dozee’s Shravan offers continuous, contactless monitoring of vital signs such as heart rate, respiration, blood pressure, and sleep patterns. Built on AI-powered Ballistocardiography, the system uses advanced AI algorithms to analyse biomarkers and provide timely alerts for any deviations, reducing the risk of health emergencies and enabling timely medical intervention. The technology is US FDA-cleared and adheres to international standards for data privacy. Health data can be accessed via a user-friendly mobile app, ensuring that NRIs stay connected to their parents’ health 24/7, regardless of distance. ]]> https://biospectrumindia.com/news/100/25197/healthcare-ai-innovator-qure-ai-completes-65-m-series-d-funding-round.html https://biospectrumindia.com/news/100/25197/healthcare-ai-innovator-qure-ai-completes-65-m-series-d-funding-round.html Thu, 26 Sep 2024 00:00:00 +0530 Mumbai-based startup Qure.ai, a global healthcare artificial intelligence (AI) innovator, has announced the completion of a $65 million Series D funding round. The investment will expedite expansion into the US market and other geographies, increase investment into foundational AI models and enable complementary med-tech company acquisitions. The Series D round saw the participation of new strategic and financial investors led by Lightspeed and 360 ONE Asset, joined by Merck Global Health Innovation Fund and Kae Capital. Existing investors also participated in the round, including Novo Holdings, Health Quad, and TeamFund. Founded in 2016, Qure.ai is on a mission to make healthcare more accessible and equitable globally. This has driven its AI solution development, positioning the company as the world’s most deployed healthcare AI. Qure.ai solutions are deployed in over 90 countries across 3000+ sites, powering the efficient identification and management of critical diseases. The company has 18 FDA-cleared indications, and its products are Class IIb certified per EU MDR regulations. Qure.ai is headquartered in Mumbai, with regional offices in New York, London, and Dubai. Prashant Warier, Co-founder and CEO of Qure.ai. “AI helps to overcome healthcare bottlenecks, from imaging reporting backlogs and low screening uptakes to workforce resource constraints, not just in western societies like the US and Europe, but in developing nations too. We also collaborate with half of the top 20 Pharma and MedTech companies including AstraZeneca, Medtronic, and J&J, to accelerate early diagnosis and timely treatment of diseases." ]]> https://biospectrumindia.com/news/100/25203/medibuddy-partners-with-philips-to-bring-advanced-heart-health-tracking-in-india.html https://biospectrumindia.com/news/100/25203/medibuddy-partners-with-philips-to-bring-advanced-heart-health-tracking-in-india.html Thu, 26 Sep 2024 00:00:00 +0530 Bengaluru-based digital healthcare platform MediBuddy has joined hands with global health technology leader Philips to redefine preventive healthcare in India. On the occasion of World Heart Day (celebrated on 29 September), this pioneering partnership will bring early warning signs detection for the heart through the Philips HeartPrint to millions of smartphones across the country, potentially saving countless lives. By integrating advanced artificial intelligence (AI) based longitudinal triaging on the users' smartphone, MediBuddy reaffirms its commitment to making high-quality healthcare accessible to all Indians. World Heart Day highlights the urgent need for proactive heart health management and this partnership addresses a critical need in India's healthcare landscape. While traditional tests like ECGs assess the current state of the heart, the Philips HeartPrint offers a regular tracking tool that can indicate future risks and track how heart health progresses over time. This proactive approach to heart health management has the potential to transform cardiac care in India by enabling early intervention and personalised health strategies. By simply scanning their finger using their smartphone's camera through the MediBuddy mobile application, users can track key biomarkers that indicate their risk of heart disease, overall health deterioration, heart resilience, and changes in heart function over time. This technology analyses patterns to indicate critical factors such as the probability of heart disease, overall health deterioration, heart resilience, and both short-term and long-term changes in cardiac function. By tracking these crucial parameters, users can take proactive steps to address potential heart conditions before they develop into chronic issues.   ]]> https://biospectrumindia.com/news/100/25154/iiit-hyderabad-offers-ai-based-online-courses-for-medical-professionals.html https://biospectrumindia.com/news/100/25154/iiit-hyderabad-offers-ai-based-online-courses-for-medical-professionals.html Tue, 17 Sep 2024 00:00:00 +0530 International Institute of Information Technology Hyderabad (IIIT-H) has launched an online course on 'AI for Medical Professionals', in collaboration with National Academy of Medical Sciences (NAMS), an autonomous organisation under the Ministry of Health & Family Welfare, Government of India, and IHub-Data. The 12-week online orientation course on artificial intelligence (AI) will equip medical professionals with the requisite skills needed to understand, evaluate, and apply AI technologies in clinical settings, improving patient care and operational efficiency. It covers both theory and tutorials covering the basics of AI, machine learning, deep learning, and case studies on clinical applications involving screening, diagnosis, prognosis, and patient management. Participants will also explore ethical and governance issues in the use of AI tools and techniques. Delivered through video lectures, weekly contact sessions, and case studies, the course includes quizzes, assignments, and assessments, leading to certification upon completion. Around 200 medical professionals, which include senior faculty/research members from premier medical institutions, with postgraduate degrees across 41 specialities spread over 24 states and 56 cities across the country, are participating in the programme. Eminent faculty mentors from IIIT-H and NAMS are involved in delivering this course. Prof. Abhay Karandikar, Secretary of DST; Dr Shiv Kumar Sarin, President of NAMS; and Prof. P J Narayanan, Director of IIIT Hyderabad launched this first-of-its-kind course virtually.   ]]> https://biospectrumindia.com/news/100/25144/policymakers-should-address-roadblocks-to-augment-ai-integration-into-healthcare-system-isb-study.html https://biospectrumindia.com/news/100/25144/policymakers-should-address-roadblocks-to-augment-ai-integration-into-healthcare-system-isb-study.html Fri, 13 Sep 2024 00:00:00 +0530 A new study by the Indian School of Business (ISB) highlights the potential to leverage Artificial Intelligence (AI) to revolutionise the Indian healthcare ecosystem while underscoring the need to address the policy gaps hindering the widespread adoption of AI. A new study titled ‘Understanding the Canvas of Artificial Intelligence (AI) in Healthcare in India’ conducted by the ISB Institute of Data Science (IIDS) and the ISB-Centre for Business Markets (ISB-CBM), highlighted that AI has the potential to transform healthcare delivery and can support improvements in clinical outcomes, patient experience, and access to quality healthcare. The study by ISB underscores the urgent need for a policy review to address the gaps in bridging the AI adoption gaps in Indian healthcare. The report recommends several policy interventions for accurate AI adoption in Indian healthcare ecosystems. These include incentivising and standardising electronic health records (EHR) adoption across healthcare providers to create a unified and robust health data infrastructure. Further, investing in the AI workforce through upskilling, and facilitating public-private partnerships to foster innovation and accelerate the development of India-centric AI solutions, is needed. Establishing clear regulatory frameworks regarding data privacy, accountability, and ethical considerations for AI usage in healthcare should all be taken into consideration. Based on in-depth interviews with leading hospitals and a comprehensive analysis of the AI Startup ecosystem, the study found emerging AI applications in healthcare such as disease detection, process optimisation, patient-facing applications powered by chatbots, and treatment interventions by assisting in personalised treatment. Presently, around 4,000 companies in India are dedicated to developing AI solutions for healthcare. Additionally, there are government initiatives to support this transition, with the Ayushman Bharat Scheme and National Digital Health Infrastructure, among others.  However, despite the promising practices and initiatives of AI integration in healthcare in India, there are several critical roadblocks for AI adoption in India that the study identifies, like data accessibility, skills gap, high infrastructure and development cost, regulatory uncertainty regarding data privacy and accountability in case of AI errors.    ]]> https://biospectrumindia.com/news/100/25136/national-health-authority-and-iit-kanpur-sign-mou-to-revolutionise-ai-in-health-research-with-innovative-data-platform.html https://biospectrumindia.com/news/100/25136/national-health-authority-and-iit-kanpur-sign-mou-to-revolutionise-ai-in-health-research-with-innovative-data-platform.html Wed, 11 Sep 2024 00:00:00 +0530 The National Health Authority (NHA) and the Indian Institute of Technology (IIT) Kanpur signed a Memorandum of Understanding (MoU) in the presence of Union Health Secretary Apurva Chandra. The MoU was signed by L. S. Changsan, Addl. Secretary, Union Ministry of Health and Family Welfare & CEO, NHA, and Prof. Manindra Agrawal, Director, IIT Kanpur. Under this MoU, a federated learning platform across a variety of machine learning model pipelines, a quality-preserving database, an open benchmarking platform for comparing & validating artificial intelligence (AI) models, and a consent management system for research under Ayushman Bharat Digital Mission (ABDM) would be developed by IIT Kanpur. The platform will subsequently be operated and governed by NHA, thereby unlocking the immense potential of AI for improving health outcomes. Speaking at the occasion, Apurva Chandra said, “this very important MoU under the Ayushman Bharat Digital Mission that will provide an open public benchmarking platform for comparing & validating AI models.” Changsan stated, “This partnership marks a significant step forward in harnessing the power of AI for our country’s healthcare. It will help provide researchers with access to high-quality data and a platform for collaboration with other stakeholders of the health ecosystem while taking into account all aspects of data privacy. It will also accelerate the development of AI-powered health solutions that address critical health challenges.” She further added that “this MoU will be a benchmark in digital public health goods that will leverage AI and upcoming technologies to strengthen digital public health infrastructure.” ]]> https://biospectrumindia.com/news/100/25113/global-ai-summit-2024-begins-in-hyderabad-aiming-to-make-ai-accessible-to-all.html https://biospectrumindia.com/news/100/25113/global-ai-summit-2024-begins-in-hyderabad-aiming-to-make-ai-accessible-to-all.html Thu, 05 Sep 2024 00:00:00 +0530 The two-day Global Artificial Intelligence (AI) Summit 2024 kicked off at the Hyderabad International Convention Centre (HICC) on Thursday, September 5. The summit, inaugurated by Telangana Chief Minister A. Revanth Reddy, positions Hyderabad as a leading hub for AI investment and innovation in India. The event will conclude on Friday, 6th September. Themed "Making AI Work for Everyone," the summit aims to explore the latest advancements in AI and address its societal impact. This is the first time Hyderabad is hosting such a global event. Chief Minister A. Revanth Reddy and State IT and Industry Minister D. Sridhar Babu were the chief guests at the inaugural event, which saw over 2,000 representatives from the global AI industry. Prominent AI leaders such as Sal Khan, founder of Khan Academy, Daniela Combe from IBM, and Peter Diamandis of XPRIZE Foundation participated, sharing their insights on AI innovations, opportunities, and challenges. During his keynote address, CM Reddy highlighted how past technological advancements like the invention of railways, airplanes, electricity, and computers transformed the world. He noted how AI represents the next big technological disruption. "Today, the greatest technological disruption is here—Artificial Intelligence," Reddy said, acknowledging both the hope AI brings for improving lives and the fears of job disruptions. The summit features discussions on AI regulation, ethics, and societal impact, along with presentations of research projects, startup demonstrations, and new AI innovations. Four additional stages have been set up for panel discussions, allowing experts to engage in a variety of AI-related topics. The Telangana government is using the summit to showcase Hyderabad's growing importance in the AI and IT sectors. As part of its long-term vision, the state announced plans to develop a 200-acre AI City within the proposed Fourth City of Greater Hyderabad. The government hopes the summit will attract global investment and attention to Telangana’s thriving AI sector. Additionally, CM Revanth Reddy unveiled a comprehensive roadmap for AI development in Telangana during the event. ]]> https://biospectrumindia.com/news/100/25054/pristyn-care-unveils-innovation-lab-to-drive-ai-advancements-in-indian-healthcare-system.html https://biospectrumindia.com/news/100/25054/pristyn-care-unveils-innovation-lab-to-drive-ai-advancements-in-indian-healthcare-system.html Sat, 24 Aug 2024 00:00:00 +0530 Gurugram-based startup Pristyn Care, a leader in secondary surgeries in India, has introduced the Pristyn Care Innovation Lab (PCIL), an incubator designed to drive advancements inartificial intelligence (AI) within the healthcare sector.  PCIL will provide early-stage AI startups with a unique platform to pilot and refine their solutions in real-world healthcare environments. From the 47 startups that have applied, a select few will be chosen for collaboration, with their names announced as they join the lab. This initiative aims to foster innovation and accelerate the development of groundbreaking AI technologies in healthcare. As the Indian healthcare sector is projected to reach $650 billion by 2025 (A report by Nasscom and Kantar), with AI’s market expected to grow to $1.6 billion, there is a critical need for innovative AI solutions to transform healthcare delivery.  Pristyn Care Innovation Lab addresses this by offering startups comprehensive support, including: Real-World Testing; Product Validation; Ecosystem Access; Growth & Funding; Infrastructure Support; Sales Support; Marketing and Business Expansion. According to Harsimarbir Singh, Co-founder Pristyn Care, “The adoption of AI is not just a trend but a crucial necessity for transforming the healthcare landscape in India. As the industry faces increasing demands for efficiency and improved patient outcomes, AI offers unparalleled opportunities for growth and innovation." ]]> https://biospectrumindia.com/news/100/25041/artificial-intelligence-in-healthcare-gains-momentum-with-indias-first-gastro-ai-academy.html https://biospectrumindia.com/news/100/25041/artificial-intelligence-in-healthcare-gains-momentum-with-indias-first-gastro-ai-academy.html Wed, 21 Aug 2024 00:00:00 +0530 In a landmark move that underscores its commitment to advancing healthcare technology, eminent gastroenterologists in India got together to start Gastro AI Academy. This pioneering initiative aimed at revolutionising the field of gastroenterology, where the academy will provide free AI education to gastroenterologists, or 'GI doctors', equipping them to improve patient care with advanced technology. The vision of the academy is to ensure that our healthcare experts are future ready and empowered to use technology for the betterment of the society. Fujifilm India has joined hands as an academic partner for the launch of the first ever Gastro AI academy in India. The academy was launched at an event at HN Reliance Hospital, Mumbai. The session was an amalgamation of insightful discussions, featuring lectures from both international and national gastroenterologists. The sessions explored the practical application of AI in various aspects of gastroenterology, including patient reporting, database management and predictive analysis. Special attention was given to the role of AI in diagnostic assistance and treatment planning, a tool crucial for the early detection of gastric and colon cancers. The potential of AI to enhance training programmes and support research and development in clinical practice was also a key focus. Dr Amit Maydeo, Chairman at the Institute of Gastrosciences at HN Reliance Hospital, and a renowned Gastroenterologist emphasised the transformative power of AI in his address, stating, “The field of gastroenterology has been constantly evolving with latest innovations and technologies. Gastro AI Academy will bring together the top global AI experts to impart knowledge on AI, its ethical use and integration into the patient workflow. This academy aims to work towards improving the healthcare ecosystem in the most populous country of the world."   ]]> https://biospectrumindia.com/news/100/25016/medibuddy-unveils-ai-powered-sherlock-to-combat-healthcare-fraud-.html https://biospectrumindia.com/news/100/25016/medibuddy-unveils-ai-powered-sherlock-to-combat-healthcare-fraud-.html Sat, 10 Aug 2024 00:00:00 +0530 MediBuddy, Bengaluru-based digital healthcare platform, has announced the launch of its groundbreaking artificial intelligence (AI)-powered fraud detection system for healthcare reimbursement claims. This cutting-edge platform harnesses the power of advanced technologies such as artificial intelligence (AI), machine learning (ML), and data analytics to detect and prevent fraudulent claims in real-time, revolutionising the reimbursement process for healthcare providers, insurers, and patients. Organisational fraud goes beyond finances, damaging reputation and inviting regulatory scrutiny. One way to stop Fraud, Waste and Abuse (FWA) is by stopping the reimbursement process and enabling cashless solutions. MediBuddy's approach, which combines a vast cashless network with Sherlock's advanced FWA detection capabilities, has the potential to cut costs by up to 20%. This substantial saving is achieved through a 10% reduction via the cashless network and an additional 10% through Sherlock's FWA detection. By eliminating the reimbursement process, cashless solutions significantly reduce opportunities for fraud. Sherlock leverages cutting-edge AI and machine learning algorithms to provide real-time analysis and alerts, identifying potential errors or fraud before they occur. The system is highly adaptable, allowing customisation to meet the unique needs of different corporations and insurers. Sherlock automatically detects issues such as claim duplication, document tampering, pricing discrepancies, and compliance lapses, eliminating the need for constant manual review and saving both time and money. ]]> https://biospectrumindia.com/news/100/24998/siemens-healthineers-deploys-ai-based-multi-testing-diagnostic-analyser-at-mahajan-imaging-labs.html https://biospectrumindia.com/news/100/24998/siemens-healthineers-deploys-ai-based-multi-testing-diagnostic-analyser-at-mahajan-imaging-labs.html Tue, 06 Aug 2024 00:00:00 +0530 Siemens Healthineers, a global leader in medical diagnostics, has announced its pioneering implementation of the new Atellica CI, independent integrated diagnostic testing analyser at Mahajan Imaging & Labs, to make patient care more predictable and agile in today’s evolving healthcare landscape. This state-of-the-art analyser is designed to significantly enhance patient comfort by providing faster, more accurate results. The new Atellica CI analyser is a marvel of medical technology in a compact footprint, capable of analyzing over 200 parameters, covering 20 disease states. The analyser’s microvolume technology maximises test yield from a single sample aspiration. This feature is particularly beneficial for paediatric and critical cases where low-volume sample testing is essential. The analyser’s ability to process critical tests within 14 minutes, compared to the conventional 22 to 40 minutes, sets a new standard for rapid diagnostics. Additionally, emergency assays can be aspirated in just one minute, with results completed in 10 minutes, further streamlining urgent care. The analyser features a novel 'Enhanced Liver Fibrosis (ELF)' test to augment prognosis of Liver Fibrosis, a huge disease burden in India.  Approved by the US Food and Drug Administration (FDA), the analyser meets sustainability standards, utilizing less water, fewer tubes and generating less plastic waste. It supports advanced diagnostics with parameters such as FMF approved dual markers for maternal screening, AMH for assessing ovarian reserve, active vitamin B12, and ferritin testing for women's health; oncology markers that aid in the early detection of cancers like PSA (test used to screen for prostate cancer) and ovarian cancer. Enabled by advanced artificial inteligence (AI) technology, the system minimises manual errors, enhance operational efficiency, and ensures test accuracy, even after biotin or gummy intake, which many impact results from other machines. It also tests for active vitamin D levels, enhancing its versatility for comprehensive health monitoring.  ]]> https://biospectrumindia.com/news/100/24985/isb-and-aig-hospitals-collaborate-to-redefine-healthcare-innovation-with-ai.html https://biospectrumindia.com/news/100/24985/isb-and-aig-hospitals-collaborate-to-redefine-healthcare-innovation-with-ai.html Sat, 03 Aug 2024 00:00:00 +0530 The Indian School of Business (ISB) has announced a collaboration with AIG Hospitals in Hyderabad, one of the world’s top-ranked gastroenterology institutions and India’s largest super-speciality tertiary care hospital, for an initiative that redefines healthcare in India by merging the capabilities of AI with clinical experience of doctors in India. Designed as the ‘Artificial Intelligence (AI) in Healthcare Programme’, it aims to foster a new era of innovation and excellence in healthcare delivery and most importantly enhance patient experience. The initiative ‘AI in Healthcare Programme’ addresses the significant challenge of clinician involvement in tech innovation. The Max Institute of Healthcare Management (MIHM), an interdisciplinary research institute at ISB, will be the principal knowledge partner in this collaboration which aims to create an unparalleled platform for healthcare innovation in India. The programme is being co-developed by researchers at MIHM, ISB and clinicians from AIG Hospitals to empower healthcare leaders with advanced AI skills and understand AI’s implementation in clinical practices which will potentially elevate patient outcomes in both diagnostic as well as therapeutic aspects.  Delivered by ISB Executive Education, the programme is structured into two phases, conducted every six months for predominantly senior doctors and health-tech leaders. The initial phase focuses on design thinking and strategic alignment of AI technology with patient-care objectives. The subsequent phase involves creating technology competence amongst the participants, which will allow them, post-programme, to successfully identify and implement AI-led projects in their respective fields. Under this programme, participants will gain critical insights and skills to recognise and address opportunities and barriers in AI implementation, tackle unmet clinical needs with innovative solutions, and develop AI-driven business models that enhance clinical excellence and patient care. ]]> https://biospectrumindia.com/news/100/24962/biocon-foundation-and-iisc-organise-conference-on-artificial-intelligence-in-oral-cancer.html https://biospectrumindia.com/news/100/24962/biocon-foundation-and-iisc-organise-conference-on-artificial-intelligence-in-oral-cancer.html Tue, 30 Jul 2024 00:00:00 +0530 Biocon Foundation, the Corporate Social Responsibility (CSR) arm of the Biocon Group, in association with the Indian Institute of Science (IISc), Bengaluru, organised the fifth edition of the Oral Cancer Task Force (OCTF) Conference on 26–27 July 2024. The two-day conference on 'Artificial Intelligence in Oral Cancer,' was held at the IISc campus, commemorating the World Head & Neck Cancer Day.  Dr Anupama Shetty, Mission Director, Biocon Foundation, said, “This year, we were honored to host the 5th edition of the OCTF Conference at the Indian Institute of Science, centered around the theme 'Artificial Intelligence in Oral Cancer'. Leading experts and researchers from organisations such as AIIMS Cachar Cancer Center and MPMMCC (Mahamana Pandit Madan Mohan Malaviya Cancer Centre) shared advancements and best practices in preventing, diagnosing, and treating oral cancer. The publication of consensus guidelines for head and neck cancer, specific to the Indian subcontinent’s demographic and economic conditions, remains the annual highlight of the conference." The Biocon Foundation has partnered with IISc to undertake the AI-Centre of Excellence in Oral Cancer Projects. It is a multicentric study involving collaboration with 28 consortium partners, with IISc as the nodal centre. Biocon Foundation is the lead expert for phase 1 of the project. The project aims to develop an algorithm for an oral cancer screening tool – Aarogya Aarohan.  Further, the Medical-Imaging and Information Datasets for India (MIDAS) is a national initiative led by the Indian Institute of Science (IISc), in collaboration with the Indian Council of Medical Research (ICMR) and ARTPARK-IISc. The goal of MIDAS is to create a comprehensive medical imaging and other modality datasets that accurately represents India's diverse population. MIDAS will operate as a technology-enabled hub and spoke system, facilitating the growth of high-quality medical datasets and fostering research and innovation in the health sector across India. At the fifth edition of the Oral Cancer Task Force Conference, the updated India-specific guidelines on Management of Head & Neck Cancer were unveiled which is being published in the Journal of Cancer Research Statistics and Treatment. The guidelines update were presented by Dr Neera Gupta General Manager – Medical Affairs and Clinical Development, Eris Life Sciences Ltd. ]]> https://biospectrumindia.com/news/100/24902/deephealth-expands-operations-in-india.html https://biospectrumindia.com/news/100/24902/deephealth-expands-operations-in-india.html Mon, 15 Jul 2024 00:00:00 +0530 DeepHealth, a wholly-owned subsidiary of US-based RadNet, Inc. and a global leader in AI-powered radiology and health informatics, has expanded its operations in India by opening its office in Bengaluru, serving as the hub for its operations across the Indian subcontinent. The new office has commenced operations in Q3 2024. The technology hub will spearhead ground-breaking innovations to advance DeepHealth’s mission of empowering breakthroughs in care delivery. As a part of its India expansion, the company will leverage local expertise and a network of strategic partners to enhance the development of AI-powered health informatics solutions. DeepHealth has already an established presence in India through its partnerships with Persistent Systems in Pune and Infinx Healthcare, Mumbai focused on product development and service. As the company forges ahead with its ambitious expansion plans, it aims to broaden its collaborations and establish affiliations with prestigious institutions to undertake research projects and propel the Indian healthcare landscape to the forefront of global innovation. DeepHealth’s expansion in India reinforces its commitment to enhancing healthcare outcomes through cutting-edge technology solutions. Through their operations in India, DeepHealth will continue to leverage the power of AI to empower radiologists in the detection and diagnosis of diseases, expanding the boundaries of what we can do with imaging technology in healthcare. Speaking on the launch of its operations in India, Sham Sokka, Chief Operating and Technology Officer DeepHealth said, “We recognise the country’s exceptional tech capabilities and its dynamic innovation landscape. This presents a great opportunity for us to drive the development of meaningful health tech solutions in India that benefit clinicians and patients worldwide. As we expand our presence in India, we also look forward to establishing new partnerships to advance innovation in health informatics.”        ]]> https://biospectrumindia.com/news/100/24895/infinx-healthcare-expands-presence-in-india-with-rd-centre-in-bengaluru-.html https://biospectrumindia.com/news/100/24895/infinx-healthcare-expands-presence-in-india-with-rd-centre-in-bengaluru-.html Fri, 12 Jul 2024 00:00:00 +0530 Infinx, a global AI-driven company providing revenue cycle solutions for the US healthcare market, has announce the opening of its new state-of-the-art Research and Development Centre in Bengaluru.   This new facility highlights Infinx's dedication to fostering innovation and driving advancements in the healthcare revenue cycle management (RCM) field. Spanning 12,000 sq. ft., this R&D centre will significantly enhance Infinx’s capabilities with a dedicated focus on artificial intelligence (AI)-driven product development, engineering, innovation, data science, and machine learning. Infinx teams will also manage cloud operations and cloud computing from this center, propelling the company’s technological solutions for its customers. With a global workforce of over 6,000, Infinx is actively seeking new talent to strengthen its position as a leading AI-driven healthcare management enabler. Infinx’s team of engineers leads the development of advanced AI solutions that enhance predictive analytics, optimise claim processing, and improve decision-making capabilities. They are also developing a cloud-based RCM platform to ensure scalability, security, and efficiency, enabling seamless integration with various healthcare systems. Infinx focuses on creating user-friendly platforms that provide real-time insights, smooth workflows, and robust data management. By harnessing the latest innovations in microservices architecture and agile development, the company’s solutions are designed to be both flexible and resilient, meeting the dynamic needs of the healthcare industry. The firm’s solutions support 172,000 healthcare professionals across 4,000 facilities including ambulatory, acute care and post-acute care providers. It counts over 400 leading healthcare provider organisations as customers including hospitals, health systems and outpatient healthcare providers. ]]> https://biospectrumindia.com/news/100/24847/healthcare-veteran-sheetal-chand-launches-ai-based-startup-healthcare-platform-to-improve-diagnostic-accuracy.html https://biospectrumindia.com/news/100/24847/healthcare-veteran-sheetal-chand-launches-ai-based-startup-healthcare-platform-to-improve-diagnostic-accuracy.html Tue, 02 Jul 2024 00:00:00 +0530 Healthcare industry veteran Sheetal Chand, with over 22 years of experience in Research, Technology, and Molecular Laboratory Management, has announced the launch of Shealth.AI, a groundbreaking healthcare artificial intelligence (AI) startup. Shealth.AI is set to transform the healthcare industry by improving the quality of care while significantly reducing costs and time, making primary healthcare more accessible and sustainable for everyone.  The shealth startup, focusing on leveraging AI for healthcare solutions, aligns its Go-To-Market (GTM) strategy with the primary objective of enhancing healthcare delivery through advanced technology. The strategy includes deploying AI-driven tools such as virtual health assistants, medication management systems, and digital consultation services. These solutions are tailored to improve efficiency, accuracy, and patient outcomes in medical settings. The primary targets for shealth are healthcare institutions including Hospitals, Clinics, Healthcare administrations, etc. The GTM strategy involves direct engagement with these targets through partnerships, direct sales, and participation in healthcare conferences and seminars. Additionally, shealth focuses on educational initiatives to inform healthcare providers about the benefits of AI integration in medical practices. Shealth.AI is backed by an undisclosed amount of seed funding round from XVC.Tech, enabling the development and deployment of its cutting-edge technologies. ]]> https://biospectrumindia.com/news/100/24817/torchit-and-rotary-delhi-clubs-unite-to-launch-advanced-assistive-technology-jyoti-ai-.html https://biospectrumindia.com/news/100/24817/torchit-and-rotary-delhi-clubs-unite-to-launch-advanced-assistive-technology-jyoti-ai-.html Tue, 25 Jun 2024 00:00:00 +0530 In a groundbreaking event, Ahmedabad-based startup Torchit, in collaboration with over 30 Rotary Clubs from Delhi, successfully launched Jyoti AI product and distributed 1500 Saarthi devices to visually impaired individuals. The event was held at the PHD Chamber of Commerce in Hauz Khas, New Delhi, and witnessed the participation of more than 300 attendees, including Rotary members, Rotaract members, government officials, representatives from AIIMS, and over 20 NGO heads. Hunny Bhagchandani, Founder of Torchit, explained the challenges faced by the visually impaired and how the Saarthi device aids in mobility. He also launched the revolutionary Jyoti AI, which allows users to 'see' with sound, providing functionalities such as object, colour, and currency identification, along with live demonstrations. Jyoti AI is an advanced assistive technology that provides object, colour, and currency identification, scene description, and educational support through the Jyoti AI Reader. Available in various models, it is designed to be affordable and versatile. Utilising over 1200 algorithms trained on Gemini AI, powered by Google, Jyoti AI can describe complex scenes with high detail, answering questions about the environment and people’s interactions. ]]> https://biospectrumindia.com/news/100/24820/ai-health-startup-cloudphysician-raises-10-5-m-funding-led-by-peak-xv-partners.html https://biospectrumindia.com/news/100/24820/ai-health-startup-cloudphysician-raises-10-5-m-funding-led-by-peak-xv-partners.html Tue, 25 Jun 2024 00:00:00 +0530 Bengaluru-based AI health startup, Cloudphysician, has raised $10.5 million in a Series A funding round led by Peak XV Partners, with participation from Elevar Equity and venture debt firm Panthera Peak. Cloudphysician is a full-stack artificial intelligence (AI) and operations company that partners with hospitals to manage patients in their ICU and Emergency departments. Its seamlessly integrated tech, world-class treatment protocols, and best-in-class medical teams improve patient outcomes.  The fresh capital infusion will be used to propel Cloudphysician’s growth and operations within India and expand into multiple emerging markets and established markets such as the US. Additionally, the funds will be used to further enhance its innovative AI platform, RADAR, to improve its co-pilot features using data. With this latest funding, Cloudphysician is well-equipped to lead the charge in revolutionising the delivery of critical care, ensuring that high-quality care is acessible, scalable, and cost-effective for hospitals everywhere.  Dr Dhruv Joshi and Dr Dileep Raman, both intensivists trained in the US, founded Cloudphysician in 2017 to ensure delivery of high-quality critical care to all. Cloudphysician has now extended its partnership to over 200 hospitals across 23 states in the country, caring for over 1 lakh patients.      ]]> https://biospectrumindia.com/news/100/24765/indias-first-ai-powered-solutions-to-transform-sleep-health-.html https://biospectrumindia.com/news/100/24765/indias-first-ai-powered-solutions-to-transform-sleep-health-.html Thu, 13 Jun 2024 00:00:00 +0530 Bengaluru-based startup Wakefit.co, India’s largest D2C sleep and home solutions company, has announced the launch of the Wakefit Zense range, India’s first-ever line of artificial intelligence (AI)-powered sleep solutions. The latest launch includes two groundbreaking products- Regul8 and Track8. Regul8 is India’s first mattress temperature controller, which uses state-of-the-art sleep technology to change and manage the surface temperature of the mattress based on personal preferences, while Track8 is an AI-powered non-wearable (contactless) sleep tracker that gives precise and detailed insights about one’s sleep patterns. With this new launch, Wakefit.co aims to seamlessly integrate technology into the sleep environment, optimizing sleep quality and sleep health for users.   Commenting on the launch of Wakefit Zense, Ankit Garg, CEO and Co-founder of Wakefit.co, said, "All of us at Wakefit.co have been looking forward to this day, as we set foot into new terrain with an AI-powered range of sleep solutions. The Zense range was a product of a wide gap that we recognised in the Indian market, especially with our Great Indian Sleep Scorecard (GISS) showing Indians’ consistent lack of sleep every year. We are confident that the Zense range will make a significant impact on improving sleep quality across the country.” ]]> https://biospectrumindia.com/news/100/24733/innominds-and-sciinv-biosciences-unveil-ai-driven-solution-to-combat-amr.html https://biospectrumindia.com/news/100/24733/innominds-and-sciinv-biosciences-unveil-ai-driven-solution-to-combat-amr.html Thu, 06 Jun 2024 00:00:00 +0530 Innominds, a US-based digital transformation and product engineering company, has announced its partnership with Hyderabad-based startup SCIINV Biosciences to introduce AMRx, an advanced AI/ML-driven digital diagnostic tool designed to combat the growing threat of antimicrobial resistance (AMR).   This innovative tool promises to revolutionise the detection and treatment of antibiotic-resistant infections without the need for traditional cultures.   AMRx, developed by Innominds and SCIINV Biosciences, is a groundbreaking, culture-free companion diagnostic tool that utilises AI/ML to predict Urinary Tract Infections (UTIs) and determine antibiotic resistance patterns based on patient clinical history. This patented technology represents a significant advancement in the fight against AMR.   AMRx leverages patient clinical history to accurately predict UTIs, identify causative organisms (Enterobacteriaceae), and determine antibiotic resistance or susceptibility patterns without the need for traditional cultures.   By reducing unwarranted clinical investigations, AMRx saves valuable time, effort, and resources. This efficiency is particularly beneficial in resource-limited settings.   AMRx can be deployed as a clinical decision support tool, aiding healthcare professionals in making appropriate empirical antibiotic prescriptions, thereby enhancing the accuracy and effectiveness of treatment. ]]> https://biospectrumindia.com/news/100/24690/wipro-collaborates-with-centre-for-brain-research-at-iisc-for-ai-driven-health-behaviour-innovations.html https://biospectrumindia.com/news/100/24690/wipro-collaborates-with-centre-for-brain-research-at-iisc-for-ai-driven-health-behaviour-innovations.html Wed, 29 May 2024 00:00:00 +0530 Wipro Limited, a leading technology services and consulting company, has announced a collaboration with the Centre for Brain Research (CBR), an autonomous, non-profit research organisation, hosted at the Indian Institute of Science (IISc), Bengaluru. This partnership will focus on harnessing the power of artificial intelligence (AI), machine learning (ML), and big data analytics to develop new technologies that will provide precision support towards the prevention and management of long-term health disorders. Wipro’s research & development (R&D) team, part of Lab45, will design and develop a personal care engine, an AI that will take into account an individual’s health history, desired health state, and other behavioral responses, to promote healthy aging, positive lifestyle changes, and psycho-social wellbeing to meaningfully improve an individual’s health over time. The personal care engine will focus on reducing and managing the risk of cardiovascular disease and correlated neurodegenerative disorders, by using AI to personalise its interaction with users, optimizing for their long-term health and wellbeing. Wipro will test the engine through a digital app-based trial in collaboration with CBR at IISc. This trial will generate valuable evidence regarding the engine’s effectiveness for contexts that are deeply relevant for long-term health outcomes.  Wipro’s technological expertise combined with CBR’s leading brain science research will unlock new possibilities for patient care and cognitive and overall health. The combined R&D prowess of both institutions will develop systems that deliver better health outcomes at population scale.   ]]> https://biospectrumindia.com/news/100/24657/mdrf-partners-with-embedur-to-co-create-advanced-ai-models-for-diabetic-research.html https://biospectrumindia.com/news/100/24657/mdrf-partners-with-embedur-to-co-create-advanced-ai-models-for-diabetic-research.html Thu, 23 May 2024 00:00:00 +0530 In an effort to mitigate the growing prevalence of diabetes in India through research, the Madras Diabetes Research Foundation (MDRF), has entered into a strategic partnership with Chennai-based embedUR systems, a global innovation leader in AI, Edge Computing, IoT and Cloud, to co-create advanced artificial intelligence (AI) models for diabetic management.  This collaboration between embedUR and MDRF seeks to harness the transformative power of AI for diabetes research with the goal of strengthening the efficacy of clinical studies in the field and improving the quality of diabetes management in the country. The MoU between MDRF and embedUR systems was signed by Dr V Mohan, Chairman - Madras Diabetes Research Foundation (MDRF) and Rajesh C Subramanium, Founder and CEO of embedUR Systems. The collaboration will see experts from both embedUR and MDRF diving deep into MDRF's extensive Continuous Glucose Monitoring (CGM) datasets of a sample size of several thousand patients. Utilising cutting-edge AI computing tools developed by embedUR, the teams will develop sophisticated AI models capable of continual learning and refinement. Experts from both organizations will collaborate closely, employing various metrics to gauge the efficacy and relevance of the data. This will ensure that the software developed is precisely tailored to address the critical needs in diabetes management.   ]]> https://biospectrumindia.com/news/100/24644/kkr-invests-in-mumbai-based-healthcare-revenue-solutions-provider-infinx.html https://biospectrumindia.com/news/100/24644/kkr-invests-in-mumbai-based-healthcare-revenue-solutions-provider-infinx.html Tue, 21 May 2024 00:00:00 +0530 KKR, a leading global investment firm, and Infinx Services, an artificial intelligence (AI)-driven healthcare revenue cycle solutions provider, have announced the acquisition of a significant minority stake in Infinx by a KKR-managed fund. Through this investment, KKR will leverage its extensive experience in the global healthcare and technology sectors to accelerate Infinx’s growth, expand the company’s network, and support bolt-on acquisitions. Norwest Venture Partners, an existing shareholder, also participated in the transaction. Co-founded in 2012 by Sandeep Tandon and Jaideep Tandon, Infinx is a provider of innovative, data-driven revenue cycle management solutions for the healthcare sector, with a particular focus on the US market. Infinx’s Healthcare Revenue Cloud platform supports end-to-end revenue cycle business functions utilising AI, automation, payer integration, and workforce management. Recent reports have valued the US healthcare market at approximately $4.3 trillion, representing over 18% of US GDP. Today, Infinx’s solutions support 172,000 healthcare professionals across 4,000 facilities including ambulatory, acute care and post-acute care providers. Infinx counts over 400 leading healthcare provider organisations as customers including hospitals, health systems and outpatient healthcare providers.   Sudeep Tandon, Managing Director of Infinx, commented, “The strategic partnership with KKR will allow us to accelerate our growth through continued strategic acquisitions and to broaden our market reach to new healthcare specialties."       ]]> https://biospectrumindia.com/news/100/24597/clinics-on-cloud-invests-0-5-m-in-health-tech-startup-inolabs-ai.html https://biospectrumindia.com/news/100/24597/clinics-on-cloud-invests-0-5-m-in-health-tech-startup-inolabs-ai.html Tue, 07 May 2024 00:00:00 +0530 In a landmark move poised to revolutionise preventive healthcare, Clinics on Cloud has announced an investment of $0.5 million in Bengaluru-based startup Inolabs.ai, a venture spearheaded by Inovatrik, at an undisclosed valuation. This strategic collaboration marks a significant milestone in the integration of artificial intelligence (AI) into healthcare practices worldwide. With a focus on preventive healthcare and AI-driven solutions, this partnership promises to redefine patient care paradigms on a global scale. Clinics on Cloud, leading manufacturers of Health ATMs/Kiosks, stand at the forefront of healthcare innovation, leveraging technology to develop advanced solutions aimed at preventive healthcare and improving patient outcomes. Among the solutions that will emerge from the partnership are advanced AI-based nutrition plans and diagnostic tools for conditions such as ECG interpretation and diabetes management, among several others. These cutting-edge innovations are set to transform the future of healthcare in India, enhancing efficiency, accuracy, and personalised healthcare. This strategic investment will also help the company in rolling out some ground-breaking innovations in preventive diagnosis.     ]]> https://biospectrumindia.com/news/100/24544/mumbai-based-health-tech-startup-endimension-technology-raises-rs-6-cr.html https://biospectrumindia.com/news/100/24544/mumbai-based-health-tech-startup-endimension-technology-raises-rs-6-cr.html Thu, 25 Apr 2024 00:00:00 +0530 Endimension Technology, a Mumbai-based healthcare AI startup, has raised Rs 6 crore in Pre-Series A round led by Inflection Point Ventures. Other investors in this round include Sucseed Indovation, SINE IIT Bombay and individual angel investors. Endimension Technology, incubated at IIT Bombay, is driven by the vision to harness artificial intelligence (AI) technology in radiology, ensuring early and precise diagnosis for patients globally. The funds will be utilised to fuel AI research and development, team expansion, software enhancement. These strategic investments aim to bolster their market position, accelerate growth, and establish Endimension as an industry leader. Ivy Chin, Partner, Inflection Point Ventures says, “The Indian radio-diagnosis market, growing at a CAGR of 15%+ over the last decade, has got a lot of focus on equipment & infrastructure. The under-stated need is that of qualified professionals, i.e. radiologists, to manage this burgeoning demand. There has been growth across tier 1, 2 & 3 for equipment but the availability and prohibitive costs of trained radiologists exacerbates the problem of demand outstripping supply situation. Endimension focuses on leveraging AI to facilitate faster assessment and diagnosis, employing generative AI to streamline report generation and reduce the time required by radiologists. IPV is confident that this investment will contribute towards the betterment of the industry”. The global market for AI in medical imaging is expected to grow significantly in the coming years. In 2024, the market size is estimated to be around $5.86 billion and is projected to reach $20.40 billion by 2029, with a compound annual growth rate (CAGR) of 28.32% (Ref: Mordor Intelli). ]]> https://biospectrumindia.com/news/100/24545/united-we-care-partners-with-fortis-to-innovate-mental-well-being-with-ai.html https://biospectrumindia.com/news/100/24545/united-we-care-partners-with-fortis-to-innovate-mental-well-being-with-ai.html Thu, 25 Apr 2024 00:00:00 +0530 United We Care marks a significant milestone in India's mental healthcare landscape by partnering with 'Adayu Mindfulness' of Fortis Healthcare. Through this exclusive partnership both companies will offer comprehensive mental healthcare, featuring an artificial intelligence (AI)-powered holistic Mental Health Solution with world’s most advanced virtual psychological first aid, Stella.   This collaboration will leverage the power of artificial intelligence to enhance mental well-being and accessibility of care for individuals everywhere, powering it further by Adayu’s trained team of mental health experts to provide holistic care.   This visionary initiative reaffirms Fortis Healthcare's commitment to transformative healthcare solutions and underscores its role as a trailblazer in revolutionising mental healthcare services across India.   As a part of the Fortis National Mental Health programme, Adayu Mindfulness, a Fortis Group Company, has been launched as a dedicated vertical for comprehensive mental healthcare. Adayu is derived from the word ‘ayu’ which connotes age, representing the meaning ‘adding on to life’.    United We Care's innovative AI technology will integrate seamlessly with Adayu's established network of mental health professionals. This powerful combination will offer a comprehensive approach to mental wellness, including AI-powered self-assessment tools; Enhanced access to care; Self-Care Tools; and 24/7 support. ]]> https://biospectrumindia.com/news/100/24486/bayer-and-google-cloud-to-accelerate-development-of-ai-powered-healthcare-applications-for-radiologists.html https://biospectrumindia.com/news/100/24486/bayer-and-google-cloud-to-accelerate-development-of-ai-powered-healthcare-applications-for-radiologists.html Tue, 09 Apr 2024 00:00:00 +0530 Global companies Bayer and Google Cloud have announced a collaboration on the development of artificial intelligence (AI) solutions to support radiologists and ultimately better serve patients. As part of the collaboration, Bayer will further develop its innovation platform to accelerate the development and deployment of AI-powered healthcare applications with a clear focus on radiology, using Google Cloud's technology, including its generative AI (gen AI) tools. The collaboration aims to help organisations overcome many of the challenges to building scalable and compliant AI-powered medical imaging software products using leading data security capabilities, and accelerate the development of potentially groundbreaking and impactful solutions that ultimately benefit patients. The users will be able to uncover insights with AI-powered data analysis, and help design breakthrough healthcare solutions by accessing a data ecosystem, as well as using intelligent search and data preparation capabilities. In addition, users will have the ability to explore and extract information from regulations and scientific papers, all within a collaboration platform with leading data security capabilities. The platform is built on Google Cloud and uses tools like Vertex AI, BigQuery, Healthcare API and Chronicle. Bayer's platform is designed to help bring innovative medical imaging tools to market faster and more cost-effectively, and a first version for extended testing is planned to be made available later this year in the EU and United States.   ]]> https://biospectrumindia.com/news/100/24383/hilabs-closes-39-m-series-b-financing-to-advance-ai-based-solutions-for-healthcare-sector-.html https://biospectrumindia.com/news/100/24383/hilabs-closes-39-m-series-b-financing-to-advance-ai-based-solutions-for-healthcare-sector-.html Thu, 14 Mar 2024 00:00:00 +0530 HiLabs, a leading provider of artificial intelligence (AI)-powered solutions to manage dirty data, unlocking its hidden potential for healthcare transformation, has announced a $39 million Series B financing. The round was led by Eight Roads Ventures and Denali Growth Partners, with participation from F-Prime Capital. The capital raise follows rapid customer adoption of its healthcare data ingestion, cleansing, and enrichment platform, MCheck, and will support continued enhancement of the technology as well as recruitment of top-tier talent and expansion of its product teams. Founded in 2014, Pune and Bengaluru-based startup HiLabs’ mission is to ensure timely access to clean data for payers, providers, and patients at a time when healthcare organizations worldwide are transitioning toward datadriven decision-making. HiLabs’ cloud based MCheck platform ingests, cleans, and enriches critical healthcare information, resulting in significant reduction in healthcare organisations’ operational costs and improvement in patient outcomes. ]]> https://biospectrumindia.com/news/100/24375/bengaluru-based-ai-startup-cureskin-secures-20-m-in-series-b-funding-round.html https://biospectrumindia.com/news/100/24375/bengaluru-based-ai-startup-cureskin-secures-20-m-in-series-b-funding-round.html Wed, 13 Mar 2024 00:00:00 +0530 Bengaluru-based startup Cureskin, an artificial intelligence (AI)-driven dermatology platform that provides clinically validated skin & hair health solutions, has raised Series B funding of $20 million. The round was led by India’s leading digital health-focused venture capital fund, HealthQuad along with participation from existing marquee investors including JSW Ventures, Khosla Ventures and Sharrp Ventures. The latest investment brings Cureskin's total funding to $26 million, further fuelling its vision to widen access to quality dermatological care in India. India grapples with a significant shortage of access to qualified dermatologists, leaving millions without quality skin care. At the same time, there is a significant and growing demand for such a solution in India due to its young and aspirational demographic. Cureskin is expanding the skin and hair care market by bridging this gap by leveraging AI to scale the reach of dermatologists. Through its mobile app, Cureskin has treated over 15 Lakh customers so far for various conditions such as acne, hyper-pigmentation, post-acne issues, hair loss etc, with over 80% of customers in Tier 2 and 3 regions. Guna Kakulapati, CEO and Co-founder of Cureskin said, “These funds will help further enhance our AI capabilities, accelerate our growth and expand solution offerings. We aim to provide optimal skin and hair health to millions of individuals across the country.”       ]]> https://biospectrumindia.com/news/100/24365/axtria-expands-to-hyderabad-with-9th-global-innovation-and-capability-centre-in-india.html https://biospectrumindia.com/news/100/24365/axtria-expands-to-hyderabad-with-9th-global-innovation-and-capability-centre-in-india.html Tue, 12 Mar 2024 00:00:00 +0530 US headquartered Axtria Inc., a global leader in cloud software and data analytics for the life sciences industry, has announced the opening of its new centre in Hyderabad. The new centre contributes to Axtria's mission of helping life sciences companies drive better health outcomes by offering specialised data analytics and artificial intelligence (AI)-driven services, including generative AI. Axtria's latest centre spans 76,000 square feet and is the company's largest office in India. Located at DLF Cyber City, Gachibowli, Hyderabad, the centre is differently-abled-friendly, and the building has been certified LEED Platinum by the USGBC, the world's highest recognition for sustainable practices and environment-centric planning of modern-day workplace facilities. The centre has been recognised for its initiatives to be a zero-water waste facility and was awarded a Green Star Rating by GRESB. In 2023 alone, Axtria hired approximately 700 associates, a healthy mix of those with industry experience and fresh talent from campuses for emerging data science, software development, and data engineering roles. In its commitment to address emerging generative AI strategies for life science companies and maintain sustainable hiring, Axtria plans to recruit nearly 800 professionals for its global locations in the next 9-12 months. With recent expansions in Noida, Pune, and now Hyderabad, Axtria is poised to generate multiple job opportunities.  ]]> https://biospectrumindia.com/news/100/24366/movate-signs-mou-with-loyola-college-to-set-up-ai-iot-based-robotics-lab-in-india.html https://biospectrumindia.com/news/100/24366/movate-signs-mou-with-loyola-college-to-set-up-ai-iot-based-robotics-lab-in-india.html Tue, 12 Mar 2024 00:00:00 +0530 Telangana-based Movate, formerly known as CSS Corp, a digital technology and customer experience (CX) services provider, has recently signed a Memorandum of Understanding (MoU) with Loyola College in Chennai to set up an Advanced Robotics Lab. This advanced facility will be equipped with cutting-edge artificial intelligence (AI) and IoT technologies, aiming to empower students with the latest tools and skills in the dynamic field of robotics. The laboratory will encompass a total area of 750 square feet, with 600 square feet designated for real-time testing and an additional 150 square feet reserved for storage. The lab will house well-equipped robotic kits, a drone kit, 3D printers, projectors, and the necessary computing power to support students' endeavours. It will provide students with a platform to gain practical experience with advanced technologies. Additionally, Movate is also investing in specialised training for the faculty to ensure that the lab's resources are leveraged effectively to empower students and make them future-ready. Movate has entered into a partnership with Yagen Robotics, a company that specialises in manufacturing educational robotics kits for various age groups and expertise levels. It also holds recognition from the Department of Industrial Policy & Promotion and the Ministry of Commerce & Industries, Government of India. ]]> https://biospectrumindia.com/news/100/24288/sparsh-hospital-signs-mou-with-ge-healthcare-to-advance-clinical-care-in-india.html https://biospectrumindia.com/news/100/24288/sparsh-hospital-signs-mou-with-ge-healthcare-to-advance-clinical-care-in-india.html Thu, 29 Feb 2024 00:00:00 +0530 With a vision to further strengthen the healthcare infrastructure in the state of Karnataka, SPARSH Group of Hospitals has signed a Memorandum of Understanding (MoU) with GE HealthCare. This strategic collaboration is geared towards enhancing technological advancements in clinical care areas particularly in Oncology, Cardiology, and Neurology by leveraging the potential of artificial intelligence (AI), enabling preventive healthcare, precision diagnosis and treatment in a timely and affordable manner. The Indian healthcare AI market is expected to reach $1.6 billion by 2025, with a CAGR of 40.5% from 2020 to 2025. The emergence of digital healthcare such as virtual care solutions, remote patient monitoring, smarter AI-integrated MedTech devices allows for better and more purposeful treatment outcomes. Today, the way diseases are manifesting has changed leading to the need to understand the triggers and looking into preventive measures. This strategic collaboration will involve the development and validation of cutting-edge technologies like AI and Digital Platforms to enhance clinical care in Oncology, Cardiology and Neurology, aimed at helping improve patient outcomes and advancing medical research. Girish Raghavan, VP - Engineering, GE HealthCare South Asia, said, “The next decade will see some of the most profound changes in healthcare. Today, with the integration of advanced clinical and academic research, aggregated data, AI and ML, there is a tectonic shift in how we are treating, and providing the best healthcare to patients, where they need it most."   As part of this collaboration, both the organisations will engage in joint clinical research and academic activities to contribute to the growth and knowledge of the critical care areas, addressing some of the toughest healthcare challenges prevailing in the country.   Image caption- Girish Raghavan, VP – Engineering, GE HealthCare South Asia; Chaitanya Sarawate, Managing Director, Wipro GE Healthcare and President & CEO, GE HealthCare South Asia; Dr Sharan Shivraj Patil, Chairman and Chief Orthopaedic Surgeon, SPARSH Hospital; and Dr Narayana Subramaniam, Senior Consultant & Director - Head & Neck Surgery and Oncology and Director - Clinical Innovation, SPARSH Hospital ]]> https://biospectrumindia.com/news/100/24284/iit-kanpur-partners-with-up-government-to-enhance-tele-medicine-using-ai.html https://biospectrumindia.com/news/100/24284/iit-kanpur-partners-with-up-government-to-enhance-tele-medicine-using-ai.html Wed, 28 Feb 2024 00:00:00 +0530 The Gangwal School of Medical Sciences and Technology at Indian Institute of Technology (IIT) Kanpur and the Department of Medical Health and Family Welfare, Government of Uttar Pradesh (UP) have announced the signing of a Memorandum of Understanding (MoU) to revolutionise healthcare delivery and advance tele-medicine facilities in the state through the power of Artificial Intelligence (AI). The MoU was signed by Ranjan Kumar IAS, Secretary, Health & Family Welfare, Government of Uttar Pradesh, and Professor Sandeep Verma, Professor-In-Charge, Gangwal School of Medical Sciences and Technology, IIT Kanpur, in the presence of other dignitaries.   The MoU outlines several key areas of collaboration, including anchoring tele-medicine hubs and enhancing the quality of tele-medicine services, implementing AI-based solutions to address population health impact, developing point-of-care diagnostics to drive program improvements, conducting competency-based capacity building for health cadres, and utilizing database predictions and analysis for informed decision-making. This will help the Department to make optimal use of the UP Digital Health Stack (UP-DHS) and ensure that every citizen of the state, wherever they are, will be able to access healthcare when needed. In Uttar Pradesh, UP-DHS is making significant strides in implementation, with foundational NHS elements deployed across all health administrative units and the rollout of essential healthcare applications well underway. ]]> https://biospectrumindia.com/news/100/24244/worlds-first-multiomics-lab-to-be-built-in-bengaluru.html https://biospectrumindia.com/news/100/24244/worlds-first-multiomics-lab-to-be-built-in-bengaluru.html Mon, 26 Feb 2024 00:00:00 +0530 Dr Vishnuvardhan, CEO, Vizzhy has announced the establishment of the world's first Multiomics Lab in Bengaluru, marking a significant leap in healthcare innovation. The announcement came during the soft launch event of the Vizzhy Multiomics platform, showcasing a pioneering approach to understanding and treating metabolic disorders. In his address, Dr Vishnuvardhan highlighted the transformative potential of multiomics technology in deciphering the complexities of metabolic diseases. By integrating cutting-edge advancements and collaborations with esteemed institutions like the University of Illinois, Urbana-Champaign (UIUC), Vizzhy aims to revolutionise healthcare delivery. The Vizzhy Multiomics platform promises a paradigm shift in healthcare management, offering precise insights into individual metabolic profiles. Utilising state-of-the-art equipment and Health AI technology, the lab will empower physicians to identify root causes and provide tailored recommendations for patients. Moreover, the integration of AI-driven solutions, including digital signatures, will enhance medical decision-making and streamline health record management. Through the "Vizzhy GPT" platform, users can access comprehensive health summaries in multiple languages, facilitating informed healthcare interventions. The presence of a distinguished delegation from UIUC underscores the global significance of Vizzhy's initiative, heralding a new era of healthcare innovation. ]]> https://biospectrumindia.com/news/100/24250/providence-expands-global-healthcare-innovation-centre-with-new-facility-in-hyderabad.html https://biospectrumindia.com/news/100/24250/providence-expands-global-healthcare-innovation-centre-with-new-facility-in-hyderabad.html Mon, 26 Feb 2024 00:00:00 +0530 Providence India, a specialised global healthcare engineering, operations, and innovation centre, has launched an additional new office facility in Hyderabad, and announced plans to more than double its India workforce to support the growing demand for future-ready capabilities in tech-enabled healthcare.  The new office was inaugurated in the presence of IT Minister D Sridhar Babu; US Consul General – Hyderabad Jennifer Larson; Providence President and CEO Rod Hochman, M.D.; Providence CIO B.J. Moore; Chief Global Officer Murali Krishna, and other distinguished dignitaries and industry leaders. Providence India was established in February 2020 by Providence, a leading, not-for-profit US health system, to accelerate Providence’s digital transformation journey through a global capability model and run the business of Providence at scale. In their fourth year, Providence is leveraging its global capability model and expanding its scope and strategy to help multiple US health systems unlock value by accelerating digital transformation, using emerging cutting-edge technologies such as Generative AI, predictive analytics, Cloud solutions, Process Automation, global coverage and more.   The new office facility will serve as a central hub for critical functions, including cloud, cybersecurity, clinical applications and digital solutions, data and advanced analytics, product development, process automation, digital operations, enterprise services, and emerging technologies like GenAI.  Tapping into India’s diverse expertise and rich talent pools, the India hub will actively hire for skills in these areas.    ]]> https://biospectrumindia.com/news/100/24252/smartcardia-collaborates-with-kokilaben-dhirubhai-ambani-hospital-to-enhance-cardiac-arrhythmia-care.html https://biospectrumindia.com/news/100/24252/smartcardia-collaborates-with-kokilaben-dhirubhai-ambani-hospital-to-enhance-cardiac-arrhythmia-care.html Mon, 26 Feb 2024 00:00:00 +0530 SmartCardia, a renowned leader in the field of cardiac monitoring solutions, has announced an exciting partnership with Kokilaben Dhirubhai Ambani Hospital (KDAH), Mumbai to revolutionise patient care for individuals with cardiac arrhythmia, a condition when the heartbeat is irregular due to a problem with the heart’s electrical signals. This collaboration will create a more accurate and efficient monitoring system, enabling early detection and improved patient outcomes. The announcement was made at a special session for healthcare professions on the “Role of AI in Cardiology and Healthcare” held at Kokilaben Hospital. One of the key highlights of this collaboration is the introduction of the SmartCardia 7L patch, which allows for the detection of severe cardiac arrhythmia conditions earlier than ever before due to its real-time transmission of ECG and multiple vitals. This breakthrough technology provides doctors with immediate access to data, and auto alerts on cloud, enabling them to make more informed clinical decisions. With early detection, physicians can now devise tailored treatment plans, leading to more successful outcomes and increased patient satisfaction. SmartCardia leverages cutting-edge developments in AI to design systems that can identify cardiac events swiftly and accurately. This integration of AI technology enhances patient care by providing real-time updates to physicians and nurses, allowing them to proactively respond to any cardiac episodes, thereby reducing response times and improving patient outcomes.    Image caption- From Left- Dr Sunil Wani; Dr Venkant D Nagarjan, Head of Heart Rhythm & Cardiac Device; Dr Jag Singh, MD, Professor of Medicines at Harvard Medicine School, Boston, USA; Dr Santosh Shetty, Executive & CEO, KDAH; Dr Vidhyadhar Lad Head Cardiac Surgeon, KDAH   ]]> https://biospectrumindia.com/news/100/24228/niti-aayog-releases-report-for-senior-care-reforms-in-india.html https://biospectrumindia.com/news/100/24228/niti-aayog-releases-report-for-senior-care-reforms-in-india.html Mon, 19 Feb 2024 00:00:00 +0530 NITI Aayog has released a position paper titled 'Senior Care Reforms in India: Reimagining the Senior Care Paradigm'. The report was released by NITI Aayog Vice Chairman Suman Bery in the presence of Member (Health) Dr Vinod K. Paul; CEO B. V. R. Subrahmanyam; and Department of Social Justice and Empowerment (DoSJE) Secretary Saurabh Garg. Speaking on the occasion, NITI Aayog Vice Chairman Suman Bery said, “The release of this report is one of the stepping stones toward India’s commitment to achieve the goal of Viksit Bharat @2047. It is important to extensively prioritise the application of technology and Artificial Intelligence for senior care. It is time to start thinking about the special dimensions of senior care in addition to the medical and social dimensions.”. “This is the time when serious discussions should emerge on making ageing dignity driven, safe, and productive. We need to ensure the social security of the elderly and add more emphasis to wellbeing and care,” mentioned Member (Health) NITI Aayog Dr V.K. Paul in his address. “Role of family and family values is crucial in developing an ecosystem for healthy ageing. The report has brought forth appropriate policy directives for healthy ageing in India,” stated CEO, NITI Aayog B.V.R. Subrahmanyam. Saurabh Garg, Secretary, Department of Social Justice and Empowerment (DoSJE) said, “The report is a call for action on what needs to be done to bring a greater focus on senior care.”. He added that the broad focus of DoSJE is on ageing with dignity, ageing at home, and productive ageing, which will encompass social, economic, and health aspects.”. The recommendations in this position paper categorise the specific interventions needed in terms of empowerment, service delivery, and their inclusions under four core areas: Health, Social, Economic/ Financial, and Digital. It strives to push the frontiers of senior care by recognising the evolving medical and non-medical needs of seniors, thus envisioning a multi-pronged strategy for designing an effective and synergised senior care policy. ]]> https://biospectrumindia.com/news/100/24219/ivory-smiles-elevates-dental-care-in-bengaluru-with-state-of-the-art-ai-technology.html https://biospectrumindia.com/news/100/24219/ivory-smiles-elevates-dental-care-in-bengaluru-with-state-of-the-art-ai-technology.html Fri, 16 Feb 2024 00:00:00 +0530 Ivory Smiles Dental Clinic is introducing advanced artificial intelligence (AI)-controlled dentistry to Bengaluru for the first time. The clinic, with its centres located in HSR Layout and Whitefield, showcases a commitment to leveraging the latest technological innovations in dental care. With the latest technologies, such as 3D Cone beam CT/OPG and in-house intraoral scanners. Dr Amruta and her team of specialists, backed with advanced digital diagnostics and treatment tools, set Ivory Smiles apart in dental care. From precise diagnostics aided by digital X-rays and 3D imaging to personalised treatment plans formulated with the help of AI algorithms, the clinic ensures accuracy and efficiency at every step. Digitally guided implant placements allow patients to preview their post-treatment smiles. In contrast, AI-guided implant placement and digital impressions streamline the treatment process, significantly improving patient comfort and reducing chair-side time. Dr Amruta, the driving force behind Ivory Smiles, is a renowned periodontist and implantologist. She is also a member of the European Federation of Periodontology and the Indian Society of Periodontology, along with a fellowship degree in oral implantology (FICOI) from the International Congress of Oral Implantology, USA.     ]]> https://biospectrumindia.com/news/100/24220/ai-and-biotechnology-lead-funding-in-india-with-advanced-materials-emerging-report.html https://biospectrumindia.com/news/100/24220/ai-and-biotechnology-lead-funding-in-india-with-advanced-materials-emerging-report.html Fri, 16 Feb 2024 00:00:00 +0530 The India Deep Science Tech report is an in-depth analysis of the latest investment trends in the sector. For the first time ever, Ankur Capital and Tech Sprouts provide a ringside view of building IP-led technology companies from seed to commercial scale. Deep science tech innovations are driven by fundamental advances in four fields: Artificial Intelligence (AI), Biotechnology, Advanced Materials and Electronics & Photonics. The new report deep dives into the investment trends, key breakthroughs in the space, and emerging opportunities in each technology vertical.  The report reveals that AI and biotechnology have historically dominated India's funding landscape (80% of total investments since 2010), with advanced materials gaining momentum in recent years. ‍Investments in India's biotechnology sector surged post COVID-19, with nearly $900 million allocated between 2013-2023, driven by a focus on therapeutics, diagnostics, and sustainable agri-food technologies. Key investments include Molbio Diagnostics' and Bugworks'. The agri-food industry has seen growth in innovations like biostimulants and alternative proteins, with notable investments in companies like String Bio and Sea6 Energy. M&A, particularly in the pharmaceutical sector, offer exit pathways in the sector.  Recent years have seen a notable increase in follow-on funding for early AI ventures, with 2022 witnessing five investments exceeding $10M, underscoring a growing interest despite a slowdown in fresh investment. Indian deep science AI companies have predominantly focused on spectral image and genomic data analysis for applications ranging from diagnostics to robots to satellite imagery. According to the report, investment in deep science tech startups has consistently doubled every three years since 2010, with projections to surpass $10 billion by 2029, indicating robust growth and investor confidence. The number of investment rounds exceeding $5 million has doubled every three years. Since 2017, follow-on rounds have outpaced fresh funding, signaling investor commitment to doubling down on scale-up.   ]]> https://biospectrumindia.com/news/100/24209/stanford-biodesign-innovators-garage-programme-picks-iit-mandis-innovation-syncubator.html https://biospectrumindia.com/news/100/24209/stanford-biodesign-innovators-garage-programme-picks-iit-mandis-innovation-syncubator.html Tue, 13 Feb 2024 00:00:00 +0530 SynCubator, a neonatal incubator developed by Dr Gajendra Singh, Assistant Professor, Dr Satvasheel Ramesh Powar, Associate Professor, at the School of Mechanical and Materials Engineering, Indian Institute of Technology (IIT) Mandi, and Keshav Verma, BTech 3rd Year, Mechanical Engineering has been selected for the prestigious ‘Stanford Biodesign Innovators Garage’ programme. Designed as a multifunctional neonatal incubator, SynCubator offers a unique solution to the challenges faced in transporting and providing critical care to newborns. Unlike traditional incubators, the developed device doubles as both a standalone warmer and an incubator, adaptable to the specific needs of each infant. During the innovators’ discussions with the Centre of Innovation at the Government Institute of Medical Sciences in Noida regarding the medical dimensions of the SynCubator, an opportunity emerged to participate in a prestigious programme. Upon presenting the proposal to the Stanford Biodesign Team, the team’s innovative approach to improving access to healthcare in remote regions resonated with them. With India grappling with high neonatal mortality rates and a significant number of preterm births, SynCubator will play a pivotal role in improving healthcare outcomes. By leveraging Artificial Intelligence and Machine Learning technologies in the future, the core design team aims to further enhance SynCubator's capabilities, enabling predictive healthcare interventions and timely treatments.   ]]> https://biospectrumindia.com/news/100/24181/qure-ais-ai-powered-tb-solution-gets-us-fda-clearance.html https://biospectrumindia.com/news/100/24181/qure-ais-ai-powered-tb-solution-gets-us-fda-clearance.html Fri, 09 Feb 2024 00:00:00 +0530 Mumbai-based startup Qure.ai has received breakthrough device designation from the US Food and Drug Administration's (FDA) Center for Devices and Radiological Health (CDRH) for its artificial intelligence (AI)-powered Tuberculosis (TB) solution, qSpot-TB. This latest regulatory accolade for Qure.ai joins four FDA clearances and 61 European Union Medical Device Regulation (EU MDR) CE mark approvals over the last eighteen months. The qSpot-TB is a second-read computer aided detection and diagnosis device that analyses chest X-rays to localise all noted radiological signs suggestive of TB and provide an accompanying conclusion regarding the presence or absence of TB. This may support clinical workforces, especially during a recent uptick of TB incidences in developed nations including the United States (US). The breakthrough device designation granted to Qure’s qSpot-TB device by the US FDA marks a step-forward in the field of tuberculosis AI-assisted diagnosis. TB is a highly infectious disease affecting the lungs and is not just the premise of developing nations. Rates of TB in western societies such as the UK and USA have ticked upwards following the COVID-pandemic, magnifying the need for continued focus on detection and screening. ]]> https://biospectrumindia.com/news/100/24195/in-med-develops-neuroshield-ct-ai-tool-to-help-reduce-mortality-rates-in-neurotrauma.html https://biospectrumindia.com/news/100/24195/in-med-develops-neuroshield-ct-ai-tool-to-help-reduce-mortality-rates-in-neurotrauma.html Fri, 09 Feb 2024 00:00:00 +0530 In-Med AI has announced the launch of its new product, 'Neuroshield CT TBI, an artificial intelligence (AI) based neurotrauma screening and quantification tool. Grounded in robust research and built on extensive imaging data, NeuroShield CT will aid neuro-critical teams in identifying and quantifying pathologies related to Traumatic Brain Injury (TBI) cases. Leveraging AI, NeuroShield CT automates manual image processing, ensuring accurate results on timely basis. This state-of-the-art technology empowers radiologists, neurologists, and neurosurgeons with accurate data, facilitating rapid, informed decision-making around workflow prioritisation, acute triage management, and developing effective treatment plans in the case of neurotrauma. TBI is the primary cause of hospitalisation, disability, and post-injury mortality worldwide, often referred to as a "silent epidemic". Globally between 64 and 74 million people experience traumatic brain injuries (TBI) every year. According to the Indian Head Injury Foundation (IHIF), India leads the world in brain injury rates, with one in six TBI patients succumbing to their injuries. Early diagnosis is crucial, as 50% of associated mortalities occur within the first 24 hours.  Serving as a decision support tool, Neuroshield CT promptly alerts neurologists to the presence of critical pathologies, offering quantifiable insights. NeuroShield CT provides crucial information, arming neurologists with the knowledge necessary for targeted interventions and improved patient outcomes. This tool is particularly essential for early intervention, a necessity during the "Golden Hour," a critical post-trauma period. The software automatically detects and quantifies bleed (Intracranial Haemorrhage), Fracture, and Midline Shift, and Fracture.   This new product follows the pathbreaking Neuroshield MRI Volumetry product targeting neurodegenerative conditions like dementia, Alzheimer's, Parkinson's, and Epilepsy. It is currently operational in over 280 sites in India, Africa, and the Middle East and recently received the US FDA 510 clearance for sales in the US market. ]]> https://biospectrumindia.com/news/100/24187/aster-cmi-hospital-set-to-revolutionise-nerve-ultrasound-diagnostics.html https://biospectrumindia.com/news/100/24187/aster-cmi-hospital-set-to-revolutionise-nerve-ultrasound-diagnostics.html Thu, 08 Feb 2024 00:00:00 +0530 Aster CMI Hospital charges ahead as a healthcare artificial intelligence (AI) patron with its groundbreaking innovative technology, which supports the health experts on various aspects of treatment such as analysing vast amounts of data that could lead to earlier and more accurate diagnoses of diseases, developing new treatment options, and immediate monitoring of vitals for various specialties. AI Carpal Tunnel syndrome (CTS) is one such technology that is developed by the Neurology Department which is poised to revolutionise nerve ultrasound diagnostics.  This technology redefines, diagnoses, and screens efficiently. It can identify the median nerve in ultrasound videos and detect CTS with the highest accuracy (95%) marking a significant leap in healthcare innovation. The AI tool signifies a transformative stride towards precision and efficiency in CTS diagnosis, marking a new era in healthcare. “As we witness the healthcare landscape evolve from a prescriptive to a predictive model, AI emerges as the catalyst for this transformative journey. Our close collaboration with government bodies underscores our commitment to ethical AI practices, rigorous regulatory compliance, and the highest standards of data privacy and security. This transformative, technology-enabled tool marks a new dawn in healthcare”  says Dr Nitish Shetty, CEO, Aster DM Healthcare. Commenting on the occasion, Dr Lokesh Bathala, Lead Consultant Neurology said, "This lab is an exemplification to the unlimited potential of AI in healthcare. We are pushing the boundaries of medical science, designing AI tools that will transform the future of diagnosis, treatment, and prevention. These AI tools can prevent long-term complications and improve the quality of life. It can also minimize the need for repetitive examinations and invasive procedures, reducing patient’s discomfort and anxiety. While the AI tools significantly reduce the inference time, it is important to note that the final diagnosis will always be carried out by the physician.”   Left To Right:  SGS Lakshmanan, Chief Operating Officer Aster CMI Hospital; Ramesh Kumar S, CEO, Aster Hospitals; Dr Lokesh Bathala, Lead Consultant Neurology; Prof. Phaneendra Yalavarthy Dept. of Computational and Data Sciences, Indian Institute of Science at the unveiling of AI technology at Aster CMI Hospital ]]> https://biospectrumindia.com/news/100/24188/nearly-two-thirds-of-life-sciences-executives-set-sights-on-ai-to-improve-revenue-optimisation-in-2024-report.html https://biospectrumindia.com/news/100/24188/nearly-two-thirds-of-life-sciences-executives-set-sights-on-ai-to-improve-revenue-optimisation-in-2024-report.html Thu, 08 Feb 2024 00:00:00 +0530 US-based Model N, Inc., the leader in revenue optimisation and compliance, has published its sixth annual State of Revenue Report, revealing life sciences and high-tech executives’ top business priorities and challenges. The company’s 2024 report named process efficiency and cost-saving measures as priorities for executives, with greater emphasis placed on advanced analytics and artificial intelligence (AI) to achieve these priorities. For a second year in a row, supply chain disruption emerged as one of the top obstacles to innovation across all industries. Beyond persistent macroeconomic headwinds, 2024 survey results highlighted several industry-specific challenges. Among pharmaceutical manufacturers, most executives are worried about the influence of regulations on future revenue. Half of the leaders surveyed are bracing for a significant revenue impact from price negotiations with Medicare under the Inflation Reduction Act, more than double the results from the 2023 survey. For medical technology executives, communication between field sales and operations teams is a top concern, with just 38% reporting excellent communication. The MedTech industry continues to adjust to new financing and subscription models for capital equipment and software, evolving from one-time to recurring revenue. Nearly 60% of executives reported difficulties with managing such models. “Life sciences and high-tech manufacturers rely on complex, multi-stage revenue processes. Failing to consistently monitor, analyze, and optimise these processes is a recipe for increased risk,” said Suresh Kannan, Chief Product Officer, Model N. “This year’s State of Revenue Report underscores how existing business practices must evolve and harness the power of data and advanced analytics to overcome industry challenges, optimize revenue, and meet critical business needs.” ]]>